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Background: The conventional frontline therapy for fit patients with chronic lymphocytic leukaemia (CLL)
is fludarabine, cyclophosphamide and rituximab (FCR). Rituximab (Mabthera®, Roche Products Ltd) targets
the CD20 antigen, which is expressed at low levels in CLL. The standard dose of rituximab in CLL
(375 mg/m2 in cycle 1 and 500 mg/m2 in cycles 2–6) was selected based on toxicity data only. Small doses
of rituximab (as low as 20 mg) have biological activity in CLL, with an immediate reduction in circulating CLL
cells and down-regulation of CD20. Phase II trials had suggested improved efficacy with the addition of
mitoxantrone to FCR. The key assumption for the Attenuated dose Rituximab with ChemoTherapy In CLL
(ARCTIC) trial was that the addition of mitoxantrone to fludarabine, cyclophosphamide and low-dose
rituximab would be more effective than conventional FCR.
Objectives: To assess whether fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab
(FCM-miniR) (100 mg of rituximab per cycle) was non-inferior to FCR in frontline CLL. Complete response
(CR) rate was the primary end point, with the secondary end points being progression-free survival (PFS),
overall survival (OS), overall response rate, eradication of minimal residual disease (MRD), safety and
cost-effectiveness.
Design: ARCTIC was a UK multicentre, randomised, controlled, open, Phase IIB non-inferiority trial in
previously untreated CLL. A total of 206 patients with previously untreated CLL who required treatment,
according to the International Workshop on Chronic Lymphocytic Leukaemia criteria, were to be
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randomised to FCR or FCM-miniR. There was an independent Data Monitoring and Ethics Committee
(DMEC) with a pre-planned interim efficacy assessment on 103 participants.
Results: The DMEC’s interim analysis led to early trial closure. Although the response rates in both arms were
higher than anticipated, FCM-miniR had a lower CR rate than FCR. This was partly attributable to the higher
toxicity associated with mitoxantrone. A total of 100 participants completed FCR, 79 completed FCM-miniR
and 21 commenced FCM-miniR but switched to FCR following DMEC recommendations. The CR rate for
participants receiving FCR was 76%, compared with 55% for FCM-miniR (adjusted odds ratio 0.37; 95%
confidence interval 0.19 to 0.73). Key secondary end points also showed that FCR was superior, with more
participants achieving MRD negativity (57% for FCR vs. 46% for FCM-miniR). More participants experienced a
serious adverse reaction with FCM-miniR compared with FCR (50% vs. 41%). At a median of 37.3 months’
follow-up, the PFS and OS rates are good compared with previous studies, with no significant difference
between the treatment arms. The economic analysis indicates that because FCM-miniR is less effective than
FCR, FCM-miniR is not expected to be cost-effective over a lifetime horizon, producing a mean cost-saving of
–£7723, a quality-adjusted life-year loss of –0.73 and a resulting incremental net monetary loss of –£6780.
Conclusions: FCM-miniR is less well tolerated, with poorer response rates, than FCR, partly owing to the
additional toxicity associated with mitoxantrone. In view of this, FCM-miniR will not be taken forward into
a larger definitive Phase III trial. The trial demonstrated that oral FCR yields extremely high response rates
compared with historical series with intravenous chemotherapy.
Future work: We shall compare the results of ARCTIC with those of the ADMIRE (Does the ADdition of
Mitoxantrone Improve Response to FCR chemotherapy in patients with CLL?) trial, which compared FCR
with FCM-R to assess the efficacy of low- versus standard-dose rituximab, allowing for the toxicity
associated with mitoxantrone.
Trial registration: Current Controlled Trials ISRCTN16544962.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 21, No. 28. See the NIHR Journals Library website
for further project information.
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Plain English summary
What was the problem?
The first treatment that patients with chronic lymphocytic leukaemia (CLL) usually receive is a combination
of the drugs fludarabine, cyclophosphamide and rituximab (Mabthera®, Roche Products Ltd) (FCR).
However, research suggested that adding a fourth drug called mitoxantrone to FCR would improve
response rates and that a lower dose of rituximab would work just as well as the standard dose.
What did we do?
We established the Attenuated dose Rituximab with ChemoTherapy In CLL trial to compare fludarabine,
cyclophosphamide, mitoxantrone and low-dose rituximab (FCM-miniR) with the standard FCR treatment.
The trial recruited 200 participants.
What did we find?
Three months after the end of treatment, participants were assessed to see how well they had responded.
Part-way through the trial we looked at how half of the participants had responded and we found that
participants who had received FCR had better response rates and fewer side effects than participants who
had received FCM-miniR. The trial was, therefore, closed early and participants who were still receiving
FCM-miniR were offered the chance to have FCR instead.
Follow-up assessments are ongoing but, to date, disease progression and overall survival data are good for
all participants compared with previous studies.
What does this mean?
The results of this trial show that FCR is a more effective treatment than FCM-miniR, and the addition of
mitoxantrone to FCR increases side effects. FCR remains the best available therapy for CLL in patients who
are considered fit for treatment with fludarabine.
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Scientific summary
Background
The conventional therapy for patients with chronic lymphocytic leukaemia (CLL) who require therapy and
are considered fit for fludarabine-based treatment is the combination of fludarabine, cyclophosphamide
and rituximab (FCR) (Mabthera®, Roche Products Ltd). Rituximab is a monoclonal antibody targeting the
CD20 antigen, which is expressed on B-cells (both normal and malignant). CD20 is characteristically
expressed at a low level in CLL. The standard dose of rituximab used in FCR for CLL (375 mg/m2 in cycle 1
and 500 mg/m2 in cycles 2–6) was selected based on the dose approved as a single agent in follicular
lymphoma. The problem with identifying the dose of rituximab, as with many other monoclonal
antibodies, is that the maximum tolerated dose is not reached in Phase I trials owing to the specificity of
this type of targeted therapy. In effect, the maximum tolerated dose is governed by the volume that can
be infused rather than the toxicity of the molecule. The standard dose of rituximab as a single agent in
follicular lymphoma of four weekly doses of 375 mg/m2 was selected pragmatically depending on the
amount of available rituximab and the number of patients required in the original follicular lymphoma trial.
The same dose was then used when rituximab was combined with various different chemotherapy regimes
in lymphoma, with no further Phase I data to define this more accurately. The dose upon which the CLL
dose was derived was 375 mg/m2 but, as the expression of CD20 in CLL is characteristically lower than in
the other B-cell malignancies and in normal B-cells, the rituximab dose per cycle of chemotherapy in CLL
was arbitrarily increased to 500 mg/m2. When higher doses of rituximab [three doses of 500 mg/m2 per
cycle of fludarabine and cyclophosphamide (FC) compared with a single dose, which is conventional;
so-called FCR3] were used in combination with fludarabine plus cyclophosphamide in a small Phase II trial,
there was no evidence that the responses were any higher. However, there is good evidence that small
doses of rituximab have biological activity in CLL. Even small doses of rituximab, as low as 20 mg, lead to
an immediate reduction in circulating CLL cells by the end of the infusion. This is associated with a marked
reduction in the expression of CD20 on the CLL cells, which becomes apparent during the infusion. If a
similar, or larger, dose of rituximab is then given on the following day there is often no further evidence of
a fall in lymphocyte count owing to the lack of CD20 antigen expression on the CLL cells. There is
evidence that this reduction in CD20 expression may be attributable to the ‘shaving’ of CD20 from the CLL
cell. The idea behind the mechanism for CD20 shaving is that, initially, cells coated in rituximab are
removed by the reticuloendothelial system, but given the large number of CLL cells, this mechanism is
rapidly saturated. At this point, the rituximab bound to the CLL cells coalesces and these aggregates are
removed by the reticuloendothelial system, a process called trogocytosis. Therefore, bound and unbound
CD20 antigens are removed from the CLL cells, making them non-responsive to further doses of rituximab.
A possible consequence of this would be that higher doses of rituximab would remain in the plasma and
as soon as any CD20 antigen returns, the same mechanism of shaving would apply until the free rituximab
was exhausted or excreted. At this point, CD20 expression would return, allowing further doses of
rituximab to be effective. If the above is true then giving ever-increasing doses of rituximab would not be
effective and, in fact, lower doses that had biological activity but did not lead to high free plasma levels
might allow the more rapid return of the CD20 antigen, thereby enabling subsequent doses of rituximab
to have biological activity again. This would suggest that repeated lower doses of rituximab may be
equally, or even more, effective, particularly when there is a large amount of tumour antigen present
(at the initiation of therapy). The cost of rituximab constitutes approximately 80% of the acquisition costs
of FCR, and the infusions last several hours, creating logistic problems for both patients and hospitals. If
the dose of rituximab were to be reduced by several fold, then both of these issues would be ameliorated.
Two earlier Phase II trials in both previously untreated and relapsed CLL patients have suggested that the
addition of mitoxantrone to FCR results in greater efficacy and is well tolerated, although neither of
the trials was randomised to validate this.
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There were two key assumptions in the design of the Attenuated dose Rituximab with ChemoTherapy In
CLL (ARCTIC) trial. First, it was assumed that the efficacy of a low dose of rituximab [100 mg (i.e. one vial)]
was comparable to the conventional dose (500 mg/m2) when combined with combination chemotherapy in
CLL. Second, it was assumed that the addition of mitoxantrone to FC would increase the response rates
and be tolerable. Mitoxantrone was, therefore, added to the chemotherapy backbone of FC in order to
allow for the possibility that low-dose rituximab might be inferior to the conventional dose. It would then
follow that FCM-miniR should be at least non-inferior and, therefore, cost-effective when compared
with FCR.
Objectives
The objective of the ARCTIC trial was to assess whether the combination of fludarabine, cyclophosphamide
and mitoxantrone with a low dose of rituximab (FCM-miniR; 100 mg per cycle) was non-inferior to the
conventional FCR therapy in patients with CLL requiring therapy for the first time. This included the
complete remission (CR) rate as the primary end point, with important secondary end points including
progression-free survival (PFS), overall survival (OS), overall response rate (ORR), eradication of minimal
residual disease (MRD) following treatment, safety and toxicity, and cost-effectiveness. The objective was to
use the results of ARCTIC, assuming they were positive, to help design a larger, definitive, Phase III trial.
Methods
The ARCTIC trial was a multicentre, randomised, controlled, open, Phase IIB non-inferiority trial including
patients with previously untreated CLL who required treatment by International Workshop on Chronic
Lymphocytic Leukaemia (IWCLL) criteria. Patients were randomised on a 1 : 1 basis to receive FCR or
FCM-miniR. The intention was to include 206 patients from hospitals around the UK. The trial was
monitored by an independent Data Monitoring and Ethics Committee (DMEC) and a Trial Steering
Committee (TSC), and there was a pre-planned interim assessment of efficacy after 103 participants had
completed therapy.
Primary end point (response assessment) data were centrally reviewed by an independent panel of CLL
clinicians who determined, using IWCLL criteria, whether or not a CR had been achieved. A formal analysis
of the primary end point used an adjusted logistic regression model, and time-to-event analyses were
performed using adjusted Cox regression analyses. The economic evaluation used a within-trial analysis, in
which cost-effectiveness was assessed within the 24-month trial period using individual patient data
collected during the trial, and a decision analytic model analysis, in which cost-effectiveness was assessed
over a lifetime horizon using standard modelling techniques applied to the trial data in order to extrapolate
the trial results.
Results
A total of 200 of the planned 206 patients were entered into the ARCTIC trial between December 2009
and September 2012 from 34 centres across the UK. There were nine withdrawals (4.5%) during the trial,
which were balanced across the treatment arms. A total of 141 participants (70.5%) completed the
recommended six cycles of treatment, with slightly more in the FCR arm than the FCM-miniR arm (70.0%
vs. 64.6%). The majority of participants discontinuing treatment did so because of toxicity. At the DMEC’s
pre-planned interim analysis, 82.9% of participants achieved a CR in the FCR arm compared with 61.4%
of participants in the FCM-miniR arm. Although the difference between the two arms was not significant
(at the adjusted 0.5% level) the experimental treatment had the lower CR rate. As the results were
approaching significance in favour of the control group, and there was evidence of additional toxicity in
the FCM-miniR arm, the trial was closed early at the recommendation of the DMEC, and participants still
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receiving FCM-miniR were recommended to transfer to treatment with FCR for the remainder of their
treatment cycles.
At the final analysis of the primary end point (at 3 months post treatment) 100 participants had completed
FCR, 79 had completed FCM-miniR and 21 had initially received FCM-miniR but crossed over to receive
FCR at some point in their treatment following the advice of the DMEC recommendation. A total of
76.1% of participants achieved a CR in the FCR arm compared with 54.7% in the FCM-miniR arm. The
difference in proportions (FCM-miniR – FCR) was –21.4% [95% confidence interval (CI) –35.8% to –7.0%]
and the adjusted analysis gave an odds ratio of 0.37 for the treatment effect (95% CI 0.19 to 0.73),
indicating that participants in the FCM-miniR were significantly less likely to achieve a CR. Therefore, at the
final analysis there is very strong evidence that FCM-miniR is not non-inferior to FCR in terms of CR rates at
3 months post treatment, and that it is, in fact, significantly inferior. The analysis of the per-protocol
population and the sensitivity analyses support this conclusion.
The ORR was high at 92.6%, with 7.5% fewer participants achieving at least a partial response in the
FCM-miniR arm compared with the FCR arm (95% CI –15.6% to 0.6%).
The eradication of MRD in the bone marrow at the end of therapy is a strong predictor of outcome in CLL.
At 3 months post treatment, 53% of participants were MRD negative, with a higher percentage of
participants in the FCR arm than the FCM-miniR arm (57.0% vs. 46.4%). The difference in proportions
between FCR and FCM-miniR was not statistically significant (χ2 = 1.97; p = 0.160), although it was
approaching significance.
There was no significant difference between the treatment arms with respect to PFS, nor was there a
significant difference in OS. However, there was a non-significant trend towards the FCM-miniR
participants performing worse in terms of both PFS and OS. At 24 months post randomisation, 89.4% of
the FCR participants remained progression-free compared with 79.1% of the FCM-miniR participants. In
terms of OS at 24 months, 95.8% of the FCR participants remained alive compared with 88.5% of the
FCM-miniR participants.
In the exploratory subgroup analyses, PFS and OS were significantly improved for participants who were
MRD negative or who had achieved a CR at 3 months post treatment, or who received more than
three cycles of treatment. In addition, of those participants who were MRD positive, OS was worse in
participants who received FCM-miniR than in those who received FCR, suggesting that after progression
the participants initially treated with FCM-miniR may respond more poorly to, or be too unwell to receive,
salvage therapies. Longer follow-up data are required to be able to assess reliably the time-to-event
outcomes, and these will be updated in future.
More participants experienced a serious adverse event (SAE) in the FCM-miniR arm compared with the FCR
arm (58.2% vs. 49.0%), as well as a serious adverse reaction (49.4% vs. 41.0%). More participants in the
FCM-miniR arm were hospitalised for a SAE during the trial (51.9% vs. 46.0%) and six SAEs were deemed
to be life-threatening or resulted in death compared with three in the FCR arm. A similar proportion of
participants experienced an adverse event (AE) in each treatment arm, but a higher proportion of Common
Terminology Criteria for Adverse Events grade 3 and 4 AEs were reported in the FCM-miniR arm (22.4% vs.
15.0%). There were no treatment-related mortalities within 3 months of completing protocol treatment.
The results of the economic analysis indicate that FCM-miniR is cost-effective in the short term, but only as a
result of saving money at the expense of worse health outcomes, and is unlikely to be cost-effective in the
long term. Over the 24-month trial period, FCM-miniR produced a mean cost saving of £6619 and a mean
quality-adjusted life-year (QALY) loss of –0.059 compared with FCR. The incremental cost-effectiveness ratio
(ICER) was £112,193, indicating that for every £112,193 saved by adopting FCM-miniR, one QALY would
be lost. At a willingness-to-pay threshold of £20,000 per QALY, this leads to a net benefit gain of £5439
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(equivalent to 0.27 QALYs), and there was a 100% probability that FCM-miniR is cost-effective. However,
the cost-effectiveness of FCM-miniR was not sustained in the long-term analysis. Results of the decision
model indicate that over a lifetime horizon, FCM-miniR produces a mean cost saving of £7723 and a mean
QALY loss of –0.73. The associated ICER is £10,651, indicating that for every £10,651 saved by adopting
FCM-miniR, one QALY would be lost. At a £20,000 per QALY threshold, this leads to a net loss of –£6780
(–0.34 QALYs), with a 19% chance that FCM-miniR is cost-effective.
Conclusions
Participants randomised to FCM-miniR had a significantly lower CR rate than those randomised to FCR
(FCM-miniR 55% vs. FCR 76%), indicating that FCR is the more effective treatment. This seemed, at least in
part, to be attributable to the higher toxicity associated with the addition of mitoxantrone to FCR. Key
secondary end points also indicated that FCR had greater efficacy, with a higher proportion of participants
achieving eradication of MRD (57% for FCR compared with 46% for FCM-miniR). The follow-up in the
trial is still immature (median 37.3 months from randomisation) but, to date, the PFS and OS are good
compared with previous studies and there is no significant difference between the two treatment arms,
although there is a possible trend towards FCR patients having improved PFS and OS. The cost-effectiveness
analysis indicates that, although FCM-miniR is expected to be cost-effective in the short term, it is unlikely to
be cost-effective when taking into account long-term costs and health benefits.
In summary, there is strong evidence to suggest that FCM-miniR is not non-inferior to FCR in terms of
CR at 3 months post treatment and that the addition of mitoxantrone adds toxicity to FCR. Although
FCM-miniR was found to be cost-effective over the trial period, it is unlikely to be cost-effective in the long
term. In view of this, FCM-miniR will not be taken forward into a larger, definitive, Phase III trial.
The trial demonstrated that oral FCR yields extremely high response rates compared with historical series in
which the chemotherapy was given intravenously and it remains the gold-standard therapy for CLL in
patients considered fit for fludarabine-based therapy.
Trial registration
The trial is registered as ISRCTN16544962.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Sections of this chapter have been reproduced from Howard et al.1 with permission.
Scientific background
Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia, affecting approximately 6.9 per
100,000 of the population. The incidence of CLL increases with age and twice as many men are affected
as women. CLL results from the clonal proliferation of B-cells and is diagnosed by the pattern of expression
of various cell surface antigens on the CLL cells. Patients most commonly present with lymphocytosis,
lymphadenopathy, splenomegaly and systemic symptoms, such as fatigue, weight loss and malaise.
The clinical course of CLL is highly variable, with a median survival from diagnosis in the region of 7 years.
Patients with more advanced disease (Binet stages B, C and stage A progressive) have a significantly
worse survival.
Standard therapy for chronic lymphocytic leukaemia
Fludarabine combined with cyclophosphamide is one of the more frequently used combinations of drugs
for treating CLL in second and subsequent line use. The MD Anderson Cancer Center reported the use
of fludarabine and cyclophosphamide combined with rituximab (Mabthera®, Roche Products Ltd) (FCR)
in both previously untreated and refractory CLL.2,3 The response rates for FCR are very impressive and
compare extremely positively with historical controls treated with fludarabine, either alone or in
combination with cyclophosphamide. In previously untreated patients, complete remission was
demonstrated in 217/300 (72%) patients, nodular partial remission in 31 (10%), partial remission in
37 (12%), no response in 13 (4%) and early death in 2 (< 1%) patients.2 The same group also reported their
experience with FCR in 284 patients with previously treated CLL.3 The estimated median progression-free
survival (PFS) was 21 months, with a median overall survival (OS) of 47 months. The median number of
prior treatments was two: 67 patients were alkylating agent refractory, 52 were fludarabine refractory and
98 patients had prior rituximab. Using National Cancer Institute (NCI) criteria, 30% of patients achieved a
complete remission rate, 14% achieved nodular partial remission and 30% had partial response (PR),
giving an overall response rate (ORR) of 74%.
The German CLL Study Group (GCLLSG) completed the German CLL8 trial, which compared FCR with
fludarabine and cyclophosphamide (FC) in patients with CLL who had previously been untreated and
required therapy according to conventional criteria.4 It was reported that 811 patients were entered into
the GCLLSG CLL8 trial and randomly assigned to receive either FC or FCR. The ORR was significantly
higher in the FCR arm (95%; 370/390 patients) than the FC arm (88%; 328/371) (p = 0.001). The
complete response (CR) rate of the FCR arm was 52% compared with 27.0% in the FC arm (p < 0.0001).
PFS was 65% at 3 years in the FCR arm and 45% in the FC arm (p < 0.0001). Updated data showed that
at a median follow-up of 5.9 years, the PFS was 38% in the FCR group compared with 27.4% in the FC
group (p < 0.0001). A total of 69.4% of the patients were alive in the FCR group versus 62.3% in the
FC group. The median OS was 86 months in the FC group but the median OS was not reached in the FCR
arm (p < 0.001).5 In 2009, the European Medicines Evaluation Agency granted a product licence for
rituximab combined with FC in previously untreated CLL.
Rituximab dose
The dose of rituximab has not been established systematically in CLL. It has been extrapolated from the earlier
trials with use of rituximab in B-cell malignancies. However, rituximab monotherapy at a dose of 375 mg/m2
induced an ORR of 13% in previously treated CLL/small lymphocytic lymphoma (SLL).6,7 This poor response was
thought to be attributable to low CD20 expression on CLL cells and binding of rituximab to CD20 positive
cellular debris. Subsequent studies investigating thrice weekly doses of rituximab (375 mg/m2) and higher
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weekly doses of rituximab (500–2250mg/m2) in previously untreated patients induced modest ORRs of 43%
and 40%, respectively.8–10 The combination of intravenous FC along with rituximab at variable dose (375 mg/m2
in cycle 1 and 500 mg/m2 in cycles 2–6) was used in the Phase III CLL8 trial, showing an excellent ORR, PFS and
OS.5 However, the rationale of using higher doses of rituximab has not been formally assessed.
Rituximab binds specifically to the transmembrane antigen CD20, a non-glycosylated phosphoprotein located
on pre-B and mature B lymphocytes. The antigen is expressed on > 95% of all B-cell non-Hodgkin’s
lymphomas. CD20 is found on both normal and malignant B-cells, but not on haematopoietic stem cells,
pro-B-cells, normal plasma cells or other normal tissue. The phenomenon of CD20 shaving on CLL cells with
rituximab has been established in CLL. Most of the CLL cells were cleared after 30 mg of rituximab followed
by recrudescence of CLL cells which have lost > 90% of CD20 expression. These data suggested that
low-dose rituximab thrice weekly at much lower doses of 20–60mg/m2 may promote enhanced clearance of
CLL cells by preserving CD20 expression.11 Subcutaneous rituximab at a dose of 20mg three times a week
resulted in the reduction of CD20 expression on CLL cells, but sufficient expression was maintained during the
course of 6–12 weeks in another study.12 A combination of low-dose rituximab (20 mg/m2 three times a
week), alemtuzumab (Lemtrada®, Genzyme Therapeutics) and pentostatin (Nipent®, Hospira UK Ltd) in
high-risk CLL showed that this low dose of rituximab is able to opsonise and clear the majority of circulating
cells, but the loss of CD20 is less pronounced. There was also evidence of complement activation owing to C3d
deposition on CLL cells and natural killer cell activation owing to down-modulation of CD16, up-regulation
of CD54 and a decrease in the number of natural killer cells.13 Hence, there is considerable evidence that
rituximab at doses as low as 20mg/m2 can be effective and can reduce the phenomenon of CD20 shaving,
as seen with the higher dosing of rituximab used in CLL.
Rituximab has also been used in lower doses in a variety of autoimmune conditions, such as refractory
systemic lupus erythematosus and rheumatoid arthritis, where it is standard to use two intravenous doses
of 1000 mg 2 weeks apart.14–17 Rituximab at a dose of 100 mg once a week for 4 weeks has been used in
autoimmune haemolytic anaemia and immune thrombocytopenic purpura with relative similar efficacy to
the standard dose of 375 mg/m2, although there are no randomised controlled trials to compare the
two doses.18,19 Furthermore, two infusions of 250 mg/m2 of rituximab in mixed cryoglobulinaemia are as
effective as four infusions of standard-dose rituximab.20
In summary, the dose of rituximab in the treatment of CLL has not been systematically established and
there is good evidence to suggest that low-dose rituximab would be effective in combination with
chemotherapy.
Addition of mitoxantrone
Mitoxantrone is a synthetic anthracenedione that is structurally similar to doxorubicin and daunorubicin.
It was synthesised with the aim of reducing side effects, especially cardiotoxicity. It is indicated, either in
combination therapy or as a single agent, in the treatment of acute non-lymphocytic leukaemia, metastatic
breast cancer, hepatoma, lymphoma and paediatric sarcoma.
The addition of mitoxantrone to the fludarabine-based therapy has been found to result in high response
rates in a variety of indolent lymphoproliferative disorders, including follicular lymphoma21 and mantle cell
lymphoma.22 The combination of fludarabine, cyclophosphamide and mitoxantrone (FCM) has been
reported in 60 patients who have relapsed or resistant CLL.23 The ORR in this series was of 78% with
30 patients (50%) achieving a complete remission. It was of considerable importance that 10 of the
patients in CR had an eradication of detectable minimal residual disease (MRD) by a sensitive four-colour
flow cytometric test, and that these patients had a significantly prolonged survival compared with the
other patients in this series. In addition, FCM plus rituximab (FCM-R) appears to be a very promising
combination in Phase II trials for CLL. The Barcelona group have reported the use of FCM-R in a
non-randomised Phase II trial reporting a complete remission rate of 82% and an ORR of 93% in
previously untreated CLL.24 In this study, 46% of the CR patients had undetectable MRD. The National
Cancer Research Institute (NCRI) CLL subgroup has recently completed a randomised Phase II study
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including FCM and FCM-R in previously treated patients with CLL. This study recruited 52 patients, with
26 in each arm, and reported a 65% CR rate for FCM-R compared with a 58% CR rate for FCM, with five
and three patients, respectively, achieving eradication of MRD following FCM-R and FCM.25
Rationale for design
As we previously demonstrated that the combination of fludarabine, cyclophosphamide, mitoxantrone and
rituximab can be delivered safely25 and that there is evidence of synergistic effect in this combination,
the aim of this trial was to test the hypothesis that the low dose of rituximab (100 mg per cycle) in
combination with FCM would be as effective as the current standard care, which is the combination of
FCR. The data from the use of low-dose rituximab suggest that it can result in effective B-cell depletion
with relative preservation of CD20 expression on CLL cells, which would be important in terms of
maintaining the efficacy of rituximab. The higher dose of rituximab used in CLL is based primarily on the
efficacy of the drug as a single agent where higher doses resulted in better ORRs. However, it can be
postulated that higher doses are required as a single agent owing to the tumour burden. The combination
of chemotherapy with rituximab might not require the higher dose of rituximab as there is effective
clearance of tumour load, and preservation of CD20 expression on CLL cells may be important to maintain
the efficacy of rituximab.
Based on scientific rationale, another important aspect in the design of the trial was to assess the
cost-effectiveness of delivering the combination of FCM and rituximab at a low dose. The total cost of
six cycles of rituximab at the current recommended dose in the UK is estimated to be £10,128 for an
average body surface area (BSA) of 1.93m2 (average BSA in CLL8 trial).17 This does not include the hospital
cost for delivery of the infusion. The cost of six cycles of rituximab at a standard dose of 100 mg would be
£1048. The infusion time to deliver this dose will be considerably lower than the standard dose. It can be
suggested that the chances of developing infusion-related reactions requiring hospital admission would
be lower at the lower dose of rituximab. The cost of six cycles of mitoxantrone at a dose of 6 mg/m2
intravenously with this combination is estimated to be £600. The cost-effectiveness analysis of comparing
the two arms of the trial would be crucial in establishing whether or not the use of a lower dose of
rituximab is a reasonable alternative to the standard-arm FCR. Also, the non-inferiority design of the trial
helps to ascertain whether lowering the dose of rituximab, and hence reducing the cost of treatment, does
not affect the efficacy in terms of CR rates, as well as the longer-term outcomes of PFS and OS.
In summary, the trial answers a critical scientific question of whether or not reducing the dose of rituximab
and using a combination of mitoxantrone with oral FC would be as effective as standard care, and
whether or not this would, in turn, have an effect on the toxicity and cost-effectiveness of the regimes.
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Chapter 2 Methods
Sections of this chapter have been reproduced from Howard et al.1 with permission.
Aims and objectives
The aim of the ARCTIC trial was to establish whether the addition of mitoxantrone, with a low dose
of rituximab, to fludarabine and cyclophosphamide (i.e. FCM-miniR), is as effective as FCR in terms of
response in patients with previously untreated CLL.
The primary objective of the statistical analysis was to compare the CR rates as defined by IWCLL criteria26
in each treatment group, in order to determine whether FCM-miniR was non-inferior to FCR.
The secondary objectives were:
l to assess the rate of eradication of detectable MRD following treatment with FCR or FCM-miniR
l to assess the ORR (complete or partial remission defined by IWCLL criteria) between the
treatment groups
l to assess the safety and toxicity of low-dose rituximab and mitoxantrone in combination with FC
l to evaluate PFS
l to evaluate OS
l to evaluate time to MRD relapse.
The primary objective of the economic evaluation was to evaluate the incremental cost-effectiveness of
treating patients with CLL with FCM-miniR compared with the standard treatment of FCR. Two economic
evaluations were undertaken in this phase:
l a within-trial analysis comparing the outcomes and costs up to 24 months’ follow-up
l a long-term cost-effectiveness analysis modelling outcomes and costs over a lifetime horizon.
The evaluation followed the reference case guidance for technology appraisals set out by the National
Institute for Health and Care Excellence (NICE).27
Trial design
The ARCTIC trial is a multicentre, randomised, controlled, open, Phase IIB non-inferiority trial in patients
who are newly diagnosed with B-cell chronic lymphocytic leukaemia (B-CLL). Patients were randomised on
a 1 : 1 basis to receive one of two trial interventions, FCR or FCM-miniR.
The trial was reviewed and approved by the National Research Ethics Service Leeds (East) Research Ethics
Committee (REC) (reference 09/H1306/54) and was registered as an International Standard Randomised
Controlled Trial, number ISRCTN16544962. The trial was registered on the European Clinical Trials
Database (EudraCT), number 2009–010998–20.
Patient and public involvement
The trial was overseen by the NCRI CLL Subgroup Committee which includes two patient and public
involvement (PPI) representatives. Trial updates were presented to this committee three times per year and
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the PPI representatives would provide feedback on the trial during these meetings. There was involvement
from a PPI representative on the Trial Steering Committee (TSC) who provided input into the initial
production of, and any amendments to, the Participant Information Sheet and other trial documentation
intended for use by participants. Through membership of the TSC the PPI representatives also provided
input into the design and conduct of the trial through annual meetings. The Plain English summary has
been reviewed by a PPI representative who is part of the Trial Management Group (TMG).
Participants
The trial sought to recruit 206 participants with previously untreated CLL from ethically approved hospitals
around the UK. Participants had to meet the following eligibility criteria in order to participate in the trial:
Inclusion criteria
l At least 18 years of age.
l B-CLL with a characteristic immunophenotype, including SLL.
l Binet’s stage A progressive or B, or stage C.
l Requiring therapy by the IWCLL criteria in that they must have at least one of the following:
¢ evidence of progressive marrow failure as manifested by the development of, or worsening of,
anaemia and/or thrombocytopenia
¢ massive (i.e. 6 cm below the left costal margin) or progressive or symptomatic splenomegaly
¢ massive nodes (i.e. 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy
¢ progressive lymphocytosis with an increase of more than 50% over a 2-month period or
lymphocyte doubling time of < 6 months as long as the lymphocyte count is over 30 × 109/l
¢ a minimum of any one of the following disease-related symptoms must be present:
¢ unintentional weight loss more than or equal to 10% within the previous 6 months
¢ significant fatigue (i.e. Eastern Cooperative Oncology Group performance status 2 or worse;
cannot work or unable to perform usual activities)
¢ fevers of greater than 38.0 °C for 2 or more weeks without other evidence of infection
¢ night sweats for more than 1 month without evidence of infection.
l No prior therapy for CLL.
l World Health Organization (WHO) performance status of 0, 1 or 2.
l Able to provide written informed consent.
Exclusion criteria
l Prior therapy for CLL.
l Active infection.
l Past history of anaphylaxis following exposure to rat- or mouse-derived complementarity determining
region-grafted humanised monoclonal antibodies.
l Pregnancy, lactation or women of child-bearing potential unwilling to use medically approved
contraception while receiving treatment and for 12 months after treatment has finished.
l Men whose partners are capable of having children but who are not willing to use appropriate
medically approved contraception while receiving treatment and for 12 months after treatment has
finished, unless they are surgically sterile.
l Central nervous system involvement with CLL.
l Mantle cell lymphoma.
METHODS
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l Symptomatic cardiac failure not controlled by therapy or unstable angina not adequately controlled by
current therapy (in patients with a significant cardiac history the left ventricular function should be
assessed and patients with severe impairment should be excluded).
l Other severe, concurrent diseases or mental disorders.
l Known to be human immunodeficiency virus (HIV)-positive.
l Patient has active or prior hepatitis B or C.
l Active secondary malignancy excluding basal cell carcinoma.
l Persisting severe pancytopenia (neutrophils < 0.5 × 109/l or platelets < 50 × 109/l) or transfusion-
dependent anaemia unless attributable to direct marrow infiltration by CLL.
l Active haemolysis (patients with haemolysis controlled with prednisolone at a dose of 10 mg or less per
day can be entered into the trial).
l Patients with a creatinine clearance of < 30 ml/minute (either measured by or derived from the
Cockcroft–Gault formula).
Recruitment procedure
Participants were recruited from multiple research centres around the UK. Research centres were identified via
a feasibility assessment to determine the most appropriate centres to participate in the trial. Research centres
were required to have obtained ethical and management approvals and undertaken a site initiation meeting
with the Clinical Trials Research Unit (CTRU) based at the University of Leeds prior to the start of recruitment
into the trial. Potential participants were identified by the clinical team at participating centres and were
approached to participate in the trial during standard clinic visits. Each participating centre was required to
maintain a log of all patients screened for eligibility and to record reasons for non-randomisation.
Randomisation
Participants who fulfilled the eligibility criteria were randomised on a 1 : 1 basis to receive either FCR or
FCM-miniR. A computer-generated minimisation program that incorporated a random element was used
to ensure that treatment groups were well-balanced for the following characteristics:
l centre
l Binet staging (A progressive or B, C)
l age (≤ 65 years, > 65 years)
l sex (male, female).
Informed consent
A verbal explanation of the trial was provided by the attending medical staff and a Participant Information
Sheet and Informed Consent Document was provided for the patient to consider. This included detailed
information about the rationale, design and personal implications of the trial. Following information
provision, participants had as long as they needed to consider participation (normally a minimum of
24 hours) and were given the opportunity to discuss the study with their family and other health-care
professionals before they decided whether they would be willing to take part in the study.
Assenting patients were then invited to provide informed, written consent and to be formally assessed for
eligibility. A record of the consent process including the date of consent and all those present was to be
kept in the participants’ medical notes. The original consent form was kept at the research centre, filed in
the Investigator Site File, and copies of the consent form were given to the participant and the CTRU at
the University of Leeds.
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Participants were free to withdraw from the trial at any time. The specific wishes of any participant wanting
to withdraw consent for further involvement in the trial, be that from further treatment and/or follow-up
data collection, was documented to ensure appropriate processes were followed after withdrawal.
Interventions
Participants were randomised to receive six cycles of either FCR or FCM-miniR according to the regimens
outlined below (Tables 1 and 2).
Cycles of FCR and FCM-miniR were repeated every 28 days for a total of six cycles.
Participants who experienced nausea and vomiting or diarrhoea were given FC via the intravenous route
owing to concerns over drug absorption. Intravenous fludarabine was given at a dose of 25 mg/m2/day for
3 days (bioequivalent to 24 mg/m2/day for 5 days given orally) and cyclophosphamide was given at a dose
of 250 mg/m2/day for 3 days.
Routine concomitant medications
Participants received prophylaxis against Pneumocystis carinii pneumonia (PCP) with 960 mg of co-trimoxazole
bi-daily on Monday/Wednesday/Friday or 480mg on a daily basis. Participants who were allergic to
co-trimoxazole received an alternative, such as dapsone (Dapsone, Actavis UK Ltd) [100mg once daily (OD)] or
nebulised pentamidine (Pentacavinat, Sanofi) (monthly). PCP prophylaxis continued throughout treatment
and for at least 2 months after the last course of treatment. Aciclovir (400 mg bi-daily) was recommended as
prophylaxis against herpes virus reactivation for all participants. Allopurinol at a dose of 300mg/day was
recommended for all participants for at least the first 28 days of therapy.
TABLE 1 Fludarabine, cyclophosphamide and rituximab
Drug name Entry route Dosage Number of days
Fludarabine Oral 24 mg/m2/day Days 1–5
Cyclophosphamide Oral 150mg/m2/day Days 1–5
Rituximab Intravenous 375mg/m2 Day 1 (Cycle 1)
Rituximab Intravenous 500mg/m2 Day 1 (Cycles 2–6)
TABLE 2 Fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab
Drug name Entry route Dosage Number of days
Fludarabine Oral 24 mg/m2/day Days 1–5
Cyclophosphamide Oral 150 mg/m2/day Days 1–5
Mitoxantrone Intravenous 6 mg/m2/day Day 1
Low-dose rituximab Intravenous 100 mg Day 1
METHODS
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Dose delays and reductions
Treatment was delayed or reduced in the following circumstances:
Rituximab-related infusion reactions
The infusion was temporarily stopped until the reaction was resolved and then restarted at half the speed
of infusion.
Impaired renal function
Fludarabine was not to be given to participants with a creatinine clearance of < 30 ml/minute. Participants
with a creatinine clearance of < 30 ml/minute could have a delay of treatment for up to 4 weeks but were
withdrawn from the trial treatment if their creatinine clearance did not improve. Participants with a
creatinine clearance of between 30 and 60 ml/minute were permitted to have a 50% dose of fludarabine
at the discretion of the treating clinician.
Neutropenia
If neutrophils were < 1.0 × 109/l owing to trial chemotherapy rather than bone marrow involvement,
treatment was delayed for up to 2 weeks, with a 25% dose reduction of FC in subsequent treatment
cycles. Participants who had a neutrophil count of < 1.0 × 109/l at day 28 of any cycle of therapy received
granulocyte colony-stimulating factor {GCSF [lenograstim (Granuocyte, Chungai Pharma UK Ltd)]} at
a recommended dose of 263 µg/day from days 7–13 for the next and all subsequent cycles of
chemotherapy. Further dose reductions were permitted if neutropenia recurred after the 25% dose
reduction. If the neutrophil count recovered to > 1.0 × 109/l the doses of chemotherapy were re-escalated
with continuing GCSF support.
Other haematological toxicities
If platelets were < 75 × 109/l as a result of trial chemotherapy rather than bone marrow involvement,
treatment was delayed for up to 2 weeks, with a 25% dose reduction of FC in subsequent treatment
cycles. If on subsequent cycles of therapy platelets had recovered to over 100 × 109/l, the chemotherapy
doses were re-escalated. If further haematological toxicity occurred after the 25% dose reduction further
dose reductions were permitted.
Data collection and management
Data collection took place via paper case report forms (CRFs), which centres returned to the CTRU for
entry onto a central database. Initial validation checks of the forms were carried out and the trial database
also validated most dates and data in line with pre-programmed validation rules.
Safety monitoring
All AEs, both related and unrelated to the treatment of CLL, were collected for all patients and evaluated
for duration and intensity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE)
version 3.0. AEs were collected from randomisation until 30 days after the last dose of treatment with FCR
or FCM-miniR.
Serious adverse events (SAEs) were defined as any untoward medical occurrence or effect that:
l resulted in death
l was life-threatening
l required inpatient hospitalisation or prolongation of existing hospitalisation
l resulted in persistent or significant disability or incapacity
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l consisted of a congenital anomaly or birth defect
l may have jeopardised the patient and required medical or surgical intervention to prevent one of the
outcomes listed above.
Where a SAE was deemed to have been related to an Investigational Medicinal Product (IMP) used within
the trial (fludarabine, cyclophosphamide, rituximab or mitoxantrone) the event was termed as a serious
adverse reaction (SAR).
A Suspected Unexpected Serious Adverse Reaction (SUSAR) was defined as a SAR that also demonstrated
the characteristics of being unexpected, the nature and severity of which was not consistent with the
information about the medicinal product in question set out in the summary of product characteristics for
that product.
Serious adverse events were collected from the time of randomisation until 30 days post treatment. SARs
and SUSARs were collected from the time of randomisation and for the duration of the trial.
All SAEs, SARs and SUSARs were reported by the CTRU to the Chief Investigator of the trial as they
occurred. A summary of how many SAEs and SUSARs had been received was reported at each TMG
meeting. A summary of all SAEs and SUSARs was presented by treatment arm to the DMEC at all annual
meetings and in an interim report every 6 months, with any safety concerns being fed back to the TSC.
Outcome measures
Primary outcome measure
l Proportion of participants achieving a CR at 3 months post therapy, as assessed by IWCLL criteria.26
Secondary outcome measures
l Proportion of participants with eradicated MRD at 3 months post therapy: MRD is defined as negative
or undetectable owing to the presence of < 0.01% CLL cells in the blood or bone marrow by
IWCLL criteria.26
l Overall response rate at 3 months post therapy: defined as complete or partial remission by
IWCLL criteria.26
l Safety and toxicity: reported based on AEs (as graded by CTCAE V3.0), SAEs, SUSARs and treatment-
related mortalities within 3 months of discontinuing protocol treatment. Determined by routine clinical
assessments at each centre.
l Economic evaluation: quality-adjusted life-years (QALYs) were used to measure health benefit.
Health-related quality of life was estimated using responses to health economics participant
questionnaires, which included the European Quality of Life-5 Dimensions (EQ-5D™) and Short Form
questionnaire-12 items (SF-12) [converted to Short Form questionnaire-6 Dimensions (SF-6D)].28
l Progression-free survival at 2 years: time from randomisation to first documented evidence of disease
progression or death. Participants without evidence of disease progression at the time of analysis are
censored at the last date on which they were known to be alive and progression free. The initial
analysis was planned once all participants had been followed for 2 years post randomisation.
l Overall survival: time from randomisation to date of death. Participants still alive at the time of analysis
are censored at the date on which they were last followed up. The initial analysis was planned once all
participants had been followed for 2 years post randomisation.
l Time to MRD relapse in participants who are MRD negative 3 months post treatment: time from the
3-month post-treatment visit, for those participants who became MRD negative, to when the
METHODS
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participant became MRD positive. Participants who were alive and MRD negative at the time of
analysis, or participants dying from causes unrelated to CLL, were censored. If participants were lost to
follow-up, their MRD relapse-free survival time was censored at the time at which they were last
known to be alive and MRD negative.
Independent primary end point review
The primary end point data, response at 3 months post treatment by IWCLL criteria, was centrally reviewed
by an independent panel in order to enhance the consistency and accuracy in the reporting of the primary
end point, and to eliminate potential local assessment bias. The independent review panel consisted of CLL
clinicians who were identified via the NCRI CLL Subgroup Committee. The independent reviews were
performed using anonymised data with no information regarding which treatment was provided for each
participant. Each response assessment was made by two independent clinicians and where the outcome of
the assessments differed the data were sent to a third clinician, an independent arbiter, to make a final
decision on response.
Sample size
A total of 206 participants were required. From previous studies it was anticipated that FCR would produce
response rates of at least 50%. In particular, the results from the GCLLSG, presented at the American Society
of Haematology conference 2008, showed a 52% CR rate with FCR.4,29 It was anticipated that FCM-miniR
would actually have a superior response rate to FCR. This was based on, firstly, the assumption that miniR was
as good, or nearly as good, as full-dose rituximab,30 and, secondly, the hypothesis that mitoxantrone increases
the response rate when added to FCR. It was, therefore, hypothesised that FCM-miniR may increase the
response rate by approximately 10%. If this was the case, and FCM-miniR really had a 10% better response
rate when compared with FCR, a non-inferiority Phase IIB trial was considered practicable. Under this assumed
10% difference in favour of FCM-miniR, to have 80% power to show non-inferiority, where this is defined as
FCM-miniR being not more than 10% worse in terms of response rate than FCR, the trial would require the
randomisation of 98 participants per arm, 196 in total.31
Note that if the FCR response rate deviates in either direction from 50%, the sample size required to show
that the CR rate in the FCM-miniR group is not inferior by more than 10% would decrease. Therefore,
this calculation was conservative, in that deviations from this assumption increase the power to assess
FCM-miniR being not more than 10% worse in terms of response rate than FCR.
To account for a 5% dropout, 206 participants (103 per arm) were sought to be randomised. This approach
used a one-sided 97.5% confidence interval (CI), that is, an α (type I) error rate of 2.5%, equivalent to a
conventional α of 5% for the superiority setting.31
Statistical analysis
A full statistical analysis plan was written and signed off in accordance with current CTRU standard
operating procedures.
Analysis populations
All analyses were conducted on the intention-to-treat (ITT) population, in which participants were included
according to the treatment they were randomised to.
For the outcome measures assessing response, participants without an available response assessment, who
had not withdrawn for toxicity or died, were excluded from the denominators. This was felt to be appropriate
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as it was strongly assumed that response end point data would be missing completely at random, given
that participants were unlikely to refuse to have assessments performed owing to their level of response
or treatment allocation. Assessments were more likely to be unavailable as a result of samples being
un-assessable or missed in error. Reasons for missing response data were monitored and have been
summarised (see Table 24).
A per-protocol (PP) analysis was planned for the primary end point assessment in addition to the ITT,
where only participants who received at least one cycle of treatment in line with the protocol, who were
not major eligibility violators and for whom primary end point data were available are included. For the
primary analysis, equal weighting is given to both the ITT analysis and the PP analyses, as the ITT analysis is
likely to be the least conservative approach when assessing non-inferiority.
Safety end points were assessed based on the safety population, which included participants according to
the treatment they actually received and who had been exposed to at least one dose of the study treatment.
Missing data handling
In the evaluation of response for the primary end point, the analysis was based on the centrally reviewed
data at 3 months post treatment. Participants without an assessment of response were treated as
non-responders in the ITT and PP analyses if they either:
1. died from CLL or protocol treatment prior to the 3-month post-treatment assessment or
2. discontinued treatment early owing to non-response or toxicity.
Trephine data are required to confirm a CR in participants who are known to be at least a PR. For
participants with at least a PR but with missing trephine data, the following rules, defined in advance
within the Statistical Analysis Plan, were applied:
1. For participants assessed as at least a PR with no evidence that were not CR/CRi:
i. MRD-negative participants were reported as ‘CR/CRi’
ii. MRD-positive participants were reported as ‘PR’
iii. Participants with missing MRD status were excluded from the analysis.
2. Participants assessed as PR with evidence that they were not a CR or CRi by the IWCLL criteria, or
participants with stable/progressive disease (PD), were treated as non-responders in the analysis.
Evaluation of MRD was based on an assessment of the bone marrow, performed centrally at the
Haematological Malignancy Diagnostic Service (HMDS), St James’s University Hospital, Leeds, at 3 months
post treatment. For participants with a missing MRD assessment, the next available observation based on
the peripheral blood was carried backwards and imputed in place of the missing 3-month observation.
This was considered to be a conservative approach as participants are not expected to improve over time
without treatment.
Frequency of analyses
Interim reports presenting recruitment, demographic, safety and toxicity data along with treatment and
protocol compliance were presented by treatment arm to the DMEC in strict confidence at approximately
yearly intervals. In addition to the full annual reports, safety data were presented to the DMEC on a
6-monthly basis. The DMEC reported its recommendations regarding the continuation of the trial to the TSC.
A single formal interim analysis was planned on the short-term efficacy data when half the number of
participants (103) had reached their primary end point; this was reported to the DMEC in September 2012.
A separate formal analysis plan was written for the interim analysis and signed off before the final data
download. The results and outcome of the meeting are reported below (see Interim analysis).
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Final analyses were carried out on all but the survival end points when the response data became available
for all participants, approximately 9 months after the close of recruitment. The survival end points were
analysed 2 years after the close of recruitment and will be updated as appropriate.
Interim analysis
The interim analysis was carried out at a stringent alpha level in order to retain an overall 5% level
(two-sided) for the final analysis. The O’Brien and Fleming32 alpha spending function was used to adjust
for multiple testing, requiring an alpha level of 0.005 (two-sided) for the interim analysis, and an alpha
level of 0.048 (two-sided) for the final analysis.
Primary end point analysis
An overall one-sided 2.4% significance level was used for the final primary response analysis.
The proportion of participants who achieved at least a CR are summarised by treatment group, and the lower
limit of the 95.2% CI (one-sided type I error rate of 2.4%) for the difference in the proportions of participants
achieving a CR between the treatment groups reported. This was obtained using one-sided binary logistic
regression to adjust for the minimisation factors: Binet stage, sex and age, but excluding centre. The
treatment estimate is presented along with the odds ratio (OR) and 95.2%Wald CI around the OR estimate.
In order to determine whether FCM-miniR was non-inferior to FCR, defined as FCM-miniR being no more
than 10% worse in terms of response rates, the lower limit of the CI for the treatment effect is compared
with the non-inferiority margin of 10%, expressed as an OR using the following formula:
OR=
π2(1− π1)
π1(1− π2)
(1)
where π1 = the proportion of responders in the FCR arm and π2 = proportion of responders in the FCR arm
minus 10%.
For the primary end point analysis, the ITT and PP populations are of joint primacy. In the event that the
analyses do not concur (i.e. one demonstrates non-inferiority and the other does not), non-inferiority
cannot be concluded.
Sensitivity analyses assess the robustness of results of the primary analysis, and the assumptions regarding
missing data:
1. treating all participants will miss primary end point data as non-responders
2. treating all participants will miss primary end point data as responders
3. excluding all participants will miss trephine data from the analysis.
Secondary end point analyses
A two-sided 5% significance level was used for all secondary superiority efficacy end point comparisons.
The proportion of participants with undetectable MRD following treatment, and the proportion of
participants who achieved an OR of at least a PR by IWCLL criteria following treatment, are each
summarised by treatment group. The differences in the proportions and exact 95% CIs are reported.
Binary logistic regression is used to provide treatment estimates with corresponding standard errors (SEs)
and p-values, along with ORs and 95% CIs around the OR estimates, after adjusting for the minimisation
factors, excluding centre.
Cox regression analysis is used to analyse time to MRD relapse, progression and death, both overall and
between treatment arms, accounting for the minimisation factors, excluding centre. Treatment and
covariate estimates, SEs, hazard ratios (HRs) and corresponding 95% CIs and p-values are presented for all
variables incorporated in the models. Median PFS, OS and time to MRD relapse and corresponding
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95% CIs are also presented per treatment arm and overall. The proportional hazards assumption is
assessed by plotting the hazards over time (i.e. the log-cumulative hazard plot) for each treatment arm,
after adjusting for the minimisation factors. In addition, MRD relapse, PFS and OS curves are calculated
using the Kaplan–Meier method.
Safety analyses summarise the number of AEs, SAEs and SUSARs occurring after randomisation. Safety data are
presented by treatment group using the safety population. Summaries of the total numbers of SAEs/SUSARs
reported and numbers of participants experiencing each event are presented, along with details of the
suspected relationship with trial medication or other causality, duration of recovered SAEs/SUSARs, seriousness
criteria, event outcome and Medical Dictionary for Regulatory Activities (MedDRA) body system coding. The
number and causes of deaths occurring from randomisation until 3 months post treatment are summarised,
and the proportion of participants with each cause of death is calculated. No statistical testing is performed
between the two groups.
Subgroup analyses
Exploratory subgroup summaries are presented to assess the heterogeneity of the treatment effect among
the following subgroups of interest for the primary end point and, where relevant, PFS and OS:
l sex (male, female)
l age group (≤ 65 years, > 65 years)
l Binet stage (A progressive or B, C)
l creatinine clearance levels (30–60 ml/minute, > 60 ml/minute)
l β2-microglobulin (β2M) concentration (< 4 mg/l, ≥ 4 mg/l)
l number of cycles of treatment received (three or fewer, more than three)
l GCSF received (yes, no)
l 17p deletion (yes, no)
l 11q deletion (yes, no)
l heavy-chain variable-region (VH) mutation risk (poor risk, standard risk).
In addition, PFS and OS are analysed by IWCLL response and MRD response to treatment, both alone and
by treatment arm.
The analyses carried out use the same populations as for the main analyses on the primary and secondary
end points. Analyses on the PP population were considered unnecessary owing to the similarity with the
ITT population. Subgroup analyses may, by chance, generate false-negative or false-positive results and
must be interpreted with caution and treated as hypothesis generating.
Economic evaluation
An economic evaluation was conducted to assess the cost-effectiveness of FCM-miniR compared with FCR
from a UK NHS and Personal Social Services (PSS) perspective. The evaluation consists of two components: a
within-trial analysis, in which cost-effectiveness is assessed within the 24-month trial period using individual
participant data collected in the trial, and a decision analytic model analysis, in which cost-effectiveness is
assessed over a lifetime horizon using standard modelling techniques applied to the trial data in order to
extrapolate the trial results.
Measurement of outcomes
The economic analysis used QALYs to measure health benefit. Health-related quality of life was estimated
using responses to health economics participant questionnaires, which included the EQ-5D.28 QALYs
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represent a quality-weighted survival value in which one QALY is equivalent to 1 year of full health.
All participants were asked to complete these questionnaires at the following time points:
l baseline
l after three cycles of therapy
l at the end of therapy
l 3 months after the end of therapy
l every 3 months after the end of therapy until 24 months post randomisation (i.e. at 6, 9, 12, 18 and
24 months post randomisation).
Standard UK tariff values were applied to these responses at each time point to obtain participant utility
values for the within-trial period. QALYs were calculated using the ‘area under the curve’ method and
formed the primary outcome measure of the cost-effectiveness study. As NICE currently recommends the
use of EQ-5D derived utilities in its reference case, EQ-5D utilities were used in all base-case analyses;
sensitivity analysis using SF-12 (converted to SF6D) utilities was also conducted.27
Measurement of costs
Participant-reported data on resource usage were collected in the trial using the health economics
participant questionnaires at similar time points as the health outcomes, except at baseline. For the
3-month follow-up data, the recall period was 3 months (i.e. participants were asked to provide
information on their use of health-care resources over the previous 3-month period). For all other cases,
the recall period was either since entering the study or since the last questionnaire was completed. The
questionnaires included the number and length of hospital inpatient stays, the number of outpatient visits,
and the number of primary/community care visits. Participants were also asked to report on the use of PSS
related to their treatment (such as the number of visits of carers and social workers).
Costs were estimated by combining participant-reported resource usage with unit cost data obtained from
national databases such as the Personal Social Services Research Unit (PSSRU) Costs of Health and Social
Care and British National Formulary (BNF).33,34
The analyses took the perspective of the NHS including the costs of health and social care. All costs are
reported in 2013 GBP (£) and future costs were discounted at an annual rate of 3.5%, as per the NICE
Methods Guide.27
Missing data
Missing data for participant-reported health-related quality of life were dealt with by using the multiple
imputation method.35,36 This method assumes that data are missing at random; missing data values are
replaced with plausible substitutes based on the distribution of observed data, with uncertainty around the
observed data values incorporated using iterative multivariable regression techniques. A set of baseline
variables and cost data from that time point were used to impute missing health outcomes data. This
approach is recommended for economic analyses alongside clinical trials as it reflects the uncertainty inherent
in missing data.37
Within-trial analysis
Main characteristics of the analysis
The within-trial analysis aimed to determine the cost-effectiveness of FCM-miniR compared with FCR over
the 24-month trial period. Individual participant data collected in the trial were used to determine the
cost and QALYs associated with each treatment arm. QALYs were derived using participant EQ-5D
questionnaire responses, and cost-effectiveness is assessed as the incremental cost per incremental QALY.
Following the trial interim analysis, carried out on the first half of participants randomised to the trial
(n = 103), 21 participants randomised to FCM-miniR transferred over to treatment with FCR. The difference
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in the CR rates at the interim analysis between the treatment arms, although not statistically significant,
was deemed by the DMEC to be clinically relevant in favour of the control group. In light of this, and
evidence of additional toxicity in the FCM-miniR arm, the trial was closed early at the recommendation of
the DMEC and all participants still receiving FCM-miniR were recommended to transfer to treatment with
FCR for the remainder of their treatment cycles. The economic evaluation base-case analysis was therefore
conducted using the trial sample with these 21 participants removed, as the treatment transfer occurred as
a result of the planned interim analysis rather than as a result of an independent participant or clinician
decision, which does not meet the definition of ITT. Sensitivity analyses were conducted to assess the
impact of removing these participants.
As the analysis spans more than 1 year, future costs and health outcomes (beyond one year) were
discounted at an annual rate of 3.5% as per the NICE Methods Guide.27 Cost-effectiveness is measured in
terms of the incremental cost-effectiveness ratio (ICER), which is calculated by dividing the mean difference
in cost between the two arms by the mean difference in QALYs between the two arms, as follows:
ICER=
(Mean CostFCM−miniR −Mean CostFCR)
(Mean QALYFCM−miniR −Mean QALYFCR)
=
ΔC
ΔE
< λ
(2)
where ΔC is the incremental cost of FCM-miniR and ΔE is the incremental health benefit of FCM-miniR
and λ is the societal willingness to pay (WTP) for one QALY. The ICER represents the additional cost per
one unit of outcome gained. This indicates the trade-off between total cost and effectiveness when
choosing between FCM-miniR and FCR therapies. When compared against the marginal trade-off for the
NHS as a whole – the cost-effectiveness threshold – this gives an indication of whether spending money
on FCM-miniR is an efficient use of resources. As a guideline rule, we used the NICE implicit WTP
threshold of £20,000–30,000 per QALY to determine cost-effectiveness. In general, a new intervention is
considered cost-effective so long as its ICER is within or below the £20,000–30,000 per QALY range.
Uncertainty
Non-parametric bootstrapping was used to determine the level of sampling uncertainty around the ICER by
generating 10,000 estimates of incremental costs and benefits from the trial results. The bootstrap approach
is a non-parametric method that considers the original sample as though it were the population and draws
multiple random samples from the original sample. Results are presented using cost-effectiveness scatterplots
to illustrate the uncertainty surrounding the cost-effectiveness estimates. On the cost-effectiveness plane
(which plots incremental QALYs against incremental costs), a result is considered cost-effective if it falls on or
below the given cost-effectiveness threshold. The cost-effectiveness acceptability curve (CEAC) is derived by
calculating the proportion of bootstrapped estimates which are cost-effective across a range of WTP
thresholds, to show the probability that FCM-miniR is cost-effective across different threshold values.37
The CEACs were constructed using the net benefit approach. The net monetary benefit (NB) is a simple
rearrangement of the ICER decision formula as shown:
ICER =
ΔC
ΔE
< λ
NB = λ  ΔE −ΔC
(3)
where ΔC is the incremental cost of the treatment strategy, ΔE is the incremental benefit of the treatment
strategy, and λ is the societal WTP per QALY threshold. Across any number of alternative interventions,
the intervention with the highest NB is considered cost-effective [i.e. an intervention is cost-effective if the
incremental net monetary benefit (INB) is positive].27 Using the NB statistic, the cost-effectiveness of each
of the bootstrap estimates can be determined in order to derive the overall probability of cost-effectiveness
for the CEAC.
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Mean INBs between the two arms were reported with 95% bootstrap CIs calculated using the
bias-corrected method.38
Sensitivity analysis
To investigate the appropriateness of the EQ-5D as the principal outcome measure, a sensitivity analysis
using SF-6D utility values derived from the SF-12 trial data was conducted.
In addition, to assess the potential impact of participant crossover in the trial, two additional sensitivity
analyses were conducted:
1. An ITT analysis was conducted, in which any transfer of participants between arms was ignored and
participants who crossed over from FCM-miniR to FCR were retained in the analysis of the
FCM-miniR arm.
2. Participants who were transferred are deemed to have been in the FCR treatment arm from randomisation.
Decision economic model analysis
Decision analytical modelling was used to compare FCR and FCM-miniR therapies over a lifetime horizon.
A discrete-time state-transition (modified-Markov) model was developed to estimate the long-term
cost-effectiveness of treating participants with CLL with FCM-miniR compared with the standard treatment
of FCR. In line with the within-trial economic evaluation, the model analysis adopts a UK NHS and PSS
perspective and future costs and QALYs were discounted at an annual rate of 3.5% in line with NICE
guidance.27 The model was built in Microsoft Excel version 2010 (Microsoft Corporation, Redmond, WA, USA).
Model structure and parameters
The model structure is presented in Figure 1. The model included three possible health states: PFS, PD
and death.
Markov models describe patient progression over time through a pathway of health states, with movement
between the health states being triggered by events such as disease progression or death. Resource use
and costs are associated with each health state and patients accumulate costs and health benefits in each
state over 3-monthly cycles. As 2-year individual patient cost and utility data were available from the trial
data, the model runs from the end of the trial in order to estimate long-term costs and health benefits.
The lifetime cost and QALY results are calculated as the sum of the trial 2-year results and the model
lifetime estimates (truncated at age 100 years).
The model inputs were derived using information from a range of sources. Where possible, data from the trial
were used directly, and published literature was used to inform remaining parameters. Where published
literature was required, focused non-systematic reviews were conducted to identify potential sources of
information. Appropriate distributions were applied using observed or published variance data; where no such
data were available, the standard deviation was assumed to be equal to the mean. As for the within-trial
analysis, the model base-case analysis excludes participants who crossed over from the FCM-miniR arm to the
FCR arm; a sensitivity analysis was conducted to assess the impact of this. The proportion of participants
Progression-free
Progressed disease
Death
FIGURE 1 Three-state Markov model.
DOI: 10.3310/hta21280 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 28
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Howard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
beginning in each health state in the model was derived directly from the proportion of participants in the
trial who remained progression-free and mortality-free at the last follow-up (24 months). Derivation of
the post-24-month rate of transition between the progression-free state and progressed disease state required
significant extrapolation beyond the relatively short follow-up period of the trial, which contained low
numbers of progression events upon which to base the extrapolation. Owing to the short follow-up of the
trial, the usual practice of fitting survival curves to the trial data in order to extrapolate results over time is
likely to produce highly uncertain, and most likely implausible, results. An alternative approach was therefore
adopted that involved fitting a parametric survival model using the Remission Duration Model (RDM) model.
The RDM model is based on a plausible biological rationale for the mechanism of disease progression.39
The model was fitted, using maximum likelihood estimation, to the control arm of the CLL8 trial conducted
in Germany which represents a comparable patient population treated with a comparable FCR regimen.4,40
The fitted model parameters were then calibrated to the PFS curve from the FCR arm of ARCTIC (Figure 2).
As chemotherapy is expected to exert its effect on PFS only during the treatment period, which was
captured within the trial follow-up period, the progression-free event rate beyond 2 years (i.e. in the
model) was assumed to be the same between arms. In a sensitivity analysis, the transition rate for
FCM-miniR was derived by applying the HR observed in the trial period to the FCR survival curve over
various durations to allow for the possibility of a carry-over effect.
Adverse events (AEs) relating to each of the treatment strategies were assumed to occur only within the
trial follow-up period (2 years post randomisation to treatment). The cost of AEs has therefore been
captured in the within-trial analysis period (in which AEs were costed separately for each arm based on the
trial individual patient data) and has not been included within the model follow-up period.
The probability of dying from the PF state was assumed to be equivalent to the general population
age- and sex-specific mortality. The probability of dying from the PD state was derived from the literature
and assumed to be identical between arms.
Death was assumed to be associated with zero utility and zero cost. For the PF health state, the associated
3-month cost and utility values were derived directly from the trial second-year data, using available data
on participants prior to disease progression. Cost and utility values were calculated using second-year data
only in order to avoid using data from participants’ primary treatment period, which would bias the results.
For the PD state, a combination of a lack of progression events and lack of completed questionnaires at
the time of progression in the trial meant that cost and utility estimates for this health state had to be
derived from the literature. For the cost of the PD, the 3-month health state cost was taken from a
previously conducted cost–utility analysis which looked at the cost-effectiveness of bendamustine (Levact,
2
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)
FIGURE 2 Progression-free survival in the FCR arm.
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Napp Pharmaceuticals) versus chlorambucil (Leukeven, Aspen) for the first line treatment of CLL in England
and Wales. Woods et al. derived resource use for CLL health states (including PD) from an advisory board
conducted in January 2010, which consisted of five haematologists who worked in the UK NHS and were
experienced in treating CLL. The reported 3-month progressed disease state cost was £1924, based on
2009 NHS reference costs; this cost was inflated to a 2013 price for use in the current model.41 For the PD
state utility, a decrement was applied to the PF state, using data from Beusterien et al.42 This was a
cross-sectional study in which 89 members of the general population in the UK (England and Scotland)
were asked to value health states describing CLL response status using standard gamble methodology.42
A full list of model parameters and distributions applied in the model is given in Table 3.
TABLE 3 Model input parameters
Model parameter Mean Distribution SE Source
Global
parameters
Annual discount rate 0.035 Fixed – NICE27
Start age, years 62.38 Fixed – ARCTIC trial data
Proportion male, % 0.66 Fixed –
Starting
distribution
PF (FCR) 0.894 Dirichlet 0.03 ARCTIC trial distribution
at 24-month follow-up
PD (FCR) 0.064 Dirichlet 0.04
Dead (FCR) 0.042 Dirichlet 0.02
PF (FCM-miniR) 0.791 Dirichlet 0.05
PD (FCM-miniR) 0.094 Dirichlet 0.06
Dead (FCM-miniR) 0.115 Dirichlet 0.04
Health state
costs
(3 months), £
PF 268 Gamma 43 ARCTIC trial data
PD 2146 Gamma 2146 Woods et al., 201241
Dead 0.00 Fixed – –
Health state
utilities
(3 months)
PF (EQ-5D) 0.82 Beta 0.01 ARCTIC trial data
PF (SF-6D) 0.70 Beta 0.03
PD utility decrement applied
to PF state value
–0.16 Log-normal 0.02a Beusterien et al., 201042
Dead 0.00 Fixed – –
Transition
probabilities/
effects
(3 months)
Risk of progression (PF to PD)
in FCR arm
Varies (drawn from
survival curve figure)
Fixed – Survival analysis of
ARCTIC within-trial data
(see Figure 2)
Risk of progression (PF to PD)
in FCM-miniR arm
Varies (drawn from
survival curve figure)
Fixed –
Mortality in PF state Varies (age- and
sex-dependent)
Fixed – Office for National
Statistics, 2013 age-
and sex-standardised
rates43
Mortality in PD state 0.14 Beta 0.03 Wierda et al., 201044
Log of HR for risk of
progression in FCM-miniR arm
vs. FCR arm (used in SA only)
0.33 Normal 0.30 ARCTIC trial data
a Standard deviation.
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Sensitivity analyses
Probabilistic sensitivity analyses were conducted to assess the impact of joint parameter uncertainty on the
results. Probabilistic analysis accounts for joint parameter uncertainty in non-linear models by assigning
probability distributions to each of the input parameters and randomly drawing from these probabilities
over 10,000 Monte Carlo model simulations to produce different cost and QALY estimates in each
simulation of the model. As for the bootstrap within-trial analysis, the results are presented on the
cost-effectiveness plane as a scatterplot, and using CEACs to show the probability that the two arms
are cost-effective across different WTP per additional QALY thresholds.
Deterministic sensitivity analysis was used to assess the impact of individual parameter uncertainty on the
results. Parameters were independently varied between upper and lower bands of plausible values, based
on increasing and decreasing each parameter by 25% of its initial value.
Three additional sensitivity analyses were conducted to assess the impact of key model assumptions:
1. SF-6D utilities. The base-case analysis was conducted using utilities derived from participant responses
to the EQ-5D questionnaire (which NICE recommends). A sensitivity analysis was conducted using
utilities derived from participant responses to the SF-12 questionnaire. For a discussion on the relative
merits of SF-12 versus EQ-5D please see Chapter 5, Economic evaluation discussion.
2. Intention to treat analysis. In the base-case analysis participants who crossed over from FCM-miniR to
FCR as a result of the trial interim analysis were excluded from the cost-effectiveness analysis. A
sensitivity analysis was conducted in which these participants were instead retained in the analysis of
the FCM-miniR arm.
3. Treatment effect. As chemotherapy is expected to exert its effect on PFS only during the treatment period,
which was captured within the trial follow-up period, the progression-free event rate beyond 2 years was
assumed to be the same between arms in the base case. In a sensitivity analysis, the transition rate for
FCM-miniR was derived by applying the HR observed in the trial to the FCR survival curve over various
durations to allow for the possibility of a carry-over effect; in addition to the base-case analysis, in which a
differential rate of progression occurs in the initial 2-year trial period only, analyses were conducted
extending the observed HR over 3, 5, 10 years and a lifetime horizon in the FCM-miniR arm.
Value of information analysis
Any model is subject to uncertainty around model parameters and assumptions, which may result in a
wrong decision being made based on the model results. If an incorrect decision is made, there will be
consequences in terms of health benefit and resources lost. The maximum amount the NHS should be
willing to invest to reduce uncertainty in the decision can be informed by the expected value of perfect
information (EVPI).45 The EVPI evaluates the expected opportunity cost of current uncertainty by assessing
the probability that a decision based on current information is wrong, multiplied by the costs of making a
wrong decision. It is calculated by applying non-parametric methods to the output from the Monte Carlo
simulation of the model.46 It is the difference between the expected value (E) of the decision made with
perfect information across j interventions and θ parameters, Eθ maxj NB(j,θ), and the expected value of the
decision made on the basis of existing evidence, maxj EθNB(j,θ):
EVPI= Eθ max jNB( j,θ)−max jEθNB( j,θ) (4)
Additional research should be considered only if the EVPI exceeds the expected cost of research. The EVPI
therefore provides an upper limit on the amount that the NHS should be willing to spend on further
research in order to resolve current uncertainties.
The value of future research can be further explored using the expected value of perfect parameter
information (EVPPI). The EVPPI is a calculation of the maximum value attributable to specific components
(parameters) of the evidence base. The EVPPI is calculated as the difference between the expected value of
the decision made with perfect information for a particular parameter or set of parameters, ϕ, across the
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remaining uncertain parameters, ψ, and the expected value of the decision made on the basis of
existing evidence:
EVPPIϕ = Eϕmax jEϕ=ψNB( j,ϕ, ψ )−max jEθNB( j, θ) (5)
The EVPPI represents the maximum cost the NHS should be willing to spend on further research to resolve
uncertainty for the given parameter or set of parameters evaluated. It is useful for isolating which specific
parameters of the decision model are fuelling the overall EVPI, and thereby indicates in what direction
future research should be focused.
The formulae above give the per-person EVPI and EVPPI values. To generate population value of information
statistics, the per-person estimates must be multiplied by the population expected to be affected by the
new treatment. This value is derived from the annual incidence of disease multiplied by the number of years
the treatment decision is expected to be relevant. Based on cancer research statistics, the annual incidence
of CLL across England and Wales is expected to be 2943.47 In the absence of quantitative data it was
assumed that the period over which the current decision problem will be relevant (i.e. the effective lifetime
over which the new treatment will be used) was 10 years. An annual discount factor of 3.5% was applied
to the population estimate.
Summary of changes to the protocol
From the time of initial ethical approval (25 June 2009), four substantial amendments to the protocol were
submitted to and subsequently approved by the REC.
Amendment 1, dated 5 November 2009 and approved 26 November 2009, included the following key changes:
l introduction of a participant diary card to collect compliance with oral treatments
l addition of a health economics participant questionnaire
l clarification regarding data collection and storage in the participant information sheet.
Amendment 2, dated 21 February 2011 and approved 17 March 2011, included the following
key changes:
l amending inclusion criteria to allow participants with SLL to enter the trial
l allowing two schedules for splitting the dose of rituximab
l stipulating the re-escalation of chemotherapy after dose reductions
l making the 6-month post-treatment blood sample compulsory for all participants
l adding information to include participant name on all samples sent to HMDS.
Amendment 3, dated 15 July 2011 and approved 29 July 2011, included the following key changes:
l correcting an error in one of the rituximab dose-splitting schedules.
Amendment 4, dated 1 October 2012 and approved 13 November 2012, included the following
key changes:
l noting the early trial closure
l updating the end of trial definition
l providing clarifications to the pharmacovigilance reporting and review requirements.
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Chapter 3 Statistical trial results
Sections of this chapter have been reproduced from Howard et al.1 with permission.
Recruitment
Between December 2009 and September 2012, 200 of a planned 206 patients were recruited into the
ARCTIC trial (Figure 3), with 100 participants randomly allocated to the FCR control arm and 100 to
the FCM-miniR intervention arm. Written informed consent was received from all participants.
Thirty-eight centres across the UK received local ethical and management approval for the trial and had
permission to randomise patients, of which 34 centres were recruited into the trial. Table 4 summarises
recruitment per centre and by allocated treatment arm. The top five recruiting centres were the Oxford Cancer
and Haematology Centre (n = 25), Birmingham Heartlands Hospital (n = 16), St James’s University Hospital
(Leeds) (n = 15), Southampton General Hospital (n = 13) and Castle Hill Hospital (Hull) (n = 12).
Early closure to recruitment
The ARCTIC trial closed early to recruitment in September 2012 owing to an urgent safety measure, on
advice from the DMEC and the TSC. This decision was made following the planned interim analysis of the
short-term efficacy data for the first half of participants randomised to the trial (n = 103).
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FIGURE 3 Cumulative and monthly recruitment.
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TABLE 4 Recruitment per centre and by allocated treatment arm
Randomising centre
FCR (n= 100) FCM-miniR (n= 100) Total (n= 200)
n (%) n (%) n (%)
Arrowe Park Hospital, Upton 0 (0.0) 1 (1.0) 1 (0.5)
Birmingham Heartlands Hospital, Birmingham 8 (8.0) 8 (8.0) 16 (8.0)
Borders General Hospital, Melrose 3 (3.0) 3 (3.0) 6 (3.0)
Buckinghamshire Hospitals NHS Trust,
Wycombe and Stoke Mandeville
6 (6.0) 5 (5.0) 11 (5.5)
Castle Hill Hospital, Hull 6 (6.0) 6 (6.0) 12 (6.0)
Christie Hospital, Manchester 1 (1.0) 0 (0.0) 1 (0.5)
Colchester General Hospital, Colchester 2 (2.0) 1 (1.0) 3 (1.5)
Epsom St Helier University Hospital NHS Trust,
Epsom and Carshalton
1 (1.0) 0 (0.0) 1 (0.5)
Glan Clwyd Hospital, Rhyl 4 (4.0) 4 (4.0) 8 (4.0)
Good Hope Hospital, Birmingham 6 (6.0) 5 (5.0) 11 (5.5)
Great Western Hospital, Swindon 2 (2.0) 2 (2.0) 4 (2.0)
Harrogate District Hospital, Harrogate 1 (1.0) 1 (1.0) 2 (1.0)
King’s College Hospital, London 0 (0.0) 2 (2.0) 2 (1.0)
Manchester Royal Infirmary, Manchester 2 (2.0) 3 (3.0) 5 (2.5)
Northwick Park Hospital, London 0 (0.0) 2 (2.0) 2 (1.0)
Oxford Cancer and Haematology Centre, Oxford 12 (12.0) 13 (13.0) 25 (12.5)
Pinderfields Hospital, Wakefield 3 (3.0) 5 (5.0) 8 (4.0)
Princess Royal University Hospital, London 2 (2.0) 0 (0.0) 2 (1.0)
Queen Elizabeth Hospital, Birmingham 1 (1.0) 1 (1.0) 2 (1.0)
Queen Elizabeth Hospital, Gateshead 2 (2.0) 3 (3.0) 5 (2.5)
Queen Elizabeth Hospital, Woolwich 2 (2.0) 0 (0.0) 2 (1.0)
Royal Blackburn Hospital, Blackburn 2 (2.0) 4 (4.0) 6 (3.0)
Royal Liverpool University Hospital, Liverpool 2 (2.0) 2 (2.0) 4 (2.0)
Royal Marsden Hospital, London 1 (1.0) 0 (0.0) 1 (0.5)
Royal United Hospital, Bath 2 (2.0) 3 (3.0) 5 (2.5)
Russells Hall Hospital, Dudley 2 (2.0) 0 (0.0) 2 (1.0)
St Batholomew’s Hospital, London 0 (0.0) 1 (1.0) 1 (0.5)
St James’s University Hospital, Leeds 8 (8.0) 7 (7.0) 15 (7.5)
Southampton General Hospital, Southampton 6 (6.0) 7 (7.0) 13 (6.5)
Southmead Hospital, Bristol 3 (3.0) 0 (0.0) 3 (1.5)
Sunderland Royal Hospital, Sunderland 3 (3.0) 3 (3.0) 6 (3.0)
University Hospital of North Tees, Stockton-on-Tees 1 (1.0) 1 (1.0) 2 (1.0)
Western General Hospital, Edinburgh 3 (3.0) 3 (3.0) 6 (3.0)
Ysbyty Gwynedd Hospital, Bangor 3 (3.0) 4 (4.0) 7 (3.5)
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The unblinded CR and ORRs (based on an independent assessment of response following the IWCLL criteria26)
were presented along with baseline demographic, treatment compliance, MRD eradication and safety and
toxicity data. The data presented showed higher CR rates in the control arm (FCR) than were expected, and the
difference in the CR rates between the treatment arms, although not statistically significant, was deemed by
the DMEC to be clinically significant in favour of FCR over FCM-miniR. In addition, there appeared to be an
increased toxicity rate and increased number of dose omissions and reductions in the FCM-miniR arm.
A detailed summary of the interim analysis results is presented in Statistical trial results.
Interim analysis recommendations
The primary aim of this Phase IIB trial was to determine whether FCM-miniR should continue to be
investigated in a Phase III trial. Given the strength and robustness of the interim data, the DMEC felt that
continuing this trial was futile, as it was highly unlikely that the data would warrant continued
investigation of the experimental treatment. As such, they recommended that recruitment into the trial
should stop with immediate effect, and these recommendations were ratified by the TSC. It was agreed
that the local site investigators should be informed of the findings of the interim analysis as soon as
possible. All participants receiving FCM-miniR were recommended to transfer to treatment with FCR for
the remainder of their treatment cycles, although this was not mandated. The decision was to be made by
the participant following detailed discussions with their clinician. It was also agreed that participants
should continue to be followed up as per the protocol.
At the time of trial closure, 200 participants had been recruited. Twenty-one out of the 23 participants still
receiving FCM-miniR at the time of trial closure chose to transfer over to receive treatment with FCR on
discussion with their treating clinician. Where appropriate, the results will categorise participants into three
treatment categories: FCR, FCM-miniR and FCM-miniR/FCR for the patients randomised to FCM-miniR who
were recommended to transfer. It is not appropriate to include the participants who transferred to FCR in
either of the other categories according to the ITT analysis, because the decision to stop FCM-miniR was
on recommendation from the DMEC, rather than a decision from the treating clinician or participant,
which violates the ITT assumption.
Participant flow
Figure 4 presents the Consolidated Standards of Reporting Trials (CONSORT) diagram of participant flow
through the trial. In total, 548 patients were reported as having been assessed for eligibility and, of these,
200 (36.5%) provided written informed consent and were randomised into the trial. Of the 348 patients
who were reported as having been assessed for the trial but who were not randomised, 177 of these were
from a single centre which used a very broad screening process which was inconsistent with other centres.
The majority of patients were excluded owing to being clinically ineligible (n = 228, 65.5%). Again, this
is biased towards the single centre which assessed 172 of these patients as being ineligible as they did not
meet key eligibility criteria such as having had no prior therapy for CLL. If this centre is excluded from
the screening data, a total of 371 patients were reported as having been assessed for eligibility with
56 (15.1%) being excluded owing to clinical ineligibility. A total of 100 participants were randomised to
the FCR control arm and 100 to the FCM-miniR intervention arm.
In the FCR arm, all but two participants received their allocated treatment (n = 98, 98.0%). One participant
was ineligible (owing to prior therapy for CLL) and went on to receive FCR off trial. The other participant
withdrew from the trial on the advice of the treating clinician as they had a 17p deletion and were treated
with a more ‘appropriate regime’ off trial. In the FCM-miniR arm, 79 participants (79.0%) received their
allocated intervention throughout the trial, with 21 participants transferring over to receive treatment with
FCR as a result of the interim analysis, two from their first cycle of treatment.
A total of nine participants (4.5%) withdrew their consent for the trial (five in the FCR arm and four in the
FCM-miniR arm). Table 5 summarises the number of participants who withdrew consent from the trial,
the type of withdrawal and reason for withdrawal. Two participants withdrew their consent for further trial
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Analysis populations
ITT (n = 92)
• Excluded from ITT analysis, n = 8
   • Missing primary end point data, n = 8
PP (n = 91)
• Excluded from PP analysis, n = 9 
   • Missing primary end point data, n = 8a
   • Breach of eligibility criteria (prior therapy for
      CLL) and did not receive any FCR, n = 1
   • Did not receive any FCR, n = 1a
Safety population (n = 100) 
• Excludes two FCR participants who failed to receive
   any treatment
• Includes two FCM-miniR participants who received
   FCR from cycle 1
Analysis populations
ITT (n = 75) 
• Excluded from ITT analysis, n = 25 
   • Missing primary end point data, n = 5b
   • Received FCR, n = 21b
PP (n = 75) 
• Excluded from PP analysis, n = 25 
   • Missing primary end point data, n = 5b
   • Received FCR, n = 21b
Safety population (n = 98) 
• FCM-miniR, n = 79
• FCM-miniR/FCR, n = 19
Assessed for eligibility (n = 548)
Excluded (n = 348) 
• Patient clinically ineligible, n = 228
• Patient did not wish to participate, n = 39
• Patient too ill to participate, n = 4
• Other reason, n = 77
Withdrawn consent from trial (n = 5) 
• From trial treatment only, n = 1
• From trial treatment and follow-up data 
   collection, n = 4
Post-randomisation ineligibility (n = 2) 
• Prior therapy for CLL, n = 1
• Active or prior hepatitis B or C, n = 1
Lost to follow-up: missing primary end point 
data (n = 8) 
• Missing trephine sample, n = 6
• Withdrew from follow-up data collection prior 
   to assessment of primary end point, n = 2
Allocated to FCR (n = 100) 
• Received FCR throughout the trial, n = 98
Did not receive any FCR (n = 2) 
• Clinical decision owing to 17p deletion, n = 1
• Breach of eligibility criteria, prior therapy 
   for CLL, n = 1
Withdrawn consent from trial (n = 4) 
• From trial treatment only, n = 1
• From trial treatment and follow-up data 
   collection, n = 2
• From follow-up data collection only, n = 1
Post-randomisation ineligibility (n = 0)
Lost to follow-up: missing primary end point 
data (n = 5) 
• Missing trephine sample, n = 4
• Unable to assess owing to insufficient clinical
   evaluations performed at 3-month post-treatment
   visit, n = 1
Allocated to FCM-miniR (n = 100) 
• Received FCM-miniR throughout the trial, n = 79
• Commenced FCM-miniR but transferred over to FCR
   as a result of the interim analysis, n = 19
Did not receive any FCM-miniR (n = 2) 
• Received FCR from cycle 1 as a result of the
   interim analysis, n = 2
Randomised (n = 200)
FIGURE 4 Consolidated Standards of Reporting Trials diagram. a, One participant did not receive any FCR and also
had missing primary end point data and is therefore recorded twice; and b, one participant received FCR and had
missing primary end point data and is therefore recorded twice. Reproduced from Howard et al.1 with permission.
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treatment only (one each in the FCR and FCM-miniR arms). Six participants withdrew their consent from
further trial treatment and follow-up data collection (four in the FCR arm and two in the FCM-miniR),
of which one ineligible participant in the FCR arm did not receive any trial treatment. Primary end point
data are available for the two FCM-miniR participants, but all participants in the FCR arm who withdrew
from follow-up did so prior to the assessment of the primary end point. One participant in the FCM-miniR
arm withdrew their consent for further follow-up data collection only after the assessment of the primary
end point, having received all six cycles of treatment.
Three participants in the FCM-miniR arm withdrew because they were unwilling to continue with trial treatment
as a result of either toxicity or being too unwell. In the FCR arm, one participant withdrew owing to non-
response to treatment, another participant felt that ‘Not enough information was given regarding neutropenic
sepsis’ and that their ‘GCSF injections were delayed due to the trial’ (categorised as ‘Other reason’ in Table 5).
The median time from randomisation to withdrawal was 2.0 months (range: 0.4–20.7 months) with a shorter
median time to withdrawal in the FCR arm (1.8 months) compared with the FCM-miniR arm (8.1 months).
Two participants in the FCR arm were found to be ineligible for the trial post randomisation. One participant
had received prior therapy for CLL; they received FCR off-trial and continued to be followed up as per the
protocol and therefore had available primary end point data within the definition of the ITT population,
although they were excluded from the PP population. The second participant had been previously infected with
hepatitis B; they continued on the trial under the approval of the Chief Investigator, with the justification that
the participant had ‘antibodies but no infection’ and, therefore, the eligibility deviation was felt to be minor.
They received all six cycles of treatment and were followed up for their primary end point.
TABLE 5 Participant withdrawals
Participant withdrawal details
FCR
(n= 100)
FCM-miniR
(n= 100)
Total
(n= 200)
Participant withdrawn, n (%) 5 (5.0) 4 (4.0) 9 (4.5)
Type of withdrawal, n (%)
Withdrawn from trial treatment only 1 (1.0) 1 (1.0) 2 (1.0)
Withdrawn from trial treatment and follow-up data collection 4 (4.0) 2 (2.0) 6 (3.0)
Withdrawn from follow-up data collection only 0 (0.0) 1 (1.0) 1 (0.5)
Reason for withdrawal
Unwilling to continue with treatment, owing to toxicity 0 (0.0) 2 (2.0) 2 (1.0)
Unwilling to continue with treatment, owing to being too unwell 0 (0.0) 1 (1.0) 1 (0.5)
Unwilling to continue with treatment 1 (1.0) 0 (0.0) 1 (0.5)
Unwilling to continue with visits 1 (1.0) 1 (1.0) 2 (1.0)
Non-response to treatment 1 (1.0) 0 (0.0) 1 (0.5)
Clinician decision 1 (1.0) 0 (0.0) 1 (0.5)
Other reason 1 (1.0) 0 (0.0) 1 (0.5)
Trial duration (months) from randomisation to withdrawal
Mean (SD) 2.2 (2.0) 9.6 (8.8) 5.4 (6.8)
Median (range) 1.8 (0.4–5.7) 8.1 (1.4–20.7) 2.0 (0.4–20.7)
N 5 4 9
SD, standard deviation.
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A total of 13 participants (6.5%) were lost to follow-up and were classed as participants with missing
primary end point data, with a similar proportion in each treatment arm (n = 8, 8.0% FCR; n = 5, 5.0%
FCM-miniR). Ten participants (six in the FCR arm and four in the FCM-miniR arm) had a missing trephine
sample at 3 months post treatment, which is required to confirm a CR. Four participants (one in the FCR
arm and three in the FCM-miniR arm) missed their 3-month post-treatment visit, and one FCM-miniR
participant failed to have sufficient clinical evaluations performed. Four participants in the FCR arm
withdrew from further follow-up prior to their assessment of response; however, two did so owing to
toxicity and non-response to treatment and were therefore included in the ITT analysis as non-responders.
For further information on the reasons for missing trephine samples, missed clinic visits, withdrawals and
how participants have been handled in the analysis, see Final analysis: primary end point.
Overall, 167 participants (83.5%) were included in the ITT analysis, with a higher proportion coming from
the FCR arm (n = 92, 92.0%) than the FCM-miniR arm (n = 75, 75.0%). Participants were excluded
from both trial arms owing to missing primary end point data (n = 13) and a further 21 participants were
excluded from the FCM-miniR arm as a result of receiving treatment with FCR following the closure of the
FCM-miniR arm. The PP population was similar to that of the ITT, with an additional participant excluded
from the FCR arm owing to breaching the eligibility criteria and not receiving any of their randomised
treatment. The participant who had previously been infected with hepatitis B was not excluded from the
PP population as this was not classed as a major protocol violation.
Baseline characteristics
Tables 6–10 summarise the baseline characteristics, including the minimisation factors, participant
characteristics, assessment of disease, clinical details and genetic markers for all randomised participants.
Overall, 62.5% (n = 125) of the trial population were aged 65 years or less, 67.5% (n = 135) were male
and 68.0% (n = 136) had Binet stage A progressive or B (Table 6). The median age of a trial participant was
63 years (range 36–80 years) and 20.0% (n = 40) were aged 70 years or more. Of the trial population,
97.0% (n = 194) were of white ethnicity (Table 7). The two treatment arms were well balanced for the
minimisation factors and participant characteristics.
Table 8 summarises the baseline assessments of disease. The median duration of disease was
approximately 2 years, with a range of less than 1 month to approximately 23 years. A total of 35.5%
of participants (n = 71) were Binet stage C, with a higher proportion in the FCR arm (n = 39, 39.0%) than
in the FCM-miniR arm (n = 32, 32.0%). These proportions are slightly different from those presented in
TABLE 6 Minimisation factors (all participants)
Minimisation factors FCR (n= 100) FCM-miniR (n= 100) Total (n= 200)
Age group (years), n (%)
≤ 65 63 (63.0) 62 (62.0) 125 (62.5)
> 65 37 (37.0) 38 (38.0) 75 (37.5)
Sex, n (%)
Male 68 (68.0) 67 (67.0) 135 (67.5)
Female 32 (32.0) 33 (33.0) 65 (32.5)
Binet stage, n (%)
A progressive or B 67 (67.0) 69 (69.0) 136 (68.0)
C 33 (33.0) 31 (31.0) 64 (32.0)
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TABLE 7 Baseline participant characteristics (all participants)
Participant characteristics FCR (n= 100) FCM-miniR (n= 100) Total (n= 200)
Age summaries, years
Mean (SD) 61.8 (8.3) 62.6 (8.3) 62.2 (8.3)
Median (range) 63 (41–77) 63 (36–80) 63 (36–80)
Age categories (years), n (%)
30–39 0 (0.0) 1 (1.0) 1 (0.5)
40–49 9 (9.0) 5 (5.0) 14 (7.0)
50–59 24 (24.0) 25 (25.0) 49 (24.5)
60–69 48 (48.0) 48 (48.0) 96 (48.0)
≥ 70 19 (19.0) 21 (21.0) 40 (20.0)
Ethnicity, n (%)
White 98 (98.0) 96 (96.0) 194 (97.0)
Mixed: white and black Caribbean 0 (0.0) 1 (1.0) 1 (0.5)
Asian: Indian 1 (1.0) 0 (0.0) 1 (0.5)
Black: Caribbean 0 (0.0) 1 (1.0) 1 (0.5)
Black: African 0 (0.0) 1 (1.0) 1 (0.5)
Other ethnic group 1 (1.0) 1 (1.0) 2 (1.0)
SD, standard deviation.
TABLE 8 Baseline assessment of disease (all participants)
Baseline assessment FCR (n= 100) FCM-miniR (n= 100) Total (n= 200)
Duration of CLL (years)
Mean (SD) 3.37 (3.60) 2.81 (3.32) 3.09 (3.46)
Median (range) 2.47 (0.01–22.74) 1.64 (0.03–17.88) 2.17 (0.01–22.74)
Binet criteria, n (%)
A progressive 20 (20.0) 14 (14.0) 34 (17.0)
B 41 (41.0) 54 (54.0) 95 (47.5)
C 39 (39.0) 32 (32.0) 71 (35.5)
B symptoms, n (%)
Yes 46 (46.0) 57 (57.0) 103 (51.5)
No 54 (54.0) 43 (43.0) 97 (48.5)
Signs of extranodal/extramedullary CLL, n (%)
Yes 11 (11.0) 14 (14.0) 25 (12.5)
No 88 (88.0) 85 (85.0) 173 (86.5)
Missing 1 (1.0) 1 (1.0) 2 (1.0)
WHO performance status, n (%)
0 55 (55.0) 61 (61.0) 116 (58.0)
1 40 (40.0) 37 (37.0) 77 (38.5)
2 5 (5.0) 2 (2.0) 7 (3.5)
SD, standard deviation.
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Table 4 because, for a minor number of cases, the incorrect Binet staging was provided at randomisation.
Overall, 51.5% (n = 103) of the trial population had B symptoms, with a higher proportion in the
FCM-miniR arm (n = 57, 57.0%) than in the FCR arm (n = 46, 46.0%). Twenty-five (12.5%) participants
had signs of extranodal or extramedullary CLL and the majority of participants (n = 116, 58.0%) were
WHO performance status 0, with 38.5% and 3.5% at performance status 1 and 2, respectively.
Table 9 summarises the baseline clinical assessments, which are reasonably well balanced between the
treatment arms. Seventy-two participants (36.0%) had a β2M concentration of < 4 mg/l and 31 (15.5%)
participants had a creatinine clearance between 30 and 60 ml/minute. Overall, 34 participants (17.0%) had
a positive direct Coombs test (DCT) and immunoglobulin G was the predominant paraprotein type after
‘None’ in 20% of participants. Results of the clinical assessments are in line with what would be expected
for this population of patients. One participant in the FCR arm was assessed as being previously infected
with hepatitis B, as described in Participant flow.
TABLE 9 Baseline clinical assessments (all participants)
Baseline assessment FCR (n= 100) FCM-miniR (n= 100) Total (n= 200)
β2M concentration (mg/l), n (%)
< 4 37 (37.0) 35 (35.0) 72 (36.0)
≥ 4 53 (53.0) 62 (62.0) 115 (57.5)
Missing 10 (10.0) 3 (3.0) 13 (6.5)
Creatinine clearance (ml/minute), n (%)
30–60 17 (17.0) 14 (14.0) 31 (15.5)
> 60 83 (83.0) 86 (86.0) 169 (84.5)
DCT, n (%)
Positive 19 (19.0) 15 (15.0) 34 (17.0)
Negative 71 (71.0) 73 (73.0) 144 (72.0)
Missing 10 (10.0) 12 (12.0) 22 (11.0)
Paraprotein type, n (%)
None 71 (71.0) 68 (68.0) 139 (69.5)
IgA 0 (0.0) 1 (1.0) 1 (0.5)
IgG 17 (17.0) 23 (23.0) 40 (20.0)
IgM 2 (2.0) 4 (4.0) 6 (3.0)
Missing 10 (10.0) 4 (4.0) 14 (7.0)
Hepatitis B, n (%)
Previously infected 1 (1.0) 0 (0.0) 1 (0.5)
Vaccinated 4 (4.0) 1 (1.0) 5 (2.5)
Negative 94 (94.0) 98 (98.0) 192 (96.0)
Missing 1 (1.0) 1 (1.0) 2 (1.0)
Hepatitis C, n (%)
Negative 100 (100) 100 (100) 200 (100)
DCT, direct Coombs test; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M.
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Table 10 summarises the genetic markers which were assessed at baseline and considered to be
prognostic for response. Seven (3.5%) participants had a 17p deletion and 30 (15.0%) participants had an
11q deletion, a higher proportion in the FCM-miniR arm (n = 20, 20.0%) than in the FCR arm (n = 10,
10.0%). This chance difference might be important, as 11q-deleted CLL may be sensitive to rituximab and
so this imbalance could affect the results.
Overall, 52.0% (n = 104) of participants were assessed to be within the VH mutation poor risk group and
43.5% (n = 87) had a positive CD38 status, a slightly higher proportion in the FCM-miniR arm (n = 46,
46.0%) than in the FCR arm (n = 41, 41.0%).
Treatment received
Tables 11–14 summarise the treatment details including treatment received, treatment discontinuations and
modifications and GCSF usage by randomisation allocation (FCR, FCM-miniR). After the interim analysis,
21 participants still receiving FCM-miniR transferred over to receive treatment with FCR. Of these, two
participants received a full six cycles of FCR; four received FCR from cycle 2; four from cycle 3; six from cycle 4;
four from cycle 5; and one participant received FCR for their final cycle of treatment, cycle 6. These
participants are summarised in addition to those who received FCR and FCM-miniR throughout the trial.
TABLE 10 Baseline genetic markers (all participants)
Genetic markers FCR (n= 100) FCM-miniR (n= 100) Total (n= 200)
17p deletion, n (%)
Yes (poorer risk) 4 (4.0) 3 (3.0) 7 (3.5)
No (standard risk) 88 (88.0) 88 (88.0) 176 (88.0)
Missing 8 (8.0) 9 (9.0) 17 (8.5)
11q deletion, n (%)
Yes (poorer risk) 10 (10.0) 20 (20.0) 30 (15.0)
No (standard risk) 83 (83.0) 75 (75.0) 158 (79.0)
Missing 7 (7.0%) 5 (5.0) 12 (6.0)
VH mutation risk group, n (%)
Poor riska 52 (52.0) 52 (52.0) 104 (52.0)
Standard riskb 30 (30.0) 31 (31.0) 61 (30.5)
Missing 18 (18.0) 17 (17.0) 35 (17.5)
CD38 status, n (%)
Positive (poorer risk) 41 (41.0) 46 (46.0) 87 (43.5)
Negative (standard risk) 55 (55.0) 52 (52.0) 107 (53.5)
Missing 4 (4.0) 2 (2.0) 6 (3.0)
a Poor risk: VH unmutated, or involving the VH3–21 gene.
b Standard risk: VH mutated and not involving the VH3–21 gene.
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Overall, 31 participants (15.5%) received three or fewer cycles of treatment (n = 15, 15.0% FCR; n = 16,
20.3% FCM-miniR; n = 0, 0.0% FCM-miniR/FCR), with 70.5% of participants receiving all six cycles
(n = 70, 70.0% FCR; n = 51, 64.6% FCM-miniR; n = 20, 95.2% FCM-miniR/FCR) (Table 11). Two
participants randomised to FCR did not receive any trial treatment. One was found to be ineligible post
randomisation as they had received prior therapy for CLL; they went on to receive FCR off trial and
continued to be followed up as per the protocol. The other participant withdrew from the trial (treatment
and follow-up) on the advice of the treating clinician as they had a 17p deletion and were treated with a
more ‘appropriate regime’ off trial.
TABLE 11 Treatment details (all participants)
Treatment details FCR (n= 100) FCM-miniR (n= 79) FCM-miniR/FCR (n= 21) Total (n= 200)
Number of treatment cycles received, n (%)
0 2 (2.0) 0 (0.0) 0 (0.0) 2 (1.0)
1 1 (1.0) 7 (8.9) 0 (0.0) 8 (4.0)
2 9 (9.0) 3 (3.8) 0 (0.0) 12 (6.0)
3 3 (3.0) 6 (7.6) 0 (0.0) 9 (4.5)
4 6 (6.0) 5 (6.3) 0 (0.0) 11 (5.5)
5 9 (9.0) 7 (8.9) 1 (4.8) 17 (8.5)
6 70 (70.0) 51 (64.6) 20 (95.2) 141 (70.5)
Treatment cycles received, n (%)
≤ 3 15 (15.0) 16 (20.3) 0 (0.0) 31 (15.5)
> 3 85 (85.0) 63 (79.7) 21 (100.0) 169 (84.5)
Summary statistics
Mean (SD) 5.2 (1.5) 5.0 (1.7) 6.0 (0.2) 5.2 (1.5)
Median (range) 6 (0–6) 6 (1–6) 6 (5–6) 6 (0–6)
SD, standard deviation.
TABLE 12 Early discontinuation of protocol treatment (all participants)
Early discontinuation details FCR (n= 100)
FCM-miniR
(n= 79)
FCM-miniR/FCR
(n= 21)
Total
(n= 200)
Number of participants discontinuing
treatment early, n (%)
30 (30.0) 28 (35.4) 1 (4.8) 59 (29.5)
Reason for early discontinuation of treatment, n (%)
Disease progression, requiring
further treatment
0 (0.0) 3 (10.7) 0 (0.0) 3 (5.1)
Toxicity 22 (73.3) 21 (75.0) 1 (100) 44 (74.6)
A prior eligibility criteria has been
violated (discussed with CTRU/CI)
1 (3.3) 0 (0.0) 0 (0.0) 1 (1.7)
Stable disease with no or minimal
response
1 (3.3) 2 (7.1) 0 (0.0) 3 (5.1)
Participant decision 2 (6.7) 1 (3.6) 0 (0.0) 3 (5.1)
Clinician decision 3 (10.0) 1 (3.6) 0 (0.0) 4 (6.8)
Other reason discontinued 1 (3.3) 0 (0.0) 0 (0.0) 1 (1.7)
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Fifty-nine participants (29.5%) discontinued treatment early: 30 of those participants who were receiving
FCR (30.0%), 28 of those participants receiving FCM-miniR (35.4%) and one of those participants in the
FCM-miniR/FCR group. Toxicity was the majority reason for early discontinuation of treatment (74.6%
of cases), with a similar proportion in the FCR and FCM-miniR treatment arms (FCR: n = 22, 73.3%;
FCM-miniR: n = 21, 75.0%) (Table 12).
Table 13 summarises the number and proportion of participants experiencing at least one modification
to their protocol-defined dose of treatment (i.e. dose omission, reduction, delay, stopped early or alternative
route of administration). A total of 135 participants (67.5%) experienced at least one modification to their
protocol treatment with a similar proportion in the FCR (n = 67, 67.0%) and FCM-miniR (n = 52, 65.8%)
treatment arms. Overall, 57.0% (n = 114) of participants experienced a delay to at least one of their doses of
treatment and 35.0% (n = 70) experienced a dose reduction with a higher proportion in the FCM-miniR arm.
Overall, 68 participants (34.0%) received treatment with GCSF during the cycles of therapy with a higher
proportion in the FCM-miniR arm (35.4%, n = 28) than the FCR arm (31.0%, n = 31) and the FCM-miniR/
FCR arm (42.9%, n = 9). Throughout the whole of the treatment period (cycles 1–6), 94 participants
(47.0%) received GCSF at some stage (FCR: 42%, n = 42; FCM-miniR: 50.6%, n = 40; and FCM-miniR/
FCR: 57.1%, n = 12) (Table 14). Rates are in line with what would be expected for these treatments.
Of the 68 participants known to have received treatment with GCSF at some stage during the first three
cycles, 88.2% (n = 60) received four or more cycles of treatment; in contrast, 98.2% (n = 108) of those
who did not receive GCSF received four or more cycles of treatment (Table 15).
TABLE 13 Treatment modifications (all participants)
Treatment modifications FCR (n= 100)
FCM-miniR
(n= 79)
FCM-miniR/FCR
(n= 21)
Total
(n= 200)
Number of participants experiencing
at least one dose modification, n (%)
67 (67.0) 52 (65.8) 16 (76.2) 135 (67.5)
Dose modification, n (%)
Dose omission 6 (6.0) 9 (11.4) 2 (9.5) 17 (8.5)
Dose reduction 31 (31.0) 28 (35.4) 11 (52.4) 70 (35.0)
Dose delay 53 (53.0) 47 (59.5) 14 (66.7) 114 (57.0)
Dose stopped early 11 (11.0) 7 (8.9) 1 (4.8) 19 (9.5)
Alternative route of administration 7 (7.0) 5 (6.3) 1 (4.8) 13 (6.5)
TABLE 14 Granulocyte colony-stimulating factor usage during treatment (all participants)
GCSF usage FCR (n= 100)
FCM-miniR
(n= 79)
FCM-miniR/FCR
(n= 21)
Total
(n= 200)
Received GCSF during the first three cycles, n (%)
Yes 31 (31.0) 28 (35.4) 9 (42.9) 68 (34.0)
No 57 (57.0) 41 (51.9) 12 (57.1) 110 (55.0)
Unknown 12 (12.0) 10 (12.7) 0 (0.0) 22 (11.0)
Received GCSF during treatment, n (%)
Yes 42 (42.0) 40 (50.6) 12 (57.1) 94 (47.0)
No 53 (53.0) 34 (43.0) 9 (42.9) 96 (48.0)
Unknown 5 (5.0) 5 (6.3) 0 (0.0) 10 (5.0)
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Interim analysis
An interim analysis of the short-term efficacy data was performed on the first 103 participants randomised
into the study: 51 allocated to the FCR control arm and 52 allocated to the FCM-miniR intervention arm.
The results of the interim analysis were presented to the DMEC in September 2012.
The interim analysis was based on all data received and entered into the trial database up to 30 August
2012. Owing to the ongoing nature of the trial, the DMEC was aware that the data on which the interim
analysis was based may not have been fully validated and could be subject to change by the time of the
final analysis. This report summarises the data as they were reported to the DMEC, even if there were
changes to these results prior to the final, clean, analysis data set.
By the time the final participant to be included in the interim analysis had reached their primary end point
(i.e. 3 months post treatment), 191 participants out of a target of 206 had been randomised from 32 UK
centres. The primary aim of the formal interim analysis was to be able to release information on any
potential large differences in efficacy between the treatment arms earlier than would have been the case
with the final analysis.
Treatment received
Of the first 103 participants randomised, 72 (69.9%) received all six cycles of treatment, with a higher
proportion of participants coming from the FCR arm (n = 38, 74.5%) than the FCM-miniR arm (n = 34,
65.4%) (Table 16). Thirty-one participants (30.1%) had discontinued treatment early (FCR: 25.5%, n = 13;
FCM-miniR: 34.6%, n = 18).
Table 17 summarises the number and proportion of participants experiencing at least one modification to their
protocol-defined dose of treatment. A higher proportion of participants in the FCM-miniR arm experienced at
least one dose omission, dose reduction and dose delay than in the FCR arm.
TABLE 15 Granulocyte colony-stimulating factor usage by number of treatment cycles received
Number of
treatment cycles
received
Received GCSF within
first three cycles
(n= 68), n (%)
Did not receive GCSF
within first three cycles
(n= 110), n (%)
Unknown
(n= 20), n (%)
Total
(n= 198), n (%)
1 0 (0.0) 0 (0.0) 8 (40.0) 8 (4.0)
2 2 (2.9) 0 (0.0) 10 (50.0) 12 (6.1)
3 6 (8.8) 2 (1.8) 1 (5.0) 9 (4.5)
4 5 (7.4) 6 (5.5) 0 (0.0) 11 (5.6)
5 5 (7.4) 12 (10.9) 0 (0.0) 17 (8.6)
6 50 (73.5) 90 (81.8) 1 (5.0) 141 (71.2)
TABLE 16 Treatment details (interim analysis population)
Treatment details FCR (n= 51) FCM-miniR (n= 52) Total (n= 103)
Number of treatment cycles received, n (%)
1 0 (0.0) 3 (5.8) 3 (2.9)
2 5 (9.8) 1 (1.9) 6 (5.8)
3 1 (2.0) 2 (3.8) 3 (2.9)
4 3 (5.9) 5 (9.6) 8 (7.8)
5 4 (7.8) 7 (13.5) 11 (10.7)
6 38 (74.5) 34 (65.4) 72 (69.9)
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Efficacy
An independent central assessment of response was carried out in order to assess formally the primary end
point data on response to treatment as defined by IWCLL criteria.26 The interim analysis of the primary
end point data was based on the ITT population, which included participants for whom written informed
consent had been received and for which primary end point data were available. A PP analysis was not
performed as, out of the first 103 participants, all received at least one cycle of their randomised
treatment. The FCR participant who had been previously infected with hepatitis B was not excluded as this
was not classed as a major protocol violation.
Of the 103 participants assessed in the interim analysis, 18 (17.5%) were excluded from the formal
analysis of the primary end point, with a slightly higher proportion coming from the FCR arm (FCR: n = 10,
19.6%; FCM-miniR: n = 8, 15.4%) (Table 18). Fifteen participants had a missing trephine sample (7 FCR;
8 FCM-miniR), which is required by the IWCLL criteria to confirm a CR, with no further evidence that they
were definitely not a CR/CRi. Of these, two trephine samples were taken but were inadequate for analysis.
Thirteen samples were not taken owing to a sample being missed in error (n = 4); a clinician’s decision
(n = 2); a participant’s decision (n = 2); a participant being unwell (n = 1); it being too painful/difficult to
sample a participant (n = 4).
In the FCR arm, two participants withdrew their consent for further trial treatment and follow-up data
collection prior to the assessment of the primary end point, and one participant discontinued treatment
after their second cycle and was subsequently lost to follow-up.
Table 19 presents the number of participants achieving a CR and the difference in response rates between
the treatment arms. Overall, 71.8% (n = 61) of participants achieved a CR, with a higher proportion in the
FCR arm (n = 34, 82.9%) than in the FCM-miniR arm (n = 27. 61.4%). The difference in the CR rates was
21.6% in favour of the FCR arm, with a 99.5% CI (–48.0% to 4.8%).
TABLE 17 Treatment modifications (interim analysis population)
Treatment modifications FCR (n= 51) FCM-miniR (n= 52) Total (n= 103)
Dose modification, n (%)
Dose omission 1 (2.0) 7 (13.5) 8 (7.8)
Dose reduction 15 (29.4) 20 (38.5) 35 (34.0)
Dose delay 23 (45.1) 28 (53.8) 51 (49.5)
TABLE 18 Exclusions from the interim analysis of the primary end point (interim analysis population)
Exclusion FCR (n= 51) FCM-miniR (n= 52) Total (n= 103)
Participants excluded from the primary end point analysis, n (%) 10 (19.6) 8 (15.4) 18 (17.5)
Reasons for exclusion, n (%)
Missing 3-month post-treatment trephine sample 7 (13.7) 8 (15.4) 15 (14.6)
Withdrew from further trial treatment and follow-up
data collection
2 (3.9) 0 (0.0) 2 (1.9)
Lost to follow-up 1 (2.0) 0 (0.0) 1 (1.0)
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A binary multivariate logistic regression model was used to assess formally the effect of treatment on the
proportion of participants achieving a CR at 3 months post treatment, adjusting for the minimisation
factors, excluding centre (Table 20). The O’Brien and Fleming32 alpha spending function was used to adjust
for multiple testing, requiring an alpha level of < 0.005 (two-sided) to indicate significance, in order to
preserve the alpha for the final analysis.
The OR for achieving a CR in the FCM-miniR arm compared with the FCR arm was 0.32 (99.5% CI: 0.07
to 1.48). With a p-value of 0.037, the difference between the treatment arms in terms of CR rates was not
significant at the reduced 0.5% significance level, although it was noted that the experimental treatment
was somewhat worse in terms of response.
Of the 103 participants included in the interim analysis, 51.5% (n = 53) had undetectable MRD at
3 months post treatment, with a higher proportion of participants in the FCR arm (n = 29, 56.9%) than in
the FCM-miniR arm (n = 24, 46.2%) (Table 21).
TABLE 19 Proportion of participants achieving a CR/CRi at 3 months post treatment (ITT population)
Achievement of the
primary end point FCR (n= 41)
FCM-miniR
(n= 44)
Total
(n= 85)
Difference in
response rates
(FCM –miniR-FCR)
99.5% CI for
difference in
response rate
Achieved a CR/CRi, n (%) 34 (82.9) 27 (61.4) 61 (71.8) –21.6 –48.0% to 4.8%
Did not achieve a CR/CRi,
n (%)
7 (17.1) 17 (38.6) 24 (28.2)
TABLE 20 Multivariate logistic regression analysis for the proportion of participants achieving a CR or CRi at
3 months post treatment, adjusted for the minimisation factors (ITT population)
Parameter df Parameter estimate SE Wald χ2 Pr > χ2 OR (99.5% CI)
Intercept 1 0.81 0.31 6.86 0.009
Treatment group: FCM-miniR vs. FCR 1 –0.56 0.27 4.34 0.037 0.32 (0.07 to 1.48)
Sex: female vs. male 1 0.31 0.31 1.02 0.312 1.87 (0.33 to 10.55)
Age group: > 65 years vs. ≤ 65 years 1 –0.56 0.28 3.91 0.048 0.32 (0.07 to 1.60)
Binet stage: C vs. A progressive or B 1 –0.42 0.28 2.35 0.125 0.43 (0.09 to 2.02)
df, degrees of freedom.
TABLE 21 Proportion of participants achieving MRD negativity at 3 months post treatment (interim analysis population)
MRD assessment FCR (n= 51) FCM-miniR (n= 52) Total (n= 103)
Assessment of MRD, n (%)
MRD negative 29 (56.9) 24 (46.2) 53 (51.5)
MRD positive 19 (37.3) 22 (42.3) 41 (39.8)
Unknown, samples not taken 0 (0.0) 5 (9.6) 5 (4.9)
Early death 0 (0.0) 1 (1.9) 1 (1.0)
Withdrew from further trial treatment and follow-up
data collection
2 (3.9) 0 (0.0) 2 (1.9)
Lost to follow-up 1 (2.0) 0 (0.0) 1 (1.0)
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Safety and toxicity
A total of 103 SAEs were reported from 60 participants out of the first 103 randomised into the trial. Of
the 103 reported SAEs, 44 events (42.7%) were from 26 participants receiving FCR and 59 events (57.3%)
were from 34 participants receiving FCM-miniR. The mean number of SAEs reported per participant (1.7)
was the same in both treatment arms (Table 22).
Of the 103 SAEs reported, 85 (82.5%) were suspected to be related to trial treatment (51 reported from
participants receiving FCM-miniR and 34 reported from participants receiving FCR). One SUSAR was
reported from a participant in the FCR arm. The participant received all six cycles of treatment and was
diagnosed with a ‘squamous cell carcinoma’ approximately 4 months after their last cycle of treatment.
The event was felt by the Principal Investigator at the site to be related to trial treatment (F, C and R) and
unexpected. The majority of SAEs required hospitalisation (n = 89, 86.4%); three participants died as a
result of their SAE (one in the FCR arm and two in the FCM-miniR arm) (Table 23).
A total of 1469 AEs were reported from 101 participants. A total of 669 events were from 49 participants
receiving FCR and 770 events from 52 participants receiving FCM-miniR.
TABLE 22 Number of participants experiencing an SAE and total number of SAEs reported (interim analysis population)
SAE summary FCR (n= 51) FCM-miniR (n= 52) Total (n= 103)
Has the participant experienced an SAE?, n (%)
Yes 26 (51.0) 34 (65.4) 60 (58.3)
No 25 (49.0) 18 (34.6) 43 (41.7)
Number of participants with one or more SAE 26 34 60
Number of SAEs reported 44 59 103
Number of SAEs per participant
Mean (SD) 1.7 (1.2) 1.7 (1.1) 1.7 (1.1)
Median (range) 1 (1–5) 1 (1–5) 1 (1–5)
SD, standard deviation.
TABLE 23 Suspected relationship with experimental treatment (interim analysis population)
SAE relationship and seriousness criteria FCR, N (%) FCM-miniR, N (%) Total, N (%)
Relationship to experimental treatment
Suspected, unexpected 1 (2.3) 0 (0.0) 1 (1.0)
Suspected, expected 33 (75.0) 51 (86.4) 84 (81.6)
Not suspected 10 (22.7) 8 (13.6) 18 (17.5)
Total 44 (100) 59 (100.0) 103 (100)
Seriousness criteria (not mutually exclusive)
Participant died as a result of the SAE 1 (2.3) 2 (3.4) 3 (2.9)
Life-threatening 1 (2.3) 3 (5.1) 4 (3.9)
Congenital anomaly/birth defect 0 (0.0) 0 (0.0) 0 (0.0)
Required/prolonged hospitalisation 39 (88.6) 50 (84.7) 89 (86.4)
Persistent or significant disability/incapacity 1 (2.3) 0 (0.0) 1 (1.0)
Jeopardised patient/required intervention to
prevent one of the above criteria
6 (13.6) 10 (16.9) 16 (15.5)
Missing 1 (2.3) 0 (0.0) 1 (1.0)
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Conclusions from the Data Monitoring and Ethics Committee
The difference in the CR rates between the treatment arms (82.9% FCR; 61.4% FCM-miniR), although not
statistically significant, was deemed by the DMEC to be clinically relevant. In light of this, and the indication of
an increased toxicity rate and increased number of dose omissions and reductions in the FCM-miniR arm, the
DMEC recommended that the trial should close the recruitment with immediate effect, and all participants
receiving FCM-miniR were recommended to transfer to treatment with FCR for the remainder of their
treatment cycles. At the time of trial closure, 200 participants had been recruited into the trial.
Final analysis: primary end point
The final participant’s clinic visit to assess their primary end point (3 months post treatment) was carried
out on 31 July 2013; the data lock for the analysis of the primary end point was performed on 30 October
2013. Owing to the non-inferiority nature of the primary end point, the primary analysis was carried out
on both the ITT and PP populations.
Participants randomised to FCM-miniR who transferred over to receive treatment with FCR after the
interim analysis (see Interim analysis for further details) were summarised in a separate group and excluded
from any formal comparisons of the treatment arms. This was felt to be appropriate, as the decision to
stop FCM-miniR was on the recommendation of the DMEC, rather than a decision from the treating
clinician or participant, which violates the ITT assumption.
Central assessment of response by International Workshop on chronic
lymphocytic leukaemia
Table 24 summarises the proportion of participants with a centrally reviewed IWCLL assessment of
response. Of the 200 participants, a response assessment was available for 166 participants (83.0%), with
the same proportion in each treatment arm. Twenty-four (12.0%) participants assessed as being at least
a PR had a missing trephine sample, which is required by the IWCLL criteria to confirm a CR. Four
participants in the FCR arm withdrew from follow-up and one FCM-miniR participant died prior to the
assessment of response. In addition, in the FCM-miniR arm, one participant’s response to treatment was
unable to be assessed and four participants (one in the FCR and three in the FCM-miniR arm) missed their
3-month post-treatment visit.
TABLE 24 Number of participants with a centrally reviewed assessment of response (IWCLL) (all participants)
IWCLL assessment of response available FCR (n= 100) FCM-miniR (n= 100) Total (n= 200)
IWCLL assessment of response, n (%)
Yes 83 (83.0) 63 (63.0) 146 (73.0)
Yes (received FCM-miniR/FCR) 0 (0.0) 20 (20.0) 20 (10.0)
No IWCLL assessment of response, n (%)
Missing trephine sample 12 (12.0) 11 (11.0) 23 (11.5)
Missing trephine sample (received FCM-miniR/FCR) 0 (0.0) 1 (1.0) 1 (0.5)
Withdrew from follow-up prior to assessment of response 4 (4.0) 0 (0.0) 4 (2.0)
Early death 0 (0.0) 1 (1.0) 1 (0.5)
Unable to assess 0 (0.0) 1 (1.0) 1 (0.5)
Missed 3-month post-treatment visit 1 (1.0) 3 (3.0) 4 (2.0)
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Numbers analysed and reasons for non-inclusion in the intention-to-treat population
Of the 200 participants randomised, 167 (83.5%) participants were included in the ITT analysis, with a
higher proportion in the FCR arm (n = 92, 92.0% FCR; n = 75, 75.0% FCM-miniR) (Table 25). Participants
who were randomised to FCM-miniR but transferred over to receive treatment with FCR after the interim
analysis were excluded from the ITT population (n = 21). In addition to the 146 participants in the FCR
and FCM-miniR arms with an assessment of response, a further 14 participants who were at least a PR
but had missing trephine samples were included in the ITT analysis owing to further clinical evidence that
confirmed that they were either a CR/CRi or PR, as per the pre-specified decision rules, specified in
Chapter 2, Missing data handling. Two participants in the FCR arm withdrew consent for the trial owing
to non-response and toxicity, and a further FCM-miniR participant died as a result of their CLL, all prior
to the assessment of their primary end point (3-month post-treatment visit). Four participants (one in the
FCR and three from the FCM-miniR arms) discontinued treatment early owing to non-response or toxicity
and subsequently missed their 3-month post-treatment visit. All seven participants (three FCR, four
FCM-miniR) were included in the ITT analysis as non-responders, as per the missing data decision rules.
A total of 33 participants were not able to be included in the ITT analysis, including the 21 treatment
arm transfers:
l There were nine participants with a missing trephine sample (six in the FCR and three in the FCM-miniR
arm), with no further clinical evidence they were definitely not a CR/CRi. Of these, three were missed
in error; two were at the discretion of the treating clinician; two were the participants’ decisions;
two were a result of it being too painful/difficult to sample participants.
l Two participants withdrew their consent for further trial treatment and follow-up data collection prior
to the assessment of the primary end point, both randomised to FCR. Of these, one participant had
a 17p deletion and on the advice of the treating clinician was treated with a ‘more appropriate regime’
off trial, prior to receiving any trial treatment. The second participant withdrew consent after receiving
one cycle of treatment, for non-treatment-related reasons: ‘Due to other tests/treatment, the
participant no longer wishes to remain on trial and feels they do not have time to continue with
trial follow-up’.
l One participant, who received two cycles of treatment with FCM-miniR, was unable to be assessed for
response owing to insufficient clinical evaluations performed at the 3-month post-treatment visit (i.e. missing
haematology tests, liver and spleen examinations and blood/trephine samples), with no reason provided.
TABLE 25 Number of participants included in the ITT analysis, and reasons for exclusion (all participants)
Reason for exclusion, n (%)
FCR
(n= 100)
FCM-miniR
(n= 100)
Total
(n= 200)
Participants included in the ITT population 92 (92.0) 75 (75.0) 167 (83.5)
IWCLL response assessment available 84 (84.0) 66 (66.0) 150 (75.0)
Missing trephine sample but clinical evidence that participant was
either a CR/CRi or PR
6 (6.0) 8 (8.0) 14 (7.0)
Withdrew from follow-up prior to assessment of response owing to
toxicity or non-response
2 (2.0) 0 (0.0) 2 (1.0)
Early death as a result of CLL 0 (0.0) 1 (1.0) 1 (0.5)
Participants excluded from the ITT population 8 (8.0) 25 (25.0) 33 (16.5)
Received FCM-miniR/FCR 0 (0.0) 21 (21.0) 21 (10.5)
Missing trephine sample with at least a PR and no evidence that
participant was not a CR/CRi
6 (6.0) 3 (3.0) 9 (4.5)
Withdrew from follow-up prior to assessment of response 2 (2.0) 0 (0.0) 2 (1.0)
Unable to assess 0 (0.0) 1 (1.0) 1 (0.5)
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These 33 participants were excluded from the ITT population in line with the guidance within the Statistical
Analysis Plan, which was signed off prior to any analysis being conducted.
In the PP population, an additional participant with an assessment of response in the FCR arm was excluded
as a result of breaching the eligibility criteria and not receiving any of their randomised treatment. The
participant in the FCR arm who had been previously infected with hepatitis B was not excluded as this was
not classed as a major protocol violation.
Table 26 presents the baseline characteristics for the ITT population compared with the 33 participants who
were not able to be included in the analysis. In the group of participants who were not included in the ITT
analysis, participants tended to be older, with a higher proportion of females and Binet stage A progressive
or B disease, although these were relatively small numbers for comparison. The excluded population
contained a slightly higher proportion of poorer risk participants in terms of 17p and 11q deletions.
TABLE 26 Comparison of the baseline characteristics for the ITT population and participant exclusions
Baseline characteristics ITT population (n= 167)
Excluded from the ITT
population (n= 33) Total (n= 200)
Minimisation factors, n (%)
Age group
≤ 65 years 106 (63.5) 19 (57.6) 125 (62.5)
> 65 years 61 (36.5) 14 (42.4) 75 (37.5)
Sex
Male 117 (70.1) 18 (54.5) 135 (67.5)
Female 50 (29.9) 15 (45.5) 65 (32.5)
Binet stage
A progressive or B 111 (66.5) 25 (75.8) 136 (68.0)
C 56 (33.5) 8 (24.2) 64 (32.0)
Genetic markers
17p deletion
Yes (poorer risk) 6 (3.6) 1 (3.0) 7 (3.5)
No (standard risk) 147 (88.0) 29 (87.9) 176 (88.0)
Missing 14 (8.4) 3 (9.1) 17 (8.5)
11q deletion
Yes (poorer risk) 24 (14.4) 6 (18.2) 30 (15.0)
No (standard risk) 133 (79.6) 25 (75.8) 158 (79.0)
Missing 10 (6.0) 2 (6.1) 12 (6.0)
VH risk group
Poor risk 87 (52.1) 17 (51.5) 104 (52.0)
Standard risk 52 (31.1) 9 (27.3) 61 (30.5)
Unknown 28 (16.8) 7 (21.2) 35 (17.5)
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Formal analysis of the primary end point
Overall, 66.5% (n = 111) of participants in the ITT population achieved a CR, a higher proportion in the
FCR arm (n = 70, 76.1%) than the FCM-miniR arm (n = 41, 54.7%) (Table 27). The difference between
the arms was 21.4%, in favour of the FCR arm (95% CI –35.8% to –7.0%), indicating that FCM-miniR
appears to be performing worse in terms of response.
A binary multivariate logistic regression model was used to assess formally the primary end point: the effect
of treatment on the proportion of participants achieving a CR at 3 months post treatment, after adjusting
for the minimisation factors, excluding centre (Table 28). The OR for achieving a CR in the FCM-miniR arm
compared with the FCR arm was 0.37 (95% CI: 0.19 to 0.73), indicating that participants in the FCM-miniR
are less likely to achieve a CR. The trial was powered on demonstrating that FCM-miniR was no more than
10% worse in terms of CR rates than FCR. With a CR rate of 76.1% in the FCR arm, a 10% reduction gives
an OR of 0.61 (see Primary end point analysis for further details of the derivation). As the lower limit of the
95% CI for the treatment effect is < 0.61, and even the mean OR is below this level, there is very strong
evidence that FCM-miniR is not non-inferior to FCR in terms of CR rates. As the upper limit of the 95% CI is
also below 1, there is evidence that FCM-miniR is significantly inferior to FCR.
The 95% CIs around the ORs for the minimisation factors all contain 1, indicating that there is no evidence
that any of the minimisation factors are significantly associated with response, although there is a suggested
trend towards participants who are aged over 65 years and with Binet stage C performing worse.
The analysis of the primary end point using the PP population concurred with the outcome of the ITT
analysis and demonstrated inferiority of FCM-miniR to FCR with an OR of 0.38 (95% CI 0.19 to 0.75)
(Table 29).
The analysis of the primary end point on both the ITT and PP populations strongly demonstrated that
FCM-miniR is not non-inferior to FCR in terms of CR rates and, in fact, there is evidence to suggest
that FCM-miniR is significantly inferior to FCR.
TABLE 27 Proportion of participants achieving a CR or CRi at 3 months post treatment (ITT population)
Achievement of the primary end point, n (%)
FCR
(n= 92)
FCM-miniR
(n= 75)
Total
(n= 167)
Difference in CR rates and
95% CIs (FCM-miniR – FCR)
Achieved a CR/CRi 70 (76.1) 41 (54.7) 111 (66.5) –21.4% (–35.8% to –7.0%)
Did not achieve a CR/CRi 22 (23.9) 34 (45.3) 56 (33.5)
TABLE 28 Multivariate logistic regression analysis for the proportion of participants achieving a CR or CRi at
3 months post treatment, adjusted for the minimisation factors (ITT population)
Parameter df Parameter estimate SE OR (95% CI estimate)
Intercept 1 1.38 0.33
Treatment group: FCM-miniR vs. FCR 1 –0.98 0.34 0.37 (0.19 to 0.73)
Sex: female vs. male 1 0.22 0.38 1.25 (0.59 to 2.63)
Age group: > 65 years vs. ≤ 65 years 1 –0.55 0.35 0.58 (0.29 to 1.15)
Binet stage: C vs. A progressive or B 1 –0.21 0.36 0.81 (0.40 to 1.63)
df, degrees of freedom.
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Sensitivity analyses
Sensitivity analyses were performed in order to assess the reliability of the analysis of primacy and the
assumptions regarding the missing primary end point data. The responses of participants that were not
included in the ITT population were imputed, with the exception of those participants who received
FCM-miniR/FCR after the FCM-miniR arm was closed (see Table 25).
The first sensitivity analysis assumed that participants who were not included in the ITT population were all
non-responders, and thus these participants were treated as not having achieved a CR in the analysis of
the primary end point (eight in the FCR arm and four in the FCM-miniR). A total of 179 participants were
included in this analysis, with 62.0% (111/179) achieving a CR compared with 66.5% (111/167) in the
analysis of primacy. A total of 70.0% (70/100) of FCR participants achieved a CR compared with 51.9%
(41/79) in the FCM-miniR arm. The OR for achieving a CR in the FCM-miniR arm compared with the FCR
arm was 0.46 (95% CI 0.24 to 0.86) (Table 30), indicating that FCM-miniR participants are less likely to
achieve a CR. With a response rate of 70.0% in the control arm, a 10% reduction (i.e. the non-inferiority
margin) gives an OR of 0.64. As the lower limit of the 95% CI for the treatment effect and the mean OR
are both < 0.64, there is very strong evidence that FCM-miniR is not non-inferior to FCR in terms of CR
rates, even after treating participants with missing data as non-responders.
The second sensitivity analysis assumed that the participants who were not included in the ITT population
were all responders, and thus these participants were treated as having achieved a CR in the analysis of
the primary end point (8 FCR, 4 FCM-miniR). A total of 179 participants were included in this analysis, with
68.7% (123/179) achieving a CR compared with 66.5% (111/167) in the analysis of primacy. A total of
TABLE 29 Multivariate logistic regression analysis for the proportion of participants achieving a CR or CRi at
3 months post treatment, adjusted for the minimisation factors (PP population)
Parameter df Parameter estimate SE OR (95% CI estimate)
Intercept 1 1.37 0.33
Treatment group: FCM-miniR vs. FCR 1 –0.97 0.34 0.38 (0.19 to 0.75)
Sex: female vs. male 1 0.23 0.38 1.26 (0.60 to 2.66)
Age group: > 65 years vs. ≤ 65 years 1 –0.57 0.35 0.57 (0.28 to 1.13)
Binet stage: C vs. A progressive or B 1 –0.20 0.36 0.82 (0.41 to 1.66)
df, degrees of freedom.
TABLE 30 Multivariate logistic regression analysis for the proportion of participants achieving a CR or CRi at
3 months post treatment, adjusted for the minimisation factors (sensitivity analysis 1)
Parameter df Parameter estimate SE OR (95% CI estimate)
Intercept 1 1.14 0.30
Treatment group: FCM-miniR vs. FCR 1 –0.78 0.32 0.46 (0.24 to 0.86)
Sex: female vs. male 1 0.03 0.34 1.03 (0.52 to 2.02)
Age group: > 65 years vs. ≤ 65 years 1 –0.52 0.32 0.60 (0.31 to 1.13)
Binet stage: C vs. A progressive or B 1 –0.28 0.33 0.75 (0.39 to 1.45)
df, degrees of freedom.
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78.0% (78/100) of FCR participants achieved a CR compared with 57.0% (45/79) in the FCM-miniR arm.
The OR for achieving a CR in the FCM-miniR arm compared with the FCR arm was 0.37 (95% CI: 0.19 to
0.72) (Table 31) indicating that participants in the FCM-miniR are less likely to achieve a CR. With a
response rate of 78.0% in the control arm, a 10% reduction (i.e. the non-inferiority margin) gives an OR
of 0.60. As the lower limit of the 95% CI for the treatment effect and the mean OR are < 0.60, there is
very strong evidence that FCM-miniR is not non-inferior to FCR in terms of CR rates, even after treating
participants with missing data as responders.
The third sensitivity analysis excluded all participants with missing trephine data from the ITT population
and thus the analysis of the primary end point (6 FCR, 8 FCM-miniR). A total of 153 participants were
included in this analysis, with 69.9% (107/153) achieving a CR compared with 66.5% (111/167) in the
analysis of primacy. A total of 79.1% (68/86) of FCR participants achieved a CR compared with 58.2%
(39/67) of participants in the FCM-miniR arm. The OR for achieving a CR in the FCM-miniR arm compared
with the FCR arm was 0.37 (95% CI: 0.18, 0.77) (Table 32), indicating that participants in the FCM-miniR
are less likely to achieve a CR. With a response rate of 79.1% in the control arm, a 10% reduction (i.e. the
non-inferiority margin) gives an OR of 0.59. As the lower limit of the 95% CI for the treatment effect and
the mean OR are < 0.59, there is very strong evidence that FCM-miniR is not non-inferior to FCR in terms
of CR rates, even after excluding participants with missing trephine data.
The results of the sensitivity analyses are consistent with the analysis of primacy and confirm that there is
strong evidence that FCM-miniR is not non-inferior to FCR in terms of CR rates at 3 months post
treatment. The results do not change considerably even after imputing the missing data, demonstrating
the robustness of the conclusions. After excluding participants with missing trephine data, the results
remained consistent with the analysis of primacy, supporting the approach to impute the response for
participants with missing trephine data but who were known to be at least a PR (as described in Missing
data handling).
TABLE 31 Multivariate logistic regression analysis for the proportion of participants achieving a CR or CRi at
3 months post treatment, adjusted for the minimisation factors (sensitivity analysis 2)
Parameter df Parameter estimate SE OR (95% CI estimate)
Intercept 1 1.45 0.33
Treatment group: FCM-miniR vs. FCR 1 –1.00 0.34 0.37 (0.19 to 0.72)
Sex: female vs. male 1 0.32 0.37 1.38 (0.66 to 2.85)
Age group: > 65 vs. ≤ 65 1 –0.51 0.34 0.60 (0.31 to 1.18)
Binet stage: C vs. A progressive or B 1 –0.22 0.35 0.81 (0.40 to 1.60)
df, degrees of freedom.
TABLE 32 Multivariate logistic regression analysis for the proportion of participants achieving a CR or CRi at
3 months post treatment, adjusted for the minimisation factors (sensitivity analysis 3)
Parameter df Parameter estimate SE OR (95% CI estimate)
Intercept 1 1.54 0.36
Treatment group: FCM-miniR vs. FCR 1 –0.99 0.37 0.37 (0.18 to 0.77)
Sex: female vs. male 1 0.47 0.43 1.61 (0.69 to 3.75)
Age group: > 65 vs. ≤ 65 1 –0.62 0.37 0.54 (0.26 to 1.13)
Binet stage: C vs. A progressive or B 1 –0.25 0.39 0.78 (0.36 to 1.67)
df, degrees of freedom.
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Subgroup analyses
Pre-specified subgroup analyses were carried out to assess the heterogeneity of the treatment effect
among subgroups of interest for the primary end point, using the ITT population. As the PP population
was very similar to that of the ITT, subgroup analyses on this population were considered unnecessary. As
the trial was not powered to look for differences in subgroups of participants, the results are to be treated
as exploratory and should be used for hypothesis-generating purposes only.
Tables 33–36 present the subgroups of interest by whether or not a CR was achieved, the difference in
response rates and 95% CIs.
Of the 163 participants included in the ITT analysis of the primary end point, a similar proportion of males
and females achieved a CR (65.0% vs. 70.0%; Table 33). The difference in response rates between the
two age groups was 11.7% (95% CI –3.3% to 26.8%), suggesting a trend towards younger participants
(aged ≤ 65 years) being more likely to achieve a CR; as the CI contains zero this difference is not statistically
significant. A higher proportion of participants with Binet stage A progressive or B achieved a CR than those
with stage C (68.5% vs. 62.5%). The 95% CI contains zero, indicating that this difference is not statistically
significant but suggesting a trend in favour of Binet stage A progressive and B participants.
TABLE 33 Minimisation factors by achievement of the primary end point (ITT population)
Minimisation factors Difference in rates (95% CI)
Sex Male (n = 117) Female (n = 50)
Achieved a CR/CRi, n (%) 76 (65.0) 35 (70.0) –5.0% (–20.4% to 10.3%)
Did not achieve a CR/CRi,
n (%)
41 (35.0) 15 (30.0)
Age group ≤ 65 years (n = 105) > 65 years (n = 58)
Achieved a CR/CRi, n (%) 75 (70.8) 36 (59.0) 11.7% (–3.3% to 26.8%)
Did not achieve a CR/CRi,
n (%)
31 (29.2) 25 (41.0)
Binet stage
Stage A progressive or B
(n = 106) Stage C (n = 56)
Achieved a CR/CRi, n (%) 76 (68.5) 35 (62.5) 6.0% (–9.4% to 21.3%)
Did not achieve a CR/CRi,
n (%)
35 (31.5) 21 (37.5)
TABLE 34 Baseline clinical details by achievement of the primary end point (ITT population)
Baseline clinical details Difference in rates (95% CI)
Creatinine clearance levels
30–60ml/minute
(n = 25)
> 60ml/minute
(n = 142)
Achieved a CR/CRi, n (%) 15 (60.0) 96 (67.6) –7.6% (–28.3% to 13.1%)
Did not achieve a CR/CRi, n (%) 10 (40.0) 46 (32.4)
β2M concentration < 4mg/l (n = 60) ≥ 4mg/l (n = 97)
Achieved a CR/CRi, n (%) 43 (71.7) 60 (61.9) 9.8% (–5.1% to 24.8%)
Did not achieve a CR/CRi, n (%) 17 (28.3) 37 (38.1)
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The difference in response rates between the two creatinine clearance groups was –7.6% (95% CI
–28.3% to 13.1%), suggesting a trend towards participants with a creatinine clearance level between
30 and 60 ml/minute being less likely to achieve a CR than those with a creatinine clearance level of
> 60 ml/minute. As the CI contains zero, this difference was not statistically significant. A higher proportion
of participants achieved a CR with a β2 M concentration < 4 mg/l compared with a concentration ≥ 4 mg/l
(71.7% vs. 61.9%). The 95% CI contains zero, indicating that this difference is not statistically significant
but suggesting a trend in favour of the lower β2M concentration group (Table 34).
A much higher proportion of participants who received more than three cycles of treatment achieved a
CR than those who received three cycles or fewer (73.2% vs. 28.0%) (Table 35). The difference in
response rates was –45.2% (95% CI –64.3% to –26.2%), indicating a significant trend in favour of
participants who received more than three cycles of treatment. Of the participants who received treatment
with GCSF at some stage during the first three treatment cycles, 67.9% achieved a CR, compared with
72.6% of those who did not. This difference (–4.8%) was non-significant, with 95% CIs that contain zero
(–19.9% to 10.4%). Of the participants who received treatment with GCSF during any treatment cycle,
64.9% achieved a CR compared with 71.1% of those who did not receive treatment with GCSF. This
TABLE 35 Treatment cycles received by achievement of the primary end point (ITT population)
Treatment cycles received
Three cycles or
fewer (n= 25)
More than three
cycles (n= 142) Difference in rates (95% CI)
Achieved a CR/CRi, n (%) 7 (28.0) 104 (73.2) –45.2% (–64.3% to –26.2%)
Did not achieve a CR/CRi, n (%) 18 (72.0) 38 (26.8)
Received GCSF during first
three cycles Yes (n = 56) No (n = 95)
Achieved a CR/CRi, n (%) 38 (67.9) 69 (72.6) –4.8% (–19.9% to 10.4%)
Did not achieve a CR/CRi, n (%) 18 (32.1) 26 (27.4)
Received GCSF during
treatment Yes (n = 77) No (n = 83)
Achieved a CR/CRi, n (%) 50 (64.9) 59 (71.1) –6.1% (–20.6% to 8.3%)
Did not achieve a CR/CRi, n (%) 27 (35.1) 24 (28.9)
TABLE 36 Baseline genetic markers by achievement of the primary end point (ITT population)
17p deletion
Yes (poorer risk)
(n= 6)
No (standard risk)
(n= 147) Difference in rates (95% CI)
Achieved a CR/CRi, n (%) 0 (0.0) 102 (69.4) –69.4% (–76.8% to –61.9%)
Did not achieve a CR/CRi, n (%) 6 (100) 45 (30.6)
11q deletion
Yes (poorer risk)
(n = 24)
No (standard risk)
(n = 133)
Achieved a CR/CRi, n (%) 14 (58.3) 90 (67.7) –9.3% (–30.6% to 11.9%)
Did not achieve a CR/CRi, n (%) 10 (41.7) 43 (32.3)
VH mutation risk Poor risk (n = 87)
Standard risk
(n = 52)
Achieved a CR/CRi, n (%) 54 (62.1) 36 (69.2) –7.2% (–23.3% to 9.0%)
Did not achieve a CR/CRi, n (%) 33 (37.9) 16 (30.8)
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difference (–6.1%) was non-significant, with 95% CIs that contain zero (–20.6% to 8.3%). This suggests
that the use of GCSF was successful in allowing the delivery of more cycles of therapy and that this
enabled participants to achieve better responses which were similar to those seen in participants not
requiring GCSF.
All participants who were 17p deleted and who had an available assessment of response (n = 6) failed to
achieve a CR. The 95% CI (–76.8% to –61.9%) is highly statistically significant. A higher proportion of
participants who did not have an 11q deletion achieved a CR compared with those who did (67.7% vs.
58.3). The difference in response rates (–9.3%) was non-significant with 95% CIs which contain zero
(Table 36). Of the 10 participants with an 11q deletion receiving FCR who had an available response
assessment, a greater number achieved a CR compared with those participants receiving FCM-miniR
[FCR = 8/10 (80.0%), FCM-miniR = 6/14 (42.9%)]. This might be expected as patients with 11q-deleted
CLL classically have a relatively high expression of CD20 and are very sensitive to rituximab when combined
with FC. Of the participants who were in the ‘poor’ VH mutation risk group, 62.1% achieved a CR
compared with 69.2% of those who were in the ‘standard’ risk group. This difference (–7.2%) was
non-significant with 95% CIs that contain zero (–23.3% to 9.0%).
Secondary end points
Overall response rate
At 3 months post treatment, of the 197 participants randomised and with a response assessment, a total
of 184 (93.4%) achieved at least a PR, including 10 participants with missing trephine data for whom it
was known that they were at least a PR (Table 37) but for whom it could not be confirmed if they were a
CR for the primary analysis. A slightly higher proportion of participants in the FCR arm achieved at least
a PR compared with the FCM-miniR arm (n = 94, 95.9% FCR; n = 69, 88.5% FCM-miniR) with all
participants receiving FCM-miniR/FCR achieving at least a PR. Thirteen participants (6.6%) did not achieve
an overall response, and there were three participants with missing data (Table 37).
Table 38 presents the proportion of participants achieving an OR (at least a PR) at 3 months post treatment
and the difference in the response rates between the arms, after excluding those FCM-miniR participants
(n = 21) who received treatment with FCR post-interim analysis. The ORR is high at 92.6% (n = 163), with a
slightly higher proportion of participants in the FCR arm achieving at least a PR compared with participants
in the FCM-miniR arm (95.9% FCR; 88.5% FCM-miniR). Approximately 7.5% fewer participants achieved
at least a PR in the FCM-miniR arm (95% CI –15.6% to 0.6%). As the CI contains zero, the difference
between the arms is not statistically significant, although it is bordering on significance.
TABLE 37 Overall response rate at 3 months post treatment
ORR FCR (n= 98) FCM-miniR (n= 78) FCM-miniR/FCR (n= 21) Total (n= 197)
Achieved at least a PR, n (%) 94 (95.9) 69 (88.5) 21 (100) 184 (93.4)
Did not achieve at least a PR, n (%) 4 (4.1) 9 (11.5) 0 (0.0) 13 (6.6)
TABLE 38 Difference in the proportion of participants achieving an overall response at 3 months post treatment
ORR
FCR
(n= 98)
FCM-miniR
(n= 78) Total (n= 176)
Difference in OR
rates (95% CI)
(FCM-miniR – FCR)
Achieved at least a PR, n (%) 94 (95.9) 69 (88.5) 163 (92.6) –7.5% (–15.6% to 0.6%)
Did not achieve at least a PR, n (%) 4 (4.1) 9 (11.5) 13 (7.4)
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When the responses to treatment are broken down into categories, as per IWCLL, 128/200 (64.0%)
participants achieved a CR, with 33.5% achieving complete remission and 30.5% achieving complete
remission with incomplete marrow recovery at 3 months’ treatment. Forty-six participants (23.0%) were
assessed as achieving partial remission. Three participants were recorded as having stable disease
(one FCR, two FCM-miniR) and three as having PD (three FCM-miniR). A total of 15 participants had
missing response data owing to being lost to follow-up prior to the 3-month post-treatment visit (n = 4),
insufficient clinical evaluations to be able to assess response (n = 1) and missing trephine data (n = 10).
The participants with missing trephine data were known to have achieved at least a PR and so are included
in the ORR analysis (Table 39). The participant who died as a result of their CLL, two of the participants
who withdrew owing to toxicity and non-response and the four participants who discontinued treatment
early owing to toxicity/non-response and were lost to follow-up are included in the CR and OR analyses as
non-responders.
Minimal residual disease
Minimal residual disease was assessed in the bone marrow at 3 months post treatment. At this time,
85/200 participants (42.5%) were MRD negative and 81/200 (40.5%) were MRD positive (Table 40).
A total of 29 participants (14.5%) had missing MRD data with proportions reasonably balanced across the
treatment arms (n = 15, 15.0% FCR; n = 13, 16.5% FCM-miniR). Reasons for missing MRD data included:
procedure attempted but unable to get sample (n = 1); participant refused to have sample taken (n = 3);
sample not taken as participant unwell (n = 2); sample not taken owing to investigator’s discretion (n = 2);
sample not taken owing to an administrative error or clinical omission (n = 10); missed visit (n = 3); reasons
unknown (n = 8).
For participants with missing MRD data at 3 months post treatment, the missing value was imputed using
the next available observation, if available, as described in Chapter 2, Missing data handling. This was the
case for 14 participants (10 FCR; three FCM-miniR; one FCM-miniR/FCR). Twelve MRD-negative results were
imputed (eight FCR; three FCM-miniR; one FCM-miniR/FCR) and two MRD-positive results (two FCR). Of the
four participants in the FCR arm who withdrew from follow-up data collection prior to the assessment of
response, two did so owing to toxicity and non-response. These participants and the participant in the
FCM-miniR arm who died early as a result of CLL (prior to 3 months post treatment) have been classed as
‘MRD positive’.
TABLE 39 International Workshop on Chronic Lymphocytic Leukaemia response assessment at 3 months post
treatment (all randomised participants)
IWCLL response assessment
FCR
(n= 100)
FCM-miniR
(n= 79)
FCM-miniR/FCR
(n= 21) Total (n= 200)
Complete remission, n (%) 40 (40.0) 18 (22.8) 9 (42.9) 67 (33.5)
Complete remission with incomplete
marrow recovery (CRi), n (%)
30 (30.0) 23 (29.1) 8 (38.1) 61 (30.5)
Partial remission, n (%) 18 (18.0) 25 (31.6) 3 (14.3) 46 (23.0)
Stable disease, n (%) 1 (1.0) 2 (2.5) 0 (0.0) 3 (1.5)
PD, n (%) 0 (0.0) 3 (3.8) 0 (0.0) 3 (1.5)
Early death, n (%) 0 (0.0) 1 (1.3) 0 (0.0) 1 (0.5)
Withdrew from further follow-up data
collection prior to assessment of
response, n (%)
4 (4.0) 0 (0.0) 0 (0.0) 4 (2.0)
Missing, n (%) 7 (7.0) 7 (8.9) 1 (4.8) 15 (7.5)
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Of the 183 participants with an assessment of MRD after imputation, over half (53.0%) were MRD negative at
3 months post treatment (Table 41). A total of 57.0% (n= 53) of FCR participants were MRD negative compared
with 46.4% (n= 32) of FCM-miniR participants and 57.1% (n= 12) of those participants randomised to
FCM-miniR who swapped over to receive treatment with FCR.
Table 42 presents the proportion of participants with undetectable MRD (MRD negative) at 3 months post
treatment and the difference in rates between the arms, excluding those FCM-miniR participants (n = 21)
who received treatment with FCR following the interim analysis. A higher proportion of participants in the
FCR arm were MRD negative than participants in the FCM-miniR arm (n = 53, 57.0% FCR; n = 32, 46.4%
FCM-miniR). Approximately 11% fewer participants were MRD negative in the FCM-miniR arm (95% CI
–26.1% to 4.9%). As the CI contains zero, there is no evidence of a significant difference between the
treatment arms, although the overall trend is in favour of the FCR arm.
A binary multivariate logistic regression model was used to assess formally the effect of treatment on the
proportion of participants achieving MRD negativity at 3 months post treatment, after adjusting for
the minimisation factors, excluding centre (Table 43).
The OR for achieving MRD negativity in the FCM-miniR arm compared with the FCR arm was 0.63
(95% CI 0.34 to 1.20), indicating that there is a non-significant trend towards FCM-miniR participants
being less likely to achieve MRD negativity at 3 months post treatment than participants in the FCR arm.
TABLE 40 Proportion of participants with an MRD assessment at 3 months post treatment (all randomised participants)
Assessment of MRD
FCR
(n= 100)
FCM-miniR
(n= 79)
FCM-miniR/FCR
(n= 21)
Total
(n= 200)
MRD negative, n (%) 45 (45.0) 29 (36.7) 11 (52.4) 85 (42.5)
MRD positive, n (%) 36 (36.0) 36 (45.6) 9 (42.9) 81 (40.5)
Withdrew from further follow-up data
collection prior to assessment of MRD, n (%)
4 (4.0) 0 (0.0) 0 (0.0) 4 (2.0)
Early death, n (%) 0 (0.0) 1 (1.3) 0 (0.0) 1 (0.5)
Missing, n (%) 15 (15.0) 13 (16.5) 1 (4.8) 29 (14.5)
TABLE 41 Proportion of participants achieving MRD negativity at 3 months post treatment
Assessment of MRD
FCR
(n= 93)
FCM-miniR
(n= 69)
FCM-miniR/FCR
(n= 21)
Total
(n= 183)
MRD negative, n (%) 53 (57.0) 32 (46.4) 12 (57.1) 97 (53.0)
MRD positive, n (%) 40 (43.0) 37 (53.6) 9 (42.9) 86 (47.0)
TABLE 42 Difference in the proportion of participants with undetectable MRD at 3 months post treatment
MRD status
FCR
(n= 93)
FCM-miniR
(n= 69) Total (n= 162)
Difference in MRD-negative
rates (95% CI) (FCM-miniR – FCR)
MRD negative, n (%) 53 (57.0) 32 (46.4) 85 (52.5) –10.6% (–26.1% to 4.9%)
MRD positive, n (%) 40 (43.0) 37 (53.6) 77 (47.5)
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Progression-free survival
The final participant’s 24-month clinic visit (after which they are followed up annually) was carried out on
13 October 2014; the data lock for the analysis of the long-term follow-up data was performed on
15 October 2014. At the time of analysis, the median follow-up time of participants who were event-free and
still in follow-up was 37.3 months (range: 24.7–58.1 months). PFS was defined as the time from randomisation
to the first documented evidence of disease progression or death. Overall, 38 participants (19.0%) had
progressed, 17 in the FCR arm (17.0%), 19 in the FCM-miniR arm (24.1%) and two participants who received
both FCM-miniR and FCR. A total of 49 (24.5%) participants had either progressed or died: 24 in the
FCM-miniR arm (30.4%) compared with 22 in the FCR arm (22.0%) (Table 44).
Figure 5 presents the Kaplan–Meier curves for PFS in months by randomisation allocation. Participants still
alive and progression-free at the time of analysis were censored at the last date on which they were known
to be alive and progression-free, indicated by a cross. Participants who were randomised to FCM-miniR but
transferred over to receive treatment with FCR were excluded from the analysis (n = 21).
The PFS curves indicate an overall trend towards an improvement in PFS for participants in the FCR arm.
More early progressions are seen with FCM-miniR than with FCR within the first 12 months, but after that
the curves remain roughly proportional. At 24 months post randomisation, the PFS probability in the FCR
arm is 89.4% compared with 79.1% in the FCM-miniR arm. There is a high number of censored
observations around and beyond the 24-month point, the time to which the majority of participants have
been followed up, so care must be taken at this stage not to over-interpret the results until longer-term
follow-up data are acquired.
A log-rank test was used to compare the differences between the PFS curves. There was no evidence of a
significant difference between the treatment arms at the 5% significance level with respect to time to
progression (p = 0.279). The Wilcoxon rank-sum test, which gives greater weight to earlier differences, was
also non-significant (p = 0.1081) (Table 45).
In a formal Cox regression analysis, after adjusting for the minimisation factors, excluding centre, there
was no evidence of a significant difference in PFS between the treatment arms at the 5% significance level
with a HR of 1.39 (95% CI 0.77 to 2.49; p = 0.2771) (Table 46), although it should be noted that the CIs
TABLE 43 Multivariate logistic regression analysis for the proportion of participants with undetectable MRD at
3 months post treatment, adjusted for the minimisation factors
Parameter df Parameter estimate SE Wald χ2 Pr > χ2 OR (95% CI)
Intercept 1 0.54 0.29 3.47 0.062
Treatment group: FCM-miniR vs. FCR 1 –0.46 0.32 1.97 0.160 0.63 (0.34 to 1.20)
Sex: female vs. male 1 0.10 0.35 0.08 0.775 1.10 (0.56 to 2.18)
Age group: > 65 years vs. ≤ 65 years 1 –0.67 0.34 3.93 0.048 0.51 (0.27 to 0.99)
Binet stage: C vs. A progressive or B 1 –0.12 0.34 0.13 0.721 0.89 (0.46 to 1.72)
df, degrees of freedom.
TABLE 44 Proportion of participants with PD (all randomised participants)
Status
FCR
(n= 100)
FCM-miniR
(n= 79)
FCM-miniR/FCR
(n= 21) Total (n= 200)
Number of participants with PD, n (%) 17 (17.0) 19 (24.1) 2 (9.5) 38 (19.0)
Number of participants with PD and/or
who have died, n (%)
22 (22.0) 24 (30.4) 3 (14.3) 49 (24.5)
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are wide owing to the relatively short follow-up period. Although non-significant, a HR of 1.39 indicates
that there is a trend in favour of the FCR arm, and that participants in the FCM-miniR arm are around
40% more likely to progress at each time point. The trial was not powered to detect a difference in PFS
and CIs around the HR are wide, indicating a lack of precision of the HR estimate owing to the small
number of events, and indicating that longer-term follow-up data are required.
The 95% CIs around the HRs for the minimisation factors all contain 1, indicating that there is no
significant evidence that any of the minimisation factors are significantly associated with PFS, although it
should be noted that the CIs are wide owing to the relatively short follow-up period.
0
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
6 12 18 24
Months from randomisation to progression/death
PF
S 
p
ro
b
ab
ili
ty
30 36 42
79
100
Number at risk
FCM-miniR
FCR
FCM-miniR
FCR
75
97
71
95
66
88
51
63
43
44
31
28
14
16
FIGURE 5 Kaplan–Meier plot of time to progression by randomisation allocation.
TABLE 45 Median time to progression and comparison between the treatment arms
Randomisation
allocation
Median time
to progression
(months) (95% CI)
Total
number of
participants
Total
number
of events
Total number
of censored
observations Test χ2 df p-value
FCM-miniR 48.5 (40.4 to NE) 79 24 55 Log-rank 1.1719 1 0.2790
FCR 52.7 (42.9 to NE) 100 22 78 Wilcoxon
rank-sum
2.5811 1 0.1081
Total 52.7 (44.5 to NE) 179 46 133
df, degrees of freedom; NE, not estimable.
TABLE 46 Cox’s proportional hazards model for the time to progression adjusted for the minimisation factors
Parameter df Parameter estimate SE χ2 p-value HR (95% CI)
Randomisation allocation: FCM-miniR
vs. FCR
1 0.33 0.30 1.18 0.2771 1.39 (0.77 to 2.49)
Age group: > 65 years vs. ≤ 65 years 1 0.05 0.32 0.03 0.8702 1.05 (0.56 to 1.97)
Sex: female vs. male 1 –0.04 0.32 0.02 0.8952 0.96 (0.51 to 1.81)
Binet stage: C vs. A progressive or B 1 –0.16 0.32 0.23 0.6298 0.86 (0.45 to 1.61)
df, degrees of freedom.
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Overall survival
At the time of analysis (October 2014), the median follow-up time for survivors was 37.7 months (range
24.7–58.1 months). OS was defined as the time from randomisation to death from any cause. In total,
24 participants (12.0%) had died: 10 in the FCR arm (10.0%), 13 in the FCM-miniR arm (16.5%) and one
participant who received FCM-miniR followed by one cycle of FCR (Table 47). The most common primary
cause of death was ‘overwhelming tumour load’ in 33.3% of cases (n = 8) and there was only one
treatment-related death in the trial, occurring in the FCR arm.
Figure 6 presents the Kaplan–Meier curves for OS in months by randomisation allocation. Participants still
alive at the time of analysis were censored at the last date on which they were known to be alive, indicated
by a cross. Participants who were randomised to FCM-miniR but transferred over to receive treatment with
FCR were excluded from the analysis (n = 21).
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FIGURE 6 Kaplan–Meier plot of OS by randomisation allocation.
TABLE 47 Proportion of participants who have died and primary cause of death
Number of participants who have died, n (%)
FCR
(n= 100)
FCM-miniR
(n= 79)
FCM-miniR/FCR
(n= 21)
Total
(n= 200)
10 (10.0) 13 (16.5) 1 (4.8) 24 (12.0)
Primary cause of death
Treatment-related death 1 (10.0) 0 (0.0) 0 (0.0) 1 (4.2)
Overwhelming tumour load 2 (20.0) 6 (46.2) 0 (0.0) 8 (33.3)
Infection owing to CLL 3 (30.0) 4 (30.8) 0 (0.0) 7 (29.2)
Infection owing to treatment 2 (20.0) 0 (0.0) 1 (100) 3 (12.5)
High-grade transformation on the background
of CLL
0 (0.0) 1 (7.7) 0 (0.0) 1 (4.2)
Other malignancies (non-haematopoietic) 0 (0.0) 1 (7.7) 0 (0.0) 1 (4.2)
Other 2 (20.0)a 1 (7.7)b 0 (0.0) 3 (12.5)
a Idiopathic thrombocytopenia; pulmonary haemorrhage.
b Acute intraparenchymal haemorrhage.
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The survival curves indicate an overall trend towards an improvement in OS for participants in the FCR arm.
As with PFS, there are a greater number of earlier events in participants on FCM-miniR, with the curves
becoming closer to parallel after 18 months. At 24 months post randomisation, the survival probability is
95.8% in the FCR arm compared with 88.5% in the FCM-miniR arm. There are a high number of censored
observations around and beyond the 24-month point, the time to which the majority of participants have
been followed up, so care must be taken at this stage not to overinterpret the results until longer-term
follow-up data are acquired.
The log-rank test was used to compare the difference between the survival curves. There was no evidence
of a significant difference between the treatment arms at the 5% significance level with respect to OS
(p = 0.2779). The Wilcoxon rank-sum test, which gives greater weight to earlier differences, was also
non-significant (p = 0.1013) (Table 48). Note, however, that there have been few events in either arm
owing to the relatively short follow-up period.
In the formal Cox regression analysis, after adjusting for the minimisation factors, excluding centre, there
was no evidence of a significant difference in OS between the treatment arms at the 5% significance level
with a HR of 1.57 (95% CI 0.68 to 3.58; p = 0.2876) (Table 49). Although non-significant, a HR of 1.57
indicates that there is a trend in favour of the FCR arm, and that participants in the FCM-miniR arm are
around 57% more likely to not survive at any time point. The trial was not powered to detect a difference
in OS and the CIs around the HR are wide, indicating a lack of precision of the HR estimate owing to the
small number of events, so longer-term follow-up data would be beneficial.
The 95% CIs around the HRs for the minimisation factors all contain 1, indicating that there is no evidence
that any of the minimisation factors are significantly associated with OS, although there is only a limited
period of follow-up at the time of reporting. There is a suggested trend in favour of participants aged
65 years or younger to have an improved survival than those aged over 65.
TABLE 48 Median time to death and comparison between treatment arms
Randomisation
allocation
Median time to
death (months)
(95% CI)
Total
number of
participants
Total
number
of events
Total number
of censored
observations Test χ2 df p-value
FCM-miniR NE 79 13 66 Log-rank 1.1771 1 0.2779
FCR NE 100 10 90 Wilcoxon
rank-sum
2.6854 1 0.1013
Total NE 179 23 156
df, degrees of freedom; NE, not estimable.
TABLE 49 Cox’s proportional hazards model for OS adjusted for the minimisation factors
Parameter df Parameter estimate SE χ2 p-value HR (95% CI)
Randomisation allocation: FCM-miniR vs.
FCR
1 0.45 0.42 1.13 0.2876 1.57 (0.68 to 3.58)
Age group: > 65 vs. ≤ 65 1 0.46 0.42 1.17 0.2797 1.58 (0.69 to 3.61)
Sex: female vs. male 1 –0.29 0.48 0.36 0.5485 0.75 (0.29 to 1.92)
Binet stage: C vs. A progressive or B 1 –0.05 0.46 0.01 0.9053 0.95 (0.39 to 2.33)
df, degrees of freedom.
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Time to minimal residual disease relapse
Participants who were MRD negative at 3 months post treatment were followed up 6-monthly until MRD
relapse (i.e. until they became MRD positive) or until 24 months post randomisation. Longer follow-up was
not possible owing to funding constraints. In the population of participants who were assessable for MRD
at 3 months post treatment, 85/162 (52.5%) participants had achieved MRD negativity (see Table 42). At
the time of analysis, it was reported that only seven participants had relapsed at the MRD level (four FCR,
three FCM-miniR); however, there was a high proportion of missing MRD data at each of the follow-up
visits. Owing to the small number of events, high proportion of missing data and lack of longer-term
follow-up data, the time to MRD relapse analysis was unable to be performed.
Subgroup analyses
Subgroup analyses were carried out to assess PFS and OS based on IWCLL and MRD response groups,
the minimisation factors, number of cycles of treatment received, GCSF usage and genetic risk groups.
As the trial was not powered for survival end points or to look for differences in subgroups of participants,
the results are to be treated as exploratory and used for hypothesis generating purposes only.
Progression-free survival by minimal residual disease response status
Figure 7 presents the Kaplan–Meier curves for time to progression by MRD status at 3 months post
treatment. Of the 85 participants who were MRD negative at this time point, eight (9.4%) have reported
an event (i.e. progression or death) compared with 30/77 (39.0%) who were MRD positive.
The curves show clear divergence from 6 months post randomisation, the end of treatment visit, with an
overall trend towards an improvement in PFS for participants who were MRD negative at 3 months post
treatment. This difference was significant at the 5% level in favour of the MRD-negative participants
(log-rank: χ2 = 23.20; p < 0.0001). At 24 months post randomisation, the PFS probability is 96.4% for
MRD-negative participants compared with 79.2% for the MRD-positive group.
Progression-free survival by minimal residual disease response status and
randomisation allocation
Figure 8 presents the Kaplan–Meier curves for time to progression by randomisation allocation and MRD
status at 3 months post treatment.
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FIGURE 7 Kaplan–Meier plot of time to progression by MRD status at 3 months post treatment.
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For the participants who became MRD negative, the PFS curves are similar for the two treatment arms.
For the participants who were MRD positive, participants in the FCR arm show a trend towards a slightly
improved time to progression compared with participants in the FCM-miniR arm until around 24–30 months
post randomisation, at which point there are a number of censored observations, indicating that longer term
follow-up would be beneficial to interpretation. At 24 months post randomisation, the PFS probabilities for
the MRD-negative participants were similar between the treatment groups (96.2% FCR, 96.9% FCM-miniR).
For MRD-positive participants, the PFS probability was 83.7% in the FCR arm compared with 74.9% in the
FCR-miniR arm.
Progression-free survival by complete response status
Figure 9 presents the Kaplan–Meier curves for time to progression by CR status at 3 months post
treatment. Of the participants who had achieved a complete remission or CRi at this time point, 16/111
(14.4%) had an event (i.e. progression or death) compared with 27/56 (48.2%) who had not achieved at
least a CR.
The curves show clear divergence from 6 months post randomisation, the end of treatment visit, with an
overall trend towards an improvement in PFS for participants who achieved a CR at 3 months post
treatment. This difference was significant at the 5% level in favour of participants who achieved at least a
CR (log-rank: χ2 = 29.41; p < 0.0001). At 24 months post randomisation, the PFS probability is 93.4% for
participants who achieved a CR compared with 65.4% for those who did not.
Progression-free survival by complete response status and randomisation
allocation
Figure 10 presents the Kaplan–Meier curves for time to progression by randomisation allocation and CR
status at 3 months post treatment.
For the participants who achieved a CR, the curves are similar for the two treatment arms, with a slight
trend towards the FCM-miniR participants doing better. For the participants who did not achieve a CR,
participants in the FCR arm have an improved time to progression compared with FCM-miniR participants.
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FIGURE 8 Kaplan–Meier plot of time to progression by randomisation allocation and MRD status at 3 months
post treatment.
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At 24 months post randomisation, the PFS probabilities for the participants who achieved a CR were
similar between the treatment groups (92.6% FCR, 94.8% FCM-miniR). For participants who did not
achieve a CR, the PFS survival probability was 74.3% in the FCR arm compared with 60.3% in the
FCR-miniR arm.
Overall survival by minimal residual disease response status
Figure 11 presents the Kaplan–Meier curves for OS by MRD status at 3 months post treatment. Of the
participants who were MRD negative at this time point, 4/85 (4.7%) had died compared with 14/77
(18.2%) who were MRD positive.
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FIGURE 9 Kaplan–Meier plot of time to progression by CR status at 3 months post treatment.
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FIGURE 10 Kaplan–Meier plot of time to progression by randomisation allocation and CR status at 3 months
post treatment.
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The curves show clear divergence from the end of treatment visit, with an overall trend towards an
improvement in OS for participants who were MRD negative at 3 months post treatment. This difference
was significant at the 5% level in favour of the MRD-negative participants (log-rank: χ2 = 9.25; p = 0.003).
At 24 months post randomisation, the OS probability for MRD-negative participants is 97.6% compared
with 91.9% for the MRD-positive group.
Overall survival by minimal residual disease response status and
randomisation allocation
Figure 12 presents the Kaplan–Meier curves for OS by randomisation allocation and MRD status at
3 months post treatment.
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FIGURE 11 Kaplan–Meier plot of OS by MRD status at 3 months post treatment.
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FIGURE 12 Kaplan–Meier plot of OS by randomisation allocation and MRD status at 3 months post treatment.
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For the participants who became MRD negative, the OS curves are similar for the two treatment arms.
A similar survival pattern was observed for MRD-positive participants receiving FCR until around 30 months
post randomisation, at which point survival worsened. OS was poorest for MRD-positive participants
who received FCM-miniR. At 24 months post randomisation, the OS probabilities for the MRD-negative
participants were similar between the treatment groups (98.1% FCR, 96.9% FCM-miniR), and for
MRD-positive participants receiving FCR (97.3%). The FCM-miniR, MRD-positive group showed the poorest
OS probability at 24 months (86.5%).
Overall survival by complete response status
Figure 13 presents the Kaplan–Meier curves for OS by CR status at 3 months post treatment. Of the
participants who had achieved a CR at this time point, 8/111 (7.2%) had died compared with 15/56
(26.8%) who had not achieved a CR.
The curves show clear divergence from 6 months post randomisation, the end of treatment visit, with
an overall trend towards an improvement in OS for participants who achieved a CR at 3 months post
treatment. This difference was significant at the 5% level in favour of participants who achieved a CR
(log-rank: χ2 = 16.92; p < 0.001). At 24 months post randomisation, the OS probability for participants
who achieved a CR is 96.4% compared with 82.9% for those who did not.
Overall survival by complete response status and randomisation allocation
Figure 14 presents the Kaplan–Meier curves for OS by randomisation allocation and CR status at 3 months
post treatment.
For the participants who achieved a CR, the curves are similar for the two treatment arms. A similar
survival pattern was observed for participants who did not achieve a CR who were receiving FCR until
around 30 months post randomisation, at which point survival worsened. OS was poorest for participants
who did not achieve a CR and who received FCM-miniR. At 24 months post randomisation, the OS
probabilities for the participants who achieved a CR were similar between the treatment groups (95.6%
FCR, 97.6% FCM-miniR), and for participants who did not achieve a CR receiving FCR (95.0%). The
FCM-miniR participants who did not achieve a CR showed the poorest OS probability at 24 months (75.8%).
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FIGURE 13 Kaplan–Meier plot of OS by CR status at 3 months post treatment.
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Progression-free survival and overall survival by minimisation factors at
baseline: sex
Figure 15 presents the Kaplan–Meier curves for time to progression by participant sex. At the time of
analysis, of the 123 male participants, 32 (26.0%) had reported an event (i.e. progression or death)
compared with 14/56 (25.0%) female participants.
At 24 months post randomisation, the PFS probability for male participants was 84.4% compared with
85.5% for females. The difference between the PFS curves for sex was non-significant (log-rank:
χ2 = 0.045; p = 0.833).
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Figure 16 presents the Kaplan–Meier curves for OS by participant sex. At the time of analysis, of the
123 male participants, 17 (13.8%) had died compared with 6/56 (10.7%) female participants.
At 24 months post randomisation, the OS probability for male participants was 92.4% compared with
92.8% for females. The difference between the OS curves for sex was non-significant (log-rank:
χ2 = 0.411; p = 0.522).
Progression-free survival and overall survival by minimisation factors at
baseline: age group
Figure 17 presents the Kaplan–Meier curves for time to progression by age group (≤ 65 years, > 65 years).
At the time of analysis, of the 113 participants aged ≤ 65 years, 31 (27.4%) had reported an event
(i.e. progression or death) compared with 15/66 (22.7%) participants aged over 65 years.
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At 24 months post randomisation, the PFS probability for participants aged ≤ 65 years was 87.0%
compared with 80.9% for those older than 65 years. Although there appears to be a trend in favour of
younger participants performing better in terms of PFS, the overall difference between the PFS curves for
age group was non-significant (log-rank: χ2 = 0.015; p = 0.902).
Figure 18 presents the Kaplan–Meier curves for OS by age group (≤ 65 years, > 65 years). At the time of
analysis, of the 113 participants aged ≤ 65 years, 13 (11.5%) had died compared with 10/66 (15.2%)
participants aged over 65 years.
At 24 months post randomisation, the OS probability for participants aged ≤ 65 years was 94.5%
compared with 89.0% for those over 65 years of age. The difference between the OS curves for age
group was non-significant (log-rank: χ2 = 1.106; p = 0.293), although there is a suggested trend for
younger participants performing better in terms of OS.
Progression-free survival and overall survival by minimisation factors at
baseline: Binet stage
Figure 19 presents the Kaplan–Meier curves for time to progression by Binet stage (A progressive or B, C).
At the time of analysis, of the 118 participants who were Binet stage A progressive or B, 32 (27.0%)
had reported an event (i.e. progression or death) compared with 14/61 (23.0%) participants who were
Binet stage C.
At 24 months post randomisation, the PFS probability for participants with Binet stage A progressive or
B was 84.8% compared with 84.7% for Binet stage C participants. The difference between the PFS curves
for Binet stage was non-significant (log-rank: χ2 = 0.217; p = 0.641).
Figure 20 presents the Kaplan–Meier curves for OS by Binet stage (A progressive or B, C). At the time of
analysis, of the 118 participants who were Binet stage A progressive or B, 16 (13.6%) had died compared
with 7/61 (11.5%) participants who were Binet stage C.
At 24 months post randomisation, the OS probability for participants with Binet stage A progressive or
B was 91.2% compared with 95.0% for Binet stage C participants. The difference between the OS curves
for Binet stage was non-significant (log-rank: χ2 = 0.030; p = 0.863).
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Progression-free survival and overall survival by treatment received
Figure 21 presents the Kaplan–Meier curves for time to progression by number of treatment cycles
received (three or fewer, more than three). At the time of analysis, of the 31 participants who received
three cycles or fewer, 16 (51.6%) had reported an event (i.e. progression or death) compared with 30/148
(20.3%) participants who received more than three cycles of treatment.
The curves show clear divergence from the end of treatment with an overall trend towards an
improvement in PFS for participants who received more than three cycles of treatment. At 24 months post
randomisation, the PFS probability for participants receiving more than three cycles of treatment was
92.3% compared with 43.9% for those receiving three or less. The overall difference between the PFS
curves was significant at the 5% level (log-rank: χ2 = 51.629; p < 0.0001).
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Figure 22 presents the Kaplan–Meier curves for OS by number of treatment cycles received (three or fewer,
more than three). At the time of analysis, of the 31 participants who received three cycles or less,
8 (25.8%) had died compared with 15/148 (10.1%) participants who received more than three cycles
of treatment.
The curves show clear divergence from the end of treatment with an overall trend towards a worse OS for
participants who received three or fewer cycles of treatment. At 24 months post randomisation, the OS
probability for participants receiving more than three cycles of treatment was 95.9% compared with
74.1% for those receiving three or fewer. The overall difference between the OS curves was significant
at the 5% level (log-rank: χ2 = 14.167; p = 0.0002).
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Progression-free survival and overall survival by granulocyte-colony
stimulating factor usage
Figure 23 presents the Kaplan–Meier curves for time to progression by GSCF usage during treatment.
At the time of analysis, of the 82 participants who had received GCSF at some stage during their
treatment, 21 (25.6%) had reported an event (i.e. progression or death) compared with 23/87 (26.4%)
participants who had not received any GSCF.
At 24 months post randomisation, the PFS probability for participants who had received GCSF at some stage
during their treatment was 87.6% compared with 83.3% for participants who had not received any GCSF. The
difference between the PFS curves for GCSF usage was non-significant (log-rank: χ2 = 0.249; p= 0.618).
Figure 24 presents the Kaplan–Meier curves for OS by GCSF usage during treatment. At the time of
analysis, of the 82 participants who had received GCSF at some stage during their treatment, 11 (13.4%)
had died compared with 12/87 (13.8%) participants who had not received any GSCF.
At 24 months post randomisation, the OS probability for participants who had received GCSF at some stage
during their treatment was 95.1% compared with 89.5% for participants who had not. The difference
between the OS curves for GCSF usage was non-significant (log-rank: χ2 = 0.067; p = 0.796).
Progression-free survival and overall survival by genetic risk factors: 17p and 11q
Given that there were only five participants with 17p deletion this analysis was not felt to be appropriate.
Figure 25 presents the Kaplan–Meier curves for time to progression by whether or not participants were 11q
deleted. At the time of analysis, of the 26 participants who had an 11q deletion, six (23.1%) had reported
an event (i.e. progression or death) compared with 37/142 (26.1%) participants who reported no event.
At 24 months post randomisation, the PFS probability for participants who were 11q deleted was 79.8%
compared with 84.5% for participants who were not. The difference between the PFS curves was
non-significant (log-rank: χ2 = 0.032; p = 0.858).
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FIGURE 23 Kaplan–Meier plot of PFS by GCSF usage.
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Figure 26 presents the Kaplan–Meier curves for PFS by whether or not participants were 11q deleted and by
treatment group. The numbers are small, with only 10 and 16 participants in the FCR and FCM-miniR groups,
respectively; however, it can be seen that only one of the FCR patients with 11q deletion progressed after
over 3 years, compared with 5/16 (31.3%) of 11q-deleted patients on FCM-miniR. Excluding these
11q-deleted patients from the PFS curves brings the FCR and FCM-miniR curves closer together than those in
Figure 5, although it can be seen that there is still a trend towards a PFS advantage with FCR over FCM-miniR.
Figure 27 presents the Kaplan–Meier curves for OS by whether or not participants were 11q deleted and by
treatment group. The numbers are small, with only 10 and 16 participants in the FCR and FCM-miniR groups,
respectively. No FCR patients with 11q deletion died, compared with 2/16 (12.5%) of 11q-deleted patients
on FCM-miniR. After excluding these 11q-deleted patients from the OS curves, there is still a trend towards a
survival advantage in the FCR group.
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Figure 28 presents the Kaplan–Meier curves for OS by whether or not participants were 11q deleted.
At the time of analysis, of the 26 participants who had an 11q deletion, 2 (7.7%) had died compared with
21/142 (14.8%) participants who had not.
At 24 months post randomisation, the OS probability was the same for participants who were 11q deleted
and those who were not (92.0%). The difference between the OS curves was non-significant (log-rank:
χ2 = 0.648; p = 0.421).
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Progression-free survival and overall survival by genetic risk factors:
VH mutation risk
Figure 29 presents the Kaplan–Meier curves for time to progression by VH mutation risk, where standard
risk indicates that the participant had a VH mutation not involving the VH3–21 gene and poor risk
indicates that the participant did not have a VH mutation, or that the VH3–21 gene was involved. At the
time of analysis, of the 91 participants with a poor VH mutation risk, 27 (29.7%) had reported an event
(i.e. progression or death) whereas 11/58 (18.0%) participants with a standard VH mutation risk had
reported an event.
At 24 months post randomisation, the PFS probability for the poor risk group was 82.6% compared with 87.4%
for the standard-risk group. Although there appears to be a slight trend in favour of standard-risk participants
performing better in terms of PFS, the difference between the PFS curves was non-significant (log-rank:
χ2= 1.672; p= 0.1960).
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Figure 30 presents the Kaplan–Meier curves for OS by VH mutation risk. At the time of analysis, of the
91 participants with a poor VH mutation risk, 16 (17.6%) had died whereas 5/58 (8.6%) participants with
a standard VH mutation risk had died.
At 24 months post randomisation, the OS probability was 91.0% for the poor-risk group compared with
94.6% for the standard-risk group. The difference between the OS curves was non-significant (log-rank:
χ2 = 2.172; p = 0.141), although there is a suggested trend for standard-risk participants performing better
in terms of OS.
Safety and toxicity
Safety summaries are based on the safety population, which includes 198 participants, 100 who received
FCR, 79 who received FCM-miniR and 19 who received FCM-miniR followed by FCR. The FCR arm
excludes two participants randomised to FCR who did not receive any protocol treatment and includes two
FCM-miniR participants who received FCR from their first treatment cycle, as planned and documented in
Chapter 2, Analysis populations.
Serious adverse events
A total of 183 SAEs [80 (43.7%) FCR; 81 (44.3%) FCM-miniR; 22 (12.0%) FCM-miniR/FCR] have been
reported from 104 (52.5%) participants. In the FCR arm, 49/100 (49.0%) participants reported at least one
SAE compared with 46/79 (58.2%) receiving FCM-miniR and 9/22 (47.4%) receiving FCM-miniR followed by
FCR (Table 50). Of the participants experiencing at least one SAE, the mean number of SAEs reported was
1.8, with a similar number for the FCR (mean = 1.6) and FCM-miniR (mean = 1.8) arms, as for rates for
all participants.
Of the 183 SAEs reported, 145 (79.2%) were suspected to be related to protocol treatment (SARs), with a
slightly higher proportion in the FCM-miniR arm (n = 67, 82.7%) than in the FCR arm (n = 62, 77.5%)
(Table 51). SARs were reported from 89 participants (44.9%), with a higher proportion of SARs reported
from participants receiving FCM-miniR (n = 39, 49.4%), compared with FCR (n = 41, 41.0%), and from
nine participants (47.4%) receiving FCM-miniR followed by FCR. There was one SUSAR reported in the trial,
from a participant in the FCR arm. This SUSAR was reported to the regulatory authorities (Medicines and
Healthcare products Regulatory Agency), sponsor and the main REC within the required timelines for
0
0.0
0.1
0.2
0.3Su
rv
iv
al
 p
ro
b
ab
ili
ty
0.4
0.5
0.6
0.7
0.8
0.9
1.0
6 12 18 24
Poor risk
Standard risk
30 36 42
91
58
Number at risk
Poor risk
Standard risk
88
56
86
55
79
53
59
44
47
35
33
22
15
10
Months from randomisation to death
FIGURE 30 Kaplan–Meier plot of OS by VH mutation risk.
DOI: 10.3310/hta21280 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 28
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Howard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
67
expedited reporting. The participant received all six cycles of treatment and was diagnosed with a
‘squamous cell carcinoma’ approximately 4 months after their last cycle of treatment. The event was felt by
the Principal Investigator at the site to be related to trial treatment (FCR) and unexpected. Further details on
this event, and all SAEs, are provided in Appendix 1.
Of the 145 SAEs suspected to be related to protocol treatment, in the FCR arm the majority (51.6%)
were suspected to be related to all three IMPs, F, C and R, with 33.9% suspected to be related to just
TABLE 50 Total number of SAEs reported overall and per participant (safety population)
SAEs FCR (n= 100)
FCM-miniR
(n= 79)
FCM-miniR/FCR
(n= 19) Total (n= 198)
Number of participants experiencing at
least one SAE, n (%)
49 (49.0) 46 (58.2) 9 (47.4) 104 (52.5)
Total number of SAEs reported 80 81 22 183
Number of SAEs per participant who had at least one event
Mean (SD) 1.6 (1.0) 1.8 (1.2) 2.4 (1.3) 1.8 (1.1)
Median (range) 1 (1–5) 1 (1–5) 2 (1–4) 1 (1–5)
N 49 46 9 104
Number of SAEs per participant (all participants)
Mean (SD) 0.8 (1.1) 1.0 (1.2) 1.2 (1.5) 0.9 (1.2)
Median (range) 0 (0–5) 1 (0–5) 0 (0–4) 1 (0–5)
N 100 79 19 198
TABLE 51 Relationship with experimental treatment (safety population)
Relationship to experimental
treatment
FCR,
N (%)
FCM-miniR,
N (%)
FCM-miniR/FCR,
N (%) Total, N (%)
Suspected, unexpected 1 (1.3) 0 (0.0) 0 (0.0) 1 (0.5)
Suspected, expected 61 (76.3) 67 (82.7) 16 (72.7) 144 (78.7)
Not suspected 18 (22.5) 14 (17.3) 6 (27.3) 38 (20.8)
Total 80 (100) 81 (100) 22 (100) 183 (100)
Suspected to be related to
Fludarabine 2 (3.2) 6 (9.0) 1 (6.3) 9 (6.2)
Cyclophosphamide 0 (0.0) 1 (1.5) 0 (0.0) 1 (0.7)
Rituximab 7 (11.3) 0 (0.0) 0 (0.0) 7 (4.8)
Low-dose rituximab 0 (0.0) 5 (7.5) 2 (12.5) 7 (4.8)
Fludarabine and cyclophosphamide 21 (33.9) 0 (0.0) 4 (25.0) 25 (17.2)
Fludarabine and mitoxantrone 0 (0.0) 2 (3.0) 0 (0.0) 2 (1.4)
Fludarabine and rituximab 0 (0.0) 0 (0.0) 1 (6.3) 1 (0.7)
Mitoxantrone and low-dose rituximab 0 (0.0) 1 (1.5) 0 (0.0) 1 (0.7)
FCM 0 (0.0) 21 (31.3) 1 (6.3) 22 (15.2)
FCR 32 (51.6) 0 (0.0) 2 (12.5) 34 (23.4)
Fludarabine, cyclophosphamide and
low-dose rituximab
0 (0.0) 1 (1.5) 0 (0.0) 1 (0.7)
FCM-miniR 0 (0.0) 30 (44.8) 5 (31.3) 35 (24.1)
Total 62 (100) 67 (100) 16 (100) 145 (100)
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F and C, and 11.3% suspected to be related to rituximab only. In the FCM-miniR arm, SAEs were
most commonly (44.8%) suspected to be related to all four IMPs, F, C, M and reduced-dose rituximab
(miniR) with 31.3% suspected to be related to F, C and M.
The majority of SAEs required (prolonged) hospitalisation (89.1%), with 92.5% coming from the FCR arm
and 84.0% from the FCM-miniR arm (Table 52).
Six SAEs in the FCM-miniR arm were deemed to be life-threatening or resulted in death, compared with
three in the FCR arm. In the FCR arm, one participant died as a result of an ‘infection’ which was
suspected to be related to trial treatment within 5 months of their last course of treatment. This participant
received two cycles of treatment. In the FCM-miniR arm, one participant died as a result of a ‘Bilateral
pneumonia’ which was suspected to be related to trial treatment within 9 months of their last course of
treatment. The participant received all six cycles of treatment. A further FCM-miniR participant died as
a result of ‘Neutropenic sepsis and infected shoulder’, which was not suspected to be related to trial
treatment, within 3 months of their last course of treatment. This participant received four cycles of
treatment. Further information on the SAEs that resulted in death are provided in Appendix 1.
All but three SAEs had recovered at the time of reporting.
The majority of SARs required (or prolonged) hospitalisation (90.3%) (93.5% in the FCR arm compared
with 86.6% in the FCM-miniR arm). All but three SARs had recovered at the time of reporting (Table 53).
Of the 198 participants in the safety population, 96 (48.5%) required hospitalisation during the trial as a
result of an SAE, with a higher proportion in the FCM-miniR arm (n = 41, 51.9%) than the FCR arm
(n = 46, 46.0%) (Table 54).
Of the 180 SAEs that were not ongoing, the median duration of an event was 5 days (range: < 1–303
days) with a similar duration in each of the treatment groups (Table 55). The median duration of SARs that
were suspected to be related to protocol treatment was the same, although there was variability in the
mean durations between the treatment arms.
TABLE 52 Seriousness criteria and outcome of each SAE (safety population)
Seriousness criteria and outcome
FCR,
N (%)
FCM-miniR,
N (%)
FCM-miniR/FCR,
N (%) Total, N (%)
Seriousness criteria
Participant died 1 (1.3) 2 (2.5) 0 (0.0) 3 (1.6)
Life-threatening 2 (2.5) 4 (4.9) 0 (0.0) 6 (3.3)
Required/prolonged hospitalisation 74 (92.5) 68 (84.0) 21 (95.5) 163 (89.1)
Persistent or significant disability/incapacity 2 (2.5) 0 (0.0) 0 (0.0) 2 (1.1)
Jeopardised participant/required
intervention to prevent one of the above
10 (12.5) 14 (17.3) 1 (4.5%) 25 (13.7%)
Outcome
Recovered 72 (90.0) 71 (87.7) 19 (86.4) 162 (88.5)
Recovered with sequelae 5 (6.3) 7 (8.6) 3 (13.6) 15 (8.2)
Condition improving 1 (1.3) 0 (0.0) 0 (0.0) 1 (0.5)
Condition still present and unchanged 1 (1.3) 1 (1.2) 0 (0.0) 2 (1.1)
Death 1 (1.3) 2 (2.5) 0 (0.0) 3 (1.6)
Total 80 (100) 81 (100) 22 (100) 183 (100)
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TABLE 53 Seriousness criteria and outcome of each SAR (safety population)
Seriousness criteria and outcome
FCR,
N (%)
FCM-miniR,
N (%)
FCM-miniR/FCR,
N (%) Total, N (%)
Seriousness criteria
Participant died 1 (1.6) 1 (1.5) 0 (0.0) 2 (1.3)
Life-threatening 2 (3.2) 4 (6.0) 0 (0.0) 6 (4.1)
Required/prolonged hospitalisation 58 (93.5) 58 (86.6) 15 (93.8) 131 (90.3)
Persistent or significant disability/incapacity 2 (3.2) 0 (0.0) 0 (0.0) 2 (1.3)
Jeopardised participant/required intervention
to prevent one of the above
8 (12.9) 11 (16.4) 1 (6.3) 20 (13.8)
Outcome
Recovered 58 (93.5) 60 (89.6) 15 (93.8) 133 (91.7)
Recovered with sequelae 1 (1.6) 5 (7.5) 1 (6.3) 7 (4.8)
Condition improving 1 (1.6) 0 (0.0) 0 (0.0) 1 (0.7)
Condition still present and unchanged 1 (1.6) 1 (1.5) 0 (0.0) 2 (1.4)
Death 1 (1.6) 1 (1.5) 0 (0.0) 2 (1.4)
Total 62 (100) 67 (100) 16 (100) 145 (100)
TABLE 54 Total number of participants requiring hospitalisation for an SAE (safety population)
Required hospitalisation for an SAE
FCR
(n= 100)
FCM-miniR
(n= 79)
FCM-miniR/FCR
(n= 19)
Total
(n= 198)
Yes, n (%) 46 (46.0) 41 (51.9) 9 (47.4) 96 (48.5)
No, n (%) 54 (54.0) 38 (48.1) 10 (52.6) 102 (51.5)
TABLE 55 Duration of SAEs and SARs (safety population)
Duration FCR, N (%)
FCM-miniR,
N (%)
FCM-miniR/FCR,
N (%) Total, N (%)
Duration of SAE (days from when SAE became serious to recovery/death)
Mean (SD) 15.9 (40.9) 15.3 (41.2) 15.9 (53.3) 15.6 (42.5)
Median (range) 4.0 (< 1–280.0) 5.0 (< 1–303.0) 4.5 (< 1–254.0) 5.0 (< 1–303.0)
N 78 80 22 180
Missing 2 1 0 3
Duration of SAR (days from when SAR became serious to recovery/death)
Mean (SD) 11.7 (22.8) 15.2 (44.5) 19.9 (62.5) 14.2 (39.4)
Median (range) 5.0 (< 1–144.0) 5.0 (< 1–303.0) 4.5 (< 1–254.0) 5.0 (< 1–303.0)
N 60 66 16 142
Missing 2 1 0 3
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Of the 145 SAEs suspected to be related to protocol treatment (SARs), the majority (n = 90, 62.1%) were
classed as ‘infections and infestations’ according to the MedDRA System Organ Class system (Table 56).
A higher proportion of events reported in the FCR arm were classed as ‘general disorders and administration
site conditions’ than those reported in the FCM-miniR arm [10 (16.1%) FCR; 6 (9.0%) FCM-miniR].
Adverse events
A total of 2163 AEs have been reported from 192 (97.0%) participants. A total of 1117 events have been
reported from 96 participants receiving FCR, 863 events from 77 participants receiving FCM-miniR and
183 from 19 participants who received FCM-miniR followed by FCR. The mean number of AEs reported was
similar for the FCR and FCM-miniR treatment groups for the population of participants experiencing at least
one event (Table 57). Line listings of all AEs by treatment received are presented in Appendix 2, Adverse event
listings.
TABLE 56 MedDRA system organ class for SAEs suspected to be related to trial treatment (SARs)
(safety population)
MedDRA system organ class FCR, n (%)
FCM-miniR,
n (%)
FCM-miniR/FCR,
n (%) Total, n (%)
Blood and lymphatic system disorders 8 (12.9) 8 (11.9) 0 (0.0) 16 (11.0)
Gastrointestinal disorders 4 (6.5) 4 (6.0) 2 (12.5) 10 (6.9)
General disorders and administration site
conditions
10 (16.1) 6 (9.0) 3 (18.8) 19 (13.1)
Immune system disorders 0 (0.0) 1 (1.5) 0 (0.0) 1 (0.7)
Infections and infestations 36 (58.1) 43 (64.2) 11 (68.8) 90 (62.1)
Musculoskeletal and connective tissue
disorders
0 (0.0) 1 (1.5) 0 (0.0) 1 (0.7)
Neoplasms benign, malignant and
unspecified (including cysts and polyps)
1 (1.6) 1 (1.5) 0 (0.0) 2 (1.4)
Psychiatric disorders 1 (1.6) 0 (0.0) 0 (0.0) 1 (0.7)
Renal and urinary disorders 0 (0.0) 2 (3.0) 0 (0.0) 2 (1.4)
Skin and subcutaneous tissue disorders 2 (3.2) 1 (1.5) 0 (0.0) 3 (2.1)
Total 62 (100) 67 (100) 16 (100) 145 (100)
TABLE 57 Total number of AEs reported overall and per participant (safety population)
AEs FCR (n= 100)
FCM-miniR
(n= 79)
FCM-miniR/FCR
(n= 19) Total (n= 198)
Number of participants experiencing at
least one AE, n (%)
96 (96.0) 77 (97.5%) 19 (100%) 192 (97.0%)
Number of AEs reported 1117 863 183 2163
Number of AEs per participant who had at least one event
Mean (SD) 11.6 (7.1) 11.2 (6.9) 9.6 (5.7) 11.3 (6.9)
Median (range) 11 (1–38) 10 (1–36) 8 (1–19) 10 (1–38)
N 96 77 19 192
Number of AEs per participant (overall)
Mean (SD) 11.2 (7.3) 10.9 (7.0) 9.6 (5.7) 10.9 (7.1)
Median (range) 11 (0–38) 10 (0–36) 8 (1–19) 10 (0–38)
N 100 79 19 198
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New AEs most commonly occurred during the first treatment cycle, with the number of new AEs occurring
gradually declining with the more treatment cycles received, although this trend will be influenced by the
declining number of participants receiving each treatment cycle (Table 58). The proportion of new AEs
occurring at each treatment cycle appears to be reasonably well balanced between FCR and FCM-miniR.
Table 59 presents the maximum CTCAE grade experienced for each AE by treatment received. The
majority of AEs were reported as a maximum CTC grade 1 (50.5%). A higher percentage of CTC
grade 3/4 AEs were experienced in the FCM-miniR arm (n = 193, 22.4%) than the FCR (n = 168, 15.0%)
and FCM-miniR/FCR arms (n = 27, 14.6%).
Treatment-related mortalities within 3 months of ending protocol treatment
There were no treatment-related mortalities within 3 months of the protocol treatment ending.
One trial participant, receiving FCM-miniR, died within 3 months of discontinuing the protocol treatment
but the cause was not suspected to be related to trial treatment. This participant discontinued treatment
after their fourth cycle owing to ‘Disease progression, requiring further treatment’. After discontinuing
treatment, and prior to death, they reported a SAE of ‘Neutropenic sepsis and infected shoulder’, which
was not suspected to be related to the trial treatment. The participant gradually deteriorated and died
within 3 months of ending protocol treatment. The primary cause of death was given as ‘Infection due to
CLL’ and the participant’s disease status at the time of death was recorded as ‘stable disease’.
Secondary cancers
The following tables summarise the secondary cancers that were reported at follow-up.
Table 60 shows that the incidence of secondary cancers was similar across the trial arms, with 11.1% of
patients reporting a secondary cancer. The most common types of secondary cancer were skin- and
haematological-related cancers.
TABLE 58 Treatment cycle where an AE first occurred (safety population)
Treatment cycle AE first
occurred FCR, N (%) FCM-miniR, N (%) FCM-miniR/FCR, N (%) Total, N (%)
1 280 (25.1) 237 (27.5) 51 (27.9) 568 (26.3)
2 217 (19.4) 156 (18.1) 45 (24.6) 418 (19.3)
3 185 (16.6) 144 (16.7) 22 (12.0) 351 (16.2)
4 164 (14.7) 114 (13.2) 26 (14.2) 304 (14.1)
5 142 (12.7) 99 (11.5) 24 (13.1) 265 (12.3)
6 129 (11.5) 113 (13.1) 15 (8.2) 257 (11.9)
Total 1117 (100) 863 (100) 183 (100) 2163 (100)
TABLE 59 Maximum CTCAE grade (safety population)
Maximum CTCAE grade FCR, N (%) FCM-miniR, N (%) FCM-miniR/FCR, N (%) Total, N (%)
1 589 (52.7) 405 (46.9) 99 (54.1) 1093 (50.5)
2 354 (31.7) 262 (30.4) 57 (31.1) 673 (31.1)
3 107 (9.6) 118 (13.7) 17 (9.3) 242 (11.2)
4 61 (5.5) 75 (8.7) 10 (5.5) 146 (6.7)
Missing 6 (0.5) 3 (0.3) 0 (0.0) 9 (0.4)
Total 1117 (100) 863 (100) 183 (100) 2163 (100)
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Table 61 further summarises the type of secondary cancer reported. Note that the results are not mutually
exclusive, as one patient was diagnosed with basal cell carcinoma twice, and another with both squamous
cell carcinoma and melanoma.
Table 62 shows the mean, median and ranges of when the secondary cancers were diagnosed from
randomisation and from end of treatment.
Summary of statistical results
There is strong evidence to suggest that FCM-miniR is not non-inferior to FCR in terms of CR at 3 months
post treatment.
TABLE 60 Incidence and type of secondary cancer
Incidence and type of secondary
cancer FCR, N (%) FCM-miniR, N (%) FCM-miniR/FCR, N (%) Total, N (%)
Has the participant reported a secondary cancer?
Yes 11 (11.0) 10 (12.7) 1 (5.3) 22 (11.1)
No 89 (89.0) 69 (87.3) 18 (94.7) 176 (88.9)
Total 100 (100) 79 (100) 19 (100) 198 (100)
Secondary cancer type
Haematological (lymphoma) 2 (16.7) 2 (18.2) 0 (0.0) 4 (16.7)
Haematological (AML/MDS) 3 (25.0) 2 (18.2) 0 (0.0) 5 (20.8)
Skin (non-melanoma) 2 (16.7) 7 (63.6) 1 (100) 10 (41.7)
Skin (melanoma) 1 (8.3) 0 (0.0) 0 (0.0) 1 (4.2)
Non-haematological (solid tumours) 4 (33.3) 0 (0.0) 0 (0.0) 4 (16.7)
Total 12 (100) 11 (100) 1 (100) 24 (100)
AML, acute myeloid leukaemia; MDS, myelodysplastic syndrome.
TABLE 61 Further detail on type of secondary cancer
Secondary cancer type FCR, N (%)
FCM-miniR,
N (%)
FCM-miniR/FCR,
N (%) Total, N (%)
Lymphoma (other) 2 (16.7) 2 (18.2) 0 (0.0) 4 (16.7)
Myelodysplastic syndrome 2 (16.7) 2 (18.2) 0 (0.0) 4 (16.7)
Acute myeloid leukaemia 1 (8.3) 0 (0.0) 0 (0.0) 1 (4.2)
Basal cell carcinoma 0 (0.0) 3 (27.3) 0 (0.0) 3 (12.5)
Squamous cell carcinoma 2 (16.7) 4 (36.4) 1 (100) 7 (29.2)
Melanoma 1 (8.3) 0 (0.0) 0 (0.0) 1 (4.2)
Lung 1 (8.3) 0 (0.0) 0 (0.0) 1 (4.2)
Hepatobiliary 1 (8.3) 0 (0.0) 0 (0.0) 1 (4.2)
Urological (prostate) 2 (16.7) 0 (0.0) 0 (0.0) 2 (8.3)
Total 12 (100) 11 (100) 1 (100) 24 (100)
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From December 2009 to September 2012, 200 of a planned 206 patients were recruited from 34 centres
across the UK. A good proportion of participants (n = 141, 70.5%) completed the recommended six cycles
of treatment, with a slightly higher proportion in the FCR arm than in the FCM-miniR arm (70% vs.
64.6%), and the majority of participants who discontinued treatment early doing so for reasons of toxicity.
A similar proportion of participants in each of the treatment arms experienced at least one dose
modification to their protocol-defined dose of treatment, and just under half (47.0%) received treatment
with GCSF at some stage during their treatment period.
At the interim analysis, carried out on the first half of patients randomised to the trial (n = 103), of those
with available data, 82.9% of participants achieved a CR in the FCR arm compared with 61.4% in the
FCM-miniR arm. The difference in proportions (FCM-miniR – FCR) was –21.6% (99.5% CI –48.0% to 4.8%),
which was not statistically significant at the 0.5% (p= 0.005) level, although the experimental treatment had
the worst performance. This was confirmed by the adjusted analysis (OR 0.32, 99.5% CI 0.07 to 1.48;
p = 0.037). The primary aim of the interim analysis was to be able to release information of any potential
large differences in efficacy between the treatment arms and inform the continued treatment of trial
participants earlier than would have been the case with the final analysis. As the results were approaching
significance in favour of the control group, and there was evidence of additional toxicity in the FCM-miniR
arm, the trial was closed early at the recommendation of the DMEC and participants still receiving FCM-miniR
were recommended to transfer to treatment with FCR for the remainder of their treatment cycles.
At the final analysis of the primary end point (at 3 months post treatment), 76.1% of participants in the
FCR arm achieved a CR compared with 54.7% in the FCM-miniR arm. The difference in proportions
(FCM-miniR – FCR) was –21.4% (95% CI –35.8% to –7.0%) and the adjusted analysis gave an OR of 0.37
for the treatment effect (95% CI 0.19 to 0.73), indicating that participants in the FCM-miniR were
significantly less likely to achieve a CR. As the lower limit of the 95% CI and the mean OR were < 0.61
(equivalent to a difference in proportions of 10% based on the observed control rate) and the upper limit
of the 95% CI was also below 1, there was very strong evidence that FCM-miniR is not non-inferior to FCR
in terms of CR rates at 3 months post treatment, and that it is in fact inferior. The analysis of the PP
population and the sensitivity analyses agreed with this conclusion. The exploratory subgroup analyses
indicated that there was a significant trend towards participants who received more than three cycles of
treatment, and those who did not have a 17p deletion, performing better in terms of response.
The ORR was high at 92.6% with 7.5% fewer participants achieving at least a PR in the FCM-miniR arm
compared with the FCR arm (95% CI –15.6% to 0.6%). The difference in the ORR proportions was
not statistically significant, although it is approaching significance.
TABLE 62 Timing of secondary cancer
Timing of secondary cancer FCR FCM-miniR FCM-miniR/FCR Total
Months from randomisation to diagnosis
Mean (SD) 23.9 (14.9) 18.7 (9.4) 24.3 21.5 (12.3)
Median (range) 25.4 (1.6–46.5) 20.0 (6.4–31.6) 24.3 (24.3–24.3) 22.3 (1.6–46.5)
n 12 11 1 24
Months from end of treatment to diagnosis
Mean (SD) 19.9 (14.3) 13.2 (8.7) 19.2 16.8 (11.9)
Median (range) 21.7 (0.3–41.5) 14.6 (1.7–25.7) 19.2 (19.2–19.2) 16.1 (0.3–41.5)
n 12 11 1 24
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At 3 months post treatment, 53.0% of participants were MRD negative, a higher percentage of participants
in the FCR arm (57.0%) than in the FCM-miniR arm (46.4%). The difference in proportions (FCM-miniR – FCR)
was –10.6% (95% CI –26.1% to 4.9%) and the adjusted analysis gave an OR of 0.63 for the treatment
effect (95% CI 0.34 to 1.20) which was not statistically significant (χ2 = 1.97; p= 0.160), although it was
approaching significance.
There was no conclusion of a significant difference between the treatment arms with respect to time to
progression (log-rank test, p = 0.2790; Wilcoxon rank-sum test, p = 0.1081), confirmed by the adjusted
Cox regression analysis (HR 1.39, 95% CI 0.77 to 2.49; p = 0.2771). There was also no conclusion of a
significant difference between the treatment arms with respect to OS (log-rank test, p = 0.2779; Wilcoxon
rank-sum test, p = 0.1013), confirmed by the adjusted Cox regression analysis (HR 1.57, 95% CI 0.68 to
3.58; p = 0.2876). However, there was a non-significant trend towards the FCM-miniR participants
performing worse. At 24 months from randomisation, 89.4% of the FCR participants remained
progression-free compared with 79.1% of the FCM-miniR participants. In terms of OS at 24 months,
95.8% of the FCR participants remained alive compared with 88.5% of the FCM-miniR participants. In
the exploratory subgroup analyses, PFS and OS were significantly improved for participants who were MRD
negative or had achieved a CR at 3 months post treatment, or who received more than three cycles of
treatment. In addition, of those participants who were MRD positive, OS was worse in participants who
received FCM-miniR than in those who received FCR, suggesting that after progression the participants
initially treated with FCM-miniR responded worse to salvage therapies or died before further treatment was
possible. Longer follow-up data are required to be able to assess reliably the time-to-event outcomes, and
these will be updated in future.
More participants experienced an SAE in the FCM-miniR arm than the FCR arm (58.2% vs. 49.0%), as well
as an SAR (49.4% vs. 41.0%). One SUSAR (‘squamous cell carcinoma’) was reported during the trial in the
FCR arm. More participants in the FCM-miniR arm were hospitalised for an SAE during the trial (51.9% vs.
46.0%) and six SAEs were deemed to be life-threatening or resulted in death compared with three in the
FCR arm. A similar proportion of participants experienced an AE in each treatment arm, but a higher
proportion of CTCAE grade 3 and 4 AEs were reported in the FCM-miniR arm (22.4% vs. 15.0%). There
were no treatment-related mortalities within 3 months of completing protocol treatment.
Throughout the duration of the trial there were nine withdrawals (4.5%), with a similar number of
participants coming from each treatment arm.
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Chapter 4 Economic evaluation
Sections of this chapter have been reproduced from Howard et al.1 with permission.
The health economics analysis was designed to provide an economic evaluation of previously untreated
patients with CLL to compare FCR and FCM-miniR. The aim was to assess the cost-effectiveness of FCR
compared with FCM-miniR from a UK NHS and PSS perspective.
Unit cost data
Unit cost of resource use
Individual-level resource use was combined with unit costs to calculate the total health-care use cost for
each participant in the trial. In order to convert resource usage figures into costs, unit cost figures
were assigned from national sources such as the PSSRU Unit Costs of Health and Social Care 2013.33
Table 63 presents the summary of unit costs.
TABLE 63 Summary of participant-reported health-care use and associated unit costs
Resource item
Face-to
face-visits, £
Phone
call, £ Source
GP surgery visit 45.00 27.00 PSSRU (2013) p. 191: including direct care staff costs with qualification;
per participant contact lasting 11.7 minutes
GP out of office
hours visit
114.00 27.00 PSSRU (2013) p. 191: including direct care staff costs with qualification
(we consider it as out of surgery visit lasting 23.4 minutes)
District nurse 70.00 N/A PSSRU (2013) p. 183: per hour of home visit including qualification
Health visitor 71.00 N/A PSSRU (2013) p. 185: per hour of home visit including qualification
Occupational
therapist
44.00 N/A PSSRU (2013) p. 201: per hour participant contact (costs including
training)
Physiotherapist 34.00 N/A PSSRU (2013) p. 175: per hour participant contact (costs including
qualification)
Counsellor 58.00 N/A PSSRU (2013) p. 54: cost per consultation
Home help or
care worker
24.00 N/A PSSRU (2013) p. 202: cost per hour weekday. Each home visit lasting
30 minutes
Psychiatrist 362.00 N/A PSSRU (2013) p. 247: per face-to-face contact
Psychologist 134.00 N/A PSSRU (2013) p. 179: per hour participant contact
Hospital inpatient
stay
598.00 PSSRU (2013) p. 107: national average non-elective short stay
2581.00 PSSRU (2013) p. 107: national average non-elective long stay
Hospital day
centre
697.00 N/A PSSRU (2013) p. 107: day cases Healthcare Resource Group data
Hospital outpatient
clinic
135.00 N/A PSSRU (2013) p. 107: weighted average of all outpatient procedures
Hospital A&E
department
131.00 N/A PSSRU (2010) p. 119: national average A&E treatments leading to
admitted (not admitted) [not updated in the latest publication]
Nursing home 750.00 N/A PSSRU (2013) p. 37: establishment cost per permanent resident week
A&E, accident and emergency; N/A, not applicable.
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Unit cost of medications
Participants were randomised to receive six cycles of either FCR or FCM-miniR. Each cycle was 28 days.
Participants were evaluated after three cycles of chemotherapy and if no response or disease progression
was observed they were stopped from receiving further therapy. These participants would still attend
follow-up assessments until 24 months after randomisation. Unit costs for medications were obtained from
the BNF 67th edition of September 2013.34 Details for medication dosages given within the six treatment
cycles were collected. The total medication costs using the dosage and the frequency provided by the
participant were calculated. If the dose of the drug was not recorded, it was assumed that the participant
received the same dosage as other participants who were given the same treatment. If the quantity was
not recorded, the average quantity for that drug as reported in the data was applied. Table 64 shows
all the unit costs for the drugs that were reported in the trial.
Treatment costs
In addition to the cost of medications used during chemotherapy, an additional cost was identified which
was the cost of administering the drug. The costs are shown in Table 65.
TABLE 64 Summary of participant-reported medication use and associated unit costs
Drug name Description Price (BNF) August 2014
Cyclophosphamide
Tablets Cyclophosphamide monohydrate BP 53.0 mg
equivalent to 50 mg anhydrous
cyclophosphamide
Tablets, s/c, cyclophosphamide (anhydrous) 50 mg,
net price 100 = £70.70. Label: 25, 27
Solution Cyclophosphamide monohydrate powder for
solution injection or infusion
Injection, powder for reconstitution, cyclophosphamide,
net price 500-mg vial= £9.20; 1-g vial= £17.06
Fludarabine
Tablets Fludarabine phosphate 50 mg Tablets, f/c, pink, fludarabine phosphate 10 mg, net price
15-tab pack = £302.48, 20-tab pack = £403.31
Solution Fludarabine phosphate 50 mg Injection, powder for reconstitution, fludarabine
phosphate, net price 50-mg vial= £147.07
Mitoxantrone
Solution Each millilitre of concentrate contains 2 mg
mitoxantrone (as hydrochloride)
Concentrate for intravenous infusion, mitoxantrone
(as hydrochloride) 2 mg/ml, net price 10-ml vial = £121.85
Each 10-ml vial contains 20 mg mitoxantrone
as hydrochloride
Rituximab (MabThera)
Solution MabThera solution for infusion Concentrate for intravenous infusion, rituximab 10mg/ml,
net price 10-ml vial = £174.63, 50-ml vial= £873.15
Composition rituximab 100mg/10 ml or
500 mg/50 ml
f/c, film coated; s/c, sugar coated.
TABLE 65 Costs of administering the drug
Drug namea Cost per cycle, £ Source
Rituximab (i.v. administration) 430 NICE, Rituximab for the first-line treatment of chronic lymphocytic
leukaemia, 200948
FC 230 NICE, Rituximab for the first-line treatment of chronic lymphocytic
leukaemia, 200948
a As mitoxantrone is also administered as an i.v. infusion and is delivered with rituximab, it is assumed that there is no
extra cost to administer mitoxantrone in this instance.
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Utility and quality-adjusted life-years
Participant health-related quality of life was assessed using EQ-5D,28 which was included along with
the participant resource-use questionnaires. Changes in EQ-5D scores at baseline, 3 months after
treatment ends, and at 12, 18 and 24 months post randomisation were evaluated using two-sample
t-tests to explore any important differences in these end points within the time frame of the trial.
In line with the NICE reference case27 the primary health outcome for the economic evaluation was QALYs
measured using the EQ-5D questionnaire. Participant responses to the EQ-5D questionnaire at each time
point were converted to utilities using the standard UK tariff values28 and the ‘area under the curve’
approach. QALYs were calculated by multiplying these values with the time spent in each state, with
quality of life linearly interpolated for the periods between the four observations provided in the trial data.
Average QALYs between adjacent time points were calculated to generate smoothed estimates between
the time points. A sensitivity analysis was conducted using the SF-12 trial questionnaire responses (instead
of the EQ-5D) to calculate QALYs.
Missing data
The mean total cost per participant was calculated for NHS and PSS perspectives by adding the costs of
inpatient stay, outpatient visit, consultations, medication, treatment and applicable interventions for all
participants where response data were available. Missing QALY data were predicted in terms of baseline
EQ-5D, visual analogue scale of health-related quality of life, treatment received, age, sex and resource use
for that time period. From the overall sample, missing data represented 33.98%. Importantly, the health
economics criteria for inclusion were slightly more restrictive than those for the statistical analysis; for those
cases in which either resource usage or quality of life data were unavailable, these figures cannot be
calculated. The complete data analysis was based on 136 participants. We addressed missingness using
multiple imputations via chained equations35,36 to complete missing data assuming missing at random and
using Stata 13 (StataCorp LP, College Station, TX, USA). A total of 10 imputations were created to stabilise
the result. Following multiple imputations, data for 162 participants were accounted for. The reported
cost-effectiveness results were synthesised based on all imputed data sets.
Within-trial cost-effectiveness analysis
Cost-effectiveness results: base case
Resource use and QALY data were available for 162 participants, with 92 participants being treated with
FCR and 70 participants with FCM-miniR.
Health-care resource use
The total costs associated with resource use during the trial are shown in Tables 66 and 67. The mean
total NHS and PSS resource use costs during therapy are £15,492 for FCR and £9049 for FCM-miniR. Costs
were significantly higher for FCR (+£6444; p = 0.00). In the 18 months following the therapy period, the
difference in resource use costs between the two arms diminished, with a mean total cost of £1756 for
FCR and £1570 for FCM-miniR (p = 0.71). There were no significant differences in NHS and PSS resource
use costs between the treatment arms following the end of therapy according to the t-tests.
Health outcomes
Table 68 presents the EQ-5D scores at baseline, 3 months after therapy ended, and 12, 18 and 24 months
post randomisation with missing values imputed. Both treatment groups showed increasing EQ-5D scores
from baseline up to 3 months after the end of therapy, with a slight dip at 12 months and 18 months post
randomisation in both arms before increasing again.
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TABLE 66 Costs of resources used in relation to CLL by treatment arms (not imputed) during therapy
Cost type FCR (n= 92), £
FCM-miniR
(n= 70), £
Difference: p-value
of t-test
Cycles 1–3 (medication and treatment) Mean (SD) 6152 (1811) 2763 (901) 0.0000
Cycles 4–6 (medication and treatment) Mean (SD) 5701 (2769) 2916 (1411) 0.0000
Health and social services usea Mean (SD) 218 (448) 254 (417) 0.5779
Hospital-based care services Mean (SD) 3421 (3989) 3116 (4261) 0.6198
Total Mean (SD) 15,492 (6478) 9049 (5516) 0.0000
SD, standard deviation.
a These costs do not include the cost of the intervention.
TABLE 67 Costs of resources used in relation to CLL by treatment arms (not imputed) from end of therapy to
24 months
Cost type FCR (n= 92), £
FCM-miniR
(n= 70), £
Difference: p-value
of t-test
Health and social services usea Mean (SD) 269 (381) 265 (306) 0.5780
Hospital-based care services Mean (SD) 1487 (2285) 1472 (4075) 0.9757
Total resource use Mean (SD) 1756 (2402) 1570 (3720) 0.7133
a The costs do not include the cost of the intervention.
TABLE 68 European Quality of Life-5 Dimensions index scores at the baseline and follow-ups, and QALYs of CLL
participants by treatment arm (imputed data)
Parameter FCR (n= 92)
FCM-miniR
(n= 70)
Difference:
p-value of t-test
Baseline Mean (SD) 0.829 (0.200) 0.774 (0.275) 0.169
Median (min.–max.) 0.814 (–0.016–1.00) 0.812 (–0.0.16–1.00)
3 months after
end of therapy
Mean (SD) 0.852 (0.141) 0.868 (0.194) 0.546
Median (min.–max.) 0.858 (0.378–1.00) 0.870 (–0.239–1.00)
12 months post
randomisation
Mean (SD) 0.838 (0.177) 0.863 (0.218) 0.434
Median (min.–max.) 0.883 (0.189–1.00) 0.934 (–0.74–1.00)
18 months post
randomisation
Mean (SD) 0.833 (0.180) 0.851 (0.184) 0.517
Median (min.–max.) 0.927 (0.145–1.00) 0.937 (–0.003–0.965)
24 months post
randomisation
Mean (SD) 0.852 (0.161) 0.871 (0.097) 0.383
Median (min.–max.) 0.895 (–0.071–0.965) 0.876 (0.498–0.965)
Total QALYs Mean (SD) 1.610 (0.329) 1.552 (0.414) 0.316
Median (min.–max.) 1.714 (0.418–2.00) 1.722 (0.049–1.974)
Max., maximum; min., minimum; SD, standard deviation.
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On average, the difference between arms was marginal. Independent sample t-tests indicated that the
changes in EQ-5D score over time were not statistically significant. The average total QALYs gained
over the 24 months was marginally higher in the FCR arm (1.61) than in the FCM-miniR arm (1.55)
(p = 0.40).
Cost-effectiveness results within the NHS and Personal Social
Services perspectives
Table 69 shows the total costs and EQ-5D-generated QALYs for each of the treatment arms. Differences in
QALYs between groups were minimal and suggested marginal health decrements in the FCM-miniR arm
compared with the FCR arm. The FCR group had the highest EQ-5D-generated QALYs over the trial period.
The mean total cost was significantly higher for the FCR group. The high standard deviation (SD) for the
deterministic cost estimates indicates the presence of a few outlying individuals who incurred significant
health service costs.
Table 70 below provides the probabilistic cost-effectiveness results, showing the incremental costs and
benefits as well as the ICER. The results suggest that FCM-miniR is associated with an incremental cost
saving of £6619 and an incremental QALY loss of 0.059. Note that, owing to the fact that FCM-miniR is
associated with both negative cost and QALY increments, the ICER result cannot be interpreted in the
usual way as the cost per additional QALY associated with FCM-miniR; the ICER instead represents the
cost saved per QALY lost. That is, if the NHS adopts FCM-miniR, it could expect to save £112,193 per
QALY lost. As this cost saving outweighs the value of a lost QALY based on a WTP of £20,000 per QALY,
the overall net benefit associated with FCM-miniR is positive (£5349) and FCM-miniR is therefore expected
to be cost-effective over a 24-month time horizon.
The uncertainty around the cost-effectiveness estimate is represented graphically on the cost-effectiveness
plane (Figure 31) using bootstrapping with 10,000 iterations. This method samples at random with
replacement from each of the 10 imputed data sets, producing 10,000 incremental cost and incremental
QALY estimates.
Figure 31 shows that all the points were below the x-axis, indicating that FCM-miniR is cost-saving
compared with FCR, and most points were to the left of the y-axis, indicating that FCM-miniR produces
fewer QALYs than FCR. The majority of points lie below the £20,000/QALY threshold line, indicating that
FCM-miniR is cost-effective.
TABLE 69 Total costs and QALYs (EQ-5D) by treatment arm (NHS and PSS perspectives, deterministic)
Total costs and QALYs FCR FCM-miniR
n 92 70
Total QALYs (SD) 1.610 (0.329) 1.552 (0.412)
Total cost, £ (SD) 17,248 (7156) 10,619 (7312)
TABLE 70 Cost-effectiveness results (NHS and PSS perspectives, probabilistic)
Strategy
Total cost,
£ (SD)
Total QALY (based
on EQ-5D) (SD)
Incremental
cost, £ (SD)
Incremental
QALY (SD) ICER, £
Incremental
NB, £ (SD)
FCR 17,241 (745) 1.610 (0.04)
FCM-miniR 10,622 (758) 1.551 (0.05) –6619 (1061) –0.059(0.06) 112,193a 5439 (1546)
a Pounds saved per QALY lost.
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The CEAC showing the probability that FCR is cost-effective is presented below in Figure 32 with a range
of cost-effectiveness WTP thresholds values. The probability that FCM-miniR is cost-effective is high and
remains above 60% up to a threshold value of £100,000 per QALY.
Sensitivity analyses within trial in the NHS and Personal Social
Services perspective
In order to test the robustness of the within-trial analysis a number of different cost-effectiveness analyses
were completed.
Sensitivity analysis of health utility measurement
A similar cost-effectiveness analysis was completed using SF-6D-generated QALYs. When the equivalent
SF-6D figures were analysed, a different pattern was observed. There was a decrease in mean SF-6D values
between baseline and 3 months post randomisation, with fluctuations in either direction at the follow-up
time points. The average total QALYs gained were slightly higher in the FCM-miniR arm (1.211) than the
FCR arm (1.195) (p = 0.81), in contrast to the EQ-5D analysis in which FCR produced a higher overall QALY
value. A statistically significant difference in the SF-6D utility values was observed at the 24 months post
randomisation time point only (Table 71).
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FIGURE 31 Cost-effectiveness plane showing the incremental costs and QALYs for FCM-miniR compared with FCR
from the bootstrap analysis of the within-trial results over 24 months (EQ-5D, NHS and PSS perspectives).
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FIGURE 32 Cost-effectiveness acceptability curves at 12 months (NHS and PSS perspectives, using EQ-5D
generated QALYs).
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Table 72 below shows the total costs and SF-6D-generated QALYs for each of the treatment arms.
FCM-miniR is associated with an incremental cost saving of £6492 and an incremental QALY gain of 0.016
compared with FCR; FCM-miniR therefore dominates FCR, being more effective and less costly, with a
positive INB of £6805.
Using the NICE WTP threshold of £20,000, FCM-miniR is expected to be 100% cost-effective over a
24-month time horizon. This is illustrated in Figure 33 by the fact that all of the simulated points in the
probabilistic sensitivity analysis lie under the WTP threshold.
Impact of crossover participants
To assess the impact of removing the 21 participants who crossed over from the FCM-miniR arm to FCR in
the base-case analysis, two further sensitivity analyses were conducted:
1. ITT, whereby any transfer of participants from one arm to another is ignored and participants who
crossed over from FCM-miniR to FCR are retained in the analysis of the FCM-miniR arm
2. participants who were transferred are deemed to have been in the FCR treatment arm from
randomisation.
The results of these analyses can be seen in Table 73. The results show consistency in the trend of costs
and QALYs in both types of analyses (i.e. using EQ-5D- or SF-6D-generated QALYs).
TABLE 71 Short Form questionnaire-6 Dimensions index scores at baseline and follow-ups, and QALYs of CLL
participants by treatment arm (imputed data)
Parameter FCR (n= 92)
FCM-miniR
(n= 89)
Difference:
p-value of t-test
Baseline Mean (SD) 0.651 (0.290) 0.670 (0.269) 0.713
Median (min.–max.) 0.723 (–0.01–1.00) 0.723 (–0.128–1.00)
3 months after
end of therapy
Mean (SD) 0.606 (0.261) 0.593 (0.242) 0.645
Median (min.–max.) 0.6592 (–0.024–1.00) 0.634 (–0.074–1.00)
12 months post
randomisation
Mean (SD) 0.715 (0.238) 0.706 (0.237) 0.814
Median (min.–max.) 0.770 (–0.127–1.00) 0.770 (–0.060–1.00)
18 months post
randomisation
Mean (SD) 0.670 (0.239) 0.722 (0.219) 0.157
Median (min.–max.) 0.711 (–0.075–0.965) 0.777 (–0.071–0.965)
24 months post
randomisation
Mean (SD) 0.612 (0.289) 0.763 (0.170) 0.000a
Median (min.–max.) 0.704 (–0.059–1.00) 0.808 (–0.014–0.965)
Total QALYs Mean (SD) 1.195 (0.414) 1.211 (0.412) 0.812
Median (min.–max.) 1.242 (0.038–1.850) 1.305 (0.126–1.820)
Max., maximum; min., minimum.
a Statistically significant at the 95% confidence level.
TABLE 72 Cost-effectiveness results (NHS and PSS perspectives, deterministic)
Strategy Total cost, £
Total QALY
(based on SF-6D)
Incremental
cost, £
Incremental
QALY ICER INB, £
FCR 17,248 1.1949
FCM-miniR 10,756 1.2105 –£6492 0.016 FCM-miniR dominates 6805
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Summary of within-trial cost-effectiveness analysis
Using the EQ-5D to generate QALYs, the results showed that participants with CLL, treated in the FCM-miniR
arm, did not show a higher QALY gain when compared with participants in the FCR arm (1.552 vs. 1.610).
However, FCM-miniR presented negative incremental costs (£6443), indicating that treatment with FCM-miniR
would lead to cost savings. This difference was driven by the higher cost of delivery of FCR, with cost
differences stemming from treatment costs during the six cycles of chemotherapy.
Based on imputed data, the analysis found the incremental QALY gain to favour FCR, despite the
difference being minimal at 0.059 (roughly equivalent to 21.5 days of full health). This result is robust to
sensitivity analysis and stochastic bootstrapping.
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FIGURE 33 Cost-effectiveness plane generated from bootstrapped mean cost and SF-6D-generated QALY
differences over 24 months (NHS and PSS perspectives).
TABLE 73 Analyses accounting for interim change
EQ-5D Incremental cost, £ Incremental QALY gain ICER, £ INB, £
Base case
FCM-miniR vs. FCR –6619 –0.0590 112,193a 5439
ITT
FCM-miniR vs. FCR –5761 –0.0467 123,298a 4826
Transferred from baseline
FCM-miniR vs. FCR –6000 –0.0523 114,657a 4954
SF-6D
Base case
FCM-miniR vs. FCR –6456 0.0176 FCM-miniR dominates 6807
ITT
FCM-miniR vs. FCR –5674 0.0305 FCM-miniR dominates 6284
Transferred from baseline
FCM-miniR vs. FCR –6031 0.0138 FCM-miniR dominates 6308
a £ saved/QALY lost.
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However, using SF-6D to generate QALYs, the results showed that participants with CLL treated with
FCM-miniR showed a slightly higher QALY gain than participants in the FCR arm (1.211 vs. 1.195). This
gain, together with the incremental cost saving of £6805, suggests that FCM-miniR dominates FCR and is
cost-effective at a £20,000 WTP threshold. Despite this difference in QALY findings between the two
quality-of-life measures, FCM-miniR was found to be cost-effective in both analyses.
The within-trial analysis is conducted on data collected over a 24-month time period. The majority of CLL
participants go on to live much longer than this; therefore, the within-trial analysis is unlikely to capture all
of the relevant differences in long-term costs and health outcomes between the two participant groups.
Hence, there is a need for decision model analysis to extrapolate these results to lifetime horizons.
Lifetime cost-effectiveness analysis
A de novo decision analytic model was developed to estimate the lifetime cost-effectiveness of FCM-miniR
compared with FCR. The base-case analysis was conducted using QALYs derived from participant EQ-5D
questionnaire responses in the trial, and it was assumed that any difference between the two treatments
in terms of rate of disease progression was contained within the first 2 years from treatment initiation
(i.e. within the trial period). The analysis was conducted from an NHS and PSS perspective and adhered to
current NICE reference case standards.27 For the base-case model, probabilistic analysis (using 10,000
Monte-Carlo simulations) was conducted in order to account for uncertainty around the model parameter
input values. In addition, deterministic one-way sensitivity analyses were conducted to assess the influence
of changes to individual model parameters and key model assumptions on the results. A value of
information analysis was conducted to determine the potential value to the NHS of conducting additional
research on the cost-effectiveness of FCM-miniR compared with FCR.
Base-case model results
Results of the base-case analyses are presented in Table 74 (deterministic results) and Table 75
(probabilistic results). Taking into account uncertainty around the model parameters (i.e. using the
TABLE 74 Deterministic model lifetime cost-effectiveness results
Strategy
Total cost,
£ Total QALY
Incremental
cost, £
Incremental
QALY ICER, £
Net benefit,
£
Incremental
net benefit, £
FCR 31,176 6.12 91,324
FCM- miniR 23,468 5.46 –7708 –0.67 11,576a 85,715 –5609
a Pounds gained per QALY lost.
TABLE 75 Probabilistic model lifetime cost-effectiveness results
Strategy
Total cost,
£ (SD)
Total QALY
(SD)
Incremental
cost, £ (SD)
Incremental
QALY (SD) ICER, £
Net benefit,
£ (SD)
Incremental
net benefit,
£ (SD)
FCR 31,314
(7237)
7.76 (0.26) 123,917
(8447)
FCM-miniR 23,590
(6997)
7.04 (0.36) –7723
(3281)
–0.73 (0.42) 10,651a 117,137
(9449)
–6780 (7907)
a Pounds gained per QALY lost.
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probabilistic results), FCM-miniR is associated with an expected lifetime cost saving of £7723 and a
lifetime QALY loss of 0.73 compared with FCR; an incremental loss of over two-thirds of a healthy
life-year. As the incremental cost and QALYs are both negative, the ICER does not represent the
incremental cost per additional QALY, but rather represents the cost saved per QALY lost associated with
adoption of FCM-miniR. The ICER therefore indicates that one QALY will be lost for every £10,624 saved
by adopting FCM-miniR. As the amount saved is less than the societal WTP for a QALY (£20,000), the
overall expected INB of FCM-miniR is negative. This indicates that adoption of FCM-miniR would lead to a
lifetime loss of benefit for the NHS and PSS, and FCM-miniR is therefore not expected to be cost-effective.
The expected lost net benefit associated with FCM-miniR is –£6780, which is equivalent to a net health
loss of 0.34 QALYs (assuming that QALYs are valued at £20,000 per QALY). There is significant
uncertainty around this result, as can be seen by the large SD value for the INB (SD = 7907).
The results of the probabilistic analysis are presented in Figure 34. Each point on the graph represents the
result of one probabilistic simulation of the model and indicates a potential incremental cost and QALY for
FCM-miniR compared with FCR. The diagonal line represents the currently accepted WTP per QALY
threshold of £20,000 per QALY. Points that lie below the threshold line are considered cost-effective;
points above the threshold line are not considered to be cost-effective. In this analysis, the points are
widely distributed, with many points lying in both cost-effective and non-cost-effective regions. This
indicates that there is significant uncertainty around the cost-effectiveness of FCM-miniR compared with
FCR over a lifetime horizon. The mean of the simulated values lies above the threshold line, indicating that,
on average, FCM-miniR is not expected to be cost-effective.
The CEAC shows the proportion of model simulation points that lie under the cost-effectiveness threshold
plane across different threshold values, which indicates the probability that each treatment is cost-effective
at given WTP values. The CEAC for FCM-miniR versus FCR is presented in Figure 35. At low cost per
additional QALY thresholds, FCM-miniR is associated with a high probability of being cost-effective.
However, as the threshold value increases the probability of FCM-miniR being cost-effective rapidly
diminishes, and FCR is associated with an increasing probability of cost-effectiveness. At a threshold value
of £20,000 per QALY, FCM-miniR is associated with 19% probability of being cost-effective; increasing the
threshold value to £30,000 per QALY results in a drop to a 12% probability of being cost-effective.
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FIGURE 34 Scatterplot of model lifetime cost-effectiveness results for FCM-miniR vs. FCR.
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Sensitivity analyses
One-way deterministic sensitivity analysis
Results of the one-way deterministic sensitivity analysis are presented in Figure 36. The vertical line indicates
the base-case deterministic INB value for FCM-miniR versus FCR (–£5609). The horizontal bars indicate the
extent to which this base-case value is altered when individual model parameter values are increased or
decreased by 25% of their base-case value. From the diagram it appears that altering the discount rate and
utility of the progression-free state results in the greatest change to the cost-effectiveness result. However,
FCM-miniR is associated with a negative INB in all of the analyses considered, indicating that FCM-miniR is
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FIGURE 36 Tornado plot of one-way deterministic sensitivity analysis results.
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FIGURE 35 Cost-effectiveness acceptability curve for model lifetime analysis.
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not expected to be cost-effective in any of the analyses. Changes in the input parameters therefore have no
effect on the overall result of the analysis.
Intention-to-treat analysis (including participants who crossed over from
fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab to
fludarabine, cyclophosphamide and mitoxantrone)
Results of the sensitivity analysis using the ITT population are shown in Table 76. Compared with the
base-case analysis in which participants who crossed over from FCM-miniR to FCR were excluded from
the analysis, the incremental cost saving associated with FCM-miniR compared with FCR is slightly reduced
(–£7708 vs. –£6593), and the incremental QALY loss is reduced (–0.67 vs. –0.56). Nevertheless, FCM-miniR
remains non-cost-effective, with a negative INB value (–£4591 compared with the base-case deterministic
value of –£5609). This indicates that the exclusion of the participants who crossed over from FCM-miniR to
FCM has no effect on the overall cost-effectiveness result.
Short Form questionnaire-6 Dimensions
Results of the sensitivity analysis using QALYs derived from participant-reported SF-12 forms (converted
to SF-6D utilities) are shown in Table 77. As for the base-case analysis using EQ-5D-derived utilities,
FCM-miniR is associated with a negative incremental cost and utility value, indicating that FCM-miniR is
expected to be cost saving but less effective than FCR. Compared with the EQ-5D analysis, using SF-6D
utilities leads to a smaller QALY loss associated with FCM-miniR (–0.55 compared with –0.67); however,
this QALY decrement still outweighs the expected cost saving, resulting in a negative INB value. FCM-miniR
is therefore still expected to be non-cost-effective over a lifetime horizon, as in the base-case analysis.
Treatment effect
Results of the sensitivity analysis extending the differential rates of progression observed between FCR and
FCM-miniR in the trial beyond the trial period are shown in Table 78. Owing to the fact that in the trial
period participants in the FCR arm progressed at a slower rate than participants in the FCM-miniR arm,
extending this effect beyond the trial period by applying the observed HR in the trial benefits the FCR arm.
The expected net benefit associated with FCM-miniR therefore decreases as the HR is applied over longer
time periods, with FCM-miniR becoming increasingly non-cost-effective as the treatment effect is
extended. The expected INB falls from –£5609 in the base case to –£9750 when the differential rates of
progression are applied over a lifetime horizon. FCM-miniR therefore remains non-cost-effective across all
the analyses.
TABLE 76 Model sensitivity analysis using ITT population
Strategy Total cost, £ Total QALY
Incremental
cost, £
Incremental
QALY ICER, £ NB, £
Incremental
NB, £
FCR 30,741 7.63 121,924
FCM-miniR 24,148 7.07 –6593 –0.56 11,790a 117,333 –4591
a Pounds gained per QALY lost.
TABLE 77 Model sensitivity analysis using QALYs derived from the SF-12 form
Strategy Total cost, £ Total QALY
Incremental
cost, £
Incremental
QALY ICER, £ NB, £
Incremental
NB, £
FCR 31,437 6.41 96,678
FCM-miniR 23,842 5.85 –7595 –0.55 13,721a 93,203 –3475
a Pounds gained per QALY lost.
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Value of information analysis
Results of the population EVPI analysis are shown in Figure 37. The EVPI value represents the absolute
maximum that the NHS should be willing to spend on further research on the cost-effectiveness of
FCM-miniR versus FCR. At a £20,000 per QALY threshold, and assuming a 10-year effective time horizon
for the new treatment, the expected value of information is £21M. The maximum EVPI value (£43M) is
reached at a £10,600/QALY threshold value (equivalent to the ICER value for FCM-miniR), as this is the
point at which uncertainty around parameter estimates in the model has the greatest influence on the
decision of whether or not to adopt the new treatment.
Results of the EVPPI analysis are shown in Figure 38. Uncertainty around the starting distributions of the
model (i.e. the proportion of participants who begin the model with progressed disease as opposed to
being disease free) is found to be the most influential factor, with the associated EVPPI values for these
parameters being substantial. These parameters are directly related to the efficacy of each of the
treatments in terms of delaying disease progression, so it is unsurprising that these have a large impact
on the model results.
The value of information results suggest that there is the potential for further research into the
cost-effectiveness of FCM-miniR compared with FCR to be of value to the NHS. However, the EVPI and
EVPPI values provide only a necessary (but not sufficient) condition for the decision to fund further research
(i.e. a positive EVPI/EVPPI value indicates that there may be value in conducting further research). The
decision of whether or not to invest in further research and what design that research should take requires
further analysis of the cost of research and the value of particular trial designs.
TABLE 78 Sensitivity analysis extending observed differential rate of progression in trial over different time
horizons (deterministic results)
Outcome
Base case (differential
effect in 2-year trial
period)
3-year time horizon
(HR applied up to
year 3)
5-year time
horizon
10-year time
horizon
Lifetime time
horizon
Incremental cost, £ –7708 –7717 –7720 –7716 –7705
Incremental QALY –0.67 –0.76 –0.84 –0.86 –0.87
FCR-miniR
incremental NB, £
–5609 –7549 –9198 –9520 –9750
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FIGURE 37 Population EVPI.
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Predicted overall survival
The predicted OS curves simulated by the base-case model are presented in Figure 39. The difference in
OS between the two arms is greatest at the beginning of the model simulation; this is attributable to the
fact that the model begins from the end of the trial 24-month period, and the proportion of participants
surviving in each arm was taken directly from the trial follow-up data which showed the given discrepancy
between the two arms. Subsequently in the model, however, it is assumed that the risk of mortality in
both the progression-free and progressed disease states is the same in both arms. In the future, validation
of the model could be achieved by comparing the predicted OS with real-world data; currently these
data are unavailable and we therefore show the OS curves for illustrative purposes only.
0
Cost_PF
Cost_PD
Utility_PS
Utility_PD
trabsprob_FCR_PD_dead
trabsprob_FCM_PD_dead
start_FCM-MiniR_PD
start_FCM-MiniR_PF
FCR_2yr_cost
FCR_2yr_QALY
FCM-MiniR_2yr_cost
FCM-MiniR_2yr_QALY
start_FCR_PD
start_FCR_PF
2 4 6
Population EVPI (£M)
8 10
FIGURE 38 Population EVPPI for base-case model (£20,000/QALY threshold, 10-year effective lifetime and annual
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Summary of decision model lifetime cost-effectiveness analysis
The results of the decision analytic model indicate that FCM-miniR is not expected to be cost-effective over
a lifetime horizon. Compared with FCR, FCM-miniR is associated with an average lifetime cost saving
of £7723 per patient, and a lifetime QALY loss of 0.73. The resulting expected INB associated with
FCM-miniR is –£6780 (equivalent to a net health loss of –0.34 QALYs), indicating that if FCM-miniR were
to be adopted instead of FCR the NHS would be worse off as a whole.
Results of the deterministic sensitivity analyses found that the results were robust to changes in individual
model parameters, with FCM-miniR remaining non-cost-effective in all of the analyses conducted.
However, when joint parameter uncertainty is considered (using probabilistic sensitivity analysis), there is
some uncertainty around the results: at a £20,000 per QALY threshold, there is a 19% chance that
FCM-miniR is cost-effective. The expected value of information analysis indicates that there is potential
benefit to conducting further research into the cost-effectiveness of FCM-miniR; however, additional
considerations (such as the cost of research and specific research design) would need to be considered
before a definitive recommendation for further research could be made.
Summary of the economic evaluation
An economic evaluation was conducted to assess the cost-effectiveness of FCM-miniR compared with FCR
from a UK NHS and PSS perspective. The evaluation consisted of two components: a within-trial analysis,
in which cost-effectiveness was assessed within the 24-month trial period using individual participant data
collected in the trial; and a decision analytic model analysis, in which cost-effectiveness was assessed over a
lifetime horizon using standard modelling techniques to extrapolate the trial analysis to a lifetime horizon.
The results of the within-trial analysis indicate that FCM-miniR is cost-effective compared with FCR over a
24-month time horizon, although it should be noted that cost-effectiveness in this instance is achieved
only by virtue of the fact that the cost savings associated with FCM-miniR in the short term outweigh the
associated QALY losses. In the base-case analysis, FCM-miniR was associated with a mean cost saving of
£6619 and a mean QALY loss of –0.059 compared with FCR. The corresponding ICER was £112,193,
indicating that for every £112,193 saved by adopting FCM-miniR, one QALY would be lost. Assuming
that one QALY is valued at £20,000 (the threshold currently adopted by NICE), FCM-miniR is therefore
associated with a positive INB of £5439, indicating that it is cost-effective compared with FCR. In a
sensitivity analysis using SF-6D QALYs derived from the SF-12 questionnaire (instead of EQ-5D as in the
base case), FCM-miniR was estimated to result in an overall QALY increase (+0.016) compared with FCR,
resulting in FCM-miniR dominating FCR (being more effective and less costly). Altering the analysis to
include participants who crossed over from FCM-miniR to FCR had minimal effect on the results. The
base-case probabilistic analysis found that at a £20,000 per QALY threshold, there is a 100% probability
that FCM-miniR is cost-effective compared with FCR over a 24-month time horizon.
However, the cost-effectiveness of FCM-miniR was not sustained in the long-term analysis. Results of the
economic decision model indicate that FCM-miniR is not expected to be cost-effective over a lifetime
horizon. The base-case analysis indicates that over a lifetime horizon FCM-miniR is expected to result in
a mean cost saving of £7723 and a mean QALY loss of 0.73 QALYs. The associated ICER is £10,651,
indicating that, for every £10,651 saved by adopting FCM-miniR, one QALY would be lost. In contrast to
the within-trial analysis, the cost saving associated with FCM-miniR is no longer sufficient to outweigh the
QALY loss, and FCM-miniR is no longer cost-effective, with an incremental net loss of –£6780. However,
lack of available data regarding long-term outcomes means that there is uncertainty around this result;
at a £20,000 per QALY threshold there is a 19% chance that FCM-miniR is cost-effective. Owing to this
uncertainty, the value of information analysis found that there is potential value in conducting further
research on the cost-effectiveness of FCM-miniR. Nevertheless, the cost of further research and the likely
value of specific research designs would need to be considered before making a definitive recommendation
regarding the value of further research.
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Chapter 5 Discussion
Sections of this chapter have been reproduced from Howard et al.1 with permission.
Interpretation
The ARCTIC trial demonstrated that the combination of FCM-miniR was not non-inferior to FCR for the
primary end point of CR. However, the CR rates observed in the trial were very high compared with
previous studies involving FCR in both Europe4,5 and the USA.2,3 It appears that the addition of
mitoxantrone to the regime created more toxicity, limiting the dose and/or duration of therapy compared
with the FCR arm. There is no sign that low-dose rituximab is as effective as the full dose when given with
chemoimmunotherapy. The trial also confirmed that patients who respond well, achieving either a CR
and/or the eradication of detectable MRD, have a better outcome than those with worse responses.
The ARCTIC trial protocolised the use of haematopoietic growth factors, namely GCSF, to support the
blood counts if they were low and delaying further courses of therapy. It appears that this planned use of
GCSF as secondary prophylaxis (given only to patients whose neutropenia was delaying subsequent cycles
of treatment) allows more patients to complete their planned therapy and that this leads to a similar
outcome when compared with those patients who do not require GCSF.
The reason for the very high response rates and the favourable PFS and OS in ARCTIC is unclear. The
reasons for this, compared with international trials with similar entry criteria, are probably multifactorial,
and there are at least five possible factors that could account for this: (1) FC were given by the oral route
in ARCTIC rather than intravenously as in previous studies; (2) the exposure for each cycle of treatment
was 5 days rather than the 3 days over which FCR is given intravenously – this might be important as
when alkylating agents are used alone they appear to be more effective when given over a few days;
(3) patients in ARCTIC received primary prophylaxis against PCP with co-trimoxazole or equivalent and
aciclovir prophylaxis to prevent herpes zoster virus reactivation; (4) the use of GCSF as secondary
prophylaxis allowed the optimisation of therapy in patients who were struggling to complete the full six
cycles of treatment; (5) the centres in the UK that recruited patients are generally large cancer centres and
the patients are cared for by haematologists rather than by small community practices.
The ARCTIC trial confirmed some important factors regarding the outcome of therapy in CLL. In particular,
patients who achieved a CR had a better outcome, with 93.4% of CR patients being progression-free at
24 months, compared with 65.4% of patients who did not achieve a CR. In addition, patients who
achieved the eradication of detectable MRD from their bone marrow 3 months after completing therapy
had a 96.4% probability of being progression-free after 24 months, compared with 79.2% for patients
not achieving a MRD-negative response. A somewhat surprising finding was that the PFS was similar for
patients aged over 65 years and those under 65 years of age, suggesting that the selection of patients for
therapy by fitness rather than age is effective. This justifies the selection of patients for FCR and the
inclusion of certain groups of patients such as those with renal dysfunction, who also fared reasonably well
in ARCTIC and who in most previous series have been excluded from FCR-like therapies. In comparison
with historical series of FC given prior to the advent of rituximab, it does appear that the addition of
low-dose rituximab to FC with mitoxantrone (FCM-miniR) is better than FC in terms of response and PFS,
although it is inferior to FCR. This indicates that low-dose rituximab is clinically active but probably less so
than the full conventional dose.
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Economic evaluation discussion
In both the within-trial and the decision model analyses, FCM-miniR was found to be associated with
negative incremental costs and benefits compared with FCR. Care needs to be taken when interpreting the
results of both analyses, given that ICERs have a different meaning when both cost and benefit increments
are negative. Typically, a new intervention is found to be more expensive and more effective than
the standard-care treatment (with results of probabilistic analyses lying in the north-east quadrant of the
cost-effectiveness plane). In such cases, the ICER represents the additional cost required to be spent on
the new treatment in order to gain an additional QALY compared with the standard-care treatment.
However, in the case of new treatment that is less costly and less effective than the comparator treatment
(with results of probabilistic analyses lying in the south-west quadrant of the cost-effectiveness plane),
the ICER instead represents the incremental cost saved per QALY lost compared with the standard-care
treatment. For example, in the economic analysis FCM-miniR is associated with an ICER of £10,651,
indicating that for every £10,651 saved by adopting FCM-miniR, one QALY will be lost compared with
FCR. Assuming a WTP of £20,000 per QALY, this means that FCM-miniR is not cost-effective, which may
not be immediately clear from the ICER result. For this reason, it is preferable to look at the INB results
rather than the ICERs, as interpretation of net benefit results does not depend on the direction of the
incremental cost and QALYs. If the INB associated with a new treatment is positive, then that treatment is
cost-effective, whereas if it is negative the treatment is not cost-effective. Thus, for the case of the decision
model analysis, FCM-miniR is associated with an INB of –£6780, indicating that FCM-miniR is not
cost-effective over a lifetime horizon.
Treatments that are both cost- and QALY-decreasing can still be cost-effective because the cost saved can
be spent on treatments or interventions elsewhere in the NHS in order to gain additional QALYs, which
may outweigh the QALY loss associated with the given intervention. That is, the overall INB of the new
treatment compared with the standard-care treatment may be positive (indicating cost-effectiveness) if the
cost saving associated with the new treatment is sufficient to outweigh the QALY loss. In the case of
the within-trial analysis, FCM-miniR was associated with a mean cost saving of £6619 and a mean QALY
loss of –0.056. In this case, the cost saved outweighs the QALYs lost, resulting in a positive INB. However,
for the decision model analysis, the cost saving associated with FCM-miniR (£7723) was unable to
outweigh the QALY loss (–0.73), resulting in a negative INB (i.e. –0.735 × 20,000 + 7723 = –£6780;
equivalent to a net health loss of –0.735 + 7723/20,000 = –0.34 QALYs).
The discrepancy in the short- and long-term cost-effectiveness analyses results (i.e. the fact that FCM-miniR
is found to be cost-effective in the within-trial analysis but not in the model lifetime analysis) is attributable
to the fact that all cost-savings associated with FCM-miniR occur in the short term (i.e. when therapy
costs are incurred). In the model it is assumed that costs in the progression-free and progressed disease
states are the same for both treatments, so the benefit of FCM-miniR in terms of reducing treatment costs
is contained in the initial trial 24-month period of the model. Over the lifetime analysis, the cost savings
associated with FCM-miniR are, therefore, diluted and are no longer sufficient to outweigh the QALY
losses associated with the new treatment.
For the within-trial analysis, the results of QALY calculations were not consistent across health utility
measures. The base-case EQ-5D analysis found FCM-miniR to be inferior to FCR in terms of QALY
production (resulting in a –0.059 QALY decrement), whereas the SF-6D analysis found FCM-miniR to be
superior to FCR (resulting in a +0.016 QALY increment). The reason for this discrepancy is unclear. The
SF-12 questionnaire used to derive the SF-6D QALYs asks more detailed questions regarding patients’
emotional states, and t-test results showed significant differences using SF-6D at 24 months post
randomisation, whereas no significant differences between arms were shown using EQ-5D. This could
suggest that the SF-12 form is more sensitive to changes in health states for this population. Nevertheless,
despite the difference in expected QALY values between the EQ-5D and SF-6D analyses, both analyses
indicate that FCM-miniR is associated with a positive INB value and therefore represents a cost-effective
investment for the NHS. Overall, there is some uncertainty around the model results (see Generalisability)
which will not have been captured in the deterministic or probabilistic sensitivity analyses. It is unclear in
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which direction this uncertainty is likely to impact on the results; therefore, some caution should be
maintained when drawing conclusions from the model results.
Summary
In summary, we have shown that FCM-miniR does not have a non-inferior CR rate compared with FCR for
the frontline therapy of CLL and that, over the lifetime of the patients, FCM-miniR was not found to be
cost-effective compared with FCR. Therefore, there is no evidence against FCR remaining the
gold-standard treatment for patients with CLL who require therapy and are considered fit for
fludarabine-based combinations.
Generalisability
The ARCTIC trial was a randomised Phase IIB rather than a Phase III trial, but it was large and well-powered
to show non-inferiority in terms of CR rates. The primary end point CR is associated with outcome in many
other studies and was rigorously assessed by three independent assessors who were blinded to the
treatment that patients received. In addition, the secondary end points, such as the eradication of MRD,
are supportive, which is strongly associated with outcome; and the follow-up of the study, with a median of
35.6 months since randomisation, is mature enough to allow some interpretation of both PFS and OS. The
efficacy outcome was consistent across the primary and secondary end points, which validates the
conclusions of the trial.
In terms of the health economic assessment, there are some limitations to the analysis. The decision
analytic model has several important limitations that should be considered when interpreting the results.
These are highlighted below:
(a) The model structure is unlikely to be sufficiently detailed to capture all the relevant differences between
the two treatments in terms of costs and benefits. In particular, the progression-free state aggregates
information on several distinct disease stages that each treatment may impact differently on and, once
in the progressed disease state, patients were not permitted to return to the progression-free state, as
does occur temporarily in practice.
(b) The rate of progression in each arm for a given time point was set to the value given by the calibrated
RDM model; each value in time was therefore fixed and this variable was not included in the
probabilistic analysis or in the value of information analysis. The results are, therefore, likely to
underestimate the uncertainty around the cost-effectiveness results and the associated value of
additional information to resolve that uncertainty.
(c) The cost and utility values for the progressed disease state are unlikely to be accurate estimates. Owing
to a lack of available data, the cost and utility values for the progressed disease state were sourced
from the literature; although care was taken to identify the most relevant estimates available, these
values are still unlikely to reflect accurately the true cost of progressed disease for CLL patients. In
addition, it may be that the cost of progressed disease is not the same across the two arms; however,
without any evidence to the contrary the cost of progressed disease was assumed equivalent.
In addition for the within-trial analysis, previous 3-month costs at baseline would have allowed for
adjustment in case of higher (or lower) initial costs for patients at the beginning of the study; however,
these costs were not collected and were instead assumed to be equivalent between arms.
The question of the value of adding mitoxantrone to FCR has been answered clearly. It also appears
that the question of whether lower doses of rituximab are as effective has been answered, although one
of the limitations of the trial is that the toxicity of adding mitoxantrone could have confounded the
interpretation of the low-dose rituximab question.
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A real strength of ARCTIC is that it is the first randomised trial in which FC were given orally in the FCR
combination. This has demonstrated that the outcomes for oral FCR appear to be superior to the historical
control series where all the drugs were given intravenously.
The patients recruited into ARCTIC were entered at 34 centres throughout the UK. Given the large number
of patients recruited and the geographical distribution of the patients, the trial population is very similar
to fit patients in the UK generally, and thus the outcome of the trial is generalisable to the whole UK CLL
patient population.
We have managed to address the key questions without the need for a larger Phase III trial. A weakness of
the trial is that over the past few years, since the design of the trial, there has been an extremely rapid
increase in the number of therapies for CLL and this has meant that the interest in chemoimmunotherapy,
such as FCR, has weakened in favour of the novel targeted treatments.
Overall evidence
In summary, the ARCTIC trial showed that the combination of FCM-miniR was not non-inferior to FCR
and, in fact, that FCM-miniR was significantly inferior in terms of CR. Even though FCM-miniR was less
expensive, it was not cost-effective in the long term to use FCM-miniR rather than FCR. Therefore, there
is no evidence against FCR remaining the gold-standard therapy for CLL in patients considered fit for
fludarabine-based therapy.
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Chapter 6 Conclusions
Implications for health care
l There is no evidence against FCR remaining the gold-standard therapy for CLL.
l Oral FC and intense supportive care (primary antibiotic prophylaxis, secondary GCSF support, etc.)
optimise the delivery of FCR-like therapies.
l Improved responses (both CR and MRD negativity) are associated with better outcomes, justifying the
planned use of MRD negativity by the European Medicines Agency as a surrogate end point for drug
approval in CLL.
l In countries in which the cost of ‘conventional’ dose rituximab is prohibitive, it appears that low-dose
rituximab (100 mg per cycle) is active and may be worth testing further.
Recommendations for research
Fludarabine, cyclophosphamide and rituximab remains the gold-standard therapy for frontline CLL and
should be used as the ‘standard’ arm in subsequent trials. It is acceptable, maybe even advisable, to allow
the use of oral FC in future trials. The surrogate end point of the eradication of MRD is a good prognostic
marker for PFS and therefore acceptable in future Phase II CLL trials.
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Appendix 1 Serious adverse event listings
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TABLE 80 Serious adverse events suspected to be related to trial treatment (details of event)
Treatment
received
MedDRA system
organ class
SAE ID
number
SAE medical
description
Suspected
relationship to
trial treatment
Suspected
product(s)
FCR Blood and lymphatic
system disorders
N00014/
00028/002
Neutropenia Suspected,
expected
FCR
FCR Blood and lymphatic
system disorders
N00076/
00187/001
Platelet count decreased Suspected,
expected
FC
FCR Blood and lymphatic
system disorders
N00080/
00032/001
Infection Suspected,
expected
FC
FCR Blood and lymphatic
system disorders
N00098/
00017/001
Extremely low Hb Suspected,
expected
FCR
FCR Blood and lymphatic
system disorders
N00098/
00017/002
Low Hb 5.9 g/dl on
Pentra
Suspected,
expected
FCR
FCR Blood and lymphatic
system disorders
N00114/
00088/001
Persistent neutropenia
related to chemotherapy
Suspected,
expected
FCR
FCR Blood and lymphatic
system disorders
N00175/
00155/001
Anaemia Suspected,
expected
FCR
FCR Blood and lymphatic
system disorders
N00230/
00033/002
Myelodysplasia: RAES Suspected,
expected
FC
FCR Gastrointestinal
disorders
N00050/
00120/001
Diarrhoea and vomiting Suspected,
expected
FC
FCR Gastrointestinal
disorders
N00098/
00060/002
Nausea and vomiting Suspected,
expected
FC
FCR Gastrointestinal
disorders
N00114/
00088/003
Gastroenteritis Suspected,
expected
FCR
FCR Gastrointestinal
disorders
N00349/
00035/001
Nausea Suspected,
expected
FC
FCR General disorders and
administration site
conditions
N00014/
00028/004
Infection/anaemia Suspected,
expected
FCR
FCR General disorders and
administration site
conditions
N00014/
00028/005
Anaemia grade 4 Suspected,
expected
FCR
FCR General disorders and
administration site
conditions
N00014/
00029/001
Rigors Suspected,
expected
Rituximab
FCR General disorders and
administration site
conditions
N00098/
00019/001
Pyrexial 38.2 °C post first
dose of Rituximab
Suspected,
expected
Rituximab
FCR General disorders and
administration site
conditions
N00114/
00055/001
Fever and rigors Suspected,
expected
Rituximab
FCR General disorders and
administration site
conditions
N00173/
00011/001
Hypoxia Suspected,
expected
Rituximab
FCR General disorders and
administration site
conditions
N00173/
00137/001
Vomiting Suspected,
expected
FC
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Other causality
(in addition to
trial medications)
Randomisation
date
Date SAE became
serious
SAE recovery
date
SAE
duration
(days)
Outcome of
SAE
21 July 2010 27 October 2010 1 November 2010 5 Recovered
CLL 21 August 2012 31 December 2012 Condition still
present and
unchanged
Other illness:
general frailty/
possible GBS
23 August 2010 6 October 2010 144 Death
CLL 30 April 2010 3 November 2010 6 November 2010 3 Recovered
with sequelae
30 April 2010 12 November 2010 13 November 2010 1 Recovered
Concomitant
medications
24 May 2011 2 November 2011 2 January 2012 61 Recovered
30 May 2012 16 October 2012 16 October 2012 0 Recovered
24 August 2010 6 May 2014 . Condition
improving
7 November 2011 20 December 2011 21 December 2011 1 Recovered
24 January 2011 28 April 2011 28 April 2011 0 Recovered
Other: suspect
take-away meal
24 May 2011 1 April 2012 2 April 2012 1 Recovered
10 September 2010 16 March 2011 15 April 2011 30 Recovered
21 July 2010 4 January 2011 11 February 2011 38 Recovered
21 July 2010 19 January 2011 10 February 2011 22 Recovered
4 August 2010 24 August 2010 26 August 2010 2 Recovered
8 June 2010 17 June 2010 18 June 2010 1 Recovered
CLL 5 January 2011 12 January 2011 18 January 2011 6 Recovered
CLL; asthma 29 March 2010 16 April 2010 21 April 2010 5 Recovered
Other: constipation 5 March 2012 8 April 2012 9 April 2012 1 Recovered
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TABLE 80 Serious adverse events suspected to be related to trial treatment (details of event) (continued )
Treatment
received
MedDRA system
organ class
SAE ID
number
SAE medical
description
Suspected
relationship to
trial treatment
Suspected
product(s)
FCR General disorders and
administration site
conditions
N00218/
00168/001
Fever and
non-specifically unwell
Suspected,
expected
FCR
FCR General disorders and
administration site
conditions
N00319/
00125/001
Allergic reaction Suspected,
expected
Rituximab
FCR General disorders and
administration site
conditions
N00391/
00194/002
Probable rituximab
reaction
Suspected,
expected
Rituximab
FCR Infections and
infestations
N00014/
00028/003
Febrile neutropenia Suspected,
expected
FCR
FCR Infections and
infestations
N00014/
00112/001
Shingles Suspected,
expected
FCR
FCR Infections and
infestations
N00040/
00056/001
Neutropenic sepsis Suspected,
expected
FC
FCR Infections and
infestations
N00046/
00185/001
Infection with grade 4
neutrophils
Suspected,
expected
FCR
FCR Infections and
infestations
N00050/
00041/001
Febrile neutropenia Suspected,
expected
FCR
FCR Infections and
infestations
N00098/
00001/001
Neutropenic sepsis Suspected,
expected
FC
FCR Infections and
infestations
N00098/
00060/001
Fever: no focus identified Suspected,
expected
FC
FCR Infections and
infestations
N00098/
00060/003
Probable late PCP/PJP Suspected,
expected
FCR
FCR Infections and
infestations
N00099/
00084/001
Pyrexia ?neutropenic
sepsis
Suspected,
expected
FC
FCR Infections and
infestations
N00099/
00105/001
Neutropenic sepsis Suspected,
expected
FC
FCR Infections and
infestations
N00106/
00130/001
Neutropenic sepsis Suspected,
expected
FCR
FCR Infections and
infestations
N00106/
00130/002
Neutropenic sepsis Suspected,
expected
FCR
FCR Infections and
infestations
N00106/
00179/001
Pyrexial, neutropenic Suspected,
expected
FCR
FCR Infections and
infestations
N00106/
00179/003
Neutropenic sepsis Suspected,
expected
FCR
FCR Infections and
infestations
N00114/
00067/001
Neutropenic sepsis Suspected,
expected
FCR
FCR Infections and
infestations
N00114/
00067/002
Neutropenic sepsis
?cause
Suspected,
expected
FC
FCR Infections and
infestations
N00114/
00067/003
?Neutropenic
sepsis
Suspected,
expected
FCR
FCR Infections and
infestations
N00114/
00067/004
Neutropenic sepsis Suspected,
expected
FCR
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Other causality
(in addition to
trial medications)
Randomisation
date
Date SAE became
serious
SAE recovery
date
SAE
duration
(days)
Outcome of
SAE
Other: ? infection
underlying – none
proven
4 July 2012 11 July 2012 13 July 2012 2 Recovered
CLL 12 December 2011 2 February 2012 2 February 2012 0 Recovered
12 September 2012 10 January 2013 14 January 2013 4 Recovered
21 July 2010 6 December 2010 13 December 2010 7 Recovered
19 October 2011 8 February 2012 11 February 2012 3 Recovered
7 January 2011 22 February 2011 28 February 2011 6 Recovered
CLL 13 August 2012 31 December 2012 4 January 2013 4 Recovered
19 October 2010 11 December 2010 14 December 2010 3 Recovered
14 December 2009 2 January 2010 5 January 2010 3 Recovered
CLL 24 January 2011 4 March 2011 7 March 2011 3 Recovered
24 January 2011 30 May 2012 6 June 2012 7 Recovered
11 May 2011 24 October 2011 27 October 2011 3 Recovered
26 August 2011 7 September 2011 17 September 2011 10 Recovered
16 January 2012 24 March 2012 28 March 2012 4 Recovered
16 January 2012 27 April 2012 1 May 2012 4 Recovered
17 July 2012 2 August 2012 7 August 2012 5 Recovered
Concomitant
medications
17 July 2012 24 October 2012 27 October 2012 3 Recovered
9 February 2011 23 May 2011 28 May 2011 5 Recovered
9 September 2011 18 July 2011 25 July 2011 7 Recovered
CLL 9 February 2011 7 October 2011 14 October 2011 7 Recovered
9 February 2011 23 January 2012 27 January 2012 4 Recovered
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TABLE 80 Serious adverse events suspected to be related to trial treatment (details of event) (continued )
Treatment
received
MedDRA system
organ class
SAE ID
number
SAE medical
description
Suspected
relationship to
trial treatment
Suspected
product(s)
FCR Infections and
infestations
N00114/
00088/002
Neutropenic sepsis Suspected,
expected
FCR
FCR Infections and
infestations
N00153/
00026/001
Infection Suspected,
expected
FCR
FCR Infections and
infestations
N00153/
00050/001
Chest infection Suspected,
expected
FCR
FCR Infections and
infestations
N00173/
00011/003
Lower respiratory tract
infection
Suspected,
expected
FCR
FCR Infections and
infestations
N00218/
00168/002
Neutropenic sepsis Suspected,
expected
FC
FCR Infections and
infestations
N00230/
00033/001
Neutropenic sepsis Suspected,
expected
FC
FCR Infections and
infestations
N00231/
00174/001
Febrile, rigors, ?septic.
Episodes of diarrhoea for
2 days
Suspected,
expected
FC
FCR Infections and
infestations
N00231/
00174/002
Febrile illness (pyrexia,
rigors)
Suspected,
expected
FC
FCR Infections and
infestations
N00231/
00174/003
Neutropenic sepsis Suspected,
expected
FC
FCR Infections and
infestations
N00255/
00138/001
Neutropenic sepsis Suspected,
expected
FCR
FCR Infections and
infestations
N00255/
00166/001
Febrile neutropenia Suspected,
expected
FCR
FCR Infections and
infestations
N00255/
00166/002
Neutropenic sepsis Suspected,
expected
FCR
FCR Infections and
infestations
N00280/
00008/001
Neutropenic sepsis Suspected,
expected
FC
FCR Infections and
infestations
N00319/
00125/002
Febrile neutropenia Suspected,
expected
FCR
FCR Infections and
infestations
N00361/
00123/002
Neutropenic sepsis Suspected,
expected
FCR
FCR Infections and
infestations
N00391/
00111/001
Neutropenic sepsis Suspected,
expected
FC
FCR Infections and
infestations
N00391/
00194/001
?Neutropenic sepsis.
?Viral infection.
?Drug-induced
gastritis
Suspected,
expected
FC
FCR Infections and
infestations
N00698/
00198/001
Febrile neutropenia Suspected,
expected
FCR
FCR Neoplasms benign,
malignant and
unspecified (including
cysts and polyps)
N00098/
00002/001
SCC: two lesions (lower
back and central chest)
Suspected,
unexpected
FCR
FCR Psychiatric disorders N00349/
00104/002
Psychotic episode Suspected,
expected
Fludarabine
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Other causality
(in addition to
trial medications)
Randomisation
date
Date SAE became
serious
SAE recovery
date
SAE
duration
(days)
Outcome of
SAE
CLL 24 May 2011 24 December 2011 3 January 2012 10 Recovered
20 July 2010 10 August 2010 11 August 2010 1 Recovered
26 November 2010 27 February 2011 1 March 2011 2 Recovered
CLL 29 March 2010 6 July 2010 12 July 2010 6 Recovered
4 July 2012 25 September 2012 4 October 2012 9 Recovered
24 August 2010 26 September 2010 5 October 2010 9 Recovered
Other: infection 9 July 2012 22 August 2012 26 August 2012 4 Recovered
Other: infection 9 July 2012 27 August 2012 10 September 2012 14 Recovered
9 July 2012 1 October 2012 18 October 2012 17 Recovered
CLL 13 March 2012 7 April 2012 16 April 2012 9 Recovered
29 June 2012 13 September 2012 18 September 2012 5 Recovered
29 June 2012 17 March 2013 30 March 2013 13 Recovered
22 March 2010 31 May 2010 07 June 2010 7 Recovered
CLL 12 December 2011 20 February 2012 24 February 2012 4 Recovered
CLL 21 November 2011 5 July 2012 9 July 2012 4 Recovered
6 October 2011 4 November 2011 10 November 2011 6 Recovered
12 September 2012 13 December 2012 15 December 2012 2 Recovered
19 September 2012 31 December 2012 5 January 2013 5 Recovered
13 January 2010 6 October 2010 14 December 2010 69 Recovered
Other illness: long
history anxiety
25 August 2011 20 December 2011 24 February 2012 66 Recovered
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TABLE 80 Serious adverse events suspected to be related to trial treatment (details of event) (continued )
Treatment
received
MedDRA system
organ class
SAE ID
number
SAE medical
description
Suspected
relationship to
trial treatment
Suspected
product(s)
FCR Skin and
subcutaneous tissue
disorders
N00349/
00070/001
Rash Suspected,
expected
Rituximab
FCR Skin and
subcutaneous tissue
disorders
N00353/
00122/001
Erythemous rash grade 3 Suspected,
expected
Fludarabine
FCM-miniR Blood and lymphatic
system disorders
N00009/
00127/001
Pleural effusion and
pulmonary embolism
Suspected,
expected
Cyclophosphamide
FCM-miniR Blood and lymphatic
system disorders
N00099/
00027/001
Neutropenic sepsis Suspected,
expected
FCM-mini-R
FCM-miniR Blood and lymphatic
system disorders
N00099/
00027/002
Neutropenic sepsis Suspected,
expected
FCM-mini-R
FCM-miniR Blood and lymphatic
system disorders
N00114/
00086/003
DCT-negative
autoimmune haemolysis
Suspected,
expected
Fludarabine
FCM-miniR Blood and lymphatic
system disorders
N00114/
00086/004
Pulmonary embolism Suspected,
expected
Fludarabine
FCM-miniR Blood and lymphatic
system disorders
N00153/
00010/001
Neutropenia Suspected,
expected
FCM-mini-R
FCM-miniR Blood and lymphatic
system disorders
N00391/
00144/001
Marked pancytopenia
post chemotherapy.
Cough and SOB
Suspected,
expected
FCM
FCM-miniR Blood and lymphatic
system disorders
N01527/
00030/001
Anaemia Suspected,
expected
Fludarabine
FCM-miniR Gastrointestinal
disorders
N00050/
00083/001
Vomiting Suspected,
expected
FCM
FCM-miniR Gastrointestinal
disorders
N00153/
00034/001
Vomiting Suspected,
expected
FCM
FCM-miniR Gastrointestinal
disorders
N00153/
00034/002
Nausea and vomiting Suspected,
expected
FCM
FCM-miniR Gastrointestinal
disorders
N01527/
00184/001
Vomiting Suspected,
expected
Fludarabine and
mitoxantrone
FCM-miniR General disorders and
administration site
conditions
N00040/
00180/001
Serious Rituximab
reaction
Suspected,
expected
Low-dose
Rituximab
FCM-miniR General disorders and
administration site
conditions
N00098/
00004/001
High-grade fever Suspected,
expected
Mitoxantrone and
low-dose
Rituximab
FCM-miniR General disorders and
administration site
conditions
N00098/
00005/003
Anaphylaxis Suspected,
expected
Low-dose
Rituximab
FCM-miniR General disorders and
administration site
conditions
N00098/
00099/001
Vasovagal episode with
first dose of rituximab
Suspected,
expected
Low-dose
Rituximab
FCM-miniR General disorders and
administration site
conditions
N00099/
00036/001
Reaction to Rituximab Suspected,
expected
Low-dose
Rituximab
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Other causality
(in addition to
trial medications)
Randomisation
date
Date SAE became
serious
SAE recovery
date
SAE
duration
(days)
Outcome of
SAE
09 March 2011 12 April 2011 13 April 2011 1 Recovered
Concomitant
medications
11 November 2011 19 December 2011 9 January 2012 21 Recovered
15 December 2011 31 December 2011 11 January 2012 11 Recovered
20 July 2010 1 October 2010 7 October 2010 6 Recovered
with sequelae
20 July 2010 17 October 2010 25 October 2010 8 Recovered
with sequelae
CLL 18 May 2011 02 November 2011 Condition still
present and
unchanged
CLL; auto-immune
haemolytic anaemia
18 May 2011 16 January 2012 14 November 2012 303 Recovered
with sequelae
Concomitant
medications
25 March 2010 7 April 2010 26 April 2010 19 Recovered
17 April 2012 6 November 2012 9 November 2012 3 Recovered
9 August 2010 27 August 2010 31 August 2010 4 Recovered
6 May 2011 10 September 2011 11 September 2011 1 Recovered
31 August 2010 21 September 2010 23 September 2010 2 Recovered
31 August 2010 16 October 2010 19 October 2010 3 Recovered
06 August 2012 04 October 2012 05 October 2012 1 Recovered
20 July 2012 30 July 2012 31 July 2012 1 Recovered
2 February 2010 24 February 2010 25 February 2010 1 Recovered
15 February 2010 17 February 2010 17 February 2010 0 Recovered
Other: high vagal
tone
27 July 2011 10 August 2011 11 August 2011 1 Recovered
16 September 2010 27 September 2010 27 September 2010 0 Recovered
continued
DOI: 10.3310/hta21280 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 28
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Howard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
147
TABLE 80 Serious adverse events suspected to be related to trial treatment (details of event) (continued )
Treatment
received
MedDRA system
organ class
SAE ID
number
SAE medical
description
Suspected
relationship to
trial treatment
Suspected
product(s)
FCM-miniR General disorders and
administration site
conditions
N00153/
00156/001
Infusion reaction Suspected,
expected
Low-dose
Rituximab
FCM-miniR Immune system
disorders
N00361/
00109/001
Haemolytic anaemia Suspected,
expected
Fludarabine
FCM-miniR Infections and
infestations
N00014/
00054/001
Sepsis Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N00040/
00108/001
Neutropenic sepsis Suspected,
expected
FCM
FCM-miniR Infections and
infestations
N00040/
00108/002
Pyrexia Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N00040/
00108/004
Neutropenic sepsis Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N00050/
00095/001
Neutropenic sepsis Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N00080/
00058/001
Infection with grade 4
neutrophils
Suspected,
expected
FCM
FCM-miniR Infections and
infestations
N00080/
00058/002
Chest infection/febrile
neutropenia
Suspected,
expected
FCM
FCM-miniR Infections and
infestations
N00098/
00005/001
Pyrexia and rigors Suspected,
expected
FCM
FCM-miniR Infections and
infestations
N00098/
00005/002
Pyrexia and diarrhoea Suspected,
expected
FCM
FCM-miniR Infections and
infestations
N00098/
00005/004
Neutropenic sepsis Suspected,
expected
FCM
FCM-miniR Infections and
infestations
N00098/
00005/005
Fever, unknown origin,
nausea
Suspected,
expected
FCM
FCM-miniR Infections and
infestations
N00098/
00115/001
Urinary tract infection Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N00099/
00027/003
Neutropenic sepsis Suspected,
expected
FCM
FCM-miniR Infections and
infestations
N00099/
00036/002
Neutropenic sepsis Suspected,
expected
Fludarabine and
mitoxantrone
FCM-miniR Infections and
infestations
N00099/
00045/001
Neutropenic sepsis Suspected,
expected
FCM
FCM-miniR Infections and
infestations
N00106/
00075/001
URTI (not neutropenic)
and anaemia
Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N00106/
00075/003
Neutropenic sepsis Suspected,
expected
FCM
FCM-miniR Infections and
infestations
N00111/
00132/001
Pyrexia neutropenia Suspected,
expected
FCM
FCM-miniR Infections and
infestations
N00111/
00132/003
Opportunistic infection
associated with
> grade 2 lymphopenia
Suspected,
expected
FCM-mini-R
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Other causality
(in addition to
trial medications)
Randomisation
date
Date SAE became
serious
SAE recovery
date
SAE
duration
(days)
Outcome of
SAE
31 May 2012 7 June 2012 7 June 2012 0 Recovered
5 October 2011 17 November 2011 15 February 2012 90 Recovered
5 January 2011 4 February 2011 22 February 2011 18 Recovered
8 September 2011 24 September 2011 2 October 2011 8 Recovered
CLL 8 September 2011 7 October 2011 18 October 2011 11 Recovered
CLL 8 September 2011 7 January 2012 13 January 2012 6 Recovered
21 July 2011 31 December 2011 4 January 2012 4 Recovered
17 January 2011 28 April 2011 3 May 2011 5 Recovered
17 January 2011 28 October 2011 3 November 2011 6 Recovered
15 February 2010 5 March 2010 8 March 2010 3 Recovered
15 February 2010 8 March 2010 12 March 2010 4 Recovered
15 February 2010 22 April 2010 28 April 2010 6 Recovered
Concomitant
medications
infection
15 February 2010 19 May 2010 21 May 2010 2 Recovered
CLL 27 October 2011 4 May 2012 14 May 2012 10 Recovered
20 July 2010 22 February 2011 25 February 2011 3 Recovered
with sequelae
16 September 2010 03 November 2010 10 November 2010 7 Recovered
with sequelae
9 November 2010 29 March 2011 3 April 2011 5 Recovered
CLL 21 March 2011 6 April 2011 8 April 2011 2 Recovered
21 March 2011 2 May 2011 4 May 2011 2 Recovered
CLL 30 January 2012 8 May 2012 14 May 2012 6 Recovered
CLL 30 January 2012 16 February 2013 8 March 2013 20 Recovered
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TABLE 80 Serious adverse events suspected to be related to trial treatment (details of event) (continued )
Treatment
received
MedDRA system
organ class
SAE ID
number
SAE medical
description
Suspected
relationship to
trial treatment
Suspected
product(s)
FCM-miniR Infections and
infestations
N00114/
00006/002
Infection Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N00114/
00023/001
Bilateral pneumonia Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N00114/
00086/001
Neutropenic sepsis Suspected,
expected
FCM
FCM-miniR Infections and
infestations
N00114/
00094/001
Dehydration and
diarrhoea, secondary to
low Hb
Suspected,
expected
FCM
FCM-miniR Infections and
infestations
N00132/
00069/001
Neutropenic sepsis Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N00132/
00069/002
Grade 2 fevers after
chemotherapy
Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N00153/
00010/002
Febrile neutropenia Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N00153/
00016/001
Neutropenic sepsis/
neutropenic fever
Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N00153/
00020/001
Neutropenic sepsis Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N00153/
00020/002
Neutropenic sepsis Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N00153/
00156/002
Lower respiratory tract
infection
Suspected,
expected
FC and low-dose R
FCM-miniR Infections and
infestations
N00161/
00047/001
Neutropenic sepsis Suspected,
expected
FCM
FCM-miniR Infections and
infestations
N00161/
00047/002
Suspected neutropenic
sepsis
Suspected,
expected
Fludarabine
FCM-miniR Infections and
infestations
N00161/
00047/003
Chest infection Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N00280/
00039/001
Septic/sepsis Suspected,
expected
FCM
FCM-miniR Infections and
infestations
N00319/
00080/001
Neutropenia Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N00319/
00080/002
Temperature 37.8 °C Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N00319/
00080/003
Temperature 37.5 °C Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N00319/
00080/004
Fever: grade 1 Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N00353/
00065/001
Fever Suspected,
expected
FCM
FCM-miniR Infections and
infestations
N00391/
00071/001
Grade 3 anaemia and
grade 4 febrile
neutropenia
Suspected,
expected
FCM
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Other causality
(in addition to
trial medications)
Randomisation
date
Date SAE became
serious
SAE recovery
date
SAE
duration
(days)
Outcome of
SAE
22 February 2010 22 February 2012 27 February 2012 5 Recovered
CLL 8 July 2010 8 July 2011 50 Death
Other: in-dwelling
Hickman line
18 May 2011 19 August 2011 26 August 2011 7 Recovered
CLL 8 July 2011 5 September 2011 7 September 2011 2 Recovered
7 March 2011 10 May 2011 12 May 2011 2 Recovered
7 March 2011 30 July 2011 3 August 2011 4 Recovered
25 March 2010 3 August 2010 7 August 2010 4 Recovered
30 April 2010 31 August 2010 8 September 2010 8 Recovered
16 June 2010 2 September 2010 12 September 2010 10 Recovered
16 June 2010 14 September 2010 19 September 2010 5 Recovered
31 May 2012 6 September 2012 10 September 2012 4 Recovered
12 November 2010 1 December 2010 3 December 2010 2 Recovered
Other illness: lung
scarring from
previous infection
12 November 2010 12 August 2011 15 August 2011 3 Recovered
CLL 12 November 2010 26 August 2011 30 August 2011 4 Recovered
13 October 2010 11 February 2011 16 February 2011 5 Recovered
3 May 2011 5 July 2011 18 July 2011 13 Recovered
CLL 3 May 2011 18 July 2011 18 July 2011 0 Recovered
3 May 2011 31 August 2011 1 September 2011 1 Recovered
3 May 2011 1 October 2011 6 October 2011 5 Recovered
9 February 2011 22 April 2011 23 April 2011 1 Recovered
11 March 2011 1 May 2011 5 May 2011 4 Recovered
continued
DOI: 10.3310/hta21280 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 28
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Howard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
151
TABLE 80 Serious adverse events suspected to be related to trial treatment (details of event) (continued )
Treatment
received
MedDRA system
organ class
SAE ID
number
SAE medical
description
Suspected
relationship to
trial treatment
Suspected
product(s)
FCM-miniR Infections and
infestations
N00391/
00142/001
Neutropenia and fever
and sweats
Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N01527/
00081/002
Febrile neutropenia Suspected,
expected
FCM-mini-R
FCM-miniR Infections and
infestations
N01527/
00081/003
Febrile neutropenia Suspected,
expected
FCM-mini-R
FCM-miniR Musculoskeletal and
connective tissue
disorders
N01527/
00081/001
Infection with normal
ANC ?septic arthritis
Suspected,
expected
FCM-mini-R
FCM-miniR Neoplasms benign,
malignant and
unspecified (including
cysts and polyps)
N01527/
00081/004
EBV – associated
lymphoproliferative
disorder
Suspected,
expected
Fludarabine
FCM-miniR Renal and urinary
disorders
N00071/
00021/001
Acute renal failure:
tumour lysis syndrome
Suspected,
expected
FCM-mini-R
FCM-miniR Renal and urinary
disorders
N00353/
00165/001
Renal failure CTCAE
grade 3
Suspected,
expected
FCM-mini-R
FCM-miniR Skin and
subcutaneous tissue
disorders
N00106/
00075/002
Pyrexia/rash: macular/
papular
Suspected,
expected
FCM-mini-R
FCM-miniR/
FCR
Gastrointestinal
disorders
N00173/
00145/001
Nausea and vomiting Suspected,
expected
FCM-mini-R
FCM-miniR/
FCR
Gastrointestinal
disorders
N00319/
00189/001
Vomiting (grade 3) Suspected,
expected
Fludarabine
FCM-miniR/
FCR
General disorders and
administration site
conditions
N00137/
00196/002
Nausea, vomiting and
dehydration
Suspected,
expected
FCM-mini-R
FCM-miniR/
FCR
General disorders and
administration site
conditions
N00349/
00164/003
Fever (absence
neutropenia)
Suspected,
expected
Low-dose
Rituximab
FCM-miniR/
FCR
General disorders and
administration site
conditions
N00349/
00164/004
Cytokine release grade 3 Suspected,
expected
Low-dose
Rituximab
FCM-miniR/
FCR
Infections and
infestations
N00076/
00169/001
Febrile neutropenia Suspected,
expected
FC
FCM-miniR/
FCR
Infections and
infestations
N00076/
00169/002
Febrile Suspected,
expected
Fludarabine and
rituximab
FCM-miniR/
FCR
Infections and
infestations
N00137/
00196/003
Neutropenic sepsis Suspected,
expected
FCR
FCM-miniR/
FCR
Infections and
infestations
N00137/
00196/004
Neutropenic sepsis Suspected,
expected
FCR
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Other causality
(in addition to
trial medications)
Randomisation
date
Date SAE became
serious
SAE recovery
date
SAE
duration
(days)
Outcome of
SAE
CLL 10 April 2012 12 June 2012 18 June 2012 6 Recovered
CLL 5 May 2011 17 August 2011 25 August 2011 8 Recovered
CLL 5 May 2011 30 September 2011 7 October 2011 7 Recovered
Other illness:
previous septic
arthritis
5 May 2011 6 June 2011 9 June 2011 3 Recovered
5 May 2011 10 December 2012 20 June 2013 192 Recovered
Other illness:
vomiting/
dehydration ?did
not take allopurinol
(patient stopped
taking aciclovir/
septrin/allopurinol
when nauseous/
vomiting)
17 June 2010 2 July 2010 20 July 2010 18 Recovered
Other illness: acute
tubular necrosis;
Hypotension
28 June 2012 13 July 2012 23 July 2012 10 Recovered
Other illness: ?Viral/
bacterial infection
21 March 2011 22 April 2011 01 June 2011 40 Recovered
30 April 2012 20 June 2012 21 June 2012 1 Recovered
30 August 2012 11 September 2012 17 September 2012 6 Recovered
17 September 2012 24 September 2012 27 September 2012 3 Recovered
28 June 2012 14 August 2012 18 August 2012 4 Recovered
28 June 2012 19 September 2012 19 September 2012 0 Recovered
4 July 2012 6 August 2012 13 August 2012 7 Recovered
4 July 2012 26 November 2012 3 December 2012 7 Recovered
17 September 2012 16 January 2013 22 January 2013 6 Recovered
with sequelae
17 September 2012 13 February 2013 25 October 2013 254 Recovered
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TABLE 80 Serious adverse events suspected to be related to trial treatment (details of event) (continued )
Treatment
received
MedDRA system
organ class
SAE ID
number
SAE medical
description
Suspected
relationship to
trial treatment
Suspected
product(s)
FCM-miniR/
FCR
Infections and
infestations
N00153/
00148/001
Febrile neutropenia Suspected,
expected
FCM-mini-R
FCM-miniR/
FCR
Infections and
infestations
N00153/
00177/001
Febrile neutropenia Suspected,
expected
FCM
FCM-miniR/
FCR
Infections and
infestations
N00153/
00186/001
Febrile neutropenia Suspected,
expected
FCM-mini-R
FCM-miniR/
FCR
Infections and
infestations
N00218/
00162/001
Neutropenic fever Suspected,
expected
FCM-mini-R
FCM-miniR/
FCR
Infections and
infestations
N00319/
00189/002
Neutropenic sepsis
(febrile neutropenia)
Suspected,
expected
FC
FCM-miniR/
FCR
Infections and
infestations
N00319/
00189/003
Febrile neutropenia Suspected,
expected
FC
FCM-miniR/
FCR
Infections and
infestations
N00319/
00189/004
Neutropenia with fever
37.8 °C
Suspected,
expected
FC
ANC, absolute neutrophil count; CTC, common toxicity criteria; CTCAE, Common Terminology Criteria for Adverse Events;
EBV, Epstein–Barr virus; HB, haemoglobin; PJP, Pneumocystis jiroveci pneumonia; SCC, squamous cell carcinoma;
SOB, shortness of breath; URTI, upper respiratory tract infection.
SAE duration: days from date SAE became serious to date of recovery/death (if known).
SAE ID number: centre code/patient ID/SAE number.
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Other causality
(in addition to
trial medications)
Randomisation
date
Date SAE became
serious
SAE recovery
date
SAE
duration
(days)
Outcome of
SAE
4 May 2012 27 May 2012 31 May 2012 4 Recovered
13 July 2012 4 August 2012 5 August 2012 1 Recovered
CLL 13 August 2012 30 August 2012 2 September 2012 3 Recovered
20 June 2012 28 August 2012 2 September 2012 5 Recovered
30 August 2012 14 November 2012 17 November 2012 3 Recovered
30 August 2012 8 January 2013 13 January 2013 5 Recovered
30 August 2012 31 January 2013 10 February 2013 10 Recovered
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TABLE 83 Serious adverse events not suspected to be related to trial treatment (details of event)
Treatment
received MedDRA system organ class SAE ID number
SAE medical
description
Suspected
relationship to
trial treatment
FCR Blood and lymphatic system
disorders
N00153/00091/001 Anaemia Not suspected
FCR Cardiac disorders N00050/00178/001 Atrial fibrillation Not suspected
FCR Cardiac disorders N00173/00011/002 Palpitations Not suspected
FCR Cardiac disorders N00173/00011/004 Pericardial effusion Not suspected
FCR Eye disorders N00014/00112/002 Left vitrectomy Not suspected
FCR Infections and infestations N00014/00028/001 ?Varicella zoster virus
infection
Not suspected
FCR Infections and infestations N00098/00001/002 Viral infection, previously
febrile neutropenia
Not suspected
FCR Infections and infestations N00098/00019/002 Pyrexia of unknown
origin
Not suspected
FCR Infections and infestations N00349/00070/002 Pyrexia Not suspected
FCR Infections and infestations N00361/00123/001 Infection? source Not suspected
FCR Injury, poisoning and
procedural complications
N00014/00025/001 Corneal abrasion Not suspected
FCR Neoplasms benign, malignant
and unspecified (including cysts
and polyps)
N01527/00076/001 Dermatology/skin/other.
Metastatic SCC
Not suspected
FCR Psychiatric disorders N00349/00104/001 Steroid-induced agitation Not suspected
FCR Renal and urinary disorders N00230/00158/001 Kidney stone/renal colic Not suspected
FCR Respiratory, thoracic and
mediastinal disorders
N00218/00159/001 SOB ?PE Not suspected
FCR Respiratory, thoracic and
mediastinal disorders
N00391/00147/001 Pleural effusion Not suspected
FCR Skin and subcutaneous tissue
disorders
N00050/00093/001 Rash Not suspected
FCR Skin and subcutaneous tissue
disorders
N00106/00179/002 Severe rash Not suspected
FCM-miniR Cardiac disorders N00098/00003/001 Tachycardia Not suspected
FCM-miniR Gastrointestinal disorders N00050/00046/001 Diarrhoea Not suspected
FCM-miniR Gastrointestinal disorders N00111/00132/002 Diarrhoea Not suspected
FCM-miniR Gastrointestinal disorders N00114/00006/001 Constipation Not suspected
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Randomisation
date
Date SAE became
serious SAE recovery date
SAE
duration
(days)
Causality
(in addition to
trial medications)
Outcome of
SAE
21 June 2011 27 June 2011 28 June 2011 1 CLL Recovered
16 July 2012 27 September 2012 28 September 2012 1 Presumed primary
cardiac disorder
Recovered
29 March 2010 6 June 2010 7 June 2010 1 Has a history of
palpitations
Recovered
29 March 2010 28 July 2010 18 January 2011 174 CLL Recovered
19 October 2011 9 May 2012 9 May 2012 0 Vitreous haemorrhage
caused by diabetic
retinopathy
Recovered
21 July 2010 27 October 2010 3 August 2011 280 Varicella zoster virus
infection
Recovered
14 December 2009 6 December 2009 10 December 2009 4 CLL Recovered
8 June 2010 29 April 2011 4 May2011 5 Recovered
9 March 2011 14 June 2011 20 June 2011 6 Recovered
21 November 2011 11 April 2012 15 April 2012 4 Acquired viral
infection
Recovered
16 July 2010 21 December 2010 23 December 2010 2 Patient tripped over
shoe and fell
Recovered
with sequelae
5 April 2011 26 May 2011 20 June 2011 25 Previous SCC Recovered
25 August 2011 9 September 2011 12 September 2011 3 Concomitant
medications
Recovered
12 June 2012 11 August 2012 15 August 2012 4 Pre-existing condition Recovered
with sequelae
14 June 2012 17 November 2012 3 December 2012 16 Immobility Recovered
with sequelae
3 May 2012 8 May 2012 10 May 2012 2 CLL Recovered
6 July 2011 14 November 2011 14 November 2011 0 Viral fever Recovered
17 July 2012 31 August 2012 10 September 2012 10 Concomitant
medications
Recovered
with sequelae
15 January 2010 29 January 2010 30 January 2010 1 Recovered
10 November 2010 24 March 2011 4 April 2011 11 Rotavirus infection Recovered
30 January 2012 4 June 2012 7 June 2012 3 Gastroenteritis Recovered
22 February 2010 7 March 2010 9 March 2010 2 Concomitant
medications;
past history of
constipation and
abdominal surgery
Recovered
continued
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TABLE 83 Serious adverse events not suspected to be related to trial treatment (details of event) (continued )
Treatment
received MedDRA system organ class SAE ID number
SAE medical
description
Suspected
relationship to
trial treatment
FCM-miniR Gastrointestinal disorders N01527/00184/002 Bowel
obstruction + femoral
hernia (right side)
Not suspected
FCM-miniR General disorders and
administration site conditions
N00153/00121/001 Allergic reaction Not suspected
FCM-miniR General disorders and
administration site conditions
N01527/00184/003 Abdominal pain and
vomiting
Not suspected
FCM-miniR Infections and infestations N00098/00040/001 Neutropenic sepsis and
infected shoulder
Not suspected
FCM-miniR Infections and infestations N00099/00096/001 Low magnesium,
neutropenic sepsis
Not suspected
FCM-miniR Infections and infestations N00114/00086/002 Ongoing line sepsis Not suspected
FCM-miniR Infections and infestations N00349/00135/001 Pyrexia Not suspected
FCM-miniR Infections and infestations N01527/00081/005 Anaemia grade 3 Not suspected
FCM-miniR Renal and urinary disorders N00040/00108/003 Renal colic Not suspected
FCM-miniR Skin and subcutaneous tissue
disorders
N00153/00014/001 Rash Not suspected
FCM-miniR/FCR Infections and infestations N00349/00164/001 Viral URTI Not suspected
FCM-miniR/FCR Infections and infestations N00349/00164/002 Pyrexia grade 1 Not suspected
FCM-miniR/FCR Musculoskeletal and connective
tissue disorders
N00137/00196/001 Back pain Not suspected
FCM-miniR/FCR Skin and subcutaneous tissue
disorders
N00153/00148/002 All over body rash Not suspected
FCM-miniR/FCR Skin and subcutaneous tissue
disorders
N00218/00162/002 Allergic rash Not suspected
FCM-miniR/FCR Skin and subcutaneous tissue
disorders
N00218/00162/003 Rash + swelling of face Not suspected
PE, pulmonary embolism; SCC, squamous cell carcinoma; SOB, shortness of breath; URTI, upper respiratory tract infection.
SAE duration: days from date SAE became serious to date of recovery/death (if known).
SAE ID number: centre code/patient ID/SAE number.
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Randomisation
date
Date SAE became
serious SAE recovery date
SAE
duration
(days)
Causality
(in addition to
trial medications)
Outcome of
SAE
6 August 2012 15 October 2012 14 November 2012 30 Now known to have
been a bowel
obstruction + right
sided femoral hernia
Recovered
7 November 2011 11 November 2011 11 November 2011 0 Concomitant
medications:
co-trimoxazole and
aciclovir
Recovered
with sequelae
6 August 2012 25 November 2012 5 December 2012 10 Cholecystitis Recovered
15 October 2010 11 March 2011 23 CLL Died
25 July 2011 29 December 2011 4 January 2012 6 Diarrhoea of
unknown cause
Recovered
with sequelae
18 May 2011 21 September 2011 27 September 2011 6 CLL Recovered
22 February 2012 31 May 2012 4 June 2012 4 CLL Recovered
5 May 2011 18 August 2011 8 September 2011 21 Sepsis Recovered
8 September 2011 1 December 2011 20 February 2012 81 Kidney stone Recovered
26 April 2010 16 May 2010 7 June 2010 22 Concomitant
medications
Recovered
28 June 2012 13 July 2012 23 July 2012 10 Viral URTI Recovered
28 June 2012 4 August 2012 10 August 2012 6 Viral illness Recovered
17 September 2012 20 September 2012 20 September 2012 0 Recovered
with sequelae
4 May 2012 15 June 2012 19 June 2012 4 Concomitant
medications
Recovered
20 June 2012 5 September 2012 12 September 2012 7 Concomitant
medications
Recovered
with sequelae
20 June 2012 14 September 2012 17 September 2012 3 Concomitant
medications
Recovered
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Appendix 2 Adverse event listings
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TABLE 84 Adverse events in participants receiving FCR
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
1 FCR Infusional reaction 2 1 Unrelated
FCR Anaemia 3 1 Probably
FCR Anaemia 4 1 Probably
FCR Neutropenia 4 2 Almost certainly
FCR Nausea 2 3 Probably
FCR Neutropenia 3 4 Probably
FCR Infections (not
neutropenic sepsis)
1 4 Possibly
2 FCR Hypotension 2 1 Unrelated
FCR Nausea 2 1 Probably
FCR Infusional reaction 2 2 Unlikely
FCR Nausea 2 2 Probably
FCR Vomiting 2 2 Probably
FCR Nausea 1 3 Probably
FCR Vomiting 1 3 Probably
FCR Nausea 2 4 Almost certainly
FCR Infections (not
neutropenic sepsis)
2 4 Possibly
FCR Nausea 2 5 Almost certainly
FCR Vomiting 2 5 Almost certainly
FCR Nausea 2 6 Almost certainly
FCR Vomiting 2 6 Almost certainly
FCR Rash/flushing 1 6 Possibly
7 FCR Constipation 1 1 Unrelated
FCR Mucositis/thrush 2 5 Unrelated
8 FCR Fatigue 1 1 Probably
FCR Hypotension 1 1 Unrelated
FCR Diarrhoea 1 3 Unrelated
FCR Fatigue 2 6 Probably
9 FCR Nausea 1 1 Almost certainly
FCR Vomiting 1 1 Almost certainly
FCR Diarrhoea 1 1 Almost certainly
FCR Fatigue 1 1 Almost certainly
FCR Fatigue 1 2 Almost certainly
FCR Non-specific pain 1 2 Unlikely
FCR Fatigue 1 3 Almost certainly
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unrelated Almost certainly 15 December 2009 Yes 15 December 2009 0
Probably Possibly 21 December 2009 No
Probably Possibly 2 January 2010 Yes 12 January 2010 10
Almost certainly Possibly 20 January 2010 No
Probably Probably 17 February 2010 Yes 22 February 2010 5
Probably Possibly 12 April 2010 No
Possibly Possibly No
Unrelated Almost certainly 14 January 2010 Yes 14 January 2010 0
Probably Possibly 15 January 2010 Yes 25 January 2010 10
Unlikely Almost certainly 11 February 2010 Yes 11 February 2010 0
Probably Possibly 11 February 2010 Yes 22 February 2010 11
Probably Possibly 11 February 2010 Yes 22 February 2010 11
Probably Possibly 11 March 2010 Yes 13 March 2010 2
Probably Possibly 11 March 2010 Yes 11 March 2010 0
Almost certainly Possibly 9 April 2010 Yes 15 April 2010 6
Possibly Possibly 19 April 2010 Yes 29 April 2010 10
Almost certainly Possibly 6 May 2010 Yes 12 May 2010 6
Almost certainly Possibly 6 May 2010 Yes 7 May 2010 1
Almost certainly Possibly 3 June 2010 Yes 8 June 2010 5
Almost certainly Possibly 3 June 2010 Yes 4 June 2010 1
Possibly Possibly No
Unrelated Unrelated 24 March 2010 Yes 29 March 2010 5
Unrelated Unrelated 14 July 2010 No
Unrelated Unrelated 26 March 2010 Yes 1 April 2010 6
Unrelated Almost certainly 25 March 2010 Yes 25 March 2010 0
Unrelated Possibly 26 March 2010 Yes 8 June 2010 74
Unrelated Unrelated 3 August 2010 Yes 8 August 2010 5
Almost certainly Almost certainly 31 March 2010 Yes 3 April 2010 3
Almost certainly Almost certainly 31 March 2010 Yes 1 April 2010 1
Almost certainly Almost certainly 2 April 2010 Yes 4 April 2010 2
Almost certainly Almost certainly 31 March 2010 Yes 4 April 2010 4
Almost certainly Almost certainly 27 April 2010 Yes 30 April 2010 3
Unlikely Unlikely Yes
Almost certainly Almost certainly 26 May 2010 Yes 28 May 2010 2
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Alopecia 1 3 Almost certainly
FCR Other AE description Varicocele 2 3 Unlikely
FCR Fatigue 1 4 Almost certainly
FCR Dry skin/erythema 1 4 Unlikely
FCR Neutropenia 4 6 Almost certainly
FCR Thrombocytopenia 2 6 Almost certainly
11 FCR Neutropenia 4 1 Almost certainly
FCR Anaemia 2 1 Almost certainly
FCR Nausea 1 1 Probably
FCR Constipation 1 1 Unrelated
FCR Thrombocytopenia 2 1 Almost certainly
FCR Anaemia 2 2 Almost certainly
FCR Neutropenia 2 2 Almost certainly
FCR Neutropenia 4 3 Almost certainly
FCR Anaemia 2 3 Almost certainly
FCR Renal impairment 1 3 Unlikely
13 FCR Infusional reaction 2 2 Unrelated
FCR Vomiting 1 3 Probably
FCR Neutropenia 3 5 Almost certainly
17 FCR Nausea 2 1 Almost certainly
FCR Vomiting 2 1 Almost certainly
FCR Rash/flushing 2 1 Possibly
FCR Cough 1 1 Possibly
FCR Neutropenia 1 2 Almost certainly
FCR Nausea 1 2 Almost certainly
FCR Rash/flushing 2 2 Possibly
FCR Headache 2 2 Possibly
FCR Nausea 2 3 Almost certainly
FCR Vomiting 2 3 Almost certainly
FCR Fatigue 2 3 Probably
FCR Cough 1 3 Possibly
FCR Anorexia/cachexia 1 3 Possibly
FCR Nausea 2 4 Almost certainly
FCR Vomiting 2 4 Almost certainly
FCR Fatigue 1 4 Almost certainly
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Almost certainly No
Unlikely Unlikely No
Almost certainly Almost certainly 22 July 2010 Yes 25 July 2010 3
Unlikely Unlikely No
Almost certainly Almost certainly 17 August 2010 No
Almost certainly Almost certainly 17 August 2010 No
Almost certainly Almost certainly 4 May 2010 Yes 26 May 2010 22
Almost certainly Almost certainly 19 May 2010 Yes 26 May 2010 7
Probably Unlikely 15 April 2010 Yes 26 April 2010 11
Unrelated Unrelated 14 April 2010 Yes 26 April 2010 12
Almost certainly Almost certainly 24 April 2010 Yes 4 May 2010 10
Almost certainly Almost certainly 11 June 2010 No
Almost certainly Almost certainly 18 June 2010 No
Almost certainly Almost certainly 12 July 2010 No
Almost certainly Almost certainly 8 July 2010 Yes 27 July 2010 19
Unlikely Unlikely 6 July 2010 Yes 7 July 2010 1
Unrelated Unrelated 9 June 2010 Yes 9 June 2010 0
Probably Unrelated 15 June 2010 Yes 16 June 2010 1
Almost certainly Almost certainly 1 September 2010 Yes 6 September 2010 5
Almost certainly Possibly 12 May 2010 Yes 17 May 2010 5
Almost certainly Possibly 12 May 2010 Yes 12 May 2010 0
Possibly Possibly 21 May 2010 Yes 28 May 2010 7
Possibly Possibly 15 May 2010 Yes 25 May 2010 10
Almost certainly Possibly No
Almost certainly Possibly 7 June 2010 Yes
Possibly Possibly 12 June 2010 Yes 16 June 2010 4
Possibly Possibly 28 June 2010 Yes 28 June 2010 0
Almost certainly Possibly 7 July 2010 Yes 10 July 2010 3
Almost certainly Possibly 8 July 2010 Yes 10 July 2010 2
Probably Probably 7 July 2010 Yes 23 July 2010 16
Possibly Possibly 12 July 2010 Yes
Possibly Possibly No
Almost certainly Possibly 4 August 2010 Yes 6 August 2010 2
Almost certainly Possibly 4 August 2010 Yes 4 August 2010 0
Almost certainly Possibly 2 August 2010 Yes
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Thrombocytopenia 1 4 Almost certainly
FCR Nausea 2 5 Almost certainly
FCR Vomiting 1 5 Almost certainly
FCR Fatigue 1 5 Probably
FCR Nausea 3 6 Almost certainly
FCR Vomiting 2 6 Almost certainly
FCR Fatigue 2 6 Almost certainly
FCR Anaemia 4 6 Almost certainly
FCR Neutropenia 4 6 Almost certainly
FCR Thrombocytopenia 3 6 Almost certainly
FCR Fatigue 4 6 Probably
FCR Anorexia/cachexia 3 6 Probably
18 FCR Nausea 1 1 Probably
FCR Neutropenia 3 1 Probably
FCR Nausea 1 2 Probably
FCR Neutropenia 4 2 Probably
FCR Diarrhoea 1 3 Possibly
FCR Neutropenia 4 3 Probably
FCR Headache 1 3 Unlikely
FCR Neutropenia 4 4 Probably
FCR Neutropenia 4 5 Probably
FCR Cough 1 5 Unlikely
19 FCR Vomiting 2 1 Unrelated
FCR Nausea 2 1 Almost certainly
FCR Diarrhoea 1 1 Probably
FCR Constipation 1 1 Possibly
FCR Nausea 1 2 Almost certainly
FCR Vomiting 1 2 Almost certainly
FCR Constipation 1 2 Possibly
FCR Fatigue 1 2 Probably
FCR Neutropenia 1 2 Almost certainly
FCR Anaemia 1 2 Probably
FCR Nausea 1 3 Almost certainly
FCR Nausea 1 4 Almost certainly
FCR Fatigue 1 4 Probably
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Possibly No
Almost certainly Possibly 14 September 2010 Yes 21 September 2010 7
Almost certainly Possibly 20 September 2010 Yes 21 September 2010 1
Probably Probably No
Almost certainly Possibly 13 October 2010 Yes 20 October 2010 7
Almost certainly Possibly 13 October 2010 Yes 15 October 2010 2
Almost certainly Possibly 13 October 2010 No
Almost certainly Possibly 3 November 2010 Yes 4 November 2010 1
Almost certainly Possibly 5 November 2010 Yes 6 November 2010 1
Almost certainly Possibly 4 November 2010 No
Probably Possibly 1 November 2010 Yes 4 November 2010 3
Probably Unlikely 13 October 2010 Yes 4 November 2010 22
Probably Unlikely 2 June 2010 Yes
Probably Probably 7 June 2010 Yes 10 June 2010 3
Probably Unlikely Yes
Probably Probably 6 July 2010 Yes 26 July 2010 20
Possibly Unlikely Yes
Probably Probably 23 August 2010 Yes 31 August 2010 8
Unlikely Unlikely Yes
Probably Probably 13 September 2010 Yes 27 September 2010 14
Probably Probably 25 October 2010 Yes 01 November 2010 7
Unlikely Unlikely Yes
Unrelated Almost certainly 17 June 2010 Yes 17 June 2010 0
Almost certainly Possibly 21 June 2010 Yes 25 June 2010 4
Probably Possibly 19 June 2010 Yes 20 June 2010 1
Possibly Possibly Yes
Almost certainly Possibly 19 July 2010 Yes 25 July 2010 6
Almost certainly Possibly 21 July 2010 Yes 22 July 2010 1
Possibly Possibly 22 July 2010 Yes 23 July 2010 1
Probably Probably 23 July 2010 Yes 25 July 2010 2
Almost certainly Almost certainly 11 August 2010 Yes 8 September 2010 28
Probably Probably 11 August 2010 Yes 8 September 2010 28
Almost certainly Possibly 15 August 2010 Yes 22 August 2010 7
Almost certainly Possibly 11 September 2010 Yes 19 September 2010 8
Probably Possibly Yes 19 September 2010
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Other AE description Gum recession
resulting in loose
tooth
1 4 Possibly
FCR Nausea 1 5 Almost certainly
FCR Nausea 2 6 Almost certainly
FCR Neutropenia 1 6 Almost certainly
24 FCR Neutropenia 2 1 Almost certainly
FCR Abdominal pain/
bloating
1 1 Possibly
FCR Neutropenia 3 2 Almost certainly
FCR Neutropenia 2 3 Almost certainly
FCR Thrombocytopenia 1 4 Almost certainly
FCR Anaemia 1 6 Almost certainly
FCR Neutropenia 1 6 Almost certainly
25 FCR Vomiting 2 2 Probably
FCR Thrombocytopenia 2 2 Probably
FCR Vomiting 2 3 Almost certainly
FCR Diarrhoea 2 3 Almost certainly
FCR Infections (not
neutropenic sepsis)
1 3 Unlikely
FCR Rash/flushing 2 3 Possibly
FCR Thrombocytopenia 2 4 Probably
FCR Diarrhoea 1 5 Unrelated
26 FCR Rash/flushing 2 1 Unrelated
FCR Sore throat 1 6 Possibly
FCR Dyspnoea 1 6 Unlikely
28 FCR Nausea 1 2 Almost certainly
FCR Pruritus 1 3 Unlikely
FCR Rash/flushing 3 4 Possibly
FCR Neutropenic sepsis 4 4 Almost certainly
FCR Fatigue 2 4 Probably
FCR Infections (not
neutropenic sepsis)
3 4 Almost certainly
FCR Anaemia 2 4 Almost certainly
FCR Neutropenia 3 4 Almost certainly
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Possibly Possibly No
Almost certainly Possibly 10 October 2010 No
Almost certainly Possibly 8 November 2010 Yes 13 November 2010 5
Almost certainly Possibly 1 December 2010 No
Almost certainly Unlikely 29 July 2010 Yes 16 August 2010 18
Possibly Possibly 22 July 2010 Yes 29 July 2010 7
Almost certainly Unlikely 8 September 2010 Yes 13 September 2010 5
Almost certainly Unlikely 6 October 2010 Yes 11 October 2010 5
Almost certainly Unlikely 3 November 2010 No
Almost certainly Unlikely 3 November 2010 Yes 27 June 2011 236
Almost certainly Unlikely 3 November 2010 Yes 6 December 2011 398
Probably Unlikely 27 August 2010 Yes 29 August 2010 2
Probably Probably 20 September 2010 No
Almost certainly Unlikely 29 September 2010 Yes 4 October 2010 5
Almost certainly Unlikely 29 September 2010 Yes 4 October 2010 5
Unlikely Unlikely 17 September 2010 Yes 29 September 2010 12
Possibly Possibly 28 August 2010 Yes 29 September 2010 32
Probably Unlikely 27 September 2010 Yes 29 November 2010 63
Unrelated Unrelated 30 December 2010 Yes 10 January 2011 11
Unrelated Unrelated 12 August 2010 Yes 14 August 2010 2
Possibly Possibly
Unlikely Unlikely
Almost certainly Unlikely 3 August 2010 Yes 7 August 2010 4
Unlikely Unlikely 15 September 2010 No
Unlikely Possibly 10 November 2010 Yes 22 December 2010 42
Almost certainly Possibly 4 December 2010 Yes 13 December 2010 9
Probably Possibly 4 December 2010 No
Almost certainly Almost certainly 28 December 2010 No
Almost certainly Almost certainly 4 January 2011 No
Almost certainly Almost certainly 4 January 2011 No
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
29 FCR Cough 2 3 Unlikely
FCR Vomiting 1 3 Unlikely
FCR Infections (not
neutropenic sepsis)
1 4 Probably
FCR Nausea 1 6 Probably
32 FCR Anorexia/cachexia 1 1 Almost certainly
FCR Fatigue 3 2 Almost certainly
FCR Nausea 2 2 Almost certainly
FCR Anorexia/cachexia 1 2 Almost certainly
33 FCR Neutropenic sepsis 4 1 Probably
FCR Allergic reaction 3 1 Unrelated
FCR Nausea 1 2 Probably
FCR Neuropathy (sensory) 1 2 Probably
FCR Bone pain 1 2 Unlikely
FCR Anxiety/depression 1 2 Unrelated
FCR Fatigue 1 3 Probably
FCR Vomiting 1 3 Almost certainly
FCR Insomnia 1 3 Unrelated
FCR Alopecia 1 5 Possibly
FCR Vomiting 1 5 Missing
FCR Anxiety/depression 1 5 Unlikely
FCR Night sweats 1 5 Unrelated
FCR Insomnia 1 6 Unrelated
FCR Nausea 1 6 Almost certainly
FCR Taste alteration 1 6 Possibly
FCR Rash/flushing 1 6 Possibly
35 FCR Dizziness 2 1 Possibly
FCR Nausea 2 1 Probably
FCR Fatigue 2 1 Probably
FCR Anorexia/cachexia 2 1 Probably
FCR Diarrhoea 1 1 Probably
FCR Anaemia 1 1 Probably
FCR Neutropenia 2 1 Probably
FCR Thrombocytopenia 1 1 Probably
FCR Nausea 2 2 Probably
FCR Vomiting 2 2 Probably
FCR Fatigue 2 2 Probably
APPENDIX 2
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unlikely Unlikely 4 October 2010 Yes 17 October 2010 13
Unlikely Unlikely 22 October 2010 Yes 26 October 2010 4
Probably Possibly 23 November 2010 Yes 30 December 2010 37
Probably Unlikely 10 January 2011 Yes 18 January 2011 8
Almost certainly Unlikely 8 September 2010 Yes 10 September 2010 2
Almost certainly Unlikely 6 October 2010 Yes 7 October 2010 1
Almost certainly Unlikely 6 October 2010 Yes 8 October 2010 2
Almost certainly Unlikely 6 October 2010 Yes 9 October 2010 3
Probably Probably 26 September 2010 Yes 5 October 2010 9
Unrelated Unrelated 28 September 2010 Yes 8 October 2010 10
Probably Probably 14 October 2010 Yes 18 October 2010 4
Probably Probably 20 October 2010 No
Unlikely Unlikely 22 October 2010 Yes 7 December 2010 46
Unrelated Unrelated 12 October 2010 Yes 7 December 2010 56
Probably Probably 11 November 2010 No
Almost certainly Almost certainly 16 November 2010 Yes 19 November 2010 3
Unrelated Unrelated 11 November 2010 No
Possibly Possibly 12 January 2011 No
Missing Missing 6 January 2011 Yes 12 January 2011 6
Unlikely Unlikely 10 January 2011 Yes 3 February 2011 24
Unrelated Unrelated 15 November 2010 Yes 3 February 2011 80
Unrelated Unrelated 11 December 2010 No
Almost certainly Almost certainly 10 December 2010 Yes 1 March 2011 81
Possibly Possibly 26 February 2011 Yes 01 March 2011 3
Possibly Possibly 1 February 2011 Yes 1 March 2011 28
Possibly Unlikely 8 October 2010 Yes 10 October 2010 2
Probably Unlikely 8 October 2010 Yes 10 October 2010 2
Probably Unlikely 8 October 2010 Yes 10 October 2010 2
Probably Unlikely 8 October 2010 Yes 10 October 2010 2
Probably Unlikely 10 October 2010 Yes 10 October 2010 0
Probably Unlikely 5 October 2010 No
Probably Unlikely 19 October 2010 Yes 5 November 2010 17
Probably Unlikely 7 October 2010 Yes 12 October 2010 5
Probably Unlikely 7 November 2010 Yes 26 November 2010 19
Probably Unlikely 7 November 2010 Yes 9 November 2010 2
Probably Unlikely 7 November 2010 Yes 12 November 2010 5
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Diarrhoea 2 2 Probably
FCR Anorexia/cachexia 2 2 Probably
FCR Anaemia 2 2 Probably
FCR Nausea 2 3 Probably
FCR Vomiting 3 3 Probably
FCR Neutropenia 4 3 Almost certainly
FCR Fatigue 2 3 Probably
FCR Anorexia/cachexia 2 3 Probably
FCR Anaemia 1 3 Probably
FCR Thrombocytopenia 1 3 Almost certainly
FCR Anorexia/cachexia 2 4 Probably
FCR Fatigue 2 4 Probably
FCR Infections (not
neutropenic sepsis)
2 4 Unlikely
FCR Neutropenia 3 4 Almost certainly
FCR Thrombocytopenia 1 4 Almost certainly
FCR Nausea 1 5 Probably
FCR Fatigue 2 5 Probably
FCR Non-specific pain 2 5 Unlikely
FCR Infections (not
neutropenic sepsis)
2 5 Unlikely
FCR Neutropenia 3 5 Almost certainly
FCR Anaemia 2 5 Probably
FCR Thrombocytopenia 1 5 Almost certainly
FCR Nausea 2 6 Probably
FCR Neutropenia 3 6 Almost certainly
FCR Fatigue 2 6 Probably
FCR Anaemia 2 6 Probably
FCR Thrombocytopenia 1 6 Almost certainly
38 FCR Dry skin/erythema 1 1 Unrelated
FCR Chest pain 1 1 Unrelated
FCR Fever 1 1 Unrelated
FCR Rigors 2 1 Unrelated
FCR Nausea 1 1 Possibly
FCR Thrombocytopenia 2 1 Unlikely
FCR Thrombocytopenia 2 6 Unlikely
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Probably Unlikely 10 November 2010 Yes 10 November 2010 0
Probably Unlikely 7 November 2010 Yes 12 November 2010 5
Probably Unlikely 18 November 2010 No
Probably Unlikely 7 December 2010 No
Probably Unlikely 8 December 2010 Yes 9 December 2010 1
Almost certainly Unlikely 18 November 2010 Yes 9 December 2010 21
Probably Unlikely 7 December 2010 Yes 24 December 2010 17
Unlikely Unlikely 7 December 2010 Yes 10 December 2010 3
Probably Unlikely 18 December 2010 No
Almost certainly Unlikely 17 December 2010 Yes 23 December 2010 6
Probably Unlikely 4 January 2011 Yes 21 January 2011 17
Probably Unlikely 4 January 2011 No
Unlikely Unlikely 19 January 2011 No
Almost certainly Unlikely 11 January 2011 Yes 1 February 2011 21
Almost certainly Unlikely 4 January 2011 No
Probably Unlikely 6 February 2011 Yes 4 March 2011 26
Probably Unlikely 1 February 2011 Yes 4 March 2011 31
Unlikely Unlikely 7 January 2011 Yes 4 March 2011 56
Unlikely Unlikely 11 February 2011 Yes 21 February 2011 10
Almost certainly Almost certainly 11 February 2011 No
Probably Unlikely 11 February 2011 No
Almost certainly Unlikely 11 February 2011 No
Probably Unlikely 15 March 2011 Yes 15 April 2011 31
Almost certainly Unlikely 7 April 2011 No
Probably Unlikely 15 March 2011 No
Probably Unlikely 31 March 2011 No
Almost certainly Unlikely 15 March 2011 No
Unrelated Probably 12 October 2010 Yes 12 October 2010 0
Unrelated Probably 12 October 2010 Yes 12 October 2010 0
Unrelated Probably 12 October 2010 Yes 12 October 2010 0
Unrelated Probably 13 October 2010 Yes 13 October 2010 0
Possibly Unlikely Yes
Unlikely Unlikely 11 October 2010 No
Unlikely Unlikely 11 October 2011 No
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
41 FCR Rigors 1 1 Unrelated
FCR Back pain 1 1 Unrelated
FCR Headache 1 1 Unrelated
FCR Nausea 1 1 Unrelated
FCR Diarrhoea 1 1 Possibly
FCR Neutropenia 4 1 Probably
FCR Nasal symptoms 2 1 Unrelated
FCR Infections (not
neutropenic sepsis)
3 2 Probably
FCR Infections (not
neutropenic sepsis)
3 2 Probably
FCR Neutropenia 4 2 Probably
42 FCR Nausea 1 1 Almost certainly
FCR Neutropenia 1 1 Possibly
FCR Anaemia 1 1 Possibly
FCR Infusional reaction 2 1 Unrelated
FCR Vomiting 2 2 Possibly
FCR Diarrhoea 1 2 Possibly
FCR Thrombocytopenia 1 3 Possibly
FCR Lymphopenia 2 3 Possibly
FCR Lymphopenia 3 3 Possibly
FCR Anaemia 1 3 Possibly
FCR Myalgias 1 4 Possibly
FCR Cutaneous herpes/
shingles
2 5 Possibly
FCR Vomiting 1 5 Probably
FCR Fatigue 1 5 Probably
FCR Neutropenia 1 5 Possibly
FCR Nausea 2 6 Probably
FCR Neutropenia 2 6 Possibly
43 FCR Anaemia 1 1 Probably
FCR Nausea 1 1 Almost certainly
FCR Vomiting 1 1 Almost certainly
FCR Fatigue 1 1 Probably
FCR Rigors 1 1 Possibly
FCR Nausea 1 2 Almost certainly
FCR Infections (not
neutropenic sepsis)
2 3 Possibly
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unrelated Almost certainly 3 November 2010 Yes 3 November 2010 0
Unrelated Almost certainly 3 November 2010 Yes 3 November 2010 0
Unrelated Almost certainly 3 November 2010 Yes 3 November 2010 0
Unrelated Almost certainly 3 November 2010 Yes 4 November 2010 1
Possibly Unlikely Yes
Probably Probably 15 November 2010 Yes 29 November 2010 14
Unrelated Unrelated 26 November 2010 No
Probably Probably 11 December 2010 Yes 11 January 2011 31
Probably Probably 14 January 2011 Yes 21 January 2011 7
Probably Probably 11 December 2010 Yes 14 December 2010 3
Almost certainly Probably Yes
Possibly Possibly 23 November 2010 Yes 25 November 2010 2
Possibly Possibly 19 July 2010 Yes 23 November 2010 127
Unrelated Almost certainly 28 October 2010 Yes 28 October 2010 0
Possibly Possibly 27 November 2010 Yes 27 November 2010 0
Possibly Possibly Yes 20 January 2011
Possibly Possibly 21 September 2010 Yes 18 January 2011 119
Possibly Possibly 21 December 2010 Yes 18 January 2011 28
Possibly Possibly 18 January 2011 No
Possibly Possibly 18 January 2011 No
Possibly Possibly Yes 17 February 2011
Possibly Possibly 18 February 2011 Yes 5 March 2011 15
Probably Possibly 2 March 2011 Yes 3 March 2011 1
Probably Possibly Yes 19 March 2011
Possibly Possibly 15 February 2011 Yes 15 March 2011 28
Probably Probably 2 March 2011 Yes 14 April 2011 43
Possibly Possibly 18 January 2011 Yes 14 April 2011 86
Probably Possibly No
Almost certainly Possibly 26 October 2010 Yes
Almost certainly Possibly Yes
Probably Probably Yes
Possibly Probably 26 October 2010 Yes 26 October 2010 0
Almost certainly Possibly 25 November 2010 Yes 28 November 2010 3
Possibly Possibly Yes
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Nausea 1 4 Almost certainly
FCR Constipation 1 4 Possibly
FCR Pruritus 1 4 Probably
FCR Nausea 1 5 Almost certainly
44 FCR Nausea 1 1 Almost certainly
FCR Constipation 2 1 Almost certainly
FCR Fatigue 1 1 Almost certainly
FCR Alopecia 1 1 Almost certainly
FCR Mucositis/thrush 1 1 Almost certainly
FCR Thrombocytopenia 2 1 Almost certainly
FCR Neutropenia 2 1 Almost certainly
FCR Neuropathy (sensory) 1 1 Unlikely
FCR Neutropenia 4 2 Almost certainly
FCR Thrombocytopenia 1 2 Almost certainly
FCR Nausea 1 2 Almost certainly
FCR Neutropenic sepsis 1 2 Almost certainly
FCR Diarrhoea 2 3 Unrelated
FCR Myalgias 1 3 Possibly
FCR Constipation 1 4 Almost certainly
FCR Nausea 1 4 Almost certainly
FCR Infections (not
neutropenic sepsis)
1 4 Unrelated
FCR Fatigue 2 4 Almost certainly
FCR Nausea 2 5 Almost certainly
FCR Infections (not
neutropenic sepsis)
2 5 Unrelated
FCR Vomiting 2 5 Almost certainly
48 FCR Headache 2 3 Unlikely
FCR Sore throat 2 4 Possibly
FCR Urinary symptoms 2 4 Possibly
FCR Dizziness 1 5 Unrelated
FCR Abdominal pain/
bloating
1 5 Possibly
FCR Fatigue 1 6 Almost certainly
FCR Nausea 2 6 Almost certainly
50 FCR Infections (not
neutropenic sepsis)
3 5 Almost certainly
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Possibly 20 January 2011 Yes 29 January 2011 9
Possibly Possibly Yes 16 February 2011
Unlikely Unlikely Yes 16 February 2011
Almost certainly Possibly 17 February 2011 Yes
Almost certainly Almost certainly 4 November 2010 Yes 10 November 2010 6
Almost certainly Almost certainly 4 November 2010 No
Almost certainly Almost certainly 4 November 2010 No
Almost certainly Almost certainly 4 November 2010 No
Almost certainly Almost certainly 4 November 2010 Yes
Almost certainly Almost certainly 30 November 2010 Yes 14 December 2010 14
Almost certainly Almost certainly 30 November 2010 Yes 14 December 2010 14
Unlikely Unlikely No
Almost certainly Almost certainly 11 January 2011 Yes 13 January 2011 2
Almost certainly Almost certainly 11 January 2011 No
Almost certainly Almost certainly 16 December 2010 Yes
Almost certainly Almost certainly 24 December 2010 Yes 27 December 2010 3
Unrelated Unrelated Yes
Possibly Possibly No
Almost certainly Almost certainly Yes
Almost certainly Almost certainly Yes
Unrelated Unrelated 1 March 2011 Yes 8 March 2011 7
Almost certainly Almost certainly 10 February 2011 Yes 14 February 2011 4
Almost certainly Almost certainly 15 March 2011 Yes
Unrelated Unrelated 21 March 2011 Yes
Almost certainly Almost certainly 15 March 2011 Yes 15 March 2011 0
Unlikely Unlikely 26 December 2010 No
Possibly Possibly 14 February 2011 Yes 14 March 2011 28
Possibly Possibly 14 February 2011 Yes 14 March 2011 28
Unrelated Unrelated 14 March 2011 Yes 11 April 2011 28
Possibly Possibly 14 March 2011 Yes 11 April 2011 28
Unlikely Unlikely 11 April 2011 Yes 9 May 2011 28
Almost certainly Almost certainly 11 April 2011 Yes 9 May 2011 28
Almost certainly Almost certainly 27 February 2011 Yes 1 March 2011 2
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
51 FCR Neutropenia 4 1 Probably
FCR Anaemia 2 2 Almost certainly
FCR Neutropenia 3 3 Missing
FCR Thrombocytopenia 1 3 Missing
FCR Thrombocytopenia 1 4 Probably
FCR Neutropenia 3 4 Probably
FCR Anaemia 1 4 Probably
55 FCR Thrombocytopenia 3 1 Almost certainly
FCR Neutropenia 3 1 Almost certainly
FCR Neutropenia 1 2 Almost certainly
FCR Anaemia 1 2 Almost certainly
FCR Neutropenia 1 3 Almost certainly
FCR Anaemia 1 3 Almost certainly
FCR Neutropenia 1 4 Almost certainly
FCR Neutropenia 3 6 Almost certainly
FCR Thrombocytopenia 1 6 Almost certainly
FCR Rash/flushing 2 6 Unrelated
59 FCR Nausea 1 3 Probably
FCR Anaemia 1 3 Possibly
FCR Nausea 1 4 Probably
FCR Neutropenia 1 6 Almost certainly
60 FCR Vomiting 2 1 Almost certainly
FCR Infusional reaction 2 1 Unrelated
FCR Fever 3 2 Probably
FCR Nausea 1 2 Unlikely
FCR Dyspnoea 1 2 Unlikely
FCR Neutropenia 1 2 Probably
FCR Nausea 1 3 Almost certainly
FCR Vomiting 3 4 Almost certainly
FCR Thrombocytopenia 1 4 Probably
FCR Neutropenia 1 4 Probably
FCR Nausea 3 5 Almost certainly
FCR Vomiting 3 5 Almost certainly
FCR Neutropenia 2 5 Almost certainly
FCR Anaemia 1 5 Almost certainly
FCR Fatigue 2 5 Possibly
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
216
Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Probably Probably 30 December 2010 Yes 31 January 2011 32
Almost certainly Missing 12 February 2011 Yes 14 March 2011 30
Missing Missing 11 April 2011 Yes 15 April 2011 4
Missing Missing 14 March 2011 No
Probably Probably 6 May 2011 No
Probably Probably 12 May 2011 No
Probably Probably 12 May 2011 No
Almost certainly Almost certainly 14 January 2011 Yes 7 February 2011 24
Almost certainly Almost certainly 14 January 2011 Yes 15 February 2011 32
Almost certainly Almost certainly 7 March 2011 Yes 4 April 2011 28
Almost certainly Almost certainly 15 February 2011 Yes 4 April 2011 48
Almost certainly Almost certainly 22 March 2011 Yes 4 April 2011 13
Almost certainly Almost certainly 22 March 2011 Yes 4 April 2011 13
Almost certainly Almost certainly 7 February 2011 No
Almost certainly Almost certainly 15 June 2011 Yes 29 June 2011 14
Almost certainly Almost certainly 7 February 2011 Yes 20 September 2011 225
Unrelated Unrelated 12 September 2011 No
Probably Unlikely 22 March 2011 Yes 26 March 2011 4
Possibly Unlikely 19 April 2011 No
Probably Unlikely 19 April 2011 Yes 23 April 2011 4
Almost certainly Unlikely 17 May 2011 Yes 8 September 2011 114
Almost certainly Almost certainly 24 January 2011 Yes 27 January 2011 3
Unrelated Almost certainly 27 January 2011 Yes 27 January 2011 0
Probably Probably 4 March 2011 Yes 7 March 2011 3
Unlikely Unlikely 7 March 2011 Yes 11 March 2011 4
Unlikely Unlikely 7 March 2011 Yes 11 March 2011 4
Probably Probably 4 March 2011 Yes 23 March 2011 19
Almost certainly Possibly 26 March 2011 Yes 31 March 2011 5
Almost certainly Unlikely 23 April 2011 Yes 04 May 2011 11
Probably Possibly 4 March 2011 Yes 18 May 2011 75
Probably Probably 20 April 2011 Yes 18 May 2011 28
Almost certainly Possibly 21 May 2011 Yes 8 June 2011 18
Almost certainly Possibly 21 May 2011 Yes 8 June 2011 18
Almost certainly Possibly No
Almost certainly Possibly 15 June 2011 No
Possibly Probably 19 May 2011 No
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Constipation 1 5 Unlikely
FCR Nausea 1 6 Almost certainly
FCR Vomiting 1 6 Almost certainly
FCR Sore throat 1 6 Almost certainly
FCR Neutropenia 3 6 Almost certainly
61 FCR Infections (not
neutropenic sepsis)
2 1 Missing
FCR Thrombocytopenia 2 1 Missing
FCR Neutropenia 4 1 Missing
FCR Constipation 1 1 Unlikely
FCR Infections (not
neutropenic sepsis)
2 2 Almost certainly
FCR Neutropenia 4 2 Almost certainly
FCR Other AE description Pancytopenia 2 2 Almost certainly
FCR Thrombocytopenia 2 3 Almost certainly
FCR Neutropenia 3 3 Almost certainly
FCR Fatigue 1 3 Almost certainly
FCR Fatigue 1 4 Almost certainly
FCR Infections (not
neutropenic sepsis)
2 4 Almost certainly
FCR Neutropenia 4 4 Almost certainly
FCR Thrombocytopenia 3 4 Almost certainly
FCR Neutropenia 4 5 Almost certainly
FCR Fatigue 1 5 Almost certainly
FCR Neutropenia 4 6 Almost certainly
FCR Thrombocytopenia 2 6 Almost certainly
62 FCR Hypotension 1 1 Unlikely
FCR Fever 1 1 Unlikely
FCR Vomiting 1 3 Probably
FCR Bone pain 1 3 Unlikely
66 FCR Thrombocytopenia 1 1 Almost certainly
FCR Neutropenia 2 1 Almost certainly
FCR Neutropenia 1 2 Almost certainly
FCR Anaemia 1 2 Almost certainly
FCR Neutropenia 4 3 Almost certainly
FCR Diarrhoea 2 3 Possibly
FCR Neutropenia 4 4 Almost certainly
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unlikely Unlikely 18 May 2011 Yes 1 June 2011 14
Almost certainly Possibly 24 February 2011 Yes 2 July 2011 128
Almost certainly Possibly 27 June 2011 Yes 2 July 2011 5
Almost certainly Unlikely Yes
Almost certainly Possibly 13 July 2011 Yes 27 July 2011 14
Missing Missing 15 February 2011 Yes 24 February 2011 9
Missing Missing 8 February 2011 Yes 18 February 2011 10
Missing Missing 18 February 2011 Yes 24 February 2011 6
Unlikely Unlikely 18 February 2011 Yes 24 February 2011 6
Almost certainly Almost certainly 7 March 2011 Yes 13 March 2011 6
Almost certainly Almost certainly 24 March 2011 Yes 24 March 2011 0
Almost certainly Almost certainly 7 March 2011 Yes 24 March 2011 17
Almost certainly Almost certainly 28 April 2011 Yes 5 May 2011 7
Almost certainly Almost certainly 14 April 2011 Yes 28 April 2011 14
Almost certainly Almost certainly 14 April 2011 Yes 28 April 2011 14
Almost certainly Almost certainly 5 May 2011 No
Almost certainly Almost certainly 16 May 2011 Yes 24 May 2011 8
Almost certainly Almost certainly 19 May 2011 Yes 15 June 2011 27
Almost certainly Almost certainly 15 June 2011 No
Almost certainly Almost certainly 6 July 2011 Yes 20 July 2011 14
Almost certainly Almost certainly 6 July 2011 Yes 14 July 2011 8
Almost certainly Almost certainly 4 August 2011 Yes 22 September 2011 49
Almost certainly Almost certainly 17 August 2011 Yes 26 August 2011 9
Unlikely Unlikely 2 February 2011 Yes 2 February 2011 0
Unlikely Unlikely 2 February 2011 Yes 2 February 2011 0
Probably Unlikely Yes
Unlikely Unlikely No
Almost certainly Almost certainly 15 March 2011 Yes 22 March 2011 7
Almost certainly Almost certainly 22 March 2011 Yes 29 March 2011 7
Almost certainly Almost certainly 20 April 2011 Yes 26 April 2011 6
Almost certainly Almost certainly 12 April 2011 Yes 20 April 2011 8
Almost certainly Almost certainly 10 May 2011 Yes 23 May 2011 13
Possibly Possibly 3 May 2011 Yes 5 May 2011 2
Almost certainly Almost certainly 7 June 2011 Yes 20 June 2011 13
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Thrombocytopenia 1 4 Almost certainly
FCR Diarrhoea 1 4 Probably
FCR Neutropenia 2 5 Almost certainly
FCR Thrombocytopenia 1 6 Almost certainly
FCR Neutropenia 2 6 Almost certainly
67 FCR Anaemia 1 1 Almost certainly
FCR Neutropenia 1 1 Almost certainly
FCR Nausea 1 1 Almost certainly
FCR Neutropenia 4 3 Almost certainly
FCR Anaemia 1 3 Almost certainly
FCR Anaemia 1 4 Almost certainly
FCR Thrombocytopenia 1 4 Almost certainly
FCR Anaemia 1 5 Almost certainly
FCR Neutropenia 3 5 Almost certainly
FCR Anaemia 2 6 Almost certainly
FCR Thrombocytopenia 2 6 Almost certainly
FCR Neutropenia 4 6 Almost certainly
FCR Nausea 2 6 Almost certainly
FCR Vomiting 2 6 Almost certainly
68 FCR Nausea 1 1 Almost certainly
FCR Vomiting 1 1 Almost certainly
FCR Infusional reaction 3 1 Unrelated
FCR Neutropenia 2 1 Almost certainly
FCR Neutropenia 2 2 Almost certainly
FCR Nausea 2 2 Almost certainly
FCR Vomiting 2 2 Almost certainly
FCR Allergic reaction 2 2 Unrelated
FCR Vomiting 1 3 Almost certainly
FCR Nausea 2 3 Almost certainly
FCR Constipation 1 3 Almost certainly
FCR Nausea 1 4 Almost certainly
FCR Headache 2 4 Probably
FCR Dizziness 2 4 Probably
FCR Constipation 1 4 Unlikely
FCR Nausea 1 5 Almost certainly
FCR Fatigue 1 5 Almost certainly
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Almost certainly 31 May 2011 Yes 7 June 2011 7
Probably Probably 29 May 2011 Yes 30 May 2011 1
Almost certainly Almost certainly 5 July 2011 Yes 26 July 2011 21
Almost certainly Almost certainly 26 July 2011 Yes 2 August 2011 7
Almost certainly Almost certainly 2 August 2011 No
Almost certainly Almost certainly 8 March 2011 Yes 21 March 2011 13
Almost certainly Almost certainly 8 March 2011 Yes 21 March 2011 13
Almost certainly Almost certainly 9 March 2011 Yes 9 March 2011 0
Almost certainly Almost certainly 16 May 2011 Yes 1 June 2011 16
Almost certainly Almost certainly 3 May 2011 Yes 16 May 2011 13
Almost certainly Almost certainly 23 May 2011 No
Almost certainly Almost certainly 23 May 2011 Yes 28 May 2011 5
Almost certainly Almost certainly 14 June 2011 No
Almost certainly Almost certainly 24 June 2011 No
Almost certainly Almost certainly 16 May 2011 No
Almost certainly Almost certainly 18 July 2011 Yes 29 July 2011 11
Almost certainly Almost certainly 21 June 2011 Yes 29 July 2011 38
Almost certainly Almost certainly 17 July 2011 Yes 19 July 2011 2
Almost certainly Unrelated 17 July 2011 Yes 19 July 2011 2
Almost certainly Possibly 6 March 2011 Yes 13 March 2011 7
Almost certainly Possibly 8 March 2011 Yes 9 March 2011 1
Unrelated Almost certainly 3 March 2011 Yes 3 March 2011 0
Almost certainly Possibly No
Almost certainly Almost certainly 27 April 2011 No
Almost certainly Almost certainly 5 April 2011 Yes 14 April 2011 9
Almost certainly Almost certainly 5 April 2011 Yes 11 April 2011 6
Unrelated Almost certainly 4 April 2011 Yes 4 April 2011 0
Almost certainly Almost certainly 4 May 2011 Yes 10 May 2011 6
Almost certainly Almost certainly 4 May 2011 Yes 13 May 2011 9
Almost certainly Almost certainly 5 May 2011 Yes 7 May 2011 2
Almost certainly Possibly 3 June 2011 Yes 5 June 2011 2
Unlikely Possibly 2 June 2011 Yes 2 June 2011 0
Unlikely Possibly 3 June 2011 Yes 3 June 2011 0
Unlikely Unlikely 4 June 2011 Yes 7 June 2011 3
Almost certainly Possibly 2 July 2011 Yes 6 July 2011 4
Possibly Probably 2 July 2011 No
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Rash/flushing 2 6 Unrelated
FCR Nausea 2 6 Possibly
FCR Anxiety/depression 2 6 Unrelated
FCR Headache 1 6 Unrelated
FCR Abdominal pain/
bloating
2 6 Unrelated
70 FCR Anaemia 3 1 Almost certainly
FCR Neutropenia 4 1 Almost certainly
FCR Thrombocytopenia 3 1 Almost certainly
FCR Allergic reaction 1 1 Unlikely
FCR Infections (not
neutropenic sepsis)
3 1 Probably
FCR Anaemia 2 2 Almost certainly
FCR Neutropenia 4 2 Almost certainly
FCR Thrombocytopenia 1 2 Almost certainly
FCR Allergic reaction 1 2 Unlikely
FCR Urinary symptoms 1 2 Unlikely
FCR Myalgias 1 2 Unlikely
FCR Anaemia 1 3 Almost certainly
FCR Neutropenia 1 3 Almost certainly
FCR Infections (not
neutropenic sepsis)
3 4 Probably
FCR Constipation 1 4 Unlikely
FCR Anaemia 1 4 Almost certainly
FCR Thrombocytopenia 1 4 Almost certainly
FCR Neutropenia 3 4 Almost certainly
FCR Abnormal electrolytes 1 4 Unlikely
FCR Neutropenia 4 5 Almost certainly
FCR Thrombocytopenia 1 5 Almost certainly
FCR Non-specific pain 1 5 Unlikely
FCR Constipation 1 5 Unlikely
FCR Neutropenia 3 6 Almost certainly
FCR Thrombocytopenia 1 6 Almost certainly
72 FCR Neutropenia 4 1 Almost certainly
FCR Thrombocytopenia 2 1 Unrelated
FCR Anaemia 1 1 Unrelated
FCR Nausea 1 1 Almost certainly
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unrelated Unrelated 31 July 2011 Yes 4 August 2011 4
Possibly Unrelated 30 July 2011 Yes 1 August 2011 2
Unrelated Unrelated Yes 26 October 2011
Unrelated Unrelated 27 July 2011 Yes 29 July 2011 2
Unrelated Unrelated 7 August 2011 Yes 8 August 2011 1
Almost certainly Possibly 11 March 2011 No
Almost certainly Possibly 11 March 2011 No
Almost certainly Possibly 11 March 2011 No
Unlikely Almost certainly 11 March 2011 Yes 12 March 2011 1
Probably Possibly 12 March 2011 Yes 25 March 2011 13
Almost certainly Possibly 12 April 2011 No
Almost certainly Possibly 12 April 2011 No
Almost certainly Possibly 12 April 2011 Yes 27 April 2011 15
Unlikely Almost certainly 12 April 2011 Yes 12 April 2011 0
Possibly Unlikely 1 May 2011 Yes 12 May 2011 11
Unlikely Unlikely No
Almost certainly Possibly 12 May 2011 No
Almost certainly Possibly 12 May 2011 No
Probably Possibly 14 June 2011 Yes 20 June 2011 6
Unlikely Unlikely 11 June 2011 Yes 16 June 2011 5
Almost certainly Possibly 10 June 2011 Yes 14 July 2011 34
Almost certainly Possibly 14 June 2011 Yes 23 June 2011 9
Almost certainly Possibly 17 June 2011 No
Unlikely Unlikely 16 June 2011 Yes 17 June 2011 1
Almost certainly Possibly 4 August 2011 No
Almost certainly Possibly 15 July 2011 No
Unlikely Unlikely 22 July 2011 No
Unlikely Unlikely 9 July 2011 Yes 13 July 2011 4
Almost certainly Possibly 19 August 2011 No
Almost certainly Possibly 12 August 2011 No
Almost certainly Almost certainly 6 April 2011 Yes 3 May 2011 27
Unrelated Unrelated 23 February 2011 No
Unrelated Unrelated 10 March 2011 No
Almost certainly Almost certainly 20 March 2011 Yes 22 March 2011 2
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Anaemia 1 2 Almost certainly
FCR Nausea 1 2 Almost certainly
FCR Vomiting 2 2 Almost certainly
FCR Anaemia 1 3 Almost certainly
FCR Neutropenia 2 3 Almost certainly
FCR Nausea 1 3 Almost certainly
FCR Vomiting 2 3 Almost certainly
FCR Neutropenia 1 4 Almost certainly
FCR Diarrhoea 1 4 Almost certainly
FCR Nausea 1 5 Almost certainly
FCR Thrombocytopenia 3 5 Unrelated
FCR Neutropenia 1 5 Almost certainly
FCR Anaemia 1 6 Almost certainly
FCR Neutropenia 1 6 Almost certainly
FCR Nausea 1 6 Almost certainly
74 FCR Infusional reaction 2 1 Unrelated
FCR Myalgias 1 1 Possibly
FCR Nausea 1 1 Probably
FCR Vomiting 1 1 Probably
FCR Infections (not
neutropenic sepsis)
2 1 Unlikely
FCR Rash/flushing 1 1 Unlikely
FCR Constipation 1 1 Possibly
FCR Neutropenia 1 2 Almost certainly
FCR Fatigue 1 2 Almost certainly
FCR Nausea 3 3 Possibly
FCR Vomiting 3 3 Possibly
FCR Neutropenia 2 3 Almost certainly
FCR Nausea 3 4 Almost certainly
FCR Vomiting 2 4 Almost certainly
FCR Thrombocytopenia 1 4 Possibly
FCR Nausea 1 5 Almost certainly
FCR Vomiting 1 5 Almost certainly
FCR Constipation 1 5 Possibly
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Almost certainly 3 May 2011 Yes 17 May 2011 14
Almost certainly Almost certainly 24 April 2011 Yes 26 April 2011 2
Almost certainly Almost certainly 22 April 2011 Yes 24 April 2011 2
Almost certainly Almost certainly 1 June 2011 Yes 5 July 2011 34
Almost certainly Almost certainly 14 June 2011 Yes 5 July 2011 21
Almost certainly Almost certainly 22 May 2011 Yes 23 May 2011 1
Almost certainly Almost certainly 22 May 2011 Yes 23 May 2011 1
Almost certainly Almost certainly 12 July 2011 Yes 2 August 2011 21
Almost certainly Almost certainly 21 July 2011 Yes 27 July 2011 6
Almost certainly Almost certainly 13 July 2011 Yes 17 July 2011 4
Unrelated Unrelated 23 February 2001 No
Almost certainly Almost certainly 9 August 2011 Yes 6 September 2011 28
Almost certainly Unrelated 6 September 2011 No
Almost certainly Unrelated 16 August 2011 Yes 6 September 2011 21
Almost certainly Unrelated 17 August 2011 Yes 25 August 2011 8
Unrelated Almost certainly 22 March 2011 Yes 22 March 2011 0
Possibly Possibly 27 March 2011 Yes 27 March 2011 0
Probably Possibly 28 March 2011 Yes 28 March 2011 0
Probably Possibly 28 March 2011 Yes 28 March 2011 0
Unlikely Unlikely 4 April 2011 Yes 10 April 2011 6
Unlikely Unlikely 19 April 2011 No
Possibly Possibly 28 March 2011 Yes 31 March 2011 3
Almost certainly Possibly 17 May 2011 No
Possibly Probably 20 April 2011 No
Possibly Possibly 21 May 2011 Yes 22 May 2011 1
Possibly Possibly 21 May 2011 Yes 22 May 2011 1
Almost certainly Possibly 14 June 2011 No
Almost certainly Possibly 18 June 2011 Yes 20 June 2011 2
Almost certainly Possibly 19 June 2011 Yes 20 June 2011 1
Possibly Possibly 29 April 2009 Yes 13 July 2011 805
Almost certainly Possibly 16 July 2011 Yes 19 July 2011 3
Almost certainly Possibly 17 July 2011 Yes 17 July 2011 0
Possibly Unlikely No
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Vomiting 2 6 Probably
FCR Nausea 1 6 Probably
78 FCR Diarrhoea 1 1 Possibly
FCR Anorexia/cachexia 1 1 Unlikely
FCR Fever 1 1 Possibly
FCR Anaemia 2 1 Possibly
FCR Thrombocytopenia 1 1 Possibly
FCR Anaemia 1 3 Possibly
FCR Urinary symptoms 1 3 Unlikely
FCR Fatigue 1 4 Possibly
FCR Diarrhoea 1 4 Possibly
FCR Vomiting 1 4 Possibly
FCR Rash/flushing 1 5 Possibly
FCR Fatigue 2 6 Possibly
FCR Anorexia/cachexia 1 6 Possibly
82 FCR Neutropenia 4 1 Almost certainly
FCR Anaemia 2 2 Almost certainly
FCR Thrombocytopenia 2 2 Almost certainly
FCR Neutropenia 3 2 Probably
FCR Neutropenia 4 3 Probably
FCR Thrombocytopenia 3 3 Probably
FCR Anaemia 2 3 Probably
FCR Infections (not
neutropenic sepsis)
3 6 Unlikely
FCR Thrombocytopenia 2 6 Possibly
84 FCR Neutropenia 1 1 Possibly
FCR Myalgias 1 1 Unlikely
FCR Neuropathy (sensory) 1 1 Possibly
FCR Nausea 1 2 Almost certainly
FCR Rash/flushing 1 3 Unlikely
FCR Infections (not
neutropenic sepsis)
2 3 Unlikely
FCR Ophthalmic infections 1 4 Unlikely
FCR Neuropathy (sensory) 1 4 Possibly
FCR Nausea 1 5 Almost certainly
FCR Fever 2 5 Almost certainly
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Probably Unlikely 15 September 2011 Yes 16 September 2011 1
Probably Unlikely 11 September 2011 Yes 17 September 2011 6
Possibly Possibly 8 May 2011 Yes 11 May 2011 3
Unlikely Unlikely 9 May 2011 Yes 31 May 2011 22
Possibly Possibly 6 May 2011 Yes 3 June 2011 28
Possibly Possibly 9 May 2011 No
Possibly Possibly 9 May 2011 Yes 28 June 2011 50
Possibly Possibly 26 July 2011 No
Unlikely Unlikely 3 June 2011 Yes 26 July 2011 53
Possibly Possibly 9 May 2011 Yes 26 August 2011 109
Possibly Possibly 1 July 2011 Yes 26 August 2011 56
Possibly Possibly 2 August 2011 Yes 26 August 2011 24
Possibly Possibly 26 August 2011 Yes 20 September 2011 25
Possibly Possibly 23 September 2011 Yes 30 September 2011 7
Possibly Possibly 23 September 2011 Yes 30 September 2011 7
Almost certainly Almost certainly 29 June 2011 Yes 4 July 2011 5
Almost certainly Unlikely 20 July 2011 No
Almost certainly Unlikely 20 July 2011 No
Almost certainly Unlikely 3 August 2011 No
Probably Probably 10 August 2011 No
Probably Probably 5 August 2011 No
Probably Probably 12 August 2011 No
Unlikely Unlikely 9 December 2011 No
Possibly Possibly 30 September 2011 No
Almost certainly Unrelated 9 June 2011 No
Unlikely Unlikely 25 May 2011 No
Unlikely Possibly 25 May 2011 No
Almost certainly Unlikely 20 June 2011 Yes 22 June 2011 2
Unlikely Unlikely 17 July 2011 No
Possibly Unlikely 17 July 2011 No
Unlikely Unlikely 17 July 2011 No
Unlikely Unlikely 26 August 2011 No
Almost certainly Unlikely 7 October 2011 Yes 24 October 2011 17
Possibly Unlikely 22 October 2011 Yes 28 October 2011 6
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Neutropenia 2 5 Almost certainly
FCR Nausea 1 6 Almost certainly
87 FCR Rash/flushing 1 1 Unlikely
FCR Thrombocytopenia 1 5 Probably
FCR Anaemia 1 6 Probably
88 FCR Thrombocytopenia 1 1 Unrelated
FCR Neutropenia 1 1 Almost certainly
FCR Thrombocytopenia 1 2 Almost certainly
FCR Neutropenia 1 2 Almost certainly
FCR Diarrhoea 1 4 Almost certainly
FCR Neutropenia 3 4 Almost certainly
FCR Thrombocytopenia 1 6 Possibly
89 FCR Neutropenia 2 1 Almost certainly
FCR Nausea 2 1 Almost certainly
FCR Vomiting 2 1 Almost certainly
FCR Nausea 2 2 Almost certainly
FCR Vomiting 2 2 Almost certainly
FCR Fatigue 2 2 Almost certainly
FCR Nausea 2 3 Almost certainly
FCR Vomiting 2 3 Almost certainly
FCR Fatigue 2 3 Almost certainly
FCR Abdominal pain/
bloating
2 3 Possibly
FCR Vomiting 2 4 Almost certainly
FCR Nausea 2 4 Almost certainly
FCR Abdominal pain/
bloating
2 4 Possibly
FCR Vomiting 1 5 Almost certainly
FCR Nausea 1 5 Almost certainly
FCR Fatigue 1 5 Almost certainly
FCR Nausea 1 6 Almost certainly
FCR Vomiting 1 6 Almost certainly
91 FCR Anxiety/depression 2 1 Unrelated
FCR Mucositis/thrush 1 2 Unrelated
FCR Anxiety/depression 2 3 Unrelated
FCR Mucositis/thrush 1 3 Unrelated
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Unlikely 24 October 2011 Yes 1 November 2011 8
Almost certainly Unlikely 9 September 2011 Yes 21 September 2011 12
Unlikely Unlikely 15 June 2011 Yes 1 August 2011 47
Probably Probably 31 October 2011 No
Probably Unlikely 30 November 2011 No
Unrelated Unrelated 24 May 2011 No
Almost certainly Almost certainly 15 June 2011 Yes 28 June 2011 13
Almost certainly Almost certainly No
Almost certainly Almost certainly 13 July 2011 No
Almost certainly Almost certainly 28 August 2011 Yes 29 August 2011 1
Almost certainly Almost certainly 17 July 2011 No
Possibly Possibly 3 July 2009 No
Almost certainly Possibly 5 July 2011 No
Almost certainly Unlikely 12 June 2011 Yes 16 June 2011 4
Almost certainly Unlikely 12 June 2011 Yes 16 June 2011 4
Almost certainly Unlikely 8 July 2011 Yes 17 July 2011 9
Almost certainly Unlikely 8 July 2011 Yes 17 July 2011 9
Almost certainly Unlikely 8 July 2011 Yes 22 July 2011 14
Almost certainly Unlikely 5 August 2011 Yes 15 August 2011 10
Almost certainly Unlikely 5 August 2011 Yes 15 August 2011 10
Almost certainly Unlikely 5 August 2011 Yes 19 August 2011 14
Possibly Unlikely 4 August 2011 No
Almost certainly Unlikely 8 September 2011 Yes 20 September 2011 12
Almost certainly Unlikely 8 September 2011 No
Possibly Unlikely 8 September 2011 No
Almost certainly Unlikely 6 October 2011 Yes 9 October 2011 3
Almost certainly Unlikely 5 October 2011 Yes 12 October 2011 7
Almost certainly Unlikely 5 October 2011 No
Almost certainly Unlikely 2 November 2011 Yes 5 November 2011 3
Almost certainly Unlikely 2 November 2011 Yes 2 November 2011 0
Unrelated Unrelated 1 July 2011 Yes 21 July 2011 20
Unrelated Unrelated 21 July 2011 No
Unrelated Unrelated 18 August 2011 No
Unrelated Unrelated 18 August 2011 Yes 19 September 2011 32
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Anxiety/depression 2 4 Unrelated
FCR Anxiety/depression 2 5 Unrelated
FCR Anaemia 2 6 Possibly
92 FCR Diarrhoea 1 1 Possibly
FCR Non-specific pain 1 3 Unrelated
FCR Neutropenia 2 6 Almost certainly
93 FCR Headache 1 1 Unlikely
FCR Allergic reaction 1 2 Unrelated
FCR Lymphopenia 1 4 Probably
FCR Pruritus 1 4 Unlikely
FCR Rash/flushing 3 5 Unlikely
FCR Neutropenia 4 5 Probably
FCR Fever 2 5 Probably
FCR Lymphopenia 3 5 Probably
FCR Lymphopenia 1 6 Probably
98 FCR Back pain 1 1 Possibly
FCR Non-specific pain 1 1 Possibly
FCR Nausea 1 1 Almost certainly
FCR Vomiting 1 1 Almost certainly
FCR Vomiting 2 2 Almost certainly
FCR Abdominal pain/
bloating
1 2 Almost certainly
FCR Dizziness 2 2 Possibly
FCR Nausea 1 3 Almost certainly
FCR Abdominal pain/
bloating
1 3 Almost certainly
FCR Headache 1 3 Possibly
FCR Constipation 1 3 Probably
FCR Fatigue 1 4 Almost certainly
FCR Nausea 1 4 Almost certainly
FCR Nausea 2 5 Almost certainly
FCR Vomiting 2 5 Almost certainly
FCR Vomiting 1 6 Almost certainly
FCR Nausea 2 6 Almost certainly
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unrelated Unrelated 19 September 2011 No
Unrelated Unrelated 17 October 2011 No
Possibly Possibly 14 November 2011 Yes 28 November 2011 14
Possibly Possibly 28 June 2011 Yes 4 July 2011 6
Unrelated Unrelated 31 August 2011 Yes 26 September 2011 26
Almost certainly Possibly 23 November 2011 Yes 30 November 2011 7
Unlikely Unlikely Yes
Unrelated Probably 12 July 2011 Yes 12 July 2011 0
Probably Probably 5 September 2011 No
Unlikely Unlikely 5 October 2011 No
Unlikely Unlikely 13 November 2011 Yes
Probably Probably 14 November 2011 Yes 28 November 2011 14
Probably Probably Yes
Probably Probably 14 November 2011 No
Probably Probably 28 November 2011 No
Possibly Possibly 30 August 2011 No
Possibly Possibly 30 August 2011 No
Almost certainly Unlikely 15 August 2011 Yes 19 August 2011 4
Almost certainly Unlikely 15 August 2011 Yes 29 August 2011 14
Almost certainly Unlikely 15 September 2011 Yes 16 September 2011 1
Almost certainly Unlikely 15 September 2011 Yes 6 October 2011 21
Possibly Possibly 16 September 2011 Yes 20 September 2011 4
Almost certainly Unlikely 10 October 2011 Yes 12 October 2011 2
Almost certainly Unlikely 7 October 2011 Yes 7 October 2011 0
Possibly Possibly 8 October 2011 Yes 8 October 2011 0
Probably Unlikely 15 September 2011 Yes 20 September 2011 5
Probably Unlikely 6 November 2011 No
Almost certainly Unlikely 6 November 2011 Yes 10 November 2011 4
Almost certainly Unlikely 4 December 2011 Yes 8 December 2011 4
Almost certainly Unlikely 4 December 2011 Yes 8 December 2011 4
Almost certainly Unlikely 7 January 2012 Yes 10 January 2012 3
Almost certainly Unlikely 7 January 2012 Yes 10 January 2012 3
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
101 FCR Nausea 1 1 Almost certainly
FCR Vomiting 1 1 Almost certainly
FCR Otalgia 2 1 Possibly
FCR Infusional reaction 1 1 Possibly
FCR Neutropenia 3 1 Probably
FCR Allergic reaction 1 2 Unrelated
FCR Neutropenia 3 2 Probably
FCR Infections (not
neutropenic sepsis)
2 4 Unlikely
FCR Infections (not
neutropenic sepsis)
2 5 Unrelated
FCR Nausea 1 6 Almost certainly
FCR Fatigue 1 6 Almost certainly
102 FCR Anaemia 2 1 Probably
FCR Thrombocytopenia 2 1 Probably
104 FCR Fatigue 2 1 Probably
FCR Nausea 2 1 Probably
FCR Vomiting 2 1 Probably
FCR Anaemia 2 1 Possibly
FCR Neutropenia 4 1 Possibly
FCR Anxiety/depression 2 1 Unlikely
FCR Taste alteration 1 1 Possibly
FCR Thrombocytopenia 1 1 Possibly
FCR Fatigue 1 2 Probably
FCR Nausea 2 2 Probably
FCR Anaemia 2 2 Possibly
FCR Neutropenia 2 2 Probably
FCR Anorexia/cachexia 1 2 Probably
FCR Infections (not
neutropenic sepsis)
2 2 Possibly
FCR Rash/flushing 2 2 Probably
FCR Rash/flushing 2 3 Unlikely
FCR Nausea 1 3 Probably
FCR Fatigue 1 3 Probably
FCR Neutropenia 4 3 Probably
FCR Anaemia 2 3 Probably
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Unrelated 25 August 2011 Yes 25 August 2011 0
Almost certainly Unrelated 26 August 2011 Yes 28 August 2011 2
Possibly Unrelated 28 September 2011 No
Possibly Unrelated 25 August 2011 Yes 26 August 2011 1
Probably Unrelated 14 September 2011 Yes 23 September 2011 9
Unrelated Almost certainly 26 September 2011 Yes 26 September 2011 0
Probably Unrelated 21 October 2011 Yes 4 November 2011 14
Unlikely Unlikely 4 January 2012 No
Unrelated Unrelated 23 January 2012 Yes 27 January 2012 4
Almost certainly Unrelated 9 February 2012 Yes 13 February 2012 4
Almost certainly Unrelated 8 February 2012 Yes 15 February 2012 7
Probably Probably 6 September 2011 Yes 12 September 2011 6
Probably Probably 6 September 2011 Yes 12 September 2011 6
Possibly Unlikely 13 September 2011 Yes 23 September 2011 10
Probably Unlikely 16 September 2011 Yes 18 September 2011 2
Probably Unlikely 17 September 2011 Yes 18 September 2011 1
Possibly Unlikely 13 September 2011 No
Possibly Unlikely 13 September 2011 Yes 29 September 2011 16
Unlikely Unlikely 9 September 2011 Yes 19 September 2011 10
Possibly Unlikely 23 September 2011 No
Possibly Unlikely 13 September 2011 Yes 29 September 2011 16
Possibly Unlikely 14 October 2011 Yes 4 November 2011 21
Probably Unlikely 15 October 2011 Yes 21 October 2011 6
Possibly Unlikely 14 October 2011 No
Probably Unlikely 1 November 2011 No
Probably Unlikely 21 October 2011 Yes 11 November 2011 21
Possibly Unlikely 28 October 2011 No
Probably Unlikely 18 October 2011 Yes 19 October 2011 1
Unlikely Unlikely 28 October 2011 Yes 2 December 2011 35
Probably Unlikely 14 November 2011 Yes 15 November 2011 1
Possibly Unlikely 18 November 2011 Yes 25 November 2011 7
Probably Unlikely 18 November 2011 Yes 25 November 2011 7
Probably Unlikely 25 November 2011 No
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Anxiety/depression 2 3 Unlikely
FCR Pruritus 1 3 Unrelated
FCR Rash/flushing 2 4 Possibly
FCR Anxiety/depression 3 4 Unlikely
FCR Other AE description Confusion 3 4 Unlikely
FCR Anaemia 2 4 Probably
FCR Thrombocytopenia 1 4 Probably
FCR Neutropenia 4 4 Probably
FCR Nausea 1 5 Probably
FCR Anaemia 1 5 Probably
FCR Neutropenia 2 5 Probably
FCR Thrombocytopenia 1 5 Probably
FCR Nausea 1 6 Probably
FCR Anxiety/depression 2 6 Unlikely
FCR Anaemia 1 6 Probably
FCR Neutropenia 2 6 Probably
FCR Thrombocytopenia 1 6 Probably
105 FCR Infusional reaction 2 1 Unlikely
FCR Nausea 1 1 Almost certainly
FCR Oedema 1 1 Unlikely
FCR Constipation 1 1 Almost certainly
FCR Nausea 1 2 Almost certainly
FCR Infusional reaction 2 2 Unlikely
FCR Constipation 1 2 Almost certainly
FCR Neutropenia 3 3 Almost certainly
FCR Anaemia 1 3 Almost certainly
FCR Lymphopenia 3 3 Almost certainly
FCR Non-specific pain 2 3 Unlikely
FCR Urinary symptoms 2 3 Unlikely
107 FCR Anaemia 1 1 Possibly
FCR Vomiting 2 1 Possibly
FCR Neutropenia 2 2 Possibly
FCR Vomiting 2 2 Possibly
FCR Constipation 1 2 Unlikely
FCR Thrombocytopenia 2 3 Possibly
FCR Nausea 1 3 Probably
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unlikely Unlikely 29 November 2011 No
Unrelated Unrelated 9 December 2011 No
Possibly Unlikely 16 December 2011 Yes 18 December 2011 2
Unlikely Unlikely 16 December 2011 No
Unlikely Unlikely 20 December 2011 Yes 6 January 2012 17
Probably Unlikely 24 December 2011 No
Probably Unlikely 16 December 2011 No
Probably Possibly 21 December 2011 Yes 6 January 2012 16
Probably Unlikely 6 January 2012 Yes 10 January 2012 4
Probably Unlikely 6 January 2012 No
Probably Possibly 13 January 2012 No
Probably Unlikely 6 January 2012 No
Probably Unlikely 6 February 2012 Yes 8 February 2012 2
Unlikely Unlikely 20 December 2011 Yes 24 February 2012 66
Probably Unlikely 3 February 2012 No
Probably Possibly 03 February 2012 No
Probably Unlikely 3 February 2012 No
Unlikely Almost certainly 5 September 2011 Yes 5 September 2011 0
Almost certainly Possibly 6 September 2011 Yes 7 September 2011 1
Unlikely Unlikely 22 October 2011 Yes 24 October 2011 2
Almost certainly Unlikely 7 September 2011 Yes 14 September 2011 7
Almost certainly Possibly 4 October 2011 Yes 5 October 2011 1
Unlikely Almost certainly 3 October 2011 Yes 3 October 2011 0
Almost certainly Unlikely 5 October 2011 Yes 12 October 2011 7
Almost certainly Possibly 27 October 2011 Yes 11 November 2011 15
Almost certainly Possibly 27 October 2011 Yes 11 November 2011 15
Almost certainly Possibly 27 October 2011 No
Unlikely Unlikely No
Unlikely Unlikely No
Possibly Unlikely 5 September 2011 No
Possibly Unlikely 19 September 2011 Yes 22 September 2011 3
Possibly Unlikely 13 October 2011 Yes 10 November 2011 28
Possibly Unlikely 14 October 2011 Yes 19 October 2011 5
Unlikely Unlikely 20 October 2011 Yes 22 October 2011 2
Possibly Unlikely 22 September 2011 Yes 10 November 2011 49
Probably Unlikely 10 November 2011 No
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Thrombocytopenia 1 4 Possibly
FCR Fatigue 1 4 Possibly
FCR Nausea 2 5 Almost certainly
FCR Diarrhoea 2 5 Possibly
110 FCR Nausea 1 1 Almost certainly
FCR Rash/flushing 1 3 Unrelated
FCR Diarrhoea 1 5 Possibly
111 FCR Diarrhoea 1 1 Possibly
FCR Rash/flushing 2 1 Unrelated
FCR Neutropenic sepsis 3 1 Almost certainly
FCR Thrombocytopenia 1 2 Almost certainly
FCR Fatigue 1 4 Unlikely
FCR Thrombocytopenia 1 4 Almost certainly
FCR Rash/flushing 1 5 Unlikely
FCR Pruritus 1 5 Unlikely
FCR Thrombocytopenia 2 6 Almost certainly
FCR Anorexia/cachexia 1 6 Unrelated
112 FCR Pruritus 2 2 Unrelated
FCR Rash/flushing 2 3 Unrelated
116 FCR Thrombocytopenia 3 1 Unrelated
FCR Anaemia 2 1 Unrelated
FCR Neutropenia 2 2 Almost certainly
FCR Vomiting 2 2 Almost certainly
FCR Nausea 1 3 Almost certainly
FCR Vomiting 1 3 Almost certainly
FCR Fatigue 1 4 Almost certainly
FCR Neutropenia 4 4 Almost certainly
FCR Thrombocytopenia 1 4 Almost certainly
FCR Nausea 1 5 Almost certainly
FCR Fatigue 1 5 Almost certainly
FCR Thrombocytopenia 2 5 Almost certainly
FCR Fatigue 1 6 Almost certainly
120 FCR Nausea 1 1 Probably
FCR Rash/flushing 1 2 Unlikely
FCR Neutropenia 1 3 Almost certainly
FCR Fatigue 1 3 Possibly
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Possibly Unlikely 5 December 2011 No
Possibly Unlikely 8 December 2011 Yes 15 December 2011 7
Almost certainly Unlikely 5 January 2012 Yes 2 February 2012 28
Possibly Unlikely 28 January 2012 Yes 16 February 2012 19
Almost certainly Unlikely Yes
Unrelated Unrelated 16 January 2012 Yes 12 March 2012 56
Possibly Unlikely 14 February 2012 Yes 18 February 2012 4
Possibly Possibly Yes 16 November 2011
Unrelated Unrelated 2 November 2011 Yes 10 November 2011 8
Almost certainly Unlikely 4 November 2011 Yes 10 November 2011 6
Almost certainly Possibly 19 October 2011 No
Unlikely Unlikely Yes 11 January 2012
Almost certainly Possibly 19 December 2011 No
Unlikely Unlikely Yes 6 February 2012
Unlikely Unlikely Yes 6 February 2012
Almost certainly Possibly 5 March 2012 No
Unrelated Unrelated Yes 8 February 2012
Unrelated Unrelated 13 December 2011 No
Unrelated Unrelated Yes 27 February 2012
Unrelated Unrelated 31 October 2011 No
Unrelated Unrelated 31 October 2011 No
Almost certainly Unlikely 23 November 2011 No
Almost certainly Possibly 28 November 2011 Yes 1 December 2011 3
Almost certainly Possibly 28 December 2011 Yes 6 January 2012 9
Almost certainly Possibly 28 December 2011 Yes 2 January 2012 5
Almost certainly Almost certainly 25 January 2012 Yes 8 February 2012 14
Almost certainly Almost certainly 8 February 2012 Yes 21 February 2012 13
Almost certainly Almost certainly 8 February 2012 No
Almost certainly Almost certainly 24 February 2012 Yes
Almost certainly Almost certainly 24 February 2012 Yes
Almost certainly Almost certainly 20 March 2012 No
Almost certainly Almost certainly 30 March 2012 Yes
Probably Unlikely Yes
Unlikely Unlikely Yes
Almost certainly Almost certainly 30 January 2012 Yes 27 February 2012 28
Possibly Possibly 11 January 2012 Yes
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Nausea 1 4 Almost certainly
FCR Infections (not
neutropenic sepsis)
2 4 Unlikely
FCR Fatigue 1 4 Possibly
FCR Neutropenia 2 5 Almost certainly
FCR Mucositis/thrush 1 5 Almost certainly
FCR Cough 1 5 Unlikely
FCR Fatigue 1 5 Possibly
FCR Fatigue 1 6 Possibly
122 FCR Nausea 1 1 Probably
FCR Vomiting 2 1 Probably
FCR Rash/flushing 2 1 Unlikely
FCR Anaemia 1 1 Possibly
FCR Nausea 1 2 Probably
FCR Rash/flushing 3 2 Probably
FCR Allergic reaction 1 2 Probably
FCR Anaemia 2 2 Possibly
123 FCR Fatigue 1 1 Unlikely
FCR Common cold 1 1 Possibly
FCR Anaemia 2 1 Unlikely
FCR Thrombocytopenia 2 1 Possibly
FCR Neutropenia 3 3 Almost certainly
FCR Abdominal pain/
bloating
1 4 Unlikely
FCR Headache 2 5 Unlikely
FCR Back pain 1 6 Unlikely
FCR Dizziness 2 6 Unlikely
FCR Neutropenia 4 6 Probably
FCR Anaemia 2 6 Possibly
125 FCR Anorexia/cachexia 3 1 Possibly
FCR Alopecia 1 1 Possibly
FCR Diarrhoea 1 1 Unlikely
FCR Infections (not
neutropenic sepsis)
3 1 Probably
FCR Rash/flushing 1 1 Unlikely
FCR Fatigue 1 2 Probably
FCR Rash/flushing 1 3 Unlikely
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Possibly 1 February 2012 Yes
Unlikely Unlikely 14 February 2012 Yes
Possibly Possibly 8 February 2012 Yes
Almost certainly Almost certainly 26 March 2012 Yes 23 April 2012 28
Almost certainly Possibly 29 February 2012 Yes 13 March 2012 13
Unlikely Unlikely No
Possibly Possibly 7 March 2012 Yes
Possibly Possibly 4 April 2012 Yes
Probably Unlikely 18 November 2011 Yes 23 November 2011 5
Probably Unlikely 18 November 2011 Yes 23 November 2011 5
Unlikely Unlikely 27 November 2011 No
Possibly Unlikely 18 November 2011 No
Probably Unlikely 16 December 2011 Yes 20 December 2011 4
Unlikely Unlikely 9 December 2011 Yes 9 January 2012 31
Unlikely Unlikely 18 November 2011 Yes 9 January 2012 52
Possibly Unlikely 21 December 2011 Yes 9 January 2012 19
Unlikely Unlikely 5 December 2011 No
Possibly Unlikely 5 December 2011 No
Unlikely Unlikely Yes 10 January 2012
Possibly Possibly 5 December 2011 No
Almost certainly Possibly 22 December 2011 Yes 22 March 2012 91
Unlikely Unlikely 11 April 2012 Yes
Unlikely Unlikely 15 March 2012 Yes 26 May 2012 72
Unlikely Unlikely 28 May 2012 Yes 5 June 2012 8
Unlikely Unlikely 29 May 2012 Yes 3 June 2012 5
Probably Probably 14 April 2012 Yes 30 July 2012 107
Possibly Possibly 6 July 2012 Yes 2 August 2012 27
Possibly Possibly No
Possibly Unlikely No
Unlikely Unlikely 22 February 2012 Yes 24 February 2012 2
Probably Probably 20 February 2012 Yes 24 February 2012 4
Unlikely Unlikely 20 February 2012 Yes 24 February 2012 4
Probably Possibly Yes
Unlikely Unlikely No
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Anaemia 3 4 Almost certainly
FCR Neutropenia 3 5 Probably
FCR Nausea 1 5 Possibly
FCR Bone pain 2 5 Unlikely
FCR Fatigue 2 6 Unrelated
FCR Constipation 1 6 Unrelated
FCR Non-specific pain 2 6 Unrelated
129 FCR Nausea 1 1 Almost certainly
FCR Neutropenia 1 1 Almost certainly
FCR Nausea 1 2 Almost certainly
FCR Thrombocytopenia 1 2 Almost certainly
FCR Neutropenia 3 2 Almost certainly
FCR Anaemia 1 2 Almost certainly
FCR Neutropenia 1 3 Almost certainly
FCR Anaemia 1 3 Almost certainly
FCR Urinary symptoms 2 3 Almost certainly
FCR Nausea 1 4 Almost certainly
FCR Anaemia 1 4 Almost certainly
FCR Thrombocytopenia 1 4 Almost certainly
FCR Fatigue 1 5 Almost certainly
FCR Anaemia 1 5 Almost certainly
FCR Thrombocytopenia 1 5 Almost certainly
FCR Anaemia 1 6 Almost certainly
FCR Thrombocytopenia 1 6 Almost certainly
130 FCR Nausea 1 1 Almost certainly
FCR Vomiting 1 2 Possibly
FCR Anaemia 2 2 Possibly
FCR Neutropenia 4 2 Possibly
FCR Neutropenia 4 3 Possibly
FCR Thrombocytopenia 2 3 Possibly
FCR Anaemia 2 3 Possibly
FCR Anaemia 2 3 Possibly
FCR Neutropenia 4 4 Possibly
FCR Anaemia 2 5 Possibly
FCR Thrombocytopenia 1 5 Possibly
FCR Anaemia 2 6 Possibly
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Possibly Possibly 22 May 2012 Yes 5 June 2012 14
Probably Possibly 25 May 2012 Yes 20 June 2012 26
Possibly Unlikely 8 June 2012 Yes 10 June 2012 2
Unlikely Unlikely 13 June 2012 No
Unrelated Unrelated 12 July 2012 No
Unrelated Unrelated Yes
Unrelated Unrelated 12 July 2012 No
Almost certainly Almost certainly 2 February 2012 Yes 3 February 2012 1
Almost certainly Almost certainly 14 February 2012 No
Almost certainly Almost certainly 1 March 2012 Yes 2 March 2012 1
Almost certainly Almost certainly 12 March 2012 Yes 17 April 2012 36
Almost certainly Almost certainly 12 March 2012 Yes 2 April 2012 21
Almost certainly Almost certainly 12 March 2012 Yes 26 March 2012 14
Almost certainly Almost certainly 26 March 2012 Yes 17 April 2012 22
Almost certainly Almost certainly 17 April 2012 Yes 30 April 2012 13
Almost certainly Almost certainly 18 April 2012 No
Almost certainly Almost certainly 1 May 2012 Yes 5 May 2012 4
Almost certainly Almost certainly 14 May 2012 Yes 28 May 2012 14
Almost certainly Almost certainly 14 May 2012 Yes 28 May 2012 14
Almost certainly Almost certainly 29 May 2012 No
Almost certainly Almost certainly 11 June 2012 Yes 25 June 2012 14
Almost certainly Almost certainly 11 June 2012 No
Almost certainly Almost certainly 9 July 2012 Yes 26 September 2012 79
Almost certainly Almost certainly 25 June 2012 No
Almost certainly Almost certainly 26 January 2012 Yes 29 January 2012 3
Probably Possibly 24 February 2012 Yes 27 February 2012 3
Probably Unlikely 13 March 2012 No
Possibly Unlikely 13 March 2012 Yes 19 March 2012 6
Possibly Unlikely 25 March 2012 Yes 10 April 2012 16
Possibly Possibly 25 March 2012 Yes 27 March 2012 2
Probably Unlikely 22 March 2012 Yes 28 March 2012 6
Probably Unlikely 10 April 2012 No
Possibly Unlikely 24 April 2012 Yes 1 May 2012 7
Probably Unlikely 15 May 2012 No
Possibly Possibly 15 May 2012 No
Probably Unlikely 12 June 2012 Yes 10 July 2012 28
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
134 FCR Thrombocytopenia 1 1 Unlikely
FCR Rash/flushing 2 2 Unrelated
FCR Nausea 1 2 Possibly
FCR Nausea 2 2 Probably
FCR Nausea 2 3 Probably
FCR Neutropenia 3 5 Possibly
FCR Nausea 2 5 Probably
FCR Fatigue 1 5 Probably
136 FCR Fatigue 2 1 Unrelated
FCR Nausea 2 1 Probably
FCR Pruritus 1 1 Possibly
FCR Constipation 1 1 Unlikely
FCR Pruritus 2 3 Probably
FCR Nausea 1 3 Probably
FCR Rigors 1 3 Unlikely
FCR Nausea 2 4 Probably
FCR Mucositis/thrush 1 5 Probably
FCR Nausea 2 5 Probably
FCR Constipation 1 5 Probably
FCR Other AE description Sore gums 1 5 Probably
FCR Otalgia 1 5 Unlikely
FCR Common cold 1 5 Unlikely
FCR Nausea 1 5 Probably
FCR Constipation 1 5 Probably
137 FCR Neutropenia 3 1 Almost certainly
FCR Vomiting 1 1 Almost certainly
FCR Visual symptoms 1 1 Unlikely
FCR Fatigue 1 1 Almost certainly
FCR Diarrhoea 1 1 Possibly
FCR Anorexia/cachexia 1 1 Probably
FCR Rash/flushing 3 2 Unlikely
FCR Fatigue 1 2 Almost certainly
FCR Pruritus 1 2 Unlikely
FCR Neutropenia 3 2 Almost certainly
FCR Nausea 3 2 Almost certainly
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unlikely Unlikely 8 November 2011 No
Unrelated Unrelated 29 March 2012 Yes 1 April 2012 3
Possibly Possibly 21 March 2012 Yes 22 March 2012 1
Probably Possibly 14 April 2012 Yes 18 April 2012 4
Probably Possibly 12 May 2012 Yes 16 May 2012 4
Possibly Possibly 3 July 2012 No
Probably Possibly 10 July 2012 Yes 14 July 2012 4
Probably Probably 10 July 2012 Yes 24 July 2012 14
Unrelated Unrelated No
Probably Unlikely 16 April 2012 Yes 18 April 2012 2
Possibly Possibly 5 May 2012 No
Unlikely Unlikely 21 April 2012 Yes 25 April 2012 4
Probably Unlikely 16 April 2012 No
Probably Unlikely 13 May 2012 Yes 16 May 2012 3
Unlikely Probably 9 May 2012 Yes 9 May 2012 0
Probably Unlikely 10 June 2012 Yes 16 June 2012 6
Probably Unlikely Yes 27 August 2012
Probably Unlikely 5 July 2012 Yes 8 July 2012 3
Probably Possibly 4 July 2012 Yes 11 July 2012 7
Probably Possibly Yes 01 August 2012
Unlikely Unlikely 14 August 2012 No
Unlikely Unlikely No
Probably Unlikely 3 August 2012 Yes 10 August 2012 7
Probably Possibly 5 August 2012 Yes 11 August 2012 6
Almost certainly Almost certainly 23 March 2012 Yes 2 April 2012 10
Almost certainly Unlikely 10 March 2012 Yes 10 March 2012 0
Unlikely Unlikely 2 April 2012 No
Almost certainly Almost certainly 16 March 2012 Yes 2 April 2012 17
Possibly Possibly 14 March 2012 Yes 14 March 2012 0
Probably Probably 16 March 2012 Yes 2 April 2012 17
Unlikely Unlikely 4 April 2012 Yes 9 April 2012 5
Almost certainly Almost certainly 19 April 2012 Yes 30 April 2012 11
Unlikely Unlikely 2 April 2012 Yes 3 April 2012 1
Almost certainly Almost certainly 19 April 2012 Yes 30 April 2012 11
Almost certainly Almost certainly 7 April 2012 Yes 9 April 2012 2
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Diarrhoea 1 2 Almost certainly
FCR Neutropenia 2 3 Almost certainly
FCR Nausea 1 3 Almost certainly
FCR Nausea 1 4 Almost certainly
FCR Vomiting 1 4 Almost certainly
138 FCR Rash/flushing 2 1 Probably
FCR Headache 1 Possibly
FCR Fever 3 1 Possibly
FCR Neutropenic sepsis 4 2 Almost certainly
FCR Other AE description Weight change 1 2 Probably
FCR Diarrhoea 2 4 Possibly
FCR Allergic reaction 2 4 Unlikely
140 FCR Nausea 1 1 Almost certainly
FCR Constipation 1 1 Almost certainly
FCR Fatigue 1 1 Almost certainly
FCR Non-specific pain 1 1 Possibly
FCR Nausea 1 2 Almost certainly
FCR Constipation 1 2 Almost certainly
FCR Fatigue 1 2 Almost certainly
FCR Back pain 1 2 Possibly
FCR Nausea 2 3 Almost certainly
FCR Taste alteration 1 3 Almost certainly
FCR Nausea 2 4 Almost certainly
FCR Vomiting 1 4 Almost certainly
141 FCR Nausea 1 2 Almost certainly
FCR Vomiting 1 2 Almost certainly
FCR Back pain 1 4 Unrelated
FCR Vomiting 1 4 Almost certainly
FCR Other AE description Dry mouth 1 4 Almost certainly
FCR Mucositis/thrush 1 4 Almost certainly
FCR Other AE description Lump on leg 1 4 Almost certainly
FCR Infections (not
neutropenic sepsis)
4 5 Probably
FCR Night sweats 2 5 Unrelated
FCR Neutropenia 3 6 Almost certainly
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Almost certainly 8 April 2012 Yes 9 April 2012 1
Almost certainly Almost certainly 16 May 2012 Yes 28 May 2012 12
Almost certainly Almost certainly 2 May 2012 Yes 7 May 2012 5
Almost certainly Almost certainly 30 May 2012 Yes 3 June 2012 4
Almost certainly Almost certainly 30 May 2012 Yes 3 June 2012 4
Probably Probably 7 April 2012 No
Possibly Possibly 7 April 2012 Yes 11 April 2012 4
Possibly Possibly 7 April 2012 Yes 10 April 2012 3
Almost certainly Almost certainly 7 April 2012 Yes 16 April 2012 9
Probably Probably Yes
Possibly Possibly 15 July 2012 Yes 15 July 2012 0
Unlikely Unlikely 13 April 2012 Yes 13 April 2012 0
Almost certainly Unlikely 6 April 2012 Yes 7 April 2012 1
Almost certainly Unlikely 7 April 2012 No
Almost certainly Unlikely 7 April 2012 No
Possibly Possibly 7 April 2012 Yes 3 May 2012 26
Almost certainly Unlikely 11 April 2012 No
Almost certainly Unlikely 3 April 2012 No
Almost certainly Unlikely 3 April 2012 No
Possibly Possibly 3 April 2012 Yes 3 May 2012 30
Almost certainly Unlikely 1 May 2012 Yes 27 May 2012 26
Almost certainly Unlikely 3 April 2012 No
Almost certainly Almost certainly 3 July 2012 Yes 9 July 2012 6
Almost certainly Almost certainly 3 July 2012 No
Almost certainly Almost certainly 2 May 2012 Yes 30 May 2012 28
Almost certainly Almost certainly 2 May 2012 Yes 30 May 2012 28
Unrelated Unrelated 15 May 2012 Yes 27 June 2012 43
Almost certainly Almost certainly 23 June 2012 Yes 25 July 2012 32
Almost certainly Almost certainly 27 June 2012 Yes 25 July 2012 28
Almost certainly Almost certainly 27 June 2012 Yes 25 July 2012 28
Almost certainly Almost certainly 27 June 2012 Yes 25 July 2012 28
Probably Probably 25 July 2012 Yes 15 August 2012 21
Unrelated Unrelated 25 July 2012 Yes 15 August 2012 21
Almost certainly Almost certainly 12 September 2012 Yes 17 September 2012 5
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
143 FCR Infusional reaction 2 1 Unrelated
FCR Nausea 2 1 Almost certainly
FCR Diarrhoea 1 2 Unlikely
FCR Fatigue 3 2 Unlikely
FCR Other AE description Worsening of
diabetes
2 2 Unlikely
FCR Urinary symptoms 2 2 Unlikely
FCR Neutropenia 3 3 Almost certainly
FCR Thrombocytopenia 2 3 Almost certainly
FCR Gout/hyperuricemia 2 4 Probably
FCR Neutropenia 3 5 Probably
FCR Thrombocytopenia 2 5 Probably
146 FCR Neutropenia 3 1 Almost certainly
FCR Anaemia 1 1 Almost certainly
FCR Rash/flushing 3 1 Unrelated
FCR Urinary symptoms 2 3 Unrelated
FCR Mucositis/thrush 1 5 Probably
FCR Constipation 2 5 Probably
FCR Dyspnoea 1 5 Possibly
FCR Rash/flushing 1 6 Unrelated
FCR Abdominal pain/
bloating
1 6 Unrelated
FCR Thrombocytopenia 1 6 Almost certainly
FCR Neutropenia 3 6 Almost certainly
147 FCR Fever 2 1 Almost certainly
FCR Mucositis/thrush 1 1 Almost certainly
FCR Anaemia 2 1 Almost certainly
FCR Constipation 1 2 Possibly
FCR Nausea 1 3 Almost certainly
FCR Neutropenia 2 3 Almost certainly
FCR Neutropenia 1 3 Almost certainly
FCR Fatigue 1 4 Unlikely
FCR Rash/flushing 2 5 Unlikely
151 FCR Fatigue 1 1 Possibly
FCR Anaemia 3 2 Possibly
FCR Neutropenia 1 3 Probably
FCR Thrombocytopenia 2 3 Probably
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unrelated Almost certainly 30 April 2012 Yes 30 April 2012 0
Almost certainly Unrelated 5 May 2012 Yes 7 May 2012 2
Unlikely Unlikely 2 June 2012 Yes 3 June 2012 1
Unlikely Unlikely 19 June 2012 Yes 20 June 2012 1
Unlikely Unlikely 20 June 2012 No
Unlikely Unlikely 20 June 2012 No
Almost certainly Unlikely 20 July 2012 Yes 31 August 2012 42
Almost certainly Unlikely 20 July 2012 No
Probably Unrelated 16 August 2012 Yes 31 August 2013 380
Probably Unlikely 3 October 2012 No
Probably Unlikely 26 September 2012 No
Probably Probably 26 June 2012 Yes 1 August 2012 36
Probably Probably 26 June 2012 Yes 28 June 2012 2
Unrelated Unrelated 3 July 2012 Yes 1 August 2012 29
Probably Unrelated 4 September 2012 Yes
Probably Probably Yes
Probably Probably Yes 21 November 2012
Unlikely Possibly Yes
Unrelated Unrelated 27 November 2012 Yes 3 December 2012 6
Unrelated Unrelated 25 December 2012 No
Almost certainly Almost certainly 30 January 2013 No
Almost certainly Almost certainly 30 January 2013 No
Almost certainly Almost certainly 16 May 2012 Yes 20 May 2012 4
Almost certainly Unlikely Yes 13 June 2012
Almost certainly Possibly 18 May 2012 Yes 22 May 2012 4
Possibly Possibly Yes 11 July 2012
Almost certainly Almost certainly 11 July 2012 Yes 15 July 2012 4
Almost certainly Unlikely 22 May 2012 Yes 7 August 2012 77
Almost certainly Unlikely 7 August 2012 No
Unlikely Unlikely Yes 5 September 2012
Unlikely Unlikely No
Possibly Possibly Yes
Possibly Possibly 9 July 2012 Yes 23 July 2012 14
Probably Unrelated 20 August 2012 Yes 17 September 2012 28
Probably Unrelated 20 August 2012 Yes 28 August 2012 8
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Lymphopenia 3 3 Probably
FCR Neutropenia 3 4 Probably
FCR Thrombocytopenia 1 6 Probably
155 FCR Vomiting 2 1 Probably
FCR Vomiting 2 2 Probably
FCR Vomiting 3 3 Probably
FCR Neutropenia 3 4 Probably
FCR Anaemia 4 5 Probably
157 FCR Nausea 1 2 Almost certainly
FCR Fatigue 1 2 Unrelated
FCR Diarrhoea 1 3 Unrelated
FCR Nausea 2 4 Almost certainly
FCR Diarrhoea 2 4 Almost certainly
FCR Cough 1 5 Unrelated
FCR Diarrhoea 2 5 Almost certainly
FCR Nausea 1 5 Almost certainly
FCR Diarrhoea 1 6 Almost certainly
FCR Infections (not
neutropenic sepsis)
2 6 Almost certainly
158 FCR Pruritus 2 1 Unlikely
FCR Rash/flushing 1 1 Unlikely
FCR Diarrhoea 1 1 Unlikely
FCR Nausea 2 1 Unlikely
FCR Headache 1 1 Unlikely
FCR Common cold 2 2 Unlikely
FCR Mucositis/thrush 1 2 Unlikely
FCR Back pain 2 2 Unrelated
FCR Nausea 2 2 Unlikely
FCR Vomiting 2 2 Unlikely
FCR Other AE description Kidney
stone – had
lithotripsy and
surgery
3 3 Unrelated
FCR Nausea 2 3 Unlikely
FCR Vomiting 2 3 Unlikely
FCR Insomnia 1 3 Unrelated
FCR Common cold 2 3 Unlikely
FCR Fatigue 1 3 Unlikely
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unrelated Probably 20 August 2012 No
Probably Unrelated 17 September 2012 Yes 24 September 2012 7
Probably Unrelated 22 October 2012 No
Probably Unlikely 8 June 2012 Yes 10 June 2012 2
Probably Unlikely 7 July 2012 Yes 9 July 2012 2
Probably Unrelated 4 August 2012 Yes 6 August 2012 2
Probably Unrelated 27 September 2012 Yes 15 October 2012 18
Probably Unrelated 15 October 2012 No
Almost certainly Almost certainly 6 June 2012 No
Unrelated Unrelated 6 June 2012 No
Unrelated Unrelated 1 August 2012 No
Almost certainly Almost certainly 23 August 2012 Yes 27 August 2012 4
Almost certainly Almost certainly 23 August 2012 Yes 27 August 2012 4
Unrelated Unrelated 26 September 2012 No
Almost certainly Almost certainly 28 September 2012 Yes 7 October 2012 9
Almost certainly Almost certainly 26 September 2012 Yes 2 October 2012 6
Almost certainly Almost certainly 17 October 2012 Yes 23 October 2012 6
Almost certainly Almost certainly 2 December 2012 Yes 2 January 2013 31
Unlikely Unlikely 1 July 2012 Yes 6 July 2012 5
Unlikely Unlikely 1 July 2012 Yes 6 July 2012 5
Probably Unlikely 20 June 2012 Yes 25 June 2012 5
Probably Unlikely 20 June 2012 Yes 25 June 2012 5
Unlikely Probably 18 June 2012 Yes 19 June 2012 1
Unlikely Unrelated 31 July 2012 Yes 10 August 2012 10
Probably Unrelated 9 August 2012 No
Unrelated Unrelated 9 August 2012 No
Probably Unrelated 20 July 2012 Yes 22 July 2012 2
Probably Unlikely 20 July 2012 Yes 22 July 2012 2
Unrelated Unrelated 9 August 2012 Yes 26 September 2012 48
Probably Unlikely 3 October 2012 Yes 9 October 2012 6
Probably Unlikely 4 October 2012 Yes 5 October 2012 1
Unrelated Unrelated 4 October 2012 Yes 5 October 2012 1
Unlikely Unlikely 2 October 2012 No
Unlikely Unlikely 18 June 2012 No
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Nausea 1 4 Unlikely
FCR Nausea 1 5 Unlikely
FCR Vomiting 1 5 Unlikely
FCR Diarrhoea 1 5 Unlikely
FCR Non-specific pain 1 5 Unrelated
FCR Nausea 1 6 Unlikely
FCR Diarrhoea 1 6 Unlikely
FCR Rash/flushing 2 6 Unlikely
FCR Arthralgias 1 6 Unlikely
159 FCR Nausea 2 1 Probably
FCR Fatigue 2 1 Possibly
FCR Taste alteration 2 1 Possibly
FCR Anorexia/cachexia 2 1 Probably
FCR Nausea 1 2 Probably
FCR Anorexia/cachexia 1 2 Probably
FCR Alopecia 1 2 Possibly
FCR Thrombocytopenia 1 2 Almost certainly
FCR Taste alteration 1 3 Possibly
FCR Neutropenia 1 3 Almost certainly
FCR Nausea 1 4 Probably
FCR Thrombocytopenia 2 4 Almost certainly
166 FCR Infusional reaction 1 Unlikely
FCR Infections (not
neutropenic sepsis)
2 1 Possibly
FCR Fatigue 2 1 Possibly
FCR Constipation 1 1 Possibly
FCR Anaemia 3 1 Possibly
FCR Neutropenia 4 2 Almost certainly
FCR Neutropenia 4 4 Possibly
FCR Neutropenia 4 5 Almost certainly
FCR Urinary symptoms 1 5 Unlikely
FCR Anaemia 1 5 Almost certainly
FCR Neutropenia 4 6 Almost certainly
FCR Raised GGT/bilirubin 1 6 Possibly
167 FCR Nausea 1 1 Probably
FCR Vomiting 1 1 Probably
FCR Nausea 1 2 Probably
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Probably Unlikely 1 November 2012 Yes 6 November 2012 5
Probably Unlikely 27 November 2012 Yes 4 December 2012 7
Probably Unlikely 29 November 2012 Yes 29 November 2012 0
Probably Unlikely 30 November 2012 Yes 5 December 2012 5
Unrelated Unrelated 30 November 2012 No
Probably Unlikely 26 December 2012 Yes 1 January 2013 6
Probably Unlikely 29 December 2012 Yes 3 January 2013 5
Unlikely Unlikely 9 January 2013 No
Unlikely Unlikely 15 January 2013 Yes 18 January 2013 3
Probably Possibly 19 July 2012 Yes 25 July 2012 6
Possibly Possibly 25 July 2012 No
Possibly Unlikely 19 July 2012 No
Probably Unlikely 19 July 2012 No
Probably Possibly 18 August 2012 Yes 21 August 2012 3
Probably Unlikely 20 August 2012 No
Possibly Unlikely 20 August 2012 No
Almost certainly Possibly 30 August 2012 Yes 6 September 2012 7
Possibly Unlikely 11 September 2012 No
Almost certainly Possibly 21 September 2012 No
Probably Possibly 11 September 2012 Yes 5 November 2012 55
Almost certainly Possibly 16 October 2012 No
Unlikely Probably 4 July 2012 Yes 5 July 2012 1
Possibly Unlikely 23 July 2012 Yes 6 August 2012 14
Possibly Possibly 10 July 2012 Yes 6 August 2012 27
Possibly Possibly 11 July 2012 Yes 26 July 2012 15
Possibly Possibly 30 July 2012 Yes 6 August 2012 7
Almost certainly Almost certainly 20 August 2012 Yes 4 September 2012 15
Possibly Possibly 30 October 2012 Yes 20 November 2012 21
Probably Probably 14 December 2012 Yes 21 December 2012 7
Unlikely Unlikely 28 December 2012
Possibly Possibly 21 December 2012 No
Probably Probably 28 December 2012 Yes 22 January 2013 25
Possibly Possibly 14 December 2012 No
Probably Possibly 25 July 2012 Yes 27 July 2012 2
Probably Possibly 25 July 2012 Yes 27 July 2012 2
Probably Possibly 25 August 2012 Yes 26 August 2012 1
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Vomiting 1 2 Probably
FCR Nausea 1 3 Probably
FCR Vomiting 1 3 Probably
FCR Neuropathy (sensory) 1 3 Possibly
FCR Fatigue 1 3 Probably
FCR Nausea 1 4 Probably
FCR Vomiting 1 4 Probably
FCR Nausea 1 5 Probably
FCR Nausea 1 6 Probably
168 FCR Anaemia 1 1 Almost certainly
FCR Nausea 1 1 Probably
FCR Rash/flushing 1 1 Probably
FCR Neutropenia 4 3 Almost certainly
FCR Infections (not
neutropenic sepsis)
3 3 Probably
FCR Anaemia 1 4 Almost certainly
FCR Anaemia 1 5 Almost certainly
FCR Neutropenia 3 5 Almost certainly
FCR Neutropenia 1 5 Almost certainly
FCR Taste alteration 1 5 Possibly
FCR Infections (not
neutropenic sepsis)
2 6 Almost certainly
171 FCR Abnormal electrolytes 3 1 Unrelated
FCR Neutropenia 3 1 Almost certainly
FCR Constipation 2 1 Unlikely
FCR Nausea 1 1 Probably
FCR Nausea 1 2 Probably
FCR Constipation 2 2 Possibly
FCR Back pain 1 2 Unrelated
FCR Nausea 3 Probably
FCR Constipation 3 Possibly
FCR Neutropenia 1 3 Probably
FCR Renal impairment 1 3 Possibly
FCR Nausea 4 Probably
FCR Renal impairment 1 4 Possibly
FCR Rash/flushing 2 5 Unlikely
FCR Renal impairment 1 5 Possibly
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Probably Possibly 25 August 2012 Yes 26 August 2012 1
Probably Possibly 19 September 2012 Yes 23 September 2012 4
Probably Possibly 19 September 2012 Yes 23 September 2012 4
Unlikely Unlikely 17 September 2012 No
Unlikely Probably 15 October 2012 No
Probably Possibly 17 October 2012 Yes 19 October 2012 2
Probably Possibly 19 October 2012 Yes 19 October 2012 0
Probably Possibly 15 November 2012 Yes 16 November 2012 1
Probably Unlikely 13 December 2012 Yes 14 December 2012 1
Almost certainly Possibly 1 August 2012 Yes 6 August 2012 5
Probably Possibly 10 July 2012 Yes 13 July 2012 3
Possibly Unlikely 9 July 2012 Yes 9 July 2012 0
Almost certainly Possibly 1 August 2012 Yes 27 September 2012 57
Probably Possibly 21 September 2012 Yes 1 October 2012 10
Almost certainly Possibly 15 August 2012 Yes 1 October 2012 47
Almost certainly Possibly 4 October 2012 No
Almost certainly Possibly 7 November 2012 Yes 21 November 2012 14
Almost certainly Possibly 5 December 2012 No
Possibly Possibly 12 November 2012 Yes 20 November 2012 8
Almost certainly Possibly 25 December 2012 No
Unrelated Unrelated 9 July 2012 Yes 11 July 2012 2
Almost certainly Unlikely 30 July 2012 Yes 6 August 2012 7
Unlikely Unlikely 9 July 2012 Yes 12 July 2012 3
Probably Unlikely 9 July 2012 Yes 12 July 2012 3
Probably Unlikely 6 August 2012 Yes 14 August 2012 8
Possibly Unlikely 6 August 2012 Yes 14 August 2012 8
Unrelated Unrelated 4 July 2012 Yes 3 September 2012 61
Probably Unlikely 3 September 2012 Yes 11 September 2012 8
Possibly Unlikely 3 September 2012 Yes 11 September 2012 8
Probably Unlikely 27 September 2012 Yes 8 October 2012 11
Possibly Possibly 6 August 2012 No
Probably Unlikely 1 October 2012 Yes
Possibly Possibly 3 September 2012 No
Unlikely Unlikely
Possibly Possibly 1 October 2012 No
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Rash/flushing 2 6 Unlikely
FCR Infections (not
neutropenic sepsis)
3 6 Unlikely
174 FCR Infusional reaction 1 1 Unrelated
FCR Thrombocytopenia 2 1 Unlikely
FCR Anaemia 1 1 Unlikely
FCR Mucositis/thrush 1 1 Possibly
FCR Other AE description Unstable diabetes
control
hyperglycaemia –
insulin
3 2 Unlikely
FCR Neutropenia 4 3 Probably
FCR Fever 1 3 Possibly
FCR Sore throat 1 3 Unrelated
FCR Anxiety/depression 1 3 Unlikely
FCR Other AE description Unstable diabetes
control
(hyperglycaemia)
3 3 Unlikely
FCR Taste alteration 1 4 Probably
FCR Fatigue 1 4 Probably
FCR Neutropenia 4 5 Probably
FCR Neutropenia 2 6 Probably
FCR Infections (not
neutropenic sepsis)
1 6 Possibly
FCR Arthralgias 1 6 Unrelated
FCR Other AE description Unstable diabetic
control
1 6 Unlikely
175 FCR Infections (not
neutropenic sepsis)
2 2 Almost certainly
FCR Dyspnoea 2 2 Unrelated
FCR Chest pain 2 2 Unrelated
178 FCR Diarrhoea 1 1 Possibly
FCR Nausea 1 1 Possibly
FCR Thrombocytopenia 1 3 Probably
FCR Lymphopenia 3 3 Probably
FCR Pruritus 2 4 Unlikely
FCR Other AE description Squamous cell
carcinoma
3 4 Unrelated
FCR Lymphopenia 3 5 Probably
APPENDIX 2
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unlikely Unlikely 29 October 2012 No
Unlikely Unlikely 1 January 2013 Yes 8 January 2013 7
Unrelated Almost certainly 24 July 2012 Yes 24 July 2012 0
Unlikely Unlikely 24 July 2012 No
Unlikely Unlikely 24 July 2012 No
Probably Unlikely 7 August 2012 Yes 21 August 2012 14
Unlikely Unlikely 7 September 2012 No
Probably Unlikely 28 August 2012 Yes 7 October 2012 40
Possibly Unrelated 17 September 2012 Yes 18 October 2012 31
Unrelated Unrelated 29 August 2012 Yes 23 October 2012 55
Unlikely Unlikely 21 August 2012 Yes 23 October 2012 63
Unlikely Unlikely 7 September 2012 No
Probably Unlikely 21 August 2012 Yes 27 November 2012 98
Probably Possibly 24 July 2012 Yes 7 November 2012 106
Probably Unlikely 7 November 2012 Yes 27 December 2012 50
Probably Unlikely 4 January 2013 No
Possibly Unrelated 31 December 2012 Yes 22 January 2013 22
Unrelated Unrelated Yes 12 December 2012
Unlikely Unlikely 7 September 2012 Yes 26 February 2013 172
Almost certainly Almost certainly 25 September 2012 No
Unrelated Unrelated 23 August 2012 Yes 24 August 2012 1
Unrelated Unrelated 23 August 2012 Yes 24 August 2012 1
Possibly Unlikely Yes
Possibly Unlikely Yes
Probably Probably 10 September 2012 No
Probably Probably 10 September 2012 Yes 8 October 2012 28
Unlikely Unlikely 15 October 2012 Yes
Unrelated Unrelated 22 October 2012 Yes
Probably Probably 5 November 2012 No
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Infections (not
neutropenic sepsis)
2 6 Possibly
FCR Other AE description Squamous cell
carcinoma in situ
of wrist
3 6 Unrelated
FCR Neutropenia 1 6 Probably
FCR Back pain 1 6 Unrelated
FCR Fatigue 1 6 Unlikely
179 FCR Neutropenia 4 1 Probably
FCR Anaemia 3 1 Probably
FCR Thrombocytopenia 2 1 Possibly
FCR Nausea 2 1 Unlikely
FCR Vomiting 2 1 Unlikely
FCR 1 Missing
FCR Diarrhoea 1 2 Unlikely
FCR Thrombocytopenia 1 2 Possibly
FCR Anaemia 1 2 Probably
FCR Rash/flushing 3 2 Unrelated
181 FCR Neutropenia 3 2 Almost certainly
FCR Rash/flushing 2 2 Unrelated
FCR Neutropenia 3 3 Almost certainly
FCR Fatigue 1 3 Almost certainly
FCR Anorexia/cachexia 1 3 Almost certainly
FCR Oedema 1 3 Almost certainly
FCR Anxiety/depression 2 4 Almost certainly
FCR Neutropenia 3 5 Almost certainly
FCR Anxiety/depression 2 5 Almost certainly
FCR Neutropenia 3 6 Almost certainly
182 FCR Rash/flushing 2 3 Unlikely
FCR Other AE description Keratoacanthoma
(removed)
2 4 Unrelated
FCR Nausea 1 6 Probably
FCR Headache 1 6 Unlikely
185 FCR Nausea 2 1 Almost certainly
FCR Fatigue 3 1 Almost certainly
FCR Fatigue 1 1 Almost certainly
FCR Constipation 1 1 Unlikely
FCR Nausea 1 2 Almost certainly
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Possibly Possibly Yes
Unrelated Unrelated Yes
Probably Probably 21 January 2013 Yes 18 February 2013 28
Unrelated Unrelated No
Unlikely Unlikely No
Probably Unlikely 25 July 2012 Yes 7 August 2012 13
Probably Possibly 3 August 2012 Yes 14 August 2012 11
Possibly Possibly 25 July 2012 No
Unlikely Possibly 31 July 2012 Yes 24 August 2012 24
Unlikely Possibly 31 July 2012 Yes 24 August 2012 24
Missing Missing Yes
Unlikely Possibly 8 September 2012 Yes 12 September 2012 4
Possibly Possibly 7 September 2012 Yes 20 September 2012 13
Probably Possibly 9 September 2012 Yes 18 September 2012 9
Unrelated Unrelated 22 August 2012 No
Almost certainly Almost certainly 22 August 2012 Yes 30 August 2012 8
Unrelated Unrelated 22 August 2012 Yes 9 October 2012 48
Almost certainly Almost certainly 26 September 2012 Yes 9 October 2012 13
Almost certainly Almost certainly 26 September 2012 Yes 27 September 2012 1
Almost certainly Almost certainly 26 September 2012 Yes 27 September 2012 1
Almost certainly Almost certainly 26 September 2012 Yes 27 September 2012 1
Almost certainly Almost certainly 6 November 2012 No
Almost certainly Almost certainly 4 December 2012 Yes 17 December 2012 13
Almost certainly Almost certainly 17 December 2012 No
Almost certainly Almost certainly 14 January 2013 Yes 22 January 2013 8
Unlikely Unlikely 12 September 2012 No
Unrelated Unrelated Yes 4 December 2012
Probably Possibly 11 December 2012 Yes 17 December 2012 6
Unlikely Possibly 11 December 2012 Yes 17 December 2012 6
Almost certainly Probably 25 August 2012 Yes 30 August 2012 5
Possibly Probably 27 August 2012 Yes 31 August 2012 4
Possibly Probably 16 September 2012 No
Unlikely Possibly 25 August 2012 No
Almost certainly Probably 20 September 2012 Yes 21 September 2012 1
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Mucositis/thrush 1 2 Possibly
FCR Rash/flushing 2 2 Unlikely
FCR Vomiting 1 3 Almost certainly
FCR Nausea 1 3 Almost certainly
FCR Infections (not
neutropenic sepsis)
2 4 Possibly
FCR Neutropenic sepsis 4 5 Almost certainly
FCR Neutropenia 4 5 Almost certainly
187 FCR Neutropenia 1 4 Almost certainly
FCR Anaemia 2 4 Almost certainly
FCR Thrombocytopenia 4 4 Almost certainly
191 FCR Fatigue 1 1 Possibly
FCR Cystitis 1 1 Unrelated
FCR Anaemia 1 1 Unrelated
FCR Thrombocytopenia 1 1 Unrelated
FCR Neutropenia 4 2 Almost certainly
FCR Anaemia 1 2 Almost certainly
FCR Thrombocytopenia 1 2 Almost certainly
192 FCR Infusional reaction 2 1 Unrelated
FCR Nausea 1 1 Probably
FCR Fatigue 2 1 Possibly
FCR Anaemia 1 1 Unrelated
FCR Neutropenia 2 1 Unrelated
FCR Infusional reaction 1 2 Unrelated
FCR Vomiting 1 2 Almost certainly
FCR Nausea 1 2 Almost certainly
FCR Neuropathy (sensory) 1 2 Possibly
FCR Fatigue 2 2 Probably
FCR Thrombocytopenia 1 2 Possibly
FCR Lymphopenia 3 2 Almost certainly
FCR Bone pain 2 3 Possibly
FCR Nausea 1 3 Almost certainly
FCR Fatigue 2 3 Almost certainly
FCR Neutropenia 1 3 Almost certainly
FCR Thrombocytopenia 1 3 Probably
FCR Vomiting 1 4 Possibly
FCR Nausea 1 4 Almost certainly
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unlikely Possibly 20 September 2012 Yes 27 September 2012 7
Unlikely Unlikely 11 October 2012 No
Almost certainly Probably 19 October 2012 Yes 19 October 2012 0
Almost certainly Probably 18 October 2012 Yes 20 October 2012 2
Possibly Possibly 17 November 2012 Yes 19 November 2012 2
Almost certainly Probably 28 December 2012 Yes 4 January 2013 7
Almost certainly Probably 31 December 2012 Yes 8 January 2013 8
Almost certainly Almost certainly 11 December 2012 Yes 20 December 2012 9
Almost certainly Almost certainly 11 December 2012 No
Almost certainly Almost certainly 11 December 2012 No
Possibly Possibly No
Unrelated Unrelated 5 November 2012 No
Unrelated Unrelated 19 October 2011 No
Unrelated Unrelated 30 March 2011 No
Almost certainly Unlikely 17 December 2012 No
Almost certainly Unlikely No
Almost certainly Unlikely No
Unrelated Almost certainly 10 September 2012 Yes 10 September 2012 0
Probably Probably 13 September 2012 Yes 17 September 2012 4
Possibly Possibly 12 September 2012 Yes 17 September 2012 5
Unrelated Unrelated 28 July 2012 Yes 9 October 2012 73
Unrelated Unrelated 7 September 2012 No
Unrelated Almost certainly 10 October 2012 Yes 10 October 2012 0
Almost certainly Unlikely 15 October 2012 Yes 15 October 2012 0
Almost certainly Unlikely 10 October 2012 Yes 17 October 2012 7
Unlikely Unlikely 5 November 2012 Yes 05 November 2012 0
Probably Possibly 10 October 2012 Yes 17 October 2012 7
Possibly Possibly 28 July 2012 Yes 6 November 2012 101
Almost certainly Possibly 6 November 2012 No
Possibly Possibly 28 November 2012 No
Almost certainly Almost certainly 8 November 2012 Yes 15 November 2012 7
Almost certainly Possibly 7 November 2012 Yes 14 November 2012 7
Almost certainly Possibly 4 December 2012 No
Probably Possibly 4 December 2012 No
Possibly Possibly 8 December 2012 Yes 8 December 2012 0
Almost certainly Almost certainly 9 December 2012 Yes 16 December 2012 7
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Fatigue 2 4 Almost certainly
FCR Cystitis 1 4 Unlikely
FCR Rash/flushing 1 4 Possibly
FCR Nausea 1 5 Almost certainly
FCR Constipation 1 5 Unlikely
FCR Fatigue 2 5 Almost certainly
FCR Vomiting 2 6 Almost certainly
193 FCR Neutropenia 4 1 Almost certainly
FCR Anaemia 1 1 Almost certainly
FCR Thrombocytopenia 1 3 Almost certainly
FCR Other AE description Ruptured Achilles
tendon
2 4 Unrelated
FCR Thrombocytopenia 1 4 Probably
FCR Neutropenia 4 5 Almost certainly
FCR Thrombocytopenia 1 5 Almost certainly
FCR Thrombocytopenia 1 6 Almost certainly
FCR Neutropenia 1 6 Almost certainly
194 FCR Abdominal pain/
bloating
1 1 Possibly
FCR Neutropenia 4 1 Almost certainly
FCR Nausea 1 1 Almost certainly
FCR Anaemia 1 1 Unlikely
FCR Cystitis 2 2 Possibly
FCR Nausea 1 2 Almost certainly
FCR Anaemia 1 3 Possibly
FCR Fatigue 2 3 Unlikely
FCR Cystitis 1 3 Almost certainly
FCR Pruritus 1 3 Unlikely
FCR Alopecia 2 3 Almost certainly
FCR Cough 1 4 Unlikely
FCR Fever 2 4 Unlikely
FCR Dyspnoea 1 4 Unlikely
FCR Vomiting 2 4 Possibly
FCR Abdominal pain/
bloating
2 4 Possibly
FCR Fever 2 4 Unlikely
FCR Vomiting 2 4 Possibly
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Possibly 7 December 2012 Yes 14 December 2012 7
Unlikely Unlikely 5 November 2012 Yes 26 November 2012 21
Possibly Possibly 27 November 2012 Yes 4 December 2012 7
Almost certainly Almost certainly 4 January 2013 Yes 12 January 2013 8
Unlikely Unlikely 7 January 2013 Yes 9 February 2013 33
Almost certainly Possibly 5 January 2013 Yes 12 January 2013 7
Almost certainly Possibly 31 January 2013 Yes 6 February 2013 6
Almost certainly Almost certainly 26 October 2012 Yes 5 November 2012 10
Almost certainly Almost certainly 26 October 2012 Yes 5 November 2012 10
Almost certainly Almost certainly 31 December 2012 No
Unrelated Unrelated 21 January 2013 No
Probably Probably 28 January 2013 No
Almost certainly Almost certainly 14 February 2013 Yes 26 February 2013 12
Almost certainly Almost certainly 14 February 2013 Yes 26 February 2013 12
Almost certainly Almost certainly 14 March 2013 No
Almost certainly Almost certainly 14 March 2013 Yes 25 March 2013 11
Possibly Possibly No
Almost certainly Almost certainly 3 October 2012 Yes 16 October 2012 13
Almost certainly Almost certainly Yes
Unlikely Unlikely 27 June 2012 Yes 16 October 2012 111
Almost certainly Unlikely 24 September 2012 Yes 17 October 2012 23
Almost certainly Almost certainly 17 October 2012 Yes 22 October 2012 5
Possibly Possibly 29 October 2012 Yes 12 December 2012 44
Unlikely Unlikely No
Almost certainly Unlikely Yes
Unlikely Unlikely No
Almost certainly Unlikely No
Unlikely Unlikely Yes 30 January 2013
Unlikely Possibly 13 December 2012 Yes 15 December 2012 2
Unlikely Possibly Yes 9 January 2013
Possibly Possibly 12 December 2012 Yes 15 December 2012 3
Possibly Possibly 12 December 2012 Yes 15 December 2012 3
Unlikely Possibly 10 January 2013 Yes 14 January 2013 4
Possibly Possibly 10 January 2013 Yes 14 January 2013 4
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
195 FCR Nausea 2 2 Almost certainly
FCR Neutropenia 2 2 Almost certainly
FCR Vomiting 2 2 Almost certainly
198 FCR Thrombocytopenia 3 1 Probably
FCR Urinary symptoms 2 1 Possibly
FCR Fatigue 1 1 Probably
FCR Bone pain 2 1 Unrelated
FCR Dizziness 1 1 Unlikely
FCR Fatigue 1 2 Probably
FCR Constipation 1 2 Unlikely
FCR Nasal symptoms 1 2 Unlikely
FCR Arthralgias 1 2 Unlikely
FCR Nausea 1 3 Almost certainly
FCR Constipation 1 3 Unlikely
FCR Taste alteration 1 3 Almost certainly
FCR Urinary symptoms 1 3 Unlikely
FCR Nasal symptoms 1 4 Unlikely
FCR Fatigue 2 4 Probably
FCR Urinary symptoms 1 4 Unlikely
FCR Nasal symptoms 2 4 Unlikely
FCR Anorexia/cachexia 1 4 Almost certainly
FCR Fatigue 2 5 Almost certainly
FCR Constipation 1 5 Unlikely
FCR Fatigue 2 6 Almost certainly
FCR Fatigue 1 6 Almost certainly
FCR Other AE description Bruising to L
orbital region
1 6 Probably
199 FCR Vomiting 2 2 Probably
FCR Allergic reaction 2 2 Unlikely
FCR Myalgias 1 2 Unlikely
FCR Other AE description Right upper jaw
lump
1 2 Unlikely
FCR Fatigue 1 3 Probably
FCR Nausea 2 3 Probably
FCR Other AE description Right upper jaw
lump
1 3 Unlikely
FCR Vomiting 2 3 Probably
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Unlikely 17 October 2012 Yes 16 January 2013 91
Almost certainly Almost certainly 11 October 2012 Yes 17 October 2012 6
Almost certainly Unlikely 17 October 2012 Yes 16 January 2013 91
Probably Possibly 4 October 2012 Yes 24 October 2012 20
Possibly Unlikely 22 September 2012 Yes 26 September 2012 4
Probably Unlikely 21 September 2012 No
Unrelated Unrelated No
Unlikely Unlikely 11 October 2012 Yes 18 October 2012 7
Probably Unlikely No
Unlikely Possibly 27 October 2012 Yes 1 November 2012 5
Unlikely Possibly 2 November 2012 No
Unlikely Possibly 26 October 2012 No
Almost certainly Unlikely 22 November 2012 Yes 26 November 2012 4
Unlikely Possibly 22 November 2012 Yes 26 November 2012 4
Almost certainly Unlikely No
Probably Unrelated 29 November 2012 No
Unlikely Possibly No
Probably Unlikely 22 November 2012 No
Probably Unrelated No
Unlikely Unlikely 10 January 2013 No
Almost certainly Unlikely No
Almost certainly Unlikely 17 January 2013 Yes 21 January 2013 4
Unlikely Possibly 14 February 2013 No
Almost certainly Unlikely 14 February 2013 Yes 28 February 2013 14
Almost certainly Unlikely 1 March 2013 Yes 14 March 2013 13
Probably Unlikely Yes
Almost certainly Unlikely 14 October 2012 Yes 14 October 2012 0
Unlikely Almost certainly 10 October 2012 Yes 10 October 2012 0
Unlikely Unlikely 2 November 2012 Yes 2 November 2012 0
Unlikely Unlikely No
Probably Unrelated 10 October 2012 Yes 10 December 2012 61
Almost certainly Unlikely 14 October 2012 Yes 10 December 2012 57
Unlikely Unlikely Yes
Almost certainly Unlikely 7 December 2012 Yes 9 December 2012 2
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TABLE 84 Adverse events in participants receiving FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCR Nausea 2 4 Probably
FCR Vomiting 2 4 Probably
FCR Fatigue 1 4 Probably
FCR Nausea 2 6 Probably
FCR Common cold 2 6 Unrelated
FCR Abdominal pain/
bloating
1 6 Unrelated
FCR Night sweats 1 6 Possibly
200 FCR Constipation 2 1 Unrelated
FCR Vomiting 2 1 Unrelated
FCR Neutropenia 3 1 Almost certainly
FCR Anaemia 2 1 Almost certainly
FCR Thrombocytopenia 1 1 Almost certainly
FCR Neutropenia 2 2 Almost certainly
FCR Renal impairment 1 2 Unrelated
FCR Dry skin/erythema 1 3 Possibly
FCR Abdominal pain/
bloating
1 3 Possibly
FCR Anaemia 1 3 Almost certainly
FCR Lymphopenia 2 4 Almost certainly
FCR Neutropenia 1 5 Almost certainly
FCR Lymphopenia 1 5 Almost certainly
FCR Anaemia 1 6 Almost certainly
FCR Thrombocytopenia 1 6 Almost certainly
GGT, gamma-glutamyl transpeptidase.
Duration of AE: days from date of onset to date of recovery (if known).
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Related to
cyclophosphamide?
Related to
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Unlikely 7 January 2013 Yes 10 January 2013 3
Almost certainly Unlikely 7 January 2013 Yes 10 January 2013 3
Probably Unrelated 10 December 2012 No
Almost certainly Unlikely 6 February 2013 Yes 8 February 2013 2
Unrelated Unrelated 18 February 2013 No
Unrelated Unrelated 5 February 2013 Yes 9 February 2013 4
Possibly Unrelated 21 February 2013 Yes 24 February 2013 3
Unrelated Unrelated 10 October 2012 Yes 12 October 2012 2
Unrelated Possibly 8 October 2012 Yes 8 October 2012 0
Almost certainly Almost certainly 31 October 2012 No
Almost certainly Almost certainly 22 October 2012 No
Almost certainly Almost certainly 10 September 2012 No
Almost certainly Almost certainly 24 September 2012 No
Unrelated Unrelated 31 October 2012 Yes 5 November 2012 5
Possibly Possibly No
Possibly Possibly Yes
Almost certainly Almost certainly 3 October 2012 Yes
Almost certainly Almost certainly 22 October 2012 No
Almost certainly Almost certainly 27 February 2013 No
Almost certainly Almost certainly No
Almost certainly Unlikely 10 April 2013 No
Almost certainly Unlikely 10 April 2013 No
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TABLE 85 Adverse events in participants receiving FCM-miniR
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
3 FCM-miniR Infusional reaction 1 1 Unrelated
FCM-miniR Arrhythmias/
palpitation
1 1 Unrelated
FCM-miniR Anaemia 4 1 Almost certainly
FCM-miniR Abdominal pain/
bloating
1 2 Unlikely
FCM-miniR Anaemia 2 3 Almost certainly
FCM-miniR Fatigue 1 4 Almost certainly
FCM-miniR Sore throat 1 4 Unlikely
FCM-miniR Anaemia 2 4 Almost certainly
FCM-miniR Pruritus 2 5 Possibly
FCM-miniR Thrombocytopenia 1 6 Probably
4 FCM-miniR Hypotension 2 1 Unrelated
FCM-miniR Allergic reaction 2 1 Unrelated
FCM-miniR Dizziness 2 1 Unrelated
FCM-miniR Nausea 1 1 Probably
FCM-miniR Hypotension 2 2 Unlikely
FCM-miniR Hypotension 1 3 Unlikely
FCM-miniR Nausea 1 4 Almost certainly
FCM-miniR Nausea 1 6 Probably
FCM-miniR Fatigue 1 6 Probably
5 FCM-miniR Neutropenia 1 1 Probably
FCM-miniR Anaemia 1 1 Probably
FCM-miniR Nausea 1 1 Probably
FCM-miniR Abdominal pain/
bloating
2 2 Possibly
FCM-miniR Diarrhoea 1 2 Possibly
FCM-miniR Nausea 1 2 Probably
FCM-miniR Nausea 2 3 Almost certainly
FCM-miniR Vomiting 1 3 Almost certainly
FCM-miniR Anaemia 2 3 Almost certainly
FCM-miniR Nausea 2 4 Almost certainly
FCM-miniR Infections (not
neutropenic sepsis)
1 4 Possibly
FCM-miniR Fever 3 4 Possibly
FCM-miniR Nausea 2 5 Almost certainly
FCM-miniR Fatigue 2 5 Almost certainly
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unrelated Unrelated Almost
certainly
18 January 2010 Yes 18 January 2010 0
Unrelated Unrelated Unrelated 29 January 2010 Yes 30 January 2010 1
Possibly Possibly Unlikely 11 February 2010 Yes 12 February 2010 1
Unlikely Unlikely Unlikely 24 February 2010 Yes 11 March 2010 15
Possibly Possibly Unlikely 8 April 2010 No
Unlikely Almost certainly Unlikely 7 May 2010 No
Possibly Almost certainly Unlikely Yes 7 May 2010
Possibly Possibly Unlikely 6 May 2010 No
Possibly Possibly Possibly 17 May 2010 Yes 3 June 2010 17
Probably Probably Possibly 1 July 2010 Yes 13 January 2011 196
Unrelated Unrelated Probably 24 February 2010 Yes 24 February 2010 0
Unrelated Possibly Probably 24 February 2010 Yes 25 February 2010 1
Unrelated Probably Probably 24 February 2010 Yes 24 February 2010 0
Probably Probably Possibly 24 February 2010 Yes 3 March 2010 7
Unlikely Unlikely Possibly 24 March 2010 Yes 24 March 2010 0
Unlikely Unlikely Probably 21 April 2010 Yes 21 April 2010 0
Almost certainly Almost certainly Possibly 19 May 2010 Yes 5 June 2010 17
Probably Probably Possibly 14 July 2010 Yes 19 July 2010 5
Probably Probably Possibly 14 July 2010 Yes 4 August 2010 21
Probably Probably Unlikely 5 March 2010 Yes 7 March 2010 2
Probably Probably Unlikely 5 March 2010 No
Probably Probably Unrelated 18 February 2010 Yes 26 February 2010 8
Possibly Possibly Missing No
Possibly Possibly Missing No
Probably Probably Missing 18 March 2010 Yes 23 March 2010 5
Almost certainly Probably Missing 16 April 2010 Yes 20 April 2010 4
Almost certainly Probably Missing 17 April 2010 Yes 17 April 2010 0
Almost certainly Almost certainly Missing 22 April 2010 Yes 26 April 2010 4
Almost certainly Almost certainly Missing 15 May 2010 Yes 19 May 2010 4
Possibly Possibly Missing 17 May 2010 Yes 21 May 2010 4
Possibly Possibly Missing 19 May 2010 Yes 21 May 2010 2
Almost certainly Almost certainly Missing 9 June 2010 Yes 12 June 2010 3
Possibly Almost certainly Missing 10 June 2010 Yes 18 June 2010 8
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCM-miniR Vomiting 2 5 Almost certainly
FCM-miniR Hypotension 3 6 Unrelated
FCM-miniR Fatigue 2 6 Almost certainly
FCM-miniR Nausea 1 6 Almost certainly
FCM-miniR Vomiting 1 6 Almost certainly
FCM-miniR Anaemia 2 6 Almost certainly
FCM-miniR Neutropenia 3 6 Probably
FCM-miniR Thrombocytopenia 1 6 Probably
FCM-miniR Neutropenia 3 6 Almost certainly
6 FCM-miniR Neutropenia 4 1 Probably
FCM-miniR Constipation 4 2 Possibly
FCM-miniR Vomiting 1 3 Probably
10 FCM-miniR Anaemia 3 1 Almost certainly
FCM-miniR Thrombocytopenia 3 1 Almost certainly
FCM-miniR Anaemia 3 2 Probably
FCM-miniR Rash/flushing 1 2 Unrelated
FCM-miniR Abnormal electrolytes 3 4 Unlikely
12 FCM-miniR Rigors 1 1 Unrelated
FCM-miniR Nausea 1 1 Probably
FCM-miniR Thrombocytopenia 2 1 Probably
FCM-miniR Neutropenia 2 1 Probably
14 FCM-miniR Thrombocytopenia 1 5 Almost certainly
FCM-miniR Diarrhoea 1 6 Possibly
FCM-miniR Thrombocytopenia 3 6 Almost certainly
15 FCM-miniR Nausea 2 1 Almost certainly
FCM-miniR Vomiting 2 1 Almost certainly
FCM-miniR Diarrhoea 1 1 Almost certainly
FCM-miniR Constipation 1 1 Almost certainly
FCM-miniR Abdominal pain/
bloating
1 1 Almost certainly
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Almost certainly Missing 9 June 2010 Yes 10 June 2010 1
Unrelated Unrelated Missing 7 July 2010 Yes 7 July 2010 0
Almost certainly Almost certainly Missing 12 July 2010 Yes 18 July 2010 6
Almost certainly Almost certainly Missing 7 July 2010 Yes 11 July 2010 4
Almost certainly Almost certainly Missing 8 July 2010 Yes 8 July 2010 0
Possibly Possibly Missing 4 August 2010 No
Almost certainly Probably Missing 4 August 2010 No
Probably Almost certainly Missing 4 August 2010 No
Almost certainly Almost certainly Missing 11 August 2010 No
Probably Probably Probably 16 March 2010 Yes 30 March 2010 14
Possibly Possibly Possibly 2 March 2010 Yes 9 March 2010 7
Probably Probably Probably 21 April 2010 Yes 27 April 2010 6
Almost certainly Almost certainly Almost
certainly
22 March 2010 No
Almost certainly Almost certainly Almost
certainly
8 April 2010 No
Probably Probably Probably 8 April 2010 Yes 7 May 2010 29
Unrelated Unrelated Unrelated 10 May 2010 Yes 17 June 2010 38
Unlikely Unlikely Unlikely 1 July 2010 Yes 5 July 2010 4
Unrelated Unrelated Probably 27 April 2010 Yes 27 April 2010 0
Probably Probably Unlikely 28 April 2010 Yes 9 May 2010 11
Probably Probably Probably 10 May 2010 No
Probably Probably Probably 26 April 2010 No
Almost certainly Almost certainly Almost
certainly
30 August 2010 Yes 12 September 2010 13
Possibly Possibly Possibly Yes
Almost certainly Almost certainly Almost
certainly
10 October 2010 No
Almost certainly Almost certainly Almost
certainly
1 May 2010 Yes 7 May 2010 6
Almost certainly Almost certainly Almost
certainly
1 May 2010 Yes 7 May 2010 6
Almost certainly Almost certainly Almost
certainly
1 May 2010 Yes 7 May 2010 6
Almost certainly Almost certainly Almost
certainly
No
Almost certainly Almost certainly Almost
certainly
30 April 2010 Yes 7 May 2010 7
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCM-miniR Fatigue 1 1 Almost certainly
FCM-miniR Neutropenia 4 1 Almost certainly
FCM-miniR Thrombocytopenia 3 1 Almost certainly
FCM-miniR Nausea 2 2 Almost certainly
FCM-miniR Vomiting 1 2 Almost certainly
FCM-miniR Fatigue 2 2 Almost certainly
FCM-miniR Thrombocytopenia 1 2 Almost certainly
FCM-miniR Nausea 2 3 Almost certainly
FCM-miniR Vomiting 1 3 Almost certainly
FCM-miniR Fatigue 2 3 Almost certainly
FCM-miniR Nausea 2 4 Almost certainly
FCM-miniR Vomiting 2 4 Almost certainly
FCM-miniR Fatigue 2 4 Almost certainly
FCM-miniR Nausea 2 5 Almost certainly
FCM-miniR Fatigue 2 5 Almost certainly
FCM-miniR Alopecia 2 5 Almost certainly
FCM-miniR Nausea 2 6 Almost certainly
FCM-miniR Fatigue 2 6 Almost certainly
16 FCM-miniR Infusional reaction 2 1 Unrelated
FCM-miniR Headache 1 2 Unrelated
FCM-miniR Nausea 1 2 Almost certainly
FCM-miniR Myalgias 2 3 Unlikely
FCM-miniR Fever 3 6 Almost certainly
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Almost certainly Almost
certainly
29 April 2010 No
Almost certainly Almost certainly Almost
certainly
10 May 2010 Yes 21 June 2010 42
Almost certainly Almost certainly Almost
certainly
29 April 2010 Yes 19 July 2010 81
Almost certainly Almost certainly Almost
certainly
29 May 2010 Yes 5 June 2010 7
Almost certainly Almost certainly Almost
certainly
29 May 2010 Yes 31 May 2010 2
Almost certainly Almost certainly Almost
certainly
27 May 2010 No
Almost certainly Almost certainly Almost
certainly
21 June 2010 Yes 19 July 2010 28
Almost certainly Almost certainly Almost
certainly
26 June 2010 Yes 30 June 2010 4
Almost certainly Almost certainly Almost
certainly
26 June 2010 Yes 30 June 2010 4
Almost certainly Almost certainly Almost
certainly
24 June 2010 No
Almost certainly Almost certainly Almost
certainly
22 July 2010 Yes 29 July 2010 7
Almost certainly Almost certainly Almost
certainly
24 July 2010 Yes 29 July 2010 5
Almost certainly Almost certainly Almost
certainly
22 July 2010 No
Almost certainly Almost certainly Almost
certainly
21 August 2010 Yes 28 August 2010 7
Almost certainly Almost certainly Almost
certainly
19 August 2010 No
Almost certainly Almost certainly Almost
certainly
19 August 2010 No
Almost certainly Almost certainly Almost
certainly
3 October 2010 Yes 13 October 2010 10
Almost certainly Almost certainly Almost
certainly
30 September 2010 No
Unrelated Unrelated Almost
certainly
5 May 2010 Yes 5 May 2010 0
Unrelated Unrelated Unrelated Yes 3 June 2010
Almost certainly Almost certainly Almost
certainly
3 June 2010 Yes 3 June 2010 0
Unlikely Unlikely Unlikely 17 June 2010 Yes 1 July 2010 14
Almost certainly Almost certainly Almost
certainly
27 August 2010 Yes 8 September 2010 12
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCM-miniR Anaemia 3 6 Almost certainly
FCM-miniR Neutropenia 4 6 Unlikely
20 FCM-miniR Nausea 2 1 Almost certainly
FCM-miniR Vomiting 2 1 Almost certainly
FCM-miniR Infections (not
neutropenic sepsis)
1 4 Unrelated
FCM-miniR Rash/flushing 1 4 Unrelated
FCM-miniR Nausea 1 6 Almost certainly
FCM-miniR Cough 1 6 Almost certainly
FCM-miniR Fatigue 1 6 Almost certainly
FCM-miniR Rigors 1 6 Almost certainly
21 FCM-miniR Nausea 1 1 Almost certainly
FCM-miniR Vomiting 1 Almost certainly
FCM-miniR Renal impairment 3 1 Almost certainly
FCM-miniR Other AE description Acidosis 4 1 Almost certainly
FCM-miniR Abnormal electrolytes 4 1 Almost certainly
FCM-miniR Abnormal electrolytes 1 Almost certainly
FCM-miniR Diarrhoea 1 Almost certainly
22 FCM-miniR Neutropenia 3 1 Almost certainly
FCM-miniR Fatigue 2 1 Almost certainly
FCM-miniR Fatigue 1 2 Unlikely
FCM-miniR Neutropenia 1 3 Probably
FCM-miniR Thrombocytopenia 1 3 Unrelated
FCM-miniR Fatigue 1 3 Probably
FCM-miniR Neutropenia 1 4 Almost certainly
FCM-miniR Thrombocytopenia 1 4 Almost certainly
FCM-miniR Neutropenia 3 5 Almost certainly
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Almost certainly Almost
certainly
2 September 2010 Yes 6 September 2010 4
Almost certainly Almost certainly Almost
certainly
31 August 2010 Yes 6 September 2010 6
Possibly Possibly Unrelated 1 July 2010 Yes 5 July 2010 4
Possibly Possibly Unrelated 1 July 2010 Yes 5 July 2010 4
Unrelated Unrelated Unrelated 25 September 2010 Yes 4 October 2010 9
Unrelated Unrelated Unrelated 11 October 2010 Yes 8 November 2010 28
Possibly Possibly Almost
certainly
11 December 2010 Yes 13 December 2010 2
Unlikely Unlikely Unlikely 30 December 2010 Yes 4 January 2011 5
Unlikely Unlikely Unlikely 11 December 2010 No
Unlikely Unlikely Almost
certainly
8 December 2010 Yes 4 January 2011 27
Almost certainly Almost certainly Almost
certainly
30 June 2010 Yes 4 July 2010 4
Almost certainly Almost certainly Almost
certainly
30 June 2010 Yes 4 July 2010 4
Almost certainly Almost certainly Almost
certainly
2 July 2010 Yes 20 July 2010 18
Almost certainly Almost certainly Almost
certainly
2 July 2010 Yes 10 July 2010 8
Almost certainly Almost certainly Almost
certainly
2 July 2010 Yes 5 July 2010 3
Almost certainly Almost certainly Almost
certainly
3 July 2010 Yes 30 July 2010 27
Almost certainly Almost certainly Almost
certainly
30 June 2010 Yes 5 July 2010 5
Almost certainly Almost certainly Almost
certainly
20 July 2010 Yes 3 August 2010 14
Almost certainly Almost certainly Almost
certainly
17 July 2010 Yes 21 July 2010 4
Unlikely Unlikely Unlikely 3 August 2010 Yes 7 August 2010 4
Probably Probably Probably 17 August 2010 Yes 31 August 2010 14
Unrelated Unrelated Unrelated 31 August 2010 No
Probably Probably Probably 31 August 2010 Yes 4 September 2010 4
Almost certainly Almost certainly Almost
certainly
12 October 2010 Yes 25 October 2010 13
Almost certainly Almost certainly Almost
certainly
25 October 2010 No
Almost certainly Almost certainly Almost
certainly
9 November 2010 Yes 22 November 2010 13
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCM-miniR Thrombocytopenia 1 5 Almost certainly
FCM-miniR Neutropenia 3 6 Almost certainly
FCM-miniR Thrombocytopenia 1 6 Almost certainly
23 FCM-miniR Neutropenia 4 2 Almost certainly
FCM-miniR Nausea 1 2 Almost certainly
FCM-miniR Neutropenia 1 3 Almost certainly
FCM-miniR Nausea 1 3 Almost certainly
FCM-miniR Anaemia 1 4 Probably
FCM-miniR Neutropenia 1 4 Probably
FCM-miniR Anaemia 1 5 Almost certainly
FCM-miniR Thrombocytopenia 1 5 Almost certainly
FCM-miniR Leucocytosis/
lymphocytosis
4 5 Almost certainly
FCM-miniR Anaemia 1 6 Almost certainly
FCM-miniR Thrombocytopenia 2 6 Almost certainly
FCM-miniR Neutropenia 4 6 Almost certainly
27 FCM-miniR Neutropenia 2 1 Almost certainly
FCM-miniR Nausea 2 1 Almost certainly
FCM-miniR Vomiting 1 1 Almost certainly
FCM-miniR Vomiting 2 2 Almost certainly
FCM-miniR Abdominal pain/
bloating
1 2 Possibly
FCM-miniR Fatigue 1 2 Probably
FCM-miniR Neuropathy (sensory) 1 2 Possibly
FCM-miniR Neutropenia 2 2 Almost certainly
FCM-miniR Thrombocytopenia 1 2 Almost certainly
FCM-miniR Infections (not
neutropenic sepsis)
1 3 Possibly
FCM-miniR Diarrhoea 2 3 Unlikely
FCM-miniR Neuropathy (sensory) 1 3 Possibly
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Almost certainly Almost
certainly
22 November 2010 No
Almost certainly Almost certainly Almost
certainly
7 December 2010 No
Almost certainly Almost certainly Almost
certainly
7 December 2010 No
Almost certainly Almost certainly Almost
certainly
28 July 2010 Yes 9 August 2010 12
Almost certainly Almost certainly Almost
certainly
28 July 2010 Yes 18 August 2010 21
Almost certainly Almost certainly Almost
certainly
17 August 2010 Yes 6 September 2010 20
Almost certainly Almost certainly Almost
certainly
7 September 2010 No
Probably Probably Probably 20 September 2010 Yes 28 September 2010 8
Probably Probably Probably 20 September 2010 Yes 28 September 2010 8
Almost certainly Almost certainly Almost
certainly
16 November 2010 Yes 29 November 2010 13
Almost certainly Almost certainly Almost
certainly
16 November 2010 No
Almost certainly Almost certainly Almost
certainly
16 November 2010 Yes 29 November 2010 13
Almost certainly Almost certainly Almost
certainly
14 October 2010 No
Almost certainly Almost certainly Almost
certainly
14 December 2010 No
Almost certainly Almost certainly Almost
certainly
14 December 2010 No
Almost certainly Almost certainly Possibly 12 August 2010 No
Almost certainly Almost certainly Unrelated 27 July 2010 Yes 30 July 2010 3
Almost certainly Almost certainly Unrelated 28 July 2010 Yes 29 July 2010 1
Almost certainly Almost certainly Possibly Yes 16 September 2010
Possibly Possibly Possibly Yes 16 September 2010
Probably Probably Probably Yes 16 September 2010
Possibly Probably Possibly Yes 16 September 2010
Almost certainly Almost certainly Possibly 14 September 2010 No
Almost certainly Unlikely Probably 14 September 2010 No
Possibly Possibly Possibly 1 October 2010 Yes 18 October 2010 17
Unlikely Unlikely Unlikely 29 September 2010 Yes 17 October 2010 18
Possibly Probably Possibly 3 October 2010 Yes 3 October 2010 0
continued
DOI: 10.3310/hta21280 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 28
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Howard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
275
TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCM-miniR Abdominal pain/
bloating
1 3 Possibly
FCM-miniR Anaemia 2 3 Probably
FCM-miniR Neutropenia 4 3 Almost certainly
FCM-miniR Neutropenia 3 3 Almost certainly
FCM-miniR Nausea 1 4 Almost certainly
FCM-miniR Dry skin/erythema 1 4 Possibly
FCM-miniR Neutropenia 2 4 Almost certainly
FCM-miniR Mucositis/thrush 2 4 Probably
FCM-miniR Anaemia 1 4 Probably
FCM-miniR Cystitis 1 5 Possibly
FCM-miniR Neutropenia 3 5 Almost certainly
FCM-miniR Neutropenia 2 5 Almost certainly
FCM-miniR Common cold 1 5 Unlikely
FCM-miniR Neutropenic sepsis 3 6 Almost certainly
FCM-miniR Diarrhoea 1 6 Possibly
FCM-miniR Neutropenia 4 6 Almost certainly
FCM-miniR Thrombocytopenia 1 6 Possibly
30 FCM-miniR Anaemia 4 1 Almost certainly
31 FCM-miniR Rigors 1 1 Unlikely
FCM-miniR Other AE description Hypertension 2 1 Unlikely
FCM-miniR Fever 1 1 Unlikely
FCM-miniR Back pain 3 2 Unrelated
FCM-miniR Neutropenia 4 2 Probably
FCM-miniR Diarrhoea 1 3 Possibly
FCM-miniR Thrombocytopenia 4 5 Almost certainly
FCM-miniR Neutropenia 4 5 Almost certainly
FCM-miniR Anaemia 4 5 Almost certainly
34 FCM-miniR Infusional reaction 2 1 Unrelated
FCM-miniR Nausea 1 3 Almost certainly
36 FCM-miniR Nausea 1 1 Almost certainly
FCM-miniR Fatigue 1 1 Almost certainly
FCM-miniR Neutropenia 1 1 Almost certainly
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Possibly Possibly Possibly 4 October 2010 Yes 4 October 2010 0
Probably Probably Probably 19 October 2010 No
Probably Probably Probably 29 September 2010 Yes 19 October 2010 20
Probably Probably Probably 19 October 2010 No
Almost certainly Almost certainly Possibly No
Possibly Possibly Possibly No
Almost certainly Almost certainly Possibly 28 October 2010 Yes 25 November 2010 28
Possibly Probably Possibly 1 October 2010 Yes 1 November 2010 31
Probably Probably Probably 25 October 2010 Yes 25 November 2010 31
Possibly Possibly Possibly Yes 29 November 2010
Almost certainly Almost certainly Possibly 29 December 2010 Yes 4 January 2011 6
Probably Probably Probably 25 October 2010 Yes 4 January 2011 71
Unlikely Unlikely Unlikely 23 December 2010 Yes 5 January 2011 13
Almost certainly Almost certainly Possibly 21 February 2011 Yes 25 February 2011 4
Possibly Possibly Possibly 21 February 2011 Yes 24 February 2011 3
Probably Probably Probably 22 February 2011 Yes 24 February 2011 2
Possibly Possibly Possibly 22 February 2011 No
Possibly Possibly Possibly 22 August 2010 Yes 31 August 2010 9
Unlikely Unlikely Probably 18 August 2010 Yes 18 August 2010 0
Unlikely Unlikely Probably 18 August 2010 Yes 18 August 2010 0
Unlikely Unlikely Probably 18 August 2010 Yes 18 August 2010 0
Unrelated Unrelated Unrelated 8 October 2010 No
Probably Probably Probably 1 September 2010 Yes 11 October 2010 40
Possibly Possibly Unlikely 13 October 2010 Yes 15 October 2010 2
Almost certainly Almost certainly Almost
certainly
4 January 2011 No
Almost certainly Almost certainly Almost
certainly
4 January 2011 No
Almost certainly Almost certainly Almost
certainly
4 January 2011 No
Unrelated Unrelated Almost
certainly
17 September 2010 Yes 17 September 2010 0
Almost certainly Almost certainly Almost
certainly
13 November 2010 Yes 17 November 2010 4
Almost certainly Almost certainly Almost
certainly
27 September 2010 No
Almost certainly Almost certainly Probably 25 October 2010 No
Almost certainly Almost certainly Possibly 21 October 2010 No
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCM-miniR Cystitis 1 2 Possibly
FCM-miniR Neutropenia 3 2 Almost certainly
FCM-miniR Lymphopenia 3 2 Possibly
FCM-miniR Anaemia 1 2 Probably
FCM-miniR Constipation 2 3 Possibly
FCM-miniR Nausea 2 3 Almost certainly
FCM-miniR Cough 1 3 Possibly
FCM-miniR Anorexia/cachexia 1 4 Probably
FCM-miniR Infections (not
neutropenic sepsis)
1 4 Probably
FCM-miniR Anorexia/cachexia 3 4 Almost certainly
FCM-miniR Oedema 1 4 Possibly
FCM-miniR Neutropenia 2 4 Almost certainly
FCM-miniR Lymphopenia 3 4 Possibly
37 FCM-miniR Mucositis/thrush 1 5 Probably
FCM-miniR Anorexia/cachexia 1 5 Probably
FCM-miniR Fatigue 1 5 Probably
FCM-miniR Nausea 1 5 Probably
FCM-miniR Nausea 1 6 Probably
39 FCM-miniR Vomiting 1 1 Probably
FCM-miniR Fatigue 1 1 Almost certainly
FCM-miniR Neutropenia 4 1 Probably
FCM-miniR Thrombocytopenia 2 1 Possibly
FCM-miniR Anaemia 1 1 Probably
FCM-miniR Nausea 1 2 Almost certainly
FCM-miniR Vomiting 1 2 Almost certainly
FCM-miniR Neuropathy (sensory) 1 2 Almost certainly
FCM-miniR Vomiting 2 3 Almost certainly
FCM-miniR Fatigue 2 3 Almost certainly
FCM-miniR Nausea 2 3 Almost certainly
FCM-miniR Neutropenia 1 4 Missing
FCM-miniR Vomiting 2 4 Missing
FCM-miniR Diarrhoea 1 4 Missing
FCM-miniR Neutropenia 1 5 Missing
FCM-miniR Anaemia 2 6 Almost certainly
FCM-miniR Neutropenia 2 6 Almost certainly
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Possibly Possibly Missing 30 October 2010 Yes 18 November 2010 19
Probably Probably Missing 3 November 2010 Yes 18 November 2010 15
Possibly Possibly Missing 3 November 2010 Yes 25 November 2010 22
Probably Probably Missing 3 November 2010 No
Possibly Possibly Missing 10 November 2010 Yes 23 December 2010 43
Almost certainly Almost certainly Missing 29 November 2010 Yes 23 December 2010 24
Possibly Possibly Missing 27 October 2010 Yes 23 December 2010 57
Probably Probably Missing Yes 10 February 2011
Probably Probably Missing No
Almost certainly Almost certainly Missing 5 January 2011 Yes 10 February 2011 36
Possibly Possibly Missing 27 January 2011 Yes 10 February 2011 14
Almost certainly Almost certainly Missing 23 December 2010 Yes 10 February 2011 49
Possibly Possibly Missing 23 December 2010 Yes 10 February 2011 49
Probably Probably Unlikely Yes
Probably Probably Unlikely Yes
Probably Probably Unlikely Yes
Probably Probably Unlikely 2 February 2011 Yes 4 February 2011 2
Probably Probably Unlikely 2 March 2011 Yes 4 March 2011 2
Probably Probably Unlikely 8 November 2010 Yes 9 November 2010 1
Unrelated Unrelated Unrelated 6 November 2010 Yes 12 November 2010 6
Probably Probably Possibly 15 November 2010 Yes 30 December 2010 45
Possibly Possibly Possibly 4 November 2010 Yes 16 December 2010 42
Probably Probably Possibly 15 November 2010 Yes 30 December 2010 45
Almost certainly Almost certainly Unlikely 3 December 2010 Yes 7 December 2010 4
Almost certainly Almost certainly Unlikely 3 December 2010 Yes 4 December 2010 1
Almost certainly Almost certainly Unlikely 3 December 2010 No
Almost certainly Almost certainly Unrelated 4 January 2011 Yes 6 January 2011 2
Unrelated Unrelated Unrelated 31 December 2010 No
Almost certainly Almost certainly Unrelated 4 January 2011 Yes 6 January 2011 2
Missing Missing Missing 11 February 2011 Yes 15 February 2011 4
Missing Missing Missing 11 February 2011 Yes 13 February 2011 2
Missing Missing Missing 11 February 2011 Yes 12 February 2011 1
Missing Missing Missing 9 March 2011 Yes 24 March 2011 15
Almost certainly Almost certainly Unlikely 5 April 2011 No
Almost certainly Almost certainly Unlikely 5 April 2011 Yes 19 April 2011 14
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
40 FCM-miniR Anaemia 3 1 Possibly
FCM-miniR Infusional reaction 1 2 Unrelated
FCM-miniR Neutropenia 3 2 Probably
FCM-miniR Renal impairment 1 2 Possibly
FCM-miniR Allergic reaction 2 3 Unrelated
FCM-miniR Neutropenia 2 3 Almost certainly
FCM-miniR Thrombocytopenia 1 3 Almost certainly
FCM-miniR Anaemia 3 3 Almost certainly
FCM-miniR Bone pain 4 4 Unlikely
FCM-miniR Pruritus 3 4 Unrelated
FCM-miniR Neutropenia 3 4 Almost certainly
FCM-miniR Thrombocytopenia 4 4 Almost certainly
FCM-miniR Renal impairment 1 4 Possibly
FCM-miniR Anaemia 3 4 Almost certainly
45 FCM-miniR Vomiting 3 1 Probably
FCM-miniR Anaemia 1 1 Possibly
FCM-miniR Thrombocytopenia 1 1 Possibly
FCM-miniR Neutropenia 1 1 Probably
FCM-miniR Infusional reaction 2 1 Unrelated
FCM-miniR Infections (not
neutropenic sepsis)
2 2 Possibly
FCM-miniR Constipation 2 2 Possibly
FCM-miniR Dizziness 1 2 Possibly
FCM-miniR Neutropenia 4 3 Almost certainly
FCM-miniR Thrombocytopenia 3 3 Almost certainly
FCM-miniR Vomiting 1 3 Almost certainly
46 FCM-miniR Rigors 1 1 Unlikely
FCM-miniR Hypotension 2 1 Unlikely
FCM-miniR Arrhythmias/
palpitation
2 1 Unlikely
FCM-miniR Nausea 1 1 Probably
FCM-miniR Neutropenia 4 1 Probably
FCM-miniR Nausea 1 2 Probably
FCM-miniR Sore throat 2 2 Unlikely
FCM-miniR Vomiting 2 2 Probably
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Possibly Possibly Unlikely 16 November 2010 No
Unrelated Unrelated Almost
certainly
17 November 2010 Yes 17 November 2010 0
Probably Probably Unlikely No
Possibly Possibly Possibly 16 November 2010 Yes 14 December 2010 28
Unrelated Unrelated Almost
certainly
22 December 2010 Yes 22 December 2010 0
Almost certainly Almost certainly Possibly 17 January 2011 Yes 23 January 2011 6
Almost certainly Almost certainly Possibly 22 November 2010 Yes 23 January 2011 62
Almost certainly Almost certainly Possibly 17 January 2011 Yes 23 January 2011 6
Unlikely Unlikely Unlikely 7 March 2011 No
Unrelated Unrelated Unrelated 19 January 2011 Yes 26 January 2011 7
Almost certainly Almost certainly Possibly 28 February 2011 No
Almost certainly Almost certainly Possibly 7 March 2011 No
Possibly Possibly Possibly 17 January 2011 Yes 15 February 2011 29
Almost certainly Almost certainly Possibly 15 February 2011 No
Probably Probably Possibly Yes
Possibly Possibly Possibly 13 December 2010 No
Possibly Possibly Possibly 1 February 2010 No
Probably Probably Possibly 13 December 2010 No
Unrelated Unrelated Almost
certainly
17 November 2010 Yes 17 November 2010 0
Possibly Possibly Possibly Yes 9 January 2011
Possibly Possibly Possibly 18 November 2010 Yes 12 January 2011 55
Possibly Possibly Possibly 21 December 2010 Yes 21 December 2010 0
Almost certainly Almost certainly Unlikely 7 February 2011 Yes 21 February 2011 14
Almost certainly Almost certainly Unlikely 7 February 2011 No
Almost certainly Almost certainly Unlikely 15 January 2011 Yes 16 January 2011 1
Unlikely Unlikely Probably 11 November 2010 Yes 11 November 2010 0
Unlikely Unlikely Probably 11 November 2010 Yes 11 November 2010 0
Unlikely Unlikely Probably 11 November 2010 Yes 11 November 2010 0
Probably Probably Unlikely Yes
Probably Probably Probably 22 November 2010 Yes 6 December 2010 14
Probably Probably Unlikely 9 December 2010 Yes 10 December 2010 1
Unlikely Unlikely Unlikely 20 December 2010 Yes
Probably Probably Unlikely 31 December 2010 Yes 5 January 2011 5
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCM-miniR Diarrhoea 2 2 Probably
FCM-miniR Nausea 1 3 Probably
FCM-miniR Diarrhoea 3 5 Unlikely
FCM-miniR Abdominal pain/
bloating
2 5 Unlikely
FCM-miniR Diarrhoea 3 6 Unlikely
47 FCM-miniR Cough 2 1 Possibly
FCM-miniR Hypotension 1 1 Unrelated
FCM-miniR Nausea 1 1 Probably
FCM-miniR Neutropenia 2 2 Probably
FCM-miniR Infections (not
neutropenic sepsis)
2 2 Probably
FCM-miniR Fatigue 1 3 Possibly
FCM-miniR Diarrhoea 1 3 Probably
FCM-miniR Vomiting 1 3 Probably
FCM-miniR Neutropenia 4 3 Probably
FCM-miniR Neutropenia 4 5 Probably
FCM-miniR Neutropenia 4 6 Probably
FCM-miniR Neutropenia 4 6 Probably
FCM-miniR Cough 2 6 Possibly
49 FCM-miniR Gout/hyperuricemia 2 1 Probably
FCM-miniR Neutropenia 3 1 Almost certainly
FCM-miniR Thrombocytopenia 3 1 Almost certainly
FCM-miniR Anaemia 3 1 Almost certainly
FCM-miniR Renal impairment 1 1 Unlikely
FCM-miniR Neutropenia 4 2 Almost certainly
FCM-miniR Thrombocytopenia 2 2 Almost certainly
FCM-miniR Anaemia 2 2 Almost certainly
FCM-miniR Neutropenia 2 3 Almost certainly
FCM-miniR Thrombocytopenia 3 3 Almost certainly
FCM-miniR Anaemia 3 3 Almost certainly
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Probably Probably Unlikely 31 December 2010 Yes 5 January 2011 5
Probably Probably Unlikely 6 January 2011 Yes
Unlikely Unlikely Unlikely 6 January 2011 Yes 4 April 2011 88
Unlikely Unlikely Unlikely No
Unlikely Unlikely Unlikely Yes 28 April 2011
Possibly Possibly Possibly 6 December 2010 Yes 14 January 2010 –326
Unrelated Unrelated Possibly 26 November 2010 Yes 26 November 2010 0
Probably Probably Unrelated 26 November 2010 Yes 26 November 2010 0
Probably Probably Unrelated 14 January 2011 Yes 26 January 2011 12
Probably Probably Probably 7 January 2011 Yes 2 February 2011 26
Possibly Possibly Possibly 23 February 2011 No
Probably Probably Unrelated 26 February 2011 Yes 4 March 2011 6
Probably Probably Unrelated 1 March 2011 Yes 3 March 2011 2
Probably Probably Unrelated 7 March 2011 Yes 14 March 2011 7
Probably Probably Unrelated 21 March 2011 Yes 13 April 2011 23
Probably Probably Possibly 18 April 2011 Yes 16 May 2011 28
Probably Probably Possibly 26 May 2011 No
Possibly Possibly Possibly 6 May 2011 Yes 10 June 2011 35
Probably Probably Probably 13 April 2011 Yes 24 April 2011 11
Almost certainly Almost certainly Almost
certainly
14 April 2011 Yes 21 April 2011 7
Almost certainly Almost certainly Almost
certainly
14 April 2011 Yes 27 April 2011 13
Almost certainly Almost certainly Almost
certainly
14 April 2011 No
Unlikely Unlikely Unlikely Yes 11 July 2011
Almost certainly Almost certainly Almost
certainly
10 May 2011 Yes 17 May 2011 7
Almost certainly Almost certainly Almost
certainly
10 May 2011 Yes 13 July 2011 64
Almost certainly Almost certainly Almost
certainly
10 May 2011 No
Almost certainly Almost certainly Almost
certainly
2 June 2011 Yes 21 June 2011 19
Almost certainly Almost certainly Almost
certainly
24 May 2011 Yes 13 July 2011 50
Almost certainly Almost certainly Almost
certainly
10 June 2011 No
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
52 FCM-miniR Nausea 1 1 Unrelated
FCM-miniR Vomiting 2 1 Probably
FCM-miniR Rash/flushing 2 1 Unrelated
FCM-miniR Rash/flushing 2 2 Unrelated
FCM-miniR Vomiting 2 2 Probably
FCM-miniR Allergic reaction 1 2 Unrelated
FCM-miniR Vomiting 2 3 Probably
FCM-miniR Nausea 1 4 Probably
FCM-miniR Cough 2 5 Probably
FCM-miniR Neutropenia 1 5 Almost certainly
53 FCM-miniR Dyspnoea 2 1 Unrelated
FCM-miniR Vomiting 3 1 Almost certainly
FCM-miniR Urinary symptoms 1 2 Unlikely
FCM-miniR Infections (not
neutropenic sepsis)
2 2 Possibly
FCM-miniR Abnormal electrolytes 3 2 Unrelated
FCM-miniR Rash/flushing 2 3 Unrelated
FCM-miniR Infections (not
neutropenic sepsis)
2 6 Possibly
54 FCM-miniR Vomiting 2 1 Missing
FCM-miniR Nausea 2 1 Missing
FCM-miniR Neutropenic sepsis 4 1 Missing
FCM-miniR Vomiting 2 2 Unrelated
FCM-miniR Vomiting 2 3 Probably
FCM-miniR Thrombocytopenia 1 3 Probably
FCM-miniR Nausea 1 4 Probably
FCM-miniR Fatigue 1 5 Probably
FCM-miniR Vomiting 1 5 Probably
FCM-miniR Thrombocytopenia 2 5 Probably
FCM-miniR Anaemia 1 5 Probably
57 FCM-miniR Nausea 1 1 Probably
FCM-miniR Insomnia 1 1 Unrelated
FCM-miniR Neutropenia 3 1 Probably
FCM-miniR Mucositis/thrush 1 1 Probably
FCM-miniR Headache 1 1 Possibly
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unrelated Unrelated Almost
certainly
21 December 2010 Yes 27 December 2010 6
Probably Probably Probably 26 December 2010 Yes 27 December 2010 1
Unrelated Unrelated Almost
certainly
20 December 2010 Yes 20 December 2010 0
Unrelated Unrelated Almost
certainly
17 January 2011 Yes 17 January 2011 0
Probably Probably Probably 20 January 2011 Yes 24 January 2011 4
Unrelated Unrelated Almost
certainly
17 January 2011 Yes 17 January 2011 0
Probably Probably Probably 15 February 2011 Yes 17 February 2011 2
Probably Probably Probably 14 March 2011 Yes 20 March 2011 6
Probably Probably Unlikely 7 May 2011 No
Almost certainly Almost certainly Possibly 9 May 2011 No
Unrelated Unrelated Unrelated 23 January 2011 Yes
Almost certainly Almost certainly Unrelated Yes 8 February 2011
Unlikely Unlikely Unlikely Yes 22 March 2011
Possibly Possibly Possibly Yes 22 March 2011
Unrelated Unrelated Unrelated 11 January 2011 No
Unrelated Unrelated Unrelated 8 March 2011 Yes 19 April 2011 42
Possibly Possibly Possibly 7 June 2011 Yes 27 July 2011 50
Missing Missing Missing 23 January 2011 Yes 24 January 2011 1
Missing Missing Missing 22 January 2011 Yes 28 January 2011 6
Missing Missing Missing 16 February 2011 Yes
Probably Probably Unrelated 18 February 2011 Yes 23 February 2011 5
Probably Probably Unlikely 17 March 2011 Yes 27 March 2011 10
Probably Probably Possibly 13 April 2011 No
Probably Probably Unlikely 27 April 2011 Yes 7 May 2011 10
Probably Probably Unrelated 25 May 2011 No
Probably Probably Unrelated 26 May 2011 Yes 4 June 2011 9
Probably Probably Unrelated 22 June 2011 No
Probably Probably Unrelated 22 June 2011 Yes 6 July 2011 14
Probably Probably Unlikely 13 January 2011 Yes 25 January 2011 12
Unrelated Unrelated Unrelated 13 January 2011 No
Probably Probably Unlikely 25 January 2011 Yes 8 February 2011 14
Probably Probably Unlikely 25 January 2011 No
Possibly Possibly Missing 5 February 2011 Yes 8 February 2011 3
continued
DOI: 10.3310/hta21280 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 28
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Howard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
285
TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCM-miniR Nausea 1 2 Probably
FCM-miniR Insomnia 1 2 Unrelated
FCM-miniR Neutropenia 3 2 Probably
FCM-miniR Fatigue 1 2 Probably
FCM-miniR Nausea 1 3 Probably
FCM-miniR Insomnia 1 3 Unrelated
FCM-miniR Neutropenia 4 3 Probably
FCM-miniR Fatigue 1 3 Probably
FCM-miniR Nausea 1 4 Probably
FCM-miniR Insomnia 1 4 Unrelated
FCM-miniR Neutropenia 4 4 Probably
FCM-miniR Fatigue 1 4 Probably
FCM-miniR Nausea 1 5 Probably
FCM-miniR Insomnia 1 5 Unrelated
FCM-miniR Neutropenia 4 5 Probably
FCM-miniR Infections (not
neutropenic sepsis)
1 5 Probably
FCM-miniR Fatigue 1 5 Probably
FCM-miniR Nausea 1 6 Probably
FCM-miniR Insomnia 1 6 Unrelated
FCM-miniR Neutropenia 4 6 Probably
FCM-miniR Fatigue 1 6 Probably
58 FCM-miniR Nausea 1 1 Probably
FCM-miniR Headache 1 1 Possibly
FCM-miniR Vomiting 1 1 Probably
FCM-miniR Dry skin/erythema 1 1 Possibly
FCM-miniR Back pain 2 1 Unlikely
FCM-miniR Nausea 1 2 Probably
FCM-miniR Vomiting 1 2 Probably
FCM-miniR Headache 1 2 Possibly
FCM-miniR Cough 1 2 Possibly
FCM-miniR Fatigue 2 2 Possibly
FCM-miniR Fatigue 1 2 Possibly
FCM-miniR Nausea 1 3 Probably
FCM-miniR Fatigue 2 3 Probably
FCM-miniR Headache 1 3 Possibly
FCM-miniR Cough 1 3 Possibly
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Probably Probably Unlikely 8 February 2011 Yes 12 February 2011 4
Unrelated Unrelated Unrelated 8 February 2011 No
Probably Probably Unlikely 22 February 2011 Yes 8 March 2011 14
Probably Probably Unlikely 22 February 2011 No
Probably Probably Unlikely 8 March 2011 Yes 14 March 2011 6
Unrelated Unrelated Unrelated 8 March 2011 No
Probably Probably Probably 14 March 2011 No
Probably Probably Unlikely 8 March 2011 No
Probably Probably Unlikely 5 April 2011 Yes 11 April 2011 6
Unrelated Unrelated Unrelated 5 April 2011 No
Probably Probably Probably 18 April 2011 No
Probably Probably Unlikely 5 April 2011 No
Probably Probably Unlikely 3 May 2011 Yes 9 May 2011 6
Unrelated Unrelated Unrelated 3 May 2011 No
Probably Probably Unlikely 16 May 2011 No
Probably Probably Unlikely Yes 31 May 2011
Probably Probably Unlikely 3 May 2011 No
Probably Probably Unlikely 31 May 2011 Yes 6 June 2011 6
Unrelated Unrelated Probably 31 May 2011 No
Probably Probably Unlikely 31 May 2011 Yes 27 June 2011 27
Probably Probably Unlikely 31 May 2011 No
Probably Probably Possibly 26 January 2011 Yes 5 February 2011 10
Possibly Possibly Unlikely 29 January 2011 Yes 5 February 2011 7
Probably Probably Unrelated 29 January 2011 Yes 30 January 2011 1
Possibly Possibly Unrelated 27 January 2011 No
Unlikely Unlikely Unlikely 31 January 2011 Yes 5 February 2011 5
Probably Probably Possibly 25 February 2011 Yes 3 March 2011 6
Probably Probably Unrelated 28 February 2011 Yes 1 March 2011 1
Possibly Possibly Unlikely 25 February 2011 Yes 28 February 2011 3
Possibly Possibly Unlikely 8 March 2011 Yes 14 March 2011 6
Possibly Possibly Probably 27 January 2011 Yes 28 February 2011 32
Possibly Possibly Probably 1 March 2011 Yes 26 March 2011 25
Probably Probably Possibly 25 March 2011 Yes 29 March 2011 4
Probably Probably Possibly 27 March 2011 No
Possibly Possibly Unlikely 2 April 2011 No
Possibly Possibly Unlikely 5 April 2011 No
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCM-miniR Neutropenia 2 3 Possibly
FCM-miniR Neuropathy (sensory) 1 3 Possibly
FCM-miniR Nausea 1 4 Probably
FCM-miniR Cough 1 4 Possibly
FCM-miniR Neutropenia 4 4 Almost certainly
FCM-miniR Headache 2 4 Unlikely
FCM-miniR Constipation 2 4 Possibly
FCM-miniR Vomiting 1 4 Probably
FCM-miniR Nausea 1 5 Probably
FCM-miniR Headache 2 5 Unlikely
FCM-miniR Vomiting 1 5 Probably
FCM-miniR Neutropenia 3 5 Probably
FCM-miniR Nausea 1 6 Probably
FCM-miniR Headache 1 6 Unlikely
FCM-miniR Vomiting 1 6 Probably
FCM-miniR Dizziness 2 6 Possibly
FCM-miniR Neutropenia 4 6 Probably
FCM-miniR Thrombocytopenia 4 6 Probably
FCM-miniR Mucositis/thrush 2 6 Probably
FCM-miniR Other AE description Loss of sense
of smell
1 6 Possibly
FCM-miniR Dry skin/erythema 1 6 Possibly
63 FCM-miniR Anaemia 1 1 Almost certainly
FCM-miniR Thrombocytopenia 1 1 Almost certainly
FCM-miniR Neutropenia 3 2 Almost certainly
FCM-miniR Anaemia 2 4 Almost certainly
FCM-miniR Neutropenia 3 4 Almost certainly
FCM-miniR Neutropenia 1 6 Almost certainly
64 FCM-miniR Nausea 2 1 Almost certainly
FCM-miniR Nausea 2 2 Almost certainly
FCM-miniR Other AE description Restlessness 2 2 Unrelated
FCM-miniR Nausea 2 3 Almost certainly
FCM-miniR Nausea 2 5 Almost certainly
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Possibly Possibly Probably 15 April 2011 No
Unlikely Probably Unrelated 24 March 2011 Yes 27 March 2011 3
Probably Probably Possibly 22 April 2011 Yes 24 May 2011 32
Possibly Possibly Possibly 21 April 2011 Yes 13 May 2011 22
Almost certainly Almost certainly Unlikely 27 April 2011 Yes 16 May 2011 19
Unlikely Unlikely Unlikely 13 May 2011 Yes 27 May 2011 14
Possibly Possibly Unlikely 27 January 2011 Yes 20 April 2011 83
Probably Probably Unlikely 22 May 2011 Yes 24 May 2011 2
Probably Probably Possibly 3 June 2011 Yes 25 June 2011 22
Unlikely Unlikely Unlikely 11 June 2011 Yes 25 June 2011 14
Probably Probably Unlikely 7 June 2011 Yes 21 June 2011 14
Probably Probably Possibly 8 June 2011 Yes 28 June 2011 20
Probably Probably Possibly 29 June 2011 Yes 10 July 2011 11
Unlikely Unlikely Unlikely 30 June 2011 Yes 14 July 2011 14
Probably Probably Unlikely 1 July 2011 Yes 1 July 2011 0
Possibly Probably Unlikely 2 July 2011 Yes 19 July 2011 17
Probably Probably Possibly 6 July 2011 Yes 13 July 2011 7
Probably Probably Possibly 6 July 2011 No
Probably Probably Possibly 9 July 2011 No
Possibly Possibly Possibly 7 July 2011 No
Possibly Possibly Probably 17 July 2011 No
Almost certainly Almost certainly Almost
certainly
30 September 2011 No
Almost certainly Almost certainly Almost
certainly
30 September 2011 No
Almost certainly Almost certainly Almost
certainly
30 September 2011 Yes 7 October 2011 7
Almost certainly Almost certainly Almost
certainly
9 January 2012 No
Almost certainly Almost certainly Almost
certainly
11 January 2012 No
Almost certainly Almost certainly Almost
certainly
9 December 2011 Yes 12 March 2012 94
Almost certainly Almost certainly Unrelated 12 February 2011 Yes 18 February 2011 6
Almost certainly Almost certainly Unrelated 9 March 2011 Yes 15 March 2011 6
Unrelated Unrelated Unrelated 9 March 2011 Yes 15 March 2011 6
Almost certainly Almost certainly Unlikely 8 April 2011 Yes
Almost certainly Almost certainly Unlikely 1 June 2011 Yes 28 July 2011 57
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
65 FCM-miniR Fatigue 1 1 Almost certainly
FCM-miniR Anaemia 3 1 Possibly
FCM-miniR Dry skin/erythema 1 3 Unlikely
FCM-miniR Nausea 1 4 Possibly
FCM-miniR Neutropenia 2 4 Almost certainly
FCM-miniR Nausea 1 5 Possibly
FCM-miniR Thrombocytopenia 1 5 Almost certainly
FCM-miniR Anaemia 2 5 Possibly
FCM-miniR Neutropenia 3 6 Almost certainly
FCM-miniR Anaemia 4 6 Probably
69 FCM-miniR Neutropenia 4 1 Almost certainly
FCM-miniR Thrombocytopenia 1 1 Almost certainly
FCM-miniR Diarrhoea 1 1 Unlikely
FCM-miniR Diarrhoea 1 3 Possibly
FCM-miniR Neutropenia 2 4 Probably
FCM-miniR Fatigue 1 4 Probably
FCM-miniR Neutropenia 3 5 Probably
71 FCM-miniR Fatigue 1 1 Unrelated
FCM-miniR Cough 1 1 Unlikely
FCM-miniR Anaemia 1 1 Unrelated
FCM-miniR Vomiting 1 3 Almost certainly
FCM-miniR Diarrhoea 2 3 Possibly
FCM-miniR Nausea 3 4 Almost certainly
FCM-miniR Vomiting 1 4 Almost certainly
FCM-miniR Alopecia 1 5 Possibly
FCM-miniR Nausea 1 6 Almost certainly
FCM-miniR Diarrhoea 1 6 Possibly
73 FCM-miniR Neutropenia 3 1 Possibly
FCM-miniR Nausea 1 1 Probably
FCM-miniR Vomiting 1 1 Probably
FCM-miniR Neutropenia 3 3 Possibly
FCM-miniR Nausea 1 3 Almost certainly
FCM-miniR Neutropenia 1 4 Almost certainly
FCM-miniR Neutropenia 4 5 Almost certainly
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Almost certainly Unlikely 23 February 2011 Yes 3 March 2011 8
Possibly Possibly Unlikely 28 February 2011 Yes 18 March 2011 18
Unlikely Unlikely Unlikely 22 April 2011 No
Possibly Possibly Unlikely 15 April 2011 Yes 17 May 2011 32
Almost certainly Almost certainly Unlikely 12 May 2011 No
Possibly Possibly Unlikely 10 June 2011 Yes 15 June 2011 5
Almost certainly Almost certainly Unlikely 10 June 2011 Yes 11 July 2011 31
Possibly Possibly Unlikely 8 July 2011 Yes 11 July 2011 3
Almost certainly Almost certainly Unlikely 20 June 2011 Yes 15 July 2011 25
Probably Probably Unlikely 22 August 2011 No
Almost certainly Almost certainly Almost
certainly
10 May 2011 Yes 16 May 2011 6
Almost certainly Almost certainly Almost
certainly
11 May 2011 Yes 16 May 2011 5
Unlikely Unlikely Unlikely 7 May 2011 Yes 16 May 2011 9
Possibly Possibly Possibly 2 July 2011 Yes 7 July 2011 5
Probably Probably Probably 19 July 2011 Yes 12 September 2011 55
Probably Probably Probably 7 June 2011 Yes 20 July 2011 43
Probably Probably Probably 16 August 2011 Yes 9 September 2011 24
Unrelated Unrelated Unrelated No
Unlikely Unlikely Unlikely No
Unrelated Unrelated Unrelated 11 August 2010 No
Almost certainly Almost certainly Unlikely Yes 5 May 2011
Possibly Possibly Possibly 1 May 2011 Yes 5 May 2011 4
Almost certainly Almost certainly Unlikely 22 May 2011 Yes 16 June 2011 25
Almost certainly Almost certainly Unlikely 22 May 2011 Yes 16 June 2011 25
Possibly Possibly Unlikely No
Almost certainly Almost certainly Unlikely Yes 11 August 2011
Possibly Possibly Possibly Yes 11 August 2011
Possibly Almost certainly Possibly 4 April 2011 Yes 13 April 2011 9
Probably Almost certainly Unlikely 21 March 2011 Yes 25 March 2011 4
Probably Almost certainly Unlikely 21 March 2011 Yes 22 March 2011 1
Almost certainly Possibly Possibly 26 May 2011 Yes 3 June 2011 8
Possibly Possibly Possibly 19 May 2011 Yes 22 May 2011 3
Almost certainly Probably Probably 11 July 2011 No
Almost certainly Probably Probably 19 July 2011 No
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCM-miniR Nausea 2 5 Probably
FCM-miniR Rigors 1 5 Probably
FCM-miniR Anorexia/cachexia 2 5 Almost certainly
75 FCM-miniR Rash/flushing 1 1 Unlikely
FCM-miniR Pruritus 2 1 Unlikely
FCM-miniR Neutropenia 4 2 Probably
FCM-miniR Anaemia 2 2 Probably
FCM-miniR Thrombocytopenia 1 2 Possibly
FCM-miniR Anaemia 3 3 Probably
FCM-miniR Mucositis/thrush 1 4 Probably
FCM-miniR Pruritus 1 4 Unlikely
FCM-miniR Anaemia 2 4 Probably
FCM-miniR Neutropenia 4 4 Probably
FCM-miniR Anaemia 2 5 Probably
FCM-miniR Fever 1 6 Unrelated
FCM-miniR Anaemia 2 6 Probably
FCM-miniR Thrombocytopenia 1 6 Possibly
FCM-miniR Neutropenia 2 6 Probably
77 FCM-miniR Vomiting 1 1 Possibly
FCM-miniR Abdominal pain/
bloating
1 1 Unlikely
FCM-miniR Nausea 1 2 Almost certainly
FCM-miniR Abdominal pain/
bloating
1 3 Possibly
FCM-miniR Nausea 3 3 Almost certainly
FCM-miniR Nausea 1 3 Almost certainly
FCM-miniR Dehydration 2 3 Almost certainly
FCM-miniR Vomiting 2 3 Almost certainly
FCM-miniR Thrombocytopenia 1 3 Almost certainly
FCM-miniR Neutropenia 1 4 Almost certainly
FCM-miniR Thrombocytopenia 2 4 Almost certainly
FCM-miniR Fatigue 2 5 Possibly
FCM-miniR Thrombocytopenia 1 5 Almost certainly
Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Probably Probably Almost
certainly
19 July 2011 Yes 22 July 2011 3
Probably Probably Probably 19 July 2011 Yes 22 July 2011 3
Almost certainly Almost certainly Almost
certainly
11 July 2011 No
Unlikely Unlikely Unlikely 8 April 2011 Yes 11 April 2011 3
Unlikely Unlikely Unlikely 11 April 2011 Yes 12 April 2011 1
Probably Probably Possibly 26 April 2011 Yes 2 May 2011 6
Probably Probably Possibly 20 April 2011 Yes 3 May 2011 13
Possibly Possibly Possibly 1 May 2011 Yes 5 May 2011 4
Missing Probably Missing 4 May 2011 No
Probably Unlikely Unlikely 13 June 2011 Yes 28 June 2011 15
Unlikely Unlikely Unlikely 24 May 2011 Yes 17 June 2011 24
Probably Probably Possibly 27 June 2011 Yes 11 July 2011 14
Probably Probably Possibly 20 June 2011 Yes 7 July 2011 17
Probably Probably Unrelated 27 July 2011 Yes 3 August 2011 7
Unrelated Unrelated Unrelated 16 August 2011 Yes 24 August 2011 8
Probably Probably Possibly 17 August 2011 No
Possibly Possibly Probably 10 August 2011 No
Probably Probably Possibly 31 August 2011 No
Possibly Possibly Unlikely 20 April 2011 Yes 23 April 2011 3
Unlikely Unlikely Unlikely 24 April 2011 Yes 25 April 2011 1
Almost certainly Almost certainly Unlikely 21 May 2011 Yes 23 May 2011 2
Possibly Possibly Unlikely 22 May 2011 Yes 13 June 2011 22
Almost certainly Almost certainly Unlikely 18 June 2011 Yes 21 June 2011 3
Almost certainly Almost certainly Unlikely 22 June 2011 No
Almost certainly Almost certainly Unlikely 18 June 2011 Yes 22 June 2011 4
Almost certainly Almost certainly Unlikely 19 June 2011 Yes 22 June 2011 3
Almost certainly Almost certainly Unlikely 13 June 2011 No
Almost certainly Almost certainly Unlikely 1 September 2011 Yes 7 September 2011 6
Almost certainly Almost certainly Unlikely 13 July 2011 No
Possibly Possibly Unlikely 26 August 2011 Yes 7 September 2011 12
Almost certainly Almost certainly Unlikely 10 August 2011 No
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
79 FCM-miniR Pruritus 1 3 Unlikely
FCM-miniR Pruritus 1 3 Unlikely
FCM-miniR Neutropenia 3 3 Unlikely
FCM-miniR Neutropenia 3 3 Unlikely
FCM-miniR Neutropenia 3 4 Probably
FCM-miniR Infections (not
neutropenic sepsis)
2 4 Probably
FCM-miniR Neutropenia 3 5 Almost certainly
80 FCM-miniR Infections (not
neutropenic sepsis)
3 1 Probably
FCM-miniR Fatigue 1 1 Probably
FCM-miniR Neutropenia 4 2 Probably
FCM-miniR Nausea 2 2 Probably
FCM-miniR Vomiting 2 2 Probably
FCM-miniR Alopecia 1 2 Probably
FCM-miniR Anorexia/cachexia 1 2 Probably
FCM-miniR Nausea 2 3 Probably
FCM-miniR Fatigue 2 3 Probably
FCM-miniR Anxiety/depression 1 3 Unlikely
FCM-miniR Pruritus 1 3 Possibly
FCM-miniR Rash/flushing 2 3 Possibly
FCM-miniR Fever 1 3 Unlikely
FCM-miniR Neutropenia 3 4 Probably
FCM-miniR Infections (not
neutropenic sepsis)
3 4 Probably
FCM-miniR Nausea 2 4 Probably
FCM-miniR Vomiting 1 4 Probably
FCM-miniR Fatigue 1 4 Probably
FCM-miniR Anxiety/depression 1 4 Unrelated
FCM-miniR Rash/flushing 2 4 Probably
FCM-miniR Neutropenia 1 6 Probably
FCM-miniR Anxiety/depression 2 6 Unrelated
81 FCM-miniR Neutropenia 3 1 Possibly
FCM-miniR Anaemia 3 1 Possibly
FCM-miniR Vomiting 2 1 Almost certainly
FCM-miniR Nausea 2 1 Almost certainly
FCM-miniR Thrombocytopenia 1 1 Almost certainly
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
294
Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unlikely Unlikely Unlikely 2 July 2011 Yes 9 July 2011 7
Unlikely Unrelated Unlikely 13 July 2011 Yes 20 July 2011 7
Unlikely Unrelated Unlikely 23 June 2011 Yes 6 July 2011 13
Unlikely Unrelated Unlikely 6 July 2011 Yes 20 July 2011 14
Probably Probably Probably 17 August 2011 Yes 31 August 2011 14
Probably Probably Probably 17 August 2011 Yes 31 August 2011 14
Almost certainly Almost certainly Unrelated 28 September 2011 Yes 5 October 2011 7
Probably Probably Probably 5 July 2011 Yes 18 July 2011 13
Probably Probably Probably 17 July 2011 No
Probably Probably Probably 2 August 2011 Yes 16 August 2011 14
Probably Probably Probably 21 July 2011 Yes 24 July 2011 3
Probably Probably Probably 21 July 2011 Yes 24 July 2011 3
Probably Probably Probably 24 July 2011 No
Probably Probably Probably 21 July 2011 Yes 24 July 2011 3
Probably Probably Probably 21 August 2011 Yes 28 August 2011 7
Probably Probably Probably 22 August 2011 Yes 2 September 2011 11
Unlikely Unlikely Unlikely 28 August 2011 Yes 2 September 2011 5
Unrelated Unrelated Unrelated 31 August 2011 Yes 14 September 2011 14
Unrelated Unrelated Unrelated 31 August 2011 Yes 1 September 2011 1
Unlikely Unlikely Unlikely 31 August 2011 Yes 1 September 2011 1
Probably Probably Probably 4 October 2011 Yes 5 October 2011 1
Probably Probably Probably 1 October 2011 Yes 6 October 2011 5
Probably Unrelated Unrelated 20 September 2011 Yes 22 September 2011 2
Probably Unrelated Unrelated 20 September 2011 Yes 20 September 2011 0
Probably Probably Probably 20 September 2011 Yes 6 October 2011 16
Unrelated Unrelated Unrelated 1 October 2011 No
Unlikely Unlikely Unlikely 1 October 2011 Yes 2 October 2011 1
Probably Probably Probably 7 December 2011 No
Unrelated Unrelated Unrelated 7 December 2011 No
Probably Possibly Possibly 24 May 2011 Yes 6 June 2011 13
Probably Possibly Possibly 3 June 2011 Yes 7 June 2011 4
Possibly Possibly Possibly 13 May 2011 Yes 16 May 2011 3
Possibly Possibly Possibly 13 May 2011 Yes 16 May 2011 3
Probably Almost certainly Unlikely 24 May 2011 Yes 9 June 2011 16
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCM-miniR Anaemia 2 1 Possibly
FCM-miniR Anaemia 3 2 Possibly
FCM-miniR Neutropenia 4 2 Possibly
FCM-miniR Neutropenia 4 3 Probably
FCM-miniR Nausea 2 3 Possibly
FCM-miniR Anaemia 3 3 Possibly
FCM-miniR Thrombocytopenia 1 3 Almost certainly
FCM-miniR Anaemia 2 3 Possibly
FCM-miniR Neutropenia 4 4 Probably
FCM-miniR Thrombocytopenia 1 4 Almost certainly
FCM-miniR Thrombocytopenia 2 4 Almost certainly
FCM-miniR Thrombocytopenia 1 4 Almost certainly
FCM-miniR Anaemia 2 4 Possibly
FCM-miniR Anaemia 2 4 Possibly
83 FCM-miniR Vomiting 1 1 Probably
FCM-miniR Headache 1 1 Possibly
FCM-miniR Neutropenia 4 2 Almost certainly
FCM-miniR Nausea 2 3 Almost certainly
FCM-miniR Vomiting 2 3 Almost certainly
FCM-miniR Infusional reaction 1 3 Unlikely
FCM-miniR Vomiting 2 4 Almost certainly
FCM-miniR Rash/flushing 2 4 Unlikely
FCM-miniR Nausea 2 4 Almost certainly
FCM-miniR Vomiting 2 5 Almost certainly
FCM-miniR Fatigue 2 5 Unlikely
FCM-miniR Dyspnoea 1 5 Unlikely
FCM-miniR Nausea 2 5 Almost certainly
FCM-miniR Constipation 1 5 Unlikely
FCM-miniR Diarrhoea 1 6 Probably
85 FCM-miniR Thrombocytopenia 2 1 Possibly
FCM-miniR Anaemia 2 2 Possibly
FCM-miniR Neutropenia 3 2 Possibly
FCM-miniR Anaemia 1 3 Possibly
FCM-miniR Thrombocytopenia 1 3 Possibly
Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Probably Possibly Possibly 7 June 2011 Yes 9 June 2011 2
Probably Possibly Possibly 29 June 2011 Yes 7 July 2011 8
Probably Possibly Possibly 29 June 2011 Yes 7 July 2011 8
Almost certainly Probably Probably 14 July 2011 Yes 21 July 2011 7
Possibly Possibly Almost
certainly
7 July 2011 Yes 21 July 2011 14
Probably Possibly Possibly 21 July 2011 Yes 2 August 2011 12
Probably Almost certainly Unlikely 29 June 2011 Yes 14 July 2011 15
Probably Possibly Possibly 7 July 2011 Yes 21 July 2011 14
Almost certainly Probably Probably 15 August 2011 Yes 24 August 2011 9
Probably Almost certainly Unlikely 15 August 2011 Yes 20 August 2011 5
Probably Almost certainly Unlikely 20 August 2011 Yes 21 August 2011 1
Probably Almost certainly Unlikely 21 August 2011 Yes 8 September 2011 18
Probably Possibly Possibly 2 August 2011 Yes 18 August 2011 16
Probably Possibly Possibly 19 August 2011 Yes 8 September 2011 20
Probably Probably Unlikely 15 May 2011 Yes 15 May 2011 0
Possibly Possibly Unlikely 15 May 2011 Yes 15 May 2011 0
Almost certainly Almost certainly Probably 20 June 2011 Yes 4 July 2011 14
Almost certainly Almost certainly Unlikely 6 July 2011 Yes 9 July 2011 3
Almost certainly Almost certainly Unlikely 6 July 2011 Yes 9 July 2011 3
Unlikely Unlikely Unlikely 1 August 2011 No
Almost certainly Almost certainly Almost
certainly
2 August 2011 Yes
Unlikely Unlikely Unlikely 1 August 2011 No
Almost certainly Almost certainly Almost
certainly
2 August 2011 Yes
Almost certainly Almost certainly Unlikely 9 September 2011 Yes 11 September 2011 2
Unlikely Unlikely Unlikely No
Unlikely Unlikely Unlikely No
Almost certainly Almost certainly Unlikely 9 September 2011 Yes
Unlikely Unlikely Unlikely 11 September 2011 Yes
Probably Probably Unlikely No
Possibly Possibly Unlikely 23 June 2011 No
Possibly Possibly Unlikely 23 June 2011 Yes 18 August 2011 56
Possibly Possibly Unlikely 23 June 2011 Yes 18 July 2011 25
Possibly Possibly Unlikely 18 July 2011 No
Possibly Possibly Unlikely 18 July 2011 No
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCM-miniR Neutropenia 1 3 Possibly
FCM-miniR Fatigue 2 5 Possibly
FCM-miniR Abnormal electrolytes 1 5 Unlikely
FCM-miniR Neutropenia 3 6 Almost certainly
FCM-miniR Neutropenia 2 6 Almost certainly
FCM-miniR Fatigue 1 6 Possibly
86 FCM-miniR Thrombocytopenia 2 1 Unlikely
FCM-miniR Anaemia 1 1 Almost certainly
FCM-miniR Neutropenia 4 1 Almost certainly
FCM-miniR Anaemia 1 2 Almost certainly
FCM-miniR Neutropenia 4 2 Almost certainly
FCM-miniR Vomiting 1 2 Almost certainly
FCM-miniR Neutropenia 1 3 Almost certainly
FCM-miniR Anaemia 2 3 Almost certainly
FCM-miniR Fatigue 1 3 Almost certainly
FCM-miniR Neutropenia 4 4 Possibly
FCM-miniR Arrhythmias/
palpitation
1 4 Unlikely
FCM-miniR Fatigue 2 5 Probably
FCM-miniR Anaemia 2 5 Probably
FCM-miniR Thrombocytopenia 2 5 Possibly
FCM-miniR Neutropenia 4 5 Almost certainly
FCM-miniR Nausea 1 5 Almost certainly
FCM-miniR Anaemia 1 5 Unlikely
FCM-miniR Thrombocytopenia 2 6 Possibly
FCM-miniR Fatigue 2 6 Almost certainly
90 FCM-miniR Neutropenia 3 5 Probably
FCM-miniR Neutropenia 2 6 Probably
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Possibly Possibly Unlikely 18 July 2011 No
Possibly Possibly Unlikely 18 August 2011 Yes 29 September 2011 42
Unlikely Unlikely Unlikely 15 September 2011 Yes 13 October 2011 28
Almost certainly Almost certainly Unlikely 13 October 2011 Yes 20 October 2011 7
Almost certainly Almost certainly Unlikely 20 October 2011 Yes 10 November 2011 21
Possibly Possibly Unlikely 20 October 2011 Yes 10 November 2011 21
Unlikely Unlikely Unlikely No
Almost certainly Almost certainly Almost
certainly
31 May 2011 No
Almost certainly Almost certainly Almost
certainly
15 June 2011 No
Almost certainly Almost certainly Almost
certainly
13 July 2011 No
Almost certainly Almost certainly Almost
certainly
13 July 2011 Yes 25 July 2011 12
Almost certainly Almost certainly Almost
certainly
30 June 2011 Yes 30 June 2011 0
Almost certainly Almost certainly Almost
certainly
17 August 2011 Yes 19 August 2011 2
Almost certainly Almost certainly Almost
certainly
17 August 2011 No
Almost certainly Almost certainly Almost
certainly
19 August 2011 No
Possibly Possibly Possibly 22 August 2011 Yes 23 September 2011 32
Unlikely Unlikely Unlikely 21 September 2011 Yes 22 September 2011 1
Probably Probably Probably 4 October 2011 No
Probably Probably Probably 24 May 2011 No
Possibly Possibly Possibly 21 September 2011 No
Almost certainly Almost certainly Almost
certainly
19 October 2011 No
Almost certainly Almost certainly Almost
certainly
5 October 2011 Yes 19 October 2011 14
Unlikely Unlikely Unlikely 19 October 2011 No
Possibly Possibly Possibly 1 September 2011 No
Almost certainly Almost certainly Almost
certainly
1 November 2011 No
Probably Probably Probably 6 October 2011 No
Probably Probably Probably 8 November 2011 No
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
94 FCM-miniR Thrombocytopenia 1 1 Almost certainly
FCM-miniR Anaemia 3 1 Possibly
FCM-miniR Nausea 1 1 Almost certainly
FCM-miniR Vomiting 1 1 Possibly
FCM-miniR Thrombocytopenia 1 2 Almost certainly
FCM-miniR Rash/flushing 1 2 Unlikely
FCM-miniR Nausea 1 3 Almost certainly
FCM-miniR Vomiting 1 3 Probably
FCM-miniR Anaemia 2 3 Almost certainly
FCM-miniR Thrombocytopenia 1 3 Almost certainly
FCM-miniR Thrombocytopenia 3 4 Probably
FCM-miniR Nausea 1 4 Almost certainly
FCM-miniR Vomiting 1 4 Almost certainly
FCM-miniR Rash/flushing 1 4 Possibly
FCM-miniR Neutropenia 4 4 Almost certainly
95 FCM-miniR Nausea 1 1 Possibly
FCM-miniR Fatigue 1 1 Unlikely
FCM-miniR Fatigue 1 2 Unlikely
FCM-miniR Other AE description Weight gain 1 2 Unlikely
FCM-miniR Infusional reaction 3 2 Almost certainly
FCM-miniR Fatigue 2 4 Unlikely
FCM-miniR Dry skin/erythema 1 5 Possibly
FCM-miniR Thrombocytopenia 3 6 Probably
FCM-miniR Lymphopenia 4 6 Probably
FCM-miniR Neutropenia 4 6 Probably
FCM-miniR Anaemia 3 6 Probably
FCM-miniR Haematuria 1 6 Probably
FCM-miniR Fever 1 6 Probably
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Almost certainly Almost
certainly
22 August 2011 No
Possibly Possibly Possibly No
Almost certainly Almost certainly Almost
certainly
13 August 2011 Yes 13 August 2011 0
Possibly Possibly Possibly 5 September 2011 Yes 5 September 2011 0
Almost certainly Almost certainly Almost
certainly
26 September 2011 Yes 10 October 2011 14
Unlikely Unlikely Unlikely 28 September 2011 Yes 28 September 2011 0
Almost certainly Almost certainly Almost
certainly
12 October 2011 Yes 12 October 2011 0
Probably Probably Unlikely 12 October 2011 Yes 12 October 2011 0
Almost certainly Almost certainly Almost
certainly
28 September 2011 No
Almost certainly Almost certainly Almost
certainly
24 October 2011 No
Probably Probably Probably 31 October 2011 No
Almost certainly Almost certainly Almost
certainly
12 November 2011 Yes 13 November 2011 1
Almost certainly Almost certainly Almost
certainly
12 November 2011 Yes 13 November 2011 1
Possibly Possibly Possibly 11 November 2011 Yes 20 November 2011 9
Almost certainly Almost certainly Almost
certainly
Yes 5 December 2011
Possibly Possibly Unlikely 27 July 2011 Yes 29 July 2011 2
Unlikely Unlikely Unlikely 27 July 2011 Yes 27 July 2011 0
Unlikely Unlikely Unlikely 24 August 2011 No
Unlikely Unlikely Unlikely Yes
Almost certainly Almost certainly Almost
certainly
8 August 2011 No
Unlikely Unlikely Unlikely No
Possibly Possibly Unlikely No
Probably Probably Probably 16 January 2012 No
Probably Probably Probably 8 August 2011 No
Probably Probably Probably 1 January 2012 Yes 16 January 2012 15
Probably Probably Probably 1 January 2012 Yes 4 January 2012 3
Probably Probably Probably Yes
Probably Probably Probably 31 December 2011 Yes 1 January 2012 1
continued
DOI: 10.3310/hta21280 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 28
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Howard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
301
TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
96 FCM-miniR Nausea 1 1 Probably
FCM-miniR Fatigue 1 1 Probably
FCM-miniR Neutropenia 4 1 Almost certainly
FCM-miniR Thrombocytopenia 3 1 Almost certainly
FCM-miniR Anaemia 2 1 Almost certainly
FCM-miniR Diarrhoea 3 2 Almost certainly
97 FCM-miniR Nausea 2 1 Almost certainly
FCM-miniR Vomiting 2 1 Almost certainly
FCM-miniR Diarrhoea 1 1 Almost certainly
FCM-miniR Fatigue 2 1 Possibly
FCM-miniR Cystitis 2 2 Unlikely
FCM-miniR Infections (not
neutropenic sepsis)
2 2 Unlikely
FCM-miniR Vomiting 1 2 Almost certainly
FCM-miniR Nausea 2 2 Almost certainly
FCM-miniR Diarrhoea 1 2 Almost certainly
FCM-miniR Infusional reaction 2 2 Unrelated
FCM-miniR Thrombocytopenia 1 2 Unlikely
FCM-miniR Thrombocytopenia 2 3 Possibly
FCM-miniR Vomiting 1 3 Probably
FCM-miniR Nausea 1 3 Probably
FCM-miniR Constipation 1 3 Probably
FCM-miniR Constipation 1 3 Probably
FCM-miniR Ophthalmic infections 1 3 Unlikely
FCM-miniR Fatigue 2 4 Possibly
FCM-miniR Constipation 1 4 Probably
FCM-miniR Constipation 1 5 Probably
FCM-miniR Vomiting 1 5 Probably
FCM-miniR Ophthalmic infections 1 5 Unlikely
FCM-miniR Constipation 1 6 Probably
99 FCM-miniR Allergic reaction 3 1 Unrelated
FCM-miniR Anaemia 1 1 Almost certainly
FCM-miniR Thrombocytopenia 2 1 Almost certainly
FCM-miniR Vomiting 2 2 Probably
FCM-miniR Nausea 2 2 Probably
FCM-miniR Neutropenia 1 2 Almost certainly
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Probably Probably Possibly 3 August 2011 Yes 12 August 2011 9
Possibly Possibly Possibly 18 August 2011 No
Possibly Almost certainly Possibly 25 August 2011 No
Possibly Possibly Possibly 25 August 2011 No
Almost certainly Possibly Possibly 25 August 2011 No
Almost certainly Almost certainly Probably 15 October 2011 No
Almost certainly Almost certainly Unlikely 18 August 2011 Yes 26 August 2011 8
Almost certainly Almost certainly Unlikely 18 August 2011 Yes 24 August 2011 6
Possibly Possibly Unlikely 18 August 2011 Yes 25 August 2011 7
Possibly Possibly Unlikely 18 August 2011 Yes 31 August 2011 13
Unlikely Unlikely Unlikely 8 October 2011 Yes 13 October 2011 5
Unlikely Unlikely Unlikely 8 October 2011 Yes 13 October 2011 5
Unlikely Probably Unlikely 22 September 2011 Yes 26 September 2011 4
Unlikely Probably Unlikely 22 September 2011 Yes 26 September 2011 4
Unlikely Unlikely Unlikely 25 September 2011 Yes 25 September 2011 0
Unrelated Unrelated Almost
certainly
20 September 2011 Yes 20 September 2011 0
Unlikely Unlikely Unlikely 3 March 2010 No
Possibly Possibly Possibly 17 October 2011 No
Probably Probably Probably 28 October 2011 Yes 30 October 2011 2
Probably Probably Probably 27 October 2011 Yes 1 November 2011 5
Probably Probably Probably 29 October 2011 Yes 31 October 2011 2
Probably Probably Probably 15 November 2011 Yes 17 November 2011 2
Unlikely Unlikely Unlikely 10 November 2011 Yes 15 November 2011 5
Possibly Possibly Unlikely 10 December 2011 Yes 12 December 2011 2
Probably Probably Probably 1 December 2011 Yes 2 December 2011 1
Probably Probably Probably 29 January 2012 Yes 31 January 2012 2
Probably Probably Probably 26 January 2012 Yes 27 January 2012 1
Unlikely Unlikely Unlikely 9 February 2012 Yes 12 February 2012 3
Probably Probably Probably 23 February 2012 Yes 24 February 2012 1
Unrelated Possibly Probably 10 August 2011 Yes 10 August 2011 0
Almost certainly Almost certainly Possibly 10 June 2011 No
Almost certainly Almost certainly Possibly 5 September 2011 No
Probably Unlikely Unlikely 16 September 2011 Yes 19 September 2011 3
Probably Unlikely Unlikely 16 September 2011 Yes 19 September 2011 3
Almost certainly Almost certainly Possibly 14 September 2011 Yes 12 October 2011 28
continued
DOI: 10.3310/hta21280 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 28
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Howard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
303
TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCM-miniR Neutropenia 1 2 Almost certainly
FCM-miniR Vomiting 2 3 Almost certainly
FCM-miniR Nausea 1 3 Almost certainly
FCM-miniR Neutropenia 2 3 Almost certainly
FCM-miniR Nausea 1 4 Probably
FCM-miniR Fatigue 1 4 Probably
FCM-miniR Mucositis/thrush 1 4 Probably
FCM-miniR Neutropenia 3 4 Almost certainly
FCM-miniR Thrombocytopenia 1 4 Almost certainly
FCM-miniR Vomiting 1 4 Probably
FCM-miniR Nausea 2 5 Probably
FCM-miniR Vomiting 2 5 Probably
FCM-miniR Thrombocytopenia 1 5 Almost certainly
FCM-miniR Dyspnoea 1 5 Almost certainly
FCM-miniR Thrombocytopenia 2 5 Almost certainly
FCM-miniR Anaemia 2 5 Almost certainly
100 FCM-miniR Vomiting 2 2 Probably
FCM-miniR Nausea 2 2 Probably
FCM-miniR Nausea 2 3 Unlikely
FCM-miniR Back pain 2 3 Unrelated
FCM-miniR Fever 1 4 Possibly
FCM-miniR Infections (not
neutropenic sepsis)
2 4 Possibly
103 FCM-miniR Anorexia/cachexia 1 1 Possibly
FCM-miniR Fatigue 1 1 Probably
FCM-miniR Anorexia/cachexia 1 1 Possibly
FCM-miniR Anaemia 1 2 Probably
FCM-miniR Rash/flushing 2 4 Unrelated
FCM-miniR Infections (not
neutropenic sepsis)
2 6 Possibly
106 FCM-miniR Neutropenia 3 1 Possibly
FCM-miniR Infections (not
neutropenic sepsis)
1 5 Unlikely
FCM-miniR Sore throat 1 6 Unlikely
FCM-miniR Neutropenia 3 6 Possibly
FCM-miniR Cough 1 6 Unlikely
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Almost certainly Unrelated 5 September 2011 Yes 12 October 2011 37
Almost certainly Almost certainly Unlikely 14 October 2011 Yes 17 October 2011 3
Almost certainly Almost certainly Unlikely 14 October 2011 Yes 18 October 2011 4
Almost certainly Almost certainly Unrelated 7 November 2011 No
Probably Probably Unrelated 10 November 2011 Yes 15 November 2011 5
Probably Probably Unrelated 7 December 2011 No
Probably Probably Unrelated 7 December 2011 No
Almost certainly Almost certainly Unrelated 7 December 2011 No
Almost certainly Almost certainly Unrelated 10 September 2011 No
Probably Probably Unrelated 9 November 2011 Yes 13 November 2011 4
Probably Probably Unrelated 7 December 2011 Yes 13 December 2011 6
Probably Probably Unrelated 7 December 2011 Yes 13 December 2011 6
Almost certainly Almost certainly Possibly No
Almost certainly Almost certainly Possibly No
Almost certainly Almost certainly Possibly 3 January 2012 No
Almost certainly Almost certainly Possibly 3 January 2012 No
Probably Unrelated Probably 15 September 2011 Yes 19 September 2011 4
Probably Unrelated Probably 15 September 2011 Yes 19 September 2011 4
Unlikely Unlikely Unlikely 21 October 2011 Yes 10 November 2011 20
Unrelated Unrelated Unrelated 5 November 2011 Yes 12 November 2011 7
Possibly Possibly Possibly 2 December 2011 Yes 18 December 2011 16
Possibly Possibly Possibly 2 December 2011 Yes 18 December 2011 16
Possibly Possibly Unlikely 19 September 2011 No
Probably Possibly Unlikely 26 August 2011 Yes 27 August 2011 1
Possibly Possibly Unlikely No
Probably Probably Probably 19 September 2011 Yes 17 October 2011 28
Unrelated Possibly Unrelated 4 December 2011 No
Possibly Possibly Possibly 18 January 2012 No
Possibly Possibly Possibly 9 September 2011 Yes 27 September 2011 18
Unlikely Unlikely Unlikely 28 January 2012 Yes 7 February 2012 10
Unlikely Unlikely Unlikely 12 March 2012 Yes 19 March 2012 7
Possibly Possibly Possibly 5 April 2012 Yes 8 May 2012 33
Unlikely Unlikely Unlikely 12 March 2012 No
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
108 FCM-miniR Neutropenia 3 1 Almost certainly
FCM-miniR Thrombocytopenia 1 1 Unrelated
FCM-miniR Anaemia 1 1 Probably
FCM-miniR Nausea 1 2 Possibly
FCM-miniR Vomiting 1 2 Possibly
FCM-miniR Neutropenia 4 2 Possibly
FCM-miniR Neutropenia 2 3 Possibly
FCM-miniR Neutropenia 4 4 Possibly
FCM-miniR Thrombocytopenia 1 4 Possibly
FCM-miniR Thrombocytopenia 1 5 Possibly
FCM-miniR Mucositis/thrush 1 6 Probably
FCM-miniR Dyspnoea 2 6 Unlikely
109 FCM-miniR Nausea 2 2 Probably
FCM-miniR Vomiting 2 2 Probably
FCM-miniR Headache 1 2 Unlikely
FCM-miniR Rash/flushing 1 2 Possibly
FCM-miniR Neutropenia 3 3 Almost certainly
FCM-miniR Nausea 2 4 Missing
FCM-miniR Vomiting 2 4 Missing
FCM-miniR Fatigue 1 5 Missing
FCM-miniR Nausea 1 6 Missing
FCM-miniR Fatigue 1 6 Missing
113 FCM-miniR Neutropenia 3 1 Almost certainly
FCM-miniR Anaemia 1 1 Almost certainly
FCM-miniR Neutropenia 1 2 Almost certainly
FCM-miniR Anaemia 1 3 Almost certainly
FCM-miniR Mucositis/thrush 2 4 Possibly
FCM-miniR Gout/hyperuricemia 3 4 Unlikely
FCM-miniR Anaemia 1 4 Almost certainly
FCM-miniR Neutropenia 4 4 Almost certainly
FCM-miniR Gout/Hyperuricemia 2 5 Possibly
FCM-miniR Gout/Hyperuricemia 2 6 Unlikely
114 FCM-miniR Anaemia 3 1 Possibly
FCM-miniR Thrombocytopenia 1 1 Possibly
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
306
Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Probably Possibly Unlikely 24 September 2011 Yes 2 October 2011 8
Unrelated Unrelated Unrelated 15 July 2011 Yes 2 October 2011 79
Probably Possibly Unrelated 9 September 2011 Yes 16 November 2011 68
Possibly Possibly Possibly Yes 16 November 2011
Possibly Possibly Possibly Yes 16 November 2011
Possibly Possibly Possibly No
Possibly Possibly Possibly 21 December 2011 No
Possibly Possibly Possibly 8 January 2012 No
Possibly Possibly Possibly 3 January 2012 Yes 12 January 2012 9
Possibly Possibly Possibly 15 February 2012 No
Probably Probably Probably 3 April 2012 Yes 7 May 2012 34
Unlikely Unlikely Unlikely 10 April 2012 Yes 17 April 2012 7
Probably Probably Unlikely 21 October 2011 Yes 1 December 2011 41
Probably Probably Unlikely 21 October 2011 Yes 1 December 2011 41
Unlikely Unlikely Unlikely 21 October 2011 Yes 26 November 2011 36
Possibly Possibly Possibly 11 November 2011 Yes 12 November 2011 1
Almost certainly Almost certainly Possibly 17 November 2011 Yes 21 December 2011 34
Probably Probably Unlikely 22 December 2011 Yes 31 December 2011 9
Probably Probably Unlikely 22 December 2011 Yes 31 December 2011 9
Probably Probably Unlikely Yes 19 January 2012
Probably Probably Unlikely 18 February 2012 Yes 22 February 2012 4
Probably Probably Unlikely 18 February 2012 Yes 23 February 2012 5
Almost certainly Almost certainly Possibly 30 November 2011 Yes 5 December 2011 5
Almost certainly Almost certainly Possibly 30 November 2011 Yes 5 December 2011 5
Almost certainly Almost certainly Possibly 28 December 2011 No
Almost certainly Almost certainly Possibly 28 December 2011 Yes 1 February 2012 35
Possibly Possibly Unlikely 18 February 2012 Yes 22 February 2012 4
Unlikely Unlikely Unlikely 22 February 2012 Yes 27 February 2012 5
Almost certainly Almost certainly Possibly 29 February 2012 No
Almost certainly Almost certainly Possibly 20 February 2012 Yes 29 February 2012 9
Possibly Possibly Unlikely 22 March 2012 Yes 28 March 2012 6
Unlikely Unlikely Unlikely 21 April 2012 Yes 24 April 2012 3
Possibly Possibly Unrelated 5 December 2011 Yes 4 January 2012 30
Possibly Possibly Unrelated 5 December 2011 Yes 2 April 2012 119
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
115 FCM-miniR Nausea 1 1 Almost certainly
FCM-miniR Constipation 1 1 Probably
FCM-miniR Fatigue 1 1 Probably
FCM-miniR Abdominal pain/
bloating
2 2 Probably
FCM-miniR Neutropenia 1 2 Almost certainly
FCM-miniR Abdominal pain/
bloating
3 3 Probably
FCM-miniR Constipation 1 3 Probably
FCM-miniR Diarrhoea 2 3 Possibly
FCM-miniR Abdominal pain/
bloating
1 3 Probably
FCM-miniR Cystitis 1 3 Unlikely
FCM-miniR Thrombocytopenia 1 4 Almost certainly
FCM-miniR Abdominal pain/
bloating
2 4 Possibly
FCM-miniR Abnormal electrolytes 2 5 Unlikely
FCM-miniR Thrombocytopenia 1 5 Almost certainly
FCM-miniR Abdominal pain/
bloating
2 6 Possibly
FCM-miniR Constipation 1 6 Possibly
FCM-miniR Anorexia/cachexia 2 6 Possibly
FCM-miniR Neutropenia 1 6 Almost certainly
117 FCM-miniR Anaemia 4 1 Unrelated
FCM-miniR Neutropenia 4 1 Probably
FCM-miniR Thrombocytopenia 1 2 Probably
FCM-miniR Nausea 3 5 Almost certainly
FCM-miniR Vomiting 3 5 Almost certainly
FCM-miniR Neutropenia 4 5 Almost certainly
FCM-miniR Thrombocytopenia 1 5 Almost certainly
FCM-miniR Anaemia 2 5 Almost certainly
FCM-miniR Nausea 1 6 Almost certainly
FCM-miniR Neutropenia 3 6 Almost certainly
FCM-miniR Thrombocytopenia 2 6 Almost certainly
FCM-miniR Anaemia 3 6 Almost certainly
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Almost certainly Almost
certainly
5 November 2011 Yes 19 November 2011 14
Probably Probably Unlikely Yes
Probably Probably Unlikely Yes
Probably Probably Unlikely 3 November 2011 Yes 11 November 2011 8
Almost certainly Almost certainly Possibly 28 November 2011 Yes 25 January 2012 58
Probably Probably Unlikely 30 December 2011 Yes 7 January 2012 8
Probably Probably Unlikely 7 January 2012 Yes 10 January 2012 3
Possibly Probably Unlikely 11 January 2012 Yes 12 January 2012 1
Probably Possibly Unlikely 18 January 2012 No
Unlikely Unlikely Unlikely 18 January 2012 Yes 25 January 2012 7
Almost certainly Almost certainly Possibly 28 December 2011 Yes 22 February 2012 56
Possibly Possibly Unlikely 26 January 2012 Yes 30 January 2012 4
Unlikely Unlikely Unlikely 23 February 2012 Yes 23 February 2012 0
Almost certainly Almost certainly Possibly 28 March 2012 No
Possibly Possibly Unlikely 3 April 2012 Yes 8 April 2012 5
Possibly Possibly Unlikely 6 April 2012 Yes 10 April 2012 4
Possibly Possibly Possibly 3 April 2012 Yes 8 April 2012 5
Almost certainly Almost certainly Possibly 27 April 2012 No
Unrelated Probably Unlikely 16 November 2011 No
Probably Probably Unlikely 1 November 2011 No
Probably Probably Unlikely 1 November 2011 Yes 28 December 2011 57
Almost certainly Almost certainly Possibly 8 March 2012 Yes 12 March 2012 4
Almost certainly Almost certainly Possibly 8 March 2012 Yes 12 March 2012 4
Almost certainly Almost certainly Possibly 15 March 2012 No
Almost certainly Almost certainly Possibly 15 March 2012 Yes 28 March 2012 13
Almost certainly Almost certainly Possibly 15 March 2012 No
Almost certainly Almost certainly Possibly 8 April 2012 Yes 12 April 2012 4
Almost certainly Almost certainly Possibly 11 April 2012 No
Almost certainly Almost certainly Possibly 11 April 2012 No
Almost certainly Almost certainly Possibly 11 April 2012 No
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
118 FCM-miniR Fatigue 1 1 Unrelated
FCM-miniR Non-specific pain 1 1 Unrelated
FCM-miniR Nausea 1 2 Probably
FCM-miniR Diarrhoea 1 4 Possibly
FCM-miniR Nausea 1 4 Possibly
FCM-miniR Fatigue 1 5 Possibly
FCM-miniR Nausea 2 5 Possibly
FCM-miniR Vomiting 2 5 Possibly
FCM-miniR Nausea 2 6 Possibly
FCM-miniR Fatigue 1 6 Possibly
119 FCM-miniR Fatigue 2 1 Unlikely
FCM-miniR Nausea 2 1 Almost certainly
FCM-miniR Constipation 1 1 Unlikely
FCM-miniR Anaemia 1 1 Unlikely
FCM-miniR Thrombocytopenia 1 1 Unlikely
FCM-miniR Anaemia 1 2 Probably
FCM-miniR Thrombocytopenia 2 2 Unlikely
FCM-miniR Non-specific pain 2 2 Unlikely
124 FCM-miniR Nausea 2 1 Almost certainly
FCM-miniR Constipation 1 1 Unlikely
FCM-miniR Neutropenia 3 6 Probably
126 FCM-miniR Nausea 1 1 Almost certainly
FCM-miniR Fatigue 1 1 Almost certainly
FCM-miniR Thrombocytopenia 4 1 Unlikely
FCM-miniR Neutropenia 4 1 Almost certainly
FCM-miniR Neutropenia 4 2 Almost certainly
FCM-miniR Neutropenia 1 3 Almost certainly
FCM-miniR Anaemia 1 4 Possibly
FCM-miniR Neutropenia 3 5 Almost certainly
FCM-miniR Neutropenia 1 6 Almost certainly
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unrelated Unrelated Unrelated 3 August 2011 No
Unrelated Unrelated Unrelated Yes 20 November 2011
Probably Probably Possibly 4 December 2011 Yes 7 December 2011 3
Possibly Possibly Unlikely 16 January 2012 Yes 16 January 2012 0
Possibly Possibly Unlikely 31 December 2011 Yes 3 January 2012 3
Possibly Possibly Possibly 26 January 2012 Yes 31 January 2012 5
Possibly Possibly Unlikely 29 January 2012 Yes 2 February 2012 4
Possibly Possibly Unlikely 29 January 2012 Yes 2 February 2012 4
Possibly Possibly Unlikely 26 February 2012 Yes 2 March 2012 5
Possibly Possibly Possibly 26 February 2012 Yes 28 February 2012 2
Almost certainly Unlikely Unlikely 11 November 2011 No
Almost certainly Almost certainly Unlikely 2 December 2011 Yes 7 December 2011 5
Unlikely Unlikely Unlikely 12 November 2011 Yes 20 November 2011 8
Almost certainly Unlikely Unlikely 21 November 2011 No
Probably Unlikely Unlikely 21 November 2011 No
Almost certainly Unlikely Unlikely 9 December 2011 No
Probably Unlikely Unlikely 9 December 2011 No
Unlikely Unlikely Unlikely 1 December 2011 No
Almost certainly Unlikely Unlikely 6 December 2011 Yes 12 December 2011 6
Unlikely Unlikely Unlikely 6 December 2011 Yes 15 December 2011 9
Probably Probably Unlikely 2 May 2012 Yes 15 May 2012 13
Almost certainly Almost certainly Almost
certainly
10 January 2012 Yes 11 January 2012 1
Almost certainly Almost certainly Almost
certainly
10 January 2012 Yes 23 January 2012 13
Unlikely Unlikely Unlikely No
Almost certainly Almost certainly Almost
certainly
16 January 2012 Yes 6 February 2012 21
Almost certainly Almost certainly Almost
certainly
21 February 2012 Yes 29 February 2012 8
Almost certainly Almost certainly Almost
certainly
14 February 2012 No
Possibly Possibly Possibly Yes 8 August 2012
Almost certainly Almost certainly Almost
certainly
1 May 2012 No
Almost certainly Almost certainly Almost
certainly
29 May 2012 No
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
127 FCM-miniR Infusional reaction 2 1 Unrelated
FCM-miniR Fatigue 2 1 Possibly
FCM-miniR Dyspnoea 2 1 Possibly
FCM-miniR Other AE description Pulmonary
embolism
3 1 Unlikely
FCM-miniR Other AE description Pleural
effusion
3 1 Unlikely
FCM-miniR Neutropenia 4 1 Almost certainly
FCM-miniR Constipation 1 2 Unlikely
FCM-miniR Fatigue 2 2 Possibly
FCM-miniR Rash/flushing 1 2 Unlikely
FCM-miniR Neutropenia 2 2 Almost certainly
FCM-miniR Lymphopenia 4 2 Almost certainly
FCM-miniR Nausea 1 3 Almost certainly
FCM-miniR Vomiting 1 3 Almost certainly
FCM-miniR Constipation 1 3 Possibly
FCM-miniR Neutropenia 2 3 Almost certainly
FCM-miniR Thrombocytopenia 1 4 Almost certainly
FCM-miniR Neutropenia 3 6 Almost certainly
FCM-miniR Fatigue 2 6 Possibly
FCM-miniR Infections (not
neutropenic sepsis)
2 6 Probably
128 FCM-miniR Neutropenia 3 1 Possibly
FCM-miniR Thrombocytopenia 1 1 Possibly
FCM-miniR Thrombocytopenia 1 3 Possibly
132 FCM-miniR Rigors 1 1 Unrelated
FCM-miniR Constipation 1 1 Possibly
FCM-miniR Infections (not
neutropenic sepsis)
2 3 Unrelated
FCM-miniR Neutropenic sepsis 3 4 Almost certainly
FCM-miniR Neutropenia 4 4 Probably
FCM-miniR Diarrhoea 2 4 Unrelated
FCM-miniR Infections (not
neutropenic sepsis)
3 4 Probably
FCM-miniR Other AE description Confusion 3 4 Unlikely
FCM-miniR Neutropenia 4 4 Almost certainly
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unrelated Unrelated Almost
certainly
20 December 2011 Yes 20 December 2011 0
Possibly Possibly Unlikely 22 December 2011 Yes 27 December 2011 5
Possibly Possibly Unlikely 26 December 2011 Yes 23 February 2012 59
Possibly Unlikely Unlikely 3 January 2012 Yes 11 January 2012 8
Possibly Unlikely Unlikely 3 January 2012 Yes 23 February 2012 51
Almost certainly Almost certainly Unlikely 31 December 2011 Yes 5 January 2012 5
Unlikely Unlikely Unlikely 29 January 2012 Yes 31 January 2012 2
Possibly Possibly Unlikely 21 January 2012 Yes 2 February 2012 12
Unlikely Unlikely Unlikely 30 January 2012 Yes 9 February 2012 10
Almost certainly Almost certainly Unlikely 25 January 2012 Yes 23 February 2012 29
Almost certainly Almost certainly Almost
certainly
25 January 2012 Yes 13 November 2012 293
Almost certainly Almost certainly Unlikely 24 February 2012 Yes 1 March 2012 6
Almost certainly Almost certainly Unlikely 24 February 2012 Yes 1 March 2012 6
Possibly Possibly Unlikely 24 February 2012 Yes 8 March 2012 13
Almost certainly Almost certainly Unlikely 22 March 2012 No
Almost certainly Almost certainly Unlikely 26 April 2012 Yes 28 February 2013 308
Almost certainly Almost certainly Possibly 24 May 2012 Yes 23 August 2012 91
Possibly Possibly Possibly 1 June 2012 Yes 21 June 2012 20
Probably Probably Possibly 21 June 2012 Yes 28 February 2013 252
Possibly Possibly Possibly 20 January 2012 Yes 30 January 2012 10
Possibly Possibly Possibly 11 January 2012 Yes 30 January 2012 19
Possibly Possibly Possibly 6 February 2012 Yes 10 April 2012 64
Unrelated Unrelated Almost
certainly
1 February 2012 Yes 1 February 2012 0
Possibly Possibly Unlikely 8 February 2012 Yes 10 February 2012 2
Unrelated Unrelated Unrelated 11 April 2012 Yes 13 April 2012 2
Almost certainly Almost certainly Unrelated 7 May 2012 Yes 16 May 2012 9
Probably Probably Unlikely 8 May 2012 Yes 12 May 2012 4
Unrelated Unrelated Unrelated 1 June 2012 Yes 7 June 2012 6
Probably Probably Unlikely 8 May 2012 Yes 14 May 2012 6
Unlikely Unlikely Unlikely 8 May 2012 Yes 13 May 2012 5
Unlikely Unlikely Unlikely 3 June 2012 Yes 20 June 2012 17
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCM-miniR Anaemia 2 5 Probably
FCM-miniR Infections (not
neutropenic sepsis)
2 6 Possibly
FCM-miniR Haematuria 1 6 Possibly
FCM-miniR Neutropenia 4 6 Probably
FCM-miniR Anaemia 2 6 Probably
FCM-miniR Thrombocytopenia 3 6 Probably
133 FCM-miniR Nausea 1 1 Almost certainly
FCM-miniR Diarrhoea 1 1 Almost certainly
FCM-miniR Neutropenia 3 1 Almost certainly
FCM-miniR Thrombocytopenia 1 1 Almost certainly
FCM-miniR Thrombocytopenia 2 2 Almost certainly
FCM-miniR Fatigue 1 2 Possibly
FCM-miniR Thrombocytopenia 1 3 Almost certainly
FCM-miniR Constipation 1 5 Unrelated
FCM-miniR Vomiting 1 5 Probably
FCM-miniR Neutropenia 1 6 Probably
FCM-miniR Anaemia 1 6 Probably
135 FCM-miniR Nausea 1 1 Probably
FCM-miniR Vomiting 1 1 Unlikely
FCM-miniR Rash/flushing 1 1 Unrelated
FCM-miniR Anaemia 1 1 Possibly
FCM-miniR Neutropenia 4 1 Possibly
FCM-miniR Thrombocytopenia 3 1 Possibly
FCM-miniR Rash/flushing 2 2 Unrelated
FCM-miniR Nausea 1 2 Probably
FCM-miniR Fatigue 1 2 Possibly
FCM-miniR Anaemia 1 2 Possibly
FCM-miniR Thrombocytopenia 3 2 Possibly
FCM-miniR Neutropenia 4 2 Possibly
FCM-miniR Infections (not
neutropenic sepsis)
2 3 Possibly
FCM-miniR Anaemia 1 3 Possibly
FCM-miniR Thrombocytopenia 3 3 Possibly
FCM-miniR Neutropenia 4 3 Possibly
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Probably Probably Unrelated 7 June 2012 Yes 18 July 2012 41
Possibly Possibly Possibly 29 July 2012 Yes 5 August 2012 7
Possibly Possibly Possibly 29 July 2012 No
Probably Probably Unlikely 22 August 2012 No
Probably Probably Unlikely 22 August 2012 No
Probably Probably Unlikely 22 August 2012 No
Almost certainly Almost certainly Unlikely Yes
Almost certainly Almost certainly Unlikely Yes
Almost certainly Almost certainly Almost
certainly
27 February 2012 Yes 12 March 2012 14
Almost certainly Almost certainly Almost
certainly
12 March 2012 No
Almost certainly Almost certainly Almost
certainly
11 April 2012 No
Possibly Possibly Possibly Yes
Almost certainly Almost certainly Almost
certainly
14 May 2012 No
Unrelated Unrelated Unrelated Yes
Probably Probably Unrelated 15 June 2012 Yes 15 June 2012 0
Probably Probably Unrelated 6 August 2012 No
Probably Probably Unrelated 9 July 2012 No
Probably Probably Unlikely 16 March 2012 Yes 23 March 2012 7
Unlikely Unlikely Unlikely 23 March 2012 Yes 23 March 2012 0
Unrelated Unrelated Unrelated 5 April 2012 No
Possibly Possibly Unlikely 14 March 2012 No
Possibly Possibly Unlikely 30 March 2012 No
Possibly Possibly Unlikely 23 March 2012 No
Unrelated Unrelated Unrelated 13 April 2012 No
Probably Probably Unlikely 15 April 2012 Yes 18 April 2012 3
Possibly Possibly Unlikely 14 April 2012 Yes 26 April 2012 12
Possibly Possibly Unlikely 13 April 2012 No
Possibly Possibly Unlikely 26 April 2012 No
Possibly Possibly Unlikely 26 April 2012 No
Possibly Possibly Unlikely 31 May 2012 Yes 4 June 2012 4
Possibly Possibly Unlikely 1 June 2012 No
Possibly Possibly Unlikely 17 May 2012 No
Possibly Possibly Unlikely 23 May 2012 No
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
139 FCM-miniR Anaemia 3 1 Probably
FCM-miniR Neutropenia 4 1 Probably
FCM-miniR Thrombocytopenia 3 1 Probably
142 FCM-miniR Neutropenia 4 1 Almost certainly
FCM-miniR Anaemia 3 1 Almost certainly
FCM-miniR Thrombocytopenia 2 1 Almost certainly
144 FCM-miniR Nausea 1 1 Almost certainly
FCM-miniR Fatigue 1 1 Almost certainly
FCM-miniR Neuropathy (sensory) 1 1 Almost certainly
FCM-miniR Back pain 1 1 Unrelated
FCM-miniR Nausea 1 2 Almost certainly
FCM-miniR Fatigue 1 2 Unlikely
FCM-miniR Constipation 1 2 Possibly
FCM-miniR Infections (not
neutropenic sepsis)
1 2 Unlikely
FCM-miniR Neutropenia 1 2 Almost certainly
FCM-miniR Nausea 2 3 Almost certainly
FCM-miniR Vomiting 2 3 Almost certainly
FCM-miniR Mucositis/thrush 1 3 Almost certainly
FCM-miniR Neutropenia 3 4 Almost certainly
FCM-miniR Anaemia 1 5 Almost certainly
FCM-miniR Neutropenia 2 6 Almost certainly
FCM-miniR Thrombocytopenia 1 6 Almost certainly
FCM-miniR Anaemia 1 6 Almost certainly
FCM-miniR Anaemia 2 6 Almost certainly
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
316
Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Probably Probably Probably 9 May 2012 No
Probably Probably Probably 9 May 2012 Yes 11 July 2012 63
Probably Probably Probably 9 May 2012 No
Almost certainly Almost certainly Almost
certainly
30 May 2012 Yes 4 June 2012 5
Almost certainly Almost certainly Almost
certainly
24 May 2012 Yes 30 May 2012 6
Almost certainly Almost certainly Almost
certainly
24 May 2012 Yes 4 June 2012 11
Almost certainly Almost certainly Almost
certainly
3 May 2012 Yes 7 May 2012 4
Unlikely Unlikely Unlikely 3 May 2012 Yes 10 May 2012 7
Almost certainly Almost certainly Almost
certainly
No
Unrelated Unrelated Unrelated Yes
Almost certainly Almost certainly Almost
certainly
31 May 2012 No
Unlikely Unlikely Unlikely No
Possibly Possibly Possibly Yes
Unlikely Unlikely Unlikely Yes
Almost certainly Almost certainly Almost
certainly
26 June 2012 Yes 17 July 2012 21
Almost certainly Almost certainly Almost
certainly
No
Almost certainly Almost certainly Almost
certainly
Yes 26 July 2012
Almost certainly Almost certainly Almost
certainly
No
Almost certainly Almost certainly Almost
certainly
17 July 2012 Yes 21 August 2012 35
Almost certainly Almost certainly Almost
certainly
17 July 2012 Yes 24 July 2012 7
Almost certainly Almost certainly Almost
certainly
21 August 2012 Yes 23 October 2012 63
Almost certainly Almost certainly Almost
certainly
29 May 2012 Yes 23 October 2012 147
Almost certainly Almost certainly Almost
certainly
18 September 2012 Yes 23 October 2012 35
Almost certainly Almost certainly Almost
certainly
23 October 2012 No
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
FCM-miniR Thrombocytopenia 2 6 Almost certainly
FCM-miniR Neutropenia 3 6 Almost certainly
149 FCM-miniR Nausea 2 1 Probably
FCM-miniR Alopecia 2 1 Probably
FCM-miniR Diarrhoea 1 1 Probably
FCM-miniR Mucositis/thrush 1 1 Possibly
FCM-miniR Taste alteration 4 1 Probably
FCM-miniR Fatigue 2 1 Probably
FCM-miniR Fatigue 2 2 Probably
FCM-miniR Nausea 2 2 Probably
FCM-miniR Constipation 2 2 Probably
FCM-miniR Diarrhoea 2 2 Probably
FCM-miniR Neutropenia 3 2 Unlikely
FCM-miniR Non-specific pain 1 2 Unlikely
FCM-miniR Neutropenia 3 3 Probably
FCM-miniR Nausea 2 3 Probably
150 FCM-miniR Anaemia 3 2 Possibly
FCM-miniR Neutropenia 4 3 Probably
FCM-miniR Anaemia 2 3 Probably
FCM-miniR Neutropenia 1 4 Probably
FCM-miniR Neutropenia 1 5 Probably
FCM-miniR Lymphopenia 2 5 Probably
FCM-miniR Neutropenia 2 6 Probably
FCM-miniR Lymphopenia 3 6 Probably
154 FCM-miniR Neutropenia 4 1 Probably
FCM-miniR Thrombocytopenia 3 1 Probably
FCM-miniR Anaemia 2 1 Probably
165 FCM-miniR Neutropenia 3 1 Almost certainly
FCM-miniR Thrombocytopenia 3 1 Possibly
FCM-miniR Anaemia 2 2 Unlikely
FCM-miniR Raised GGT/bilirubin 1 3 Possibly
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Almost certainly Almost
certainly
23 October 2012 No
Almost certainly Almost certainly Almost
certainly
23 October 2012 No
Probably Probably Unrelated 21 May 2012 Yes 28 May 2012 7
Probably Unlikely Unlikely 11 June 2012 No
Unlikely Possibly Unlikely 28 May 2012 Yes 12 June 2012 15
Possibly Probably Unrelated 28 May 2012 Yes 19 June 2012 22
Probably Probably Unlikely 28 May 2012 Yes 28 May 2012 0
Probably Probably Unlikely 15 May 2012 No
Probably Probably Unlikely 18 June 2012 No
Probably Probably Unrelated 19 July 2012 No
Unlikely Possibly Unlikely 19 July 2012 No
Unlikely Possibly Unlikely 19 July 2012 Yes 24 July 2012 5
Unlikely Unlikely Unlikely 18 June 2012 Yes 16 July 2012 28
Unlikely Unlikely Unlikely 18 June 2012 Yes 16 July 2012 28
Probably Probably Unlikely 24 August 2012 Yes 3 September 2012 10
Probably Probably Unrelated 24 August 2012 Yes 3 September 2012 10
Possibly Possibly Possibly 1 June 2012 Yes 3 June 2012 2
Probably Probably Probably 25 June 2012 Yes 15 August 2012 51
Probably Probably Probably 3 June 2012 Yes 9 July 2012 36
Probably Probably Probably 10 October 2012 No
Probably Probably Probably 10 September 2012 No
Probably Probably Probably 10 September 2012 No
Probably Probably Probably 8 October 2012 Yes 14 January 2013 98
Probably Probably Probably 5 November 2012 Yes 3 December 2012 28
Probably Probably Probably 11 June 2012 No
Probably Probably Probably 11 June 2012 No
Probably Probably Probably 11 June 2012 No
Almost certainly Almost certainly Unlikely 13 July 2012 Yes 2 August 2012 20
Possibly Possibly Unlikely 13 July 2012 Yes 23 July 2012 10
Unlikely Unlikely Unrelated 13 July 2012 Yes 31 August 2012 49
Possibly Possibly Possibly 30 August 2012 No
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TABLE 85 Adverse events in participants receiving FCM-miniR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
fludarabine?
180 FCM-miniR Constipation 2 1 Almost certainly
FCM-miniR Anaemia 1 1 Almost certainly
FCM-miniR Vomiting 2 2 Almost certainly
FCM-miniR Lymphopenia 3 2 Almost certainly
FCM-miniR Urinary symptoms 2 3 Unlikely
FCM-miniR Nausea 2 4 Unlikely
FCM-miniR Constipation 2 4 Unlikely
FCM-miniR Thrombocytopenia 1 4 Almost certainly
FCM-miniR Infections (not
neutropenic sepsis)
1 5 Probably
FCM-miniR Sore throat 1 6 Possibly
FCM-miniR Pruritus 1 6 Unrelated
FCM-miniR Dry skin/erythema 1 6 Unrelated
FCM-miniR Anaemia 1 6 Almost certainly
FCM-miniR Thrombocytopenia 1 6 Almost certainly
184 FCM-miniR Thrombocytopenia 2 1 Almost certainly
FCM-miniR Anaemia 1 1 Almost certainly
FCM-miniR Nausea 2 1 Probably
FCM-miniR Vomiting 1 1 Probably
FCM-miniR Fatigue 2 1 Probably
FCM-miniR Anaemia 2 2 Almost certainly
FCM-miniR Nausea 2 2 Probably
FCM-miniR Vomiting 2 2 Probably
FCM-miniR Nausea 2 2 Possibly
FCM-miniR Vomiting 2 2 Possibly
FCM-miniR Other AE description Small bowel
obstruction
3 2 Unrelated
FCM-miniR Other AE description Femoral
hernia
3 2 Unrelated
GGT, gamma-glutamyl transpeptidase.
Duration of AE: days from date of onset to date of recovery (if known).
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Related to
cyclophosphamide?
Related to
mitoxantrone?
Related to
low-dose
rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Almost certainly Missing Missing 2 August 2012 Yes 7 August 2012 5
Almost certainly Missing Missing 14 August 2012 Yes 19 October 2012 66
Almost certainly Missing Missing Yes
Almost certainly Missing Missing 5 September 2012 No
Unlikely Missing Missing Yes 15 October 2012
Probably Missing Missing Yes 23 November 2012
Unlikely Missing Missing Yes 14 November 2012
Almost certainly Missing Missing 19 October 2012 Yes 14 November 2012 26
Probably Missing Missing Yes 14 December 2012
Possibly Missing Missing Yes
Unrelated Missing Missing Yes
Unrelated Missing Missing 11 January 2013 Yes
Almost certainly Missing Missing 22 December 2012 Yes 1 March 2013 69
Almost certainly Missing Missing 14 December 2012 Yes 1 March 2013 77
Almost certainly Almost certainly Probably 13 September 2012 No
Almost certainly Almost certainly Probably 13 September 2012 No
Probably Probably Probably 23 August 2012 Yes 20 September 2012 28
Probably Probably Probably 28 August 2012 Yes 20 September 2012 23
Possibly Probably Possibly 23 August 2012 No
Almost certainly Almost certainly Probably 19 October 2012 No
Probably Probably Probably 30 September 2012 Yes 6 October 2012 6
Probably Probably Probably 30 September 2012 Yes 6 October 2012 6
Possibly Possibly Possibly 13 October 2012 No
Possibly Possibly Possibly 13 October 2012 No
Unrelated Unrelated Unrelated 14 October 2012 No
Unrelated Unrelated Unrelated 14 October 2012 No
DOI: 10.3310/hta21280 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 28
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Howard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
321
TABLE 86 Adverse events in participants receiving FCM-miniR followed by FCR
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
Fludarabine?
Related to
Cyclophosphamide?
145 FCM-miniR/FCR Constipation 1 1 Unlikely Unlikely
FCM-miniR/FCR Fatigue 1 1 Almost
certainly
Almost certainly
FCM-miniR/FCR Neutropenia 4 1 Almost
certainly
Almost certainly
FCM-miniR/FCR Anaemia 1 1 Almost
certainly
Almost certainly
FCM-miniR/FCR Allergic reaction 3 1 Almost
certainly
Almost certainly
FCM-miniR/FCR Nausea 3 2 Almost
certainly
Almost certainly
FCM-miniR/FCR Anorexia/cachexia 2 2 Almost
certainly
Almost certainly
FCM-miniR/FCR Neutropenia 4 2 Almost
certainly
Almost certainly
FCM-miniR/FCR Anaemia 2 2 Almost
certainly
Almost certainly
FCM-miniR/FCR Raised
aminotransferases
1 2 Almost
certainly
Almost certainly
FCM-miniR/FCR Cutaneous herpes/
shingles
2 2 Almost
certainly
Almost certainly
FCM-miniR/FCR Neutropenia 3 4 Almost
certainly
Almost certainly
FCM-miniR/FCR Diarrhoea 2 5 Almost
certainly
Almost certainly
FCM-miniR/FCR Diarrhoea 1 6 Almost
certainly
Almost certainly
FCM-miniR/FCR Nausea 2 6 Almost
certainly
Almost certainly
148 FCM-miniR/FCR Neutropenic sepsis 4 2 Almost
certainly
Almost certainly
FCM-miniR/FCR Anaemia 3 2 Almost
certainly
Almost certainly
FCM-miniR/FCR Anaemia 3 2 Almost
certainly
Almost certainly
152 FCM-miniR/FCR Diarrhoea 1 2 Unrelated Unrelated
FCM-miniR/FCR Neutropenia 4 3 Probably Probably
FCM-miniR/FCR Diarrhoea 1 3 Unrelated Unrelated
153 FCM-miniR/FCR Abnormal
electrolytes
1 1 Probably Probably
FCM-miniR/FCR Anorexia/cachexia 2 2 Almost
certainly
Almost certainly
FCM-miniR/FCR Thrombocytopenia 2 2 Almost
certainly
Almost certainly
FCM-miniR/FCR Nausea 2 4 Unlikely Unlikely
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Related to
Mitoxantrone?
Related to
low-dose
Rituximab?
Related to
Rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unlikely Unlikely Missing 31 May 2012 Yes
Almost certainly Almost
certainly
Missing 31 May 2012 Yes 3 June 2012 3
Almost certainly Almost
certainly
Missing 31 May 2012 Yes 12 June 2012 12
Almost certainly Almost
certainly
Missing 31 May 2012 Yes 3 June 2012 3
Almost certainly Almost
certainly
Missing 17 May 2012 Yes 17 May 2012 0
Almost certainly Almost
certainly
Missing 16 June 2012 Yes 21 June 2012 5
Almost certainly Almost
certainly
Missing 17 May 2012 No
Almost certainly Almost
certainly
Missing 20 June 2012 Yes 28 June 2012 8
Almost certainly Almost
certainly
Missing 28 June 2012 Yes 29 June 2012 1
Almost certainly Almost
certainly
Missing 9 July 2012 Yes 11 July 2012 2
Almost certainly Almost
certainly
Missing 25 June 2012 Yes 30 June 2012 5
Almost certainly Almost
certainly
Missing 22 August 2012 Yes 3 September 2012 12
Almost certainly Almost
certainly
Missing 11 September 2012 Yes 4 October 2012 23
Missing Missing Almost
certainly
12 October 2012 No
Missing Missing Almost
certainly
11 October 2012 Yes 15 October 2012 4
Almost certainly Possibly Missing 27 May 2012 Yes 31 May 2012 4
Almost certainly Unrelated Missing 28 May 2012 Yes 28 May 2012 0
Almost certainly Unrelated Missing 16 June 2012 Yes 16 June 2012 0
Probably Possibly Missing 25 July 2012 Yes 7 August 2012 13
Probably Unlikely Missing 3 August 2012 Yes 28 August 2012 25
Probably Possibly Missing 4 August 2012 Yes 6 August 2012 2
Possibly Probably Missing 1 June 2012 Yes 3 June 2012 2
Unrelated Almost
certainly
Missing 2 July 2012 No
Unrelated Almost
certainly
Missing 25 June 2012 Yes 16 July 2012 21
Possibly Unlikely Missing 17 September 2012 No
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TABLE 86 Adverse events in participants receiving FCM-miniR followed by FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
Fludarabine?
Related to
Cyclophosphamide?
FCM-miniR/FCR Neutropenia 2 5 Almost
certainly
Almost certainly
FCM-miniR/FCR Thrombocytopenia 2 6 Almost
certainly
Almost certainly
160 FCM-miniR/FCR Hypotension 2 1 Unrelated Unrelated
FCM-miniR/FCR Dyspnoea 3 1 Unrelated Unrelated
FCM-miniR/FCR Infections (not
neutropenic sepsis)
2 1 Possibly Possibly
FCM-miniR/FCR Neutropenia 2 1 Almost
certainly
Almost certainly
FCM-miniR/FCR Abdominal pain/
bloating
2 2 Possibly Possibly
FCM-miniR/FCR Thrombocytopenia 1 2 Almost
certainly
Probably
FCM-miniR/FCR Nausea 1 3 Probably Probably
FCM-miniR/FCR Nausea 2 4 Possibly Possibly
FCM-miniR/FCR Neutropenia 3 4 Almost
certainly
Almost certainly
FCM-miniR/FCR Dyspnoea 1 5 Unrelated Unrelated
FCM-miniR/FCR Anaemia 2 5 Almost
certainly
Almost certainly
FCM-miniR/FCR Thrombocytopenia 1 5 Almost
certainly
Probably
FCM-miniR/FCR Neutropenia 2 6 Almost
certainly
Almost certainly
162 FCM-miniR/FCR Nausea 1 1 Probably Probably
FCM-miniR/FCR Neutropenia 4 3 Almost
certainly
Almost certainly
FCM-miniR/FCR Thrombocytopenia 1 3 Almost
certainly
Almost certainly
FCM-miniR/FCR Mucositis/thrush 1 3 Almost
certainly
Almost certainly
FCM-miniR/FCR Rash/flushing 2 3 Unlikely Unlikely
FCM-miniR/FCR Thrombocytopenia 1 4 Almost
certainly
Almost certainly
FCM-miniR/FCR Neutropenia 2 5 Almost
certainly
Almost certainly
FCM-miniR/FCR Neutropenia 3 5 Almost
certainly
Almost certainly
164 FCM-miniR/FCR Fever 1 1 Unlikely Unlikely
FCM-miniR/FCR Neutropenia 4 1 Possibly Possibly
FCM-miniR/FCR Vomiting 1 1 Unlikely Unlikely
FCM-miniR/FCR Fever 1 1 Unlikely Unlikely
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Related to
Mitoxantrone?
Related to
low-dose
Rituximab?
Related to
Rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Missing Missing Almost
certainly
15 October 2012 No
Missing Missing Almost
certainly
12 November 2012 No
Unrelated Almost
certainly
Missing 19 June 2012 Yes 19 June 2012 0
Unrelated Almost
certainly
Missing 19 June 2012 Yes 19 June 2012 0
Unrelated Unrelated Missing 12 July 2012 Yes 17 July 2012 5
Probably Probably Missing 13 July 2012 No
Possibly Possibly Missing 20 August 2012 Yes 24 August 2012 4
Probably Probably Missing 20 August 2012 Yes 30 August 2012 10
Probably Probably Missing 30 July 2012 No
Missing Missing Unrelated 8 October 2012 Yes
Missing Missing Almost
certainly
31 October 2012 No
Missing Missing Possibly 8 November 2012 No
Missing Missing Almost
certainly
26 November 2012 No
Missing Missing Unlikely 5 November 2012 Yes 26 November 2012 21
Missing Missing Unlikely Yes 22 March 2013
Probably Possibly Missing 27 June 2012 Yes 30 June 2012 3
Almost certainly Possibly Missing 4 July 2012 Yes 15 September 2012 73
Almost certainly Possibly Missing 14 August 2012 Yes 5 September 2012 22
Almost certainly Possibly Missing 2 August 2012 Yes 20 August 2012 18
Unlikely Unlikely Missing 5 September 2012 Yes 12 September 2012 7
Almost certainly Possibly Missing 24 September 2012 Yes 24 October 2012 30
Missing Missing Possibly 4 October 2012 Yes 1 November 2012 28
Missing Missing Possibly 15 November 2012 No
Probably Probably Missing 13 July 2012 Yes 16 July 2012 3
Possibly Unlikely Missing 23 July 2012 Yes 14 August 2012 22
Unlikely Possibly Missing 13 July 2012 Yes 16 July 2012 3
Probably Probably Missing 4 August 2012 Yes 8 August 2012 4
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TABLE 86 Adverse events in participants receiving FCM-miniR followed by FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
Fludarabine?
Related to
Cyclophosphamide?
FCM-miniR/FCR Rash/flushing 1 1 Unlikely Unlikely
FCM-miniR/FCR Cough 1 2 Possibly Possibly
FCM-miniR/FCR Vomiting 1 2 Unlikely Unlikely
FCM-miniR/FCR Rash/flushing 1 2 Unlikely Unlikely
FCM-miniR/FCR Fever 1 3 Unlikely Unlikely
FCM-miniR/FCR Nausea 1 3 Possibly Possibly
FCM-miniR/FCR Fatigue 1 3 Possibly Possibly
FCM-miniR/FCR Nausea 2 4 Possibly Possibly
FCM-miniR/FCR Anorexia/cachexia 1 4 Possibly Possibly
FCM-miniR/FCR Fatigue 1 4 Possibly Possibly
FCM-miniR/FCR Nausea 1 5 Possibly Possibly
FCM-miniR/FCR Fatigue 1 5 Possibly Possibly
FCM-miniR/FCR Nausea 1 6 Possibly Possibly
FCM-miniR/FCR Fatigue 1 6 Possibly Possibly
169 FCM-miniR/FCR Neutropenia 4 5 Probably Probably
170 FCM-miniR/FCR Anaemia 1 1 Almost
certainly
Almost certainly
FCM-miniR/FCR Thrombocytopenia 1 1 Almost
certainly
Almost certainly
FCM-miniR/FCR Neutropenia 2 1 Almost
certainly
Almost certainly
FCM-miniR/FCR Allergic reaction 1 1 Unrelated Unrelated
FCM-miniR/FCR Neutropenia 2 2 Almost
certainly
Almost certainly
FCM-miniR/FCR Anaemia 1 2 Almost
certainly
Almost certainly
FCM-miniR/FCR Anaemia 1 3 Almost
certainly
Almost certainly
FCM-miniR/FCR Neutropenia 3 3 Almost
certainly
Almost certainly
FCM-miniR/FCR Nausea 1 4 Almost
certainly
Almost certainly
FCM-miniR/FCR Fatigue 1 4 Almost
certainly
Almost certainly
FCM-miniR/FCR Anorexia/cachexia 1 4 Almost
certainly
Almost certainly
FCM-miniR/FCR Nausea 1 5 Almost
certainly
Almost certainly
FCM-miniR/FCR Nasal symptoms 1 5 Almost
certainly
Almost certainly
FCM-miniR/FCR Fatigue 1 6 Almost
certainly
Almost certainly
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Related to
Mitoxantrone?
Related to
low-dose
Rituximab?
Related to
Rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unlikely Possibly Missing 6 August 2012 Yes 14 August 2012 8
Possibly Unlikely Missing 10 July 2012 Yes 14 August 2012 35
Unlikely Possibly Missing 14 August 2012 Yes 17 August 2012 3
Unlikely Possibly Missing 14 August 2012 Yes 21 August 2012 7
Unrelated Probably Missing 19 September 2012 Yes 19 September 2012 0
Possibly Possibly Missing 18 September 2012 Yes 23 September 2012 5
Unlikely Unlikely Missing 18 September 2012 Yes 23 September 2012 5
Missing Missing Missing 16 October 2012 Yes 20 October 2012 4
Missing Missing Missing 16 October 2012 Yes 20 October 2012 4
Missing Missing Missing 16 October 2012 No
Missing Missing Missing 13 November 2012 Yes 20 November 2012 7
Missing Missing Missing 13 November 2012 Yes 4 December 2012 21
Missing Missing Missing 11 December 2012 Yes 18 December 2012 7
Missing Missing Missing 11 December 2012 No
Missing Missing Probably 28 November 2012 Yes 10 December 2012 12
Almost certainly Almost
certainly
Missing 15 August 2012 Yes 28 August 2012 13
Almost certainly Almost
certainly
Missing 13 June 2012 No
Almost certainly Almost
certainly
Missing 15 August 2012 Yes 28 August 2012 13
Unrelated Almost
certainly
Missing 31 July 2012 Yes 31 July 2012 0
Almost certainly Almost
certainly
Missing 12 September 2012 Yes 24 September 2012 12
Almost certainly Almost
certainly
Missing 12 September 2012 Yes 24 September 2012 12
Almost certainly Almost
certainly
Missing 10 October 2012 Yes 19 October 2012 9
Almost certainly Almost
certainly
Missing 10 October 2012 Yes 19 October 2012 9
Missing Missing Almost
certainly
23 October 2012 Yes 27 October 2012 4
Missing Missing Almost
certainly
23 October 2012 Yes 27 October 2012 4
Missing Missing Almost
certainly
23 October 2012 Yes 23 October 2012 0
Missing Missing Almost
certainly
24 November 2012 Yes 1 December 2012 7
Missing Missing Almost
certainly
24 November 2012 Yes 1 December 2012 7
Missing Missing Almost
certainly
18 December 2012 No
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TABLE 86 Adverse events in participants receiving FCM-miniR followed by FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
Fludarabine?
Related to
Cyclophosphamide?
173 FCM-miniR/FCR Constipation 2 1 Possibly Unlikely
FCM-miniR/FCR Renal impairment 1 1 Probably Probably
FCM-miniR/FCR Anaemia 2 1 Unrelated Unrelated
FCM-miniR/FCR Constipation 2 2 Possibly Unlikely
176 FCM-miniR/FCR Neutropenia 4 1 Almost
certainly
Almost certainly
FCM-miniR/FCR Thrombocytopenia 2 1 Almost
certainly
Probably
FCM-miniR/FCR Rash/flushing 2 1 Possibly Possibly
FCM-miniR/FCR Neutropenia 3 2 Almost
certainly
Almost certainly
FCM-miniR/FCR Thrombocytopenia 2 2 Almost
certainly
Probably
FCM-miniR/FCR Infections (not
neutropenic sepsis)
2 6 Possibly Possibly
177 FCM-miniR/FCR Rash/flushing 2 3 Unrelated Unrelated
FCM-miniR/FCR Fever 2 3 Probably Probably
FCM-miniR/FCR Neutropenia 3 3 Probably Probably
FCM-miniR/FCR Neutropenia 3 5 Almost
certainly
Almost certainly
FCM-miniR/FCR Neutropenia 3 5 Almost
certainly
Almost certainly
FCM-miniR/FCR Bone pain 1 5 Unrelated Unrelated
FCM-miniR/FCR Neutropenia 4 6 Almost
certainly
Almost certainly
183 FCM-miniR/FCR Nausea 1 1 Probably Probably
FCM-miniR/FCR Vomiting 1 1 Probably Probably
FCM-miniR/FCR Constipation 1 1 Probably Probably
FCM-miniR/FCR Fatigue 1 1 Possibly Probably
FCM-miniR/FCR Taste alteration 1 1 Possibly Possibly
FCM-miniR/FCR Vomiting 1 2 Probably Probably
FCM-miniR/FCR Diarrhoea 1 2 Probably Probably
FCM-miniR/FCR Vomiting 1 3 Probably Probably
186 FCM-miniR/FCR Infections (not
neutropenic sepsis)
2 1 Unrelated Unrelated
FCM-miniR/FCR Otalgia 3 1 Unrelated Unrelated
FCM-miniR/FCR Nausea 1 2 Almost
certainly
Almost certainly
FCM-miniR/FCR Constipation 1 2 Unlikely Unlikely
FCM-miniR/FCR Pruritus 1 3 Unrelated Unrelated
FCM-miniR/FCR Neutropenia 2 3 Almost
certainly
Almost certainly
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Related to
Mitoxantrone?
Related to
low-dose
Rituximab?
Related to
Rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unlikely Unlikely Missing 14 July 2012 Yes 17 July 2012 3
Probably Probably Missing 7 August 2012 Yes 5 September 2012 29
Unrelated Unrelated Missing 7 August 2012 Yes 5 September 2012 29
Unlikely Unlikely Missing 11 August 2012 Yes 13 August 2012 2
Almost certainly Probably Missing 15 August 2012 Yes 3 September 2012 19
Probably Probably Missing 15 August 2012 Yes 3 September 2012 19
Possibly Possibly Missing 21 August 2012 Yes 29 August 2012 8
Almost certainly Probably Missing 3 October 2012 Yes 16 October 2012 13
Probably Probably Missing 9 October 2012 Yes 16 October 2012 7
Missing Missing Possibly 1 January 2013 Yes 20 January 2013 19
Possibly Unrelated Missing 20 August 2012 Yes 31 August 2012 11
Possibly Probably Missing 20 August 2012 Yes 31 August 2012 11
Possibly Probably Missing 5 September 2012 Yes 19 September 2012 14
Missing Missing Almost
certainly
16 October 2012 Yes 23 October 2012 7
Missing Missing Almost
certainly
20 November 2012 Yes 27 November 2012 7
Missing Missing Unrelated 27 November 2012 Yes 27 December 2012 30
Missing Missing Unlikely 27 December 2012 Yes 3 January 2013 7
Probably Probably Missing 8 August 2012 No
Probably Probably Missing 9 August 2012 Yes 9 August 2012 0
Probably Probably Missing 8 August 2012 Yes 5 September 2012 28
Probably Probably Missing 8 August 2012 No
Possibly Probably Missing 8 August 2012 No
Probably Probably Missing 5 September 2012 Yes 7 September 2012 2
Probably Probably Missing 5 September 2012 Yes 10 October 2012 35
Missing Missing Probably 3 October 2012 Yes 3 October 2012 0
Unrelated Unrelated Missing 6 August 2012 Yes 12 September 2012 37
Unrelated Unrelated Missing 15 August 2012 Yes 12 September 2012 28
Almost certainly Almost
certainly
Missing 22 August 2012 Yes 10 October 2012 49
Unrelated Unlikely Missing 22 August 2012 No
Missing Missing Almost
certainly
10 October 2012 Yes 6 November 2012 27
Missing Missing Almost
certainly
10 October 2012 Yes 6 November 2012 27
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TABLE 86 Adverse events in participants receiving FCM-miniR followed by FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
Fludarabine?
Related to
Cyclophosphamide?
188 FCM-miniR/FCR Nausea 1 1 Probably Probably
FCM-miniR/FCR Vomiting 2 1 Unlikely Unlikely
FCM-miniR/FCR Headache 1 1 Unlikely Unlikely
FCM-miniR/FCR Fatigue 2 1 Probably Unlikely
FCM-miniR/FCR Alopecia 1 1 Unlikely Almost certainly
FCM-miniR/FCR Nausea 1 2 Probably Probably
FCM-miniR/FCR Abdominal pain/
bloating
2 2 Unlikely Unlikely
FCM-miniR/FCR Fatigue 2 2 Probably Unlikely
FCM-miniR/FCR Non-specific pain 1 2 Unlikely Unlikely
FCM-miniR/FCR Nausea 1 3 Probably Probably
FCM-miniR/FCR Fatigue 2 3 Probably Unlikely
FCM-miniR/FCR Non-specific pain 1 3 Unlikely Unlikely
FCM-miniR/FCR Abdominal pain/
bloating
2 3 Unlikely Unlikely
FCM-miniR/FCR Nausea 2 4 Probably Probably
FCM-miniR/FCR Non-specific pain 1 4 Unlikely Unlikely
FCM-miniR/FCR Abdominal pain/
bloating
1 4 Unlikely Unlikely
FCM-miniR/FCR Nausea 2 5 Probably Probably
FCM-miniR/FCR Mucositis/thrush 2 5 Probably Unlikely
189 FCM-miniR/FCR Vomiting 3 1 Probably Possibly
FCM-miniR/FCR Fatigue 1 1 Possibly Possibly
FCM-miniR/FCR Myalgias 1 1 Possibly Possibly
FCM-miniR/FCR Anaemia 2 1 Possibly Possibly
FCM-miniR/FCR Neutropenia 4 1 Probably Possibly
FCM-miniR/FCR Abdominal pain/
bloating
1 2 Possibly Possibly
FCM-miniR/FCR Fatigue 2 4 Probably Probably
FCM-miniR/FCR Arthralgias 1 4 Unlikely Unlikely
FCM-miniR/FCR Neutropenia 1 4 Probably Probably
FCM-miniR/FCR Fatigue 2 5 Probably Probably
FCM-miniR/FCR Arthralgias 1 5 Unlikely Unlikely
FCM-miniR/FCR Neutropenia 3 5 Probably Probably
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
330
Related to
Mitoxantrone?
Related to
low-dose
Rituximab?
Related to
Rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Probably Possibly Missing 1 September 2012 Yes 4 September 2012 3
Unlikely Unlikely Missing 3 September 2012 Yes 5 September 2012 2
Unlikely Almost
certainly
Missing 30 August 2012 Yes 31 August 2012 1
Probably Possibly Missing 4 September 2012 Yes 22 September 2012 18
Unlikely Probably Missing 21 September 2012 No
Probably Possibly Missing 27 September 2012 Yes 30 September 2012 3
Possibly Possibly Missing 30 September 2012 Yes 6 October 2012 6
Probably Possibly Missing 3 October 2012 Yes 11 October 2012 8
Unlikely Possibly Missing 13 October 2012 Yes 18 October 2012 5
Missing Missing Possibly 26 October 2012 Yes 2 November 2012 7
Missing Missing Possibly 27 October 2012 No
Missing Missing Possibly 15 October 2012 Yes 19 October 2012 4
Missing Missing Possibly 15 October 2012 Yes 19 October 2012 4
Missing Missing Possibly 23 November 2012 Yes 16 December 2012 23
Missing Missing Possibly 29 November 2012 Yes 30 November 2012 1
Missing Missing Possibly 29 November 2012 Yes 30 November 2012 1
Missing Missing Possibly 24 December 2012 Yes 7 January 2013 14
Missing Missing Probably 7 January 2013 Yes 11 January 2013 4
Possibly Unlikely Missing 10 September 2012 Yes 17 September 2012 7
Possibly Possibly Missing 2 October 2012 No
Possibly Possibly Missing 2 October 2012 No
Possibly Unlikely Missing 12 September 2012 No
Probably Possibly Missing 17 September 2012 Yes 2 October 2012 15
Missing Missing Possibly 3 October 2012 Yes 23 October 2012 20
Missing Missing Unlikely 28 November 2012 Yes 7 December 2012 9
Missing Missing Unlikely 5 December 2012 Yes 7 December 2012 2
Missing Missing Unlikely 24 December 2012 No
Missing Missing Unlikely 27 January 2013 No
Missing Missing Possibly 27 January 2013 No
Missing Missing Possibly 8 January 2013 Yes 11 January 2013 3
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TABLE 86 Adverse events in participants receiving FCM-miniR followed by FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
Fludarabine?
Related to
Cyclophosphamide?
FCM-miniR/FCR Anaemia 1 5 Probably Probably
FCM-miniR/FCR Neutropenia 2 5 Probably Probably
FCM-miniR/FCR Fatigue 2 6 Probably Probably
FCM-miniR/FCR Arthralgias 1 6 Unlikely Unlikely
FCM-miniR/FCR Headache 1 6 Unlikely Unlikely
FCM-miniR/FCR Thrombocytopenia 1 6 Probably Probably
FCM-miniR/FCR Neutropenia 3 6 Probably Probably
190 FCM-miniR/FCR Nausea 1 1 Probably Probably
FCM-miniR/FCR Vomiting 1 1 Probably Probably
FCM-miniR/FCR Neuropathy
(sensory)
1 1 Unlikely Unlikely
FCM-miniR/FCR Abdominal pain/
bloating
1 1 Probably Probably
FCM-miniR/FCR Nausea 1 2 Probably Probably
FCM-miniR/FCR Nausea 1 4 Possibly Almost certainly
FCM-miniR/FCR Vomiting 1 6 Possibly Possibly
196 FCM-miniR/FCR Fatigue 1 2 Probably Probably
FCM-miniR/FCR Back pain 2 2 Unlikely Unlikely
FCM-miniR/FCR Nausea 2 2 Almost
certainly
Almost certainly
FCM-miniR/FCR Oedema 1 2 Unlikely Unlikely
FCM-miniR/FCR Bone pain 2 3 Unlikely Unlikely
FCM-miniR/FCR Anorexia/cachexia 1 4 Probably Probably
FCM-miniR/FCR Nausea 2 4 Almost
certainly
Almost certainly
FCM-miniR/FCR Constipation 1 4 Unrelated Unrelated
FCM-miniR/FCR Back pain 2 4 Unlikely Unlikely
FCM-miniR/FCR Constipation 1 6 Unrelated Unrelated
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Related to
Mitoxantrone?
Related to
low-dose
Rituximab?
Related to
Rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Missing Missing Unlikely 13 January 2013 No
Missing Missing Possibly 13 January 2013 Yes 22 January 2013 9
Missing Missing Unlikely 24 January 2013 Yes 12 February 2013 19
Missing Missing Unlikely Yes 12 February 2013
Missing Missing Unlikely Yes 12 February 2013
Missing Missing Unlikely 31 January 2013 Yes 12 February 2013 12
Missing Missing Unlikely 31 January 2013 Yes 5 March 2013 33
Probably Unlikely Missing 8 September 2012 Yes 9 September 2012 1
Probably Unlikely Missing 8 September 2012 Yes 9 September 2012 1
Unlikely Unlikely Missing 9 September 2012 Yes 10 September 2012 1
Probably Unlikely Missing 9 September 2012 No
Probably Unlikely Missing 5 October 2012 Yes 8 October 2012 3
Missing Missing Missing 28 November 2012 Yes 3 December 2012 5
Missing Missing Missing 5 February 2013 Yes 7 February 2013 2
Missing Missing Unlikely 20 September 2012 No
Missing Missing Unlikely 17 September 2012 No
Missing Missing Unlikely 20 September 2012 Yes
Missing Missing Unlikely 2 October 2012 Yes 5 October 2012 3
Missing Missing Unrelated 29 October 2012 No
Missing Missing Unrelated 21 November 2012 No
Missing Missing Unrelated 21 November 2012 No
Missing Missing Unrelated 12 December 2012 Yes 13 December 2012 1
Missing Missing Unrelated 29 October 2012 No
Missing Missing Unrelated 7 February 2013 No
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TABLE 86 Adverse events in participants receiving FCM-miniR followed by FCR (continued )
Patient
number
Treatment
received AE description
Other AE
description
Maximum
CTCAE
grade
Treatment
cycle AE
started
Related to
Fludarabine?
Related to
Cyclophosphamide?
197 FCM-miniR/FCR Fatigue 1 1 Unrelated Unrelated
FCM-miniR/FCR Myalgias 1 1 Unrelated Unrelated
FCM-miniR/FCR Oedema 1 2 Possibly Possibly
FCM-miniR/FCR Insomnia 1 2 Possibly Possibly
FCM-miniR/FCR Anaemia 2 2 Possibly Possibly
FCM-miniR/FCR Neutropenia 2 2 Possibly Possibly
FCM-miniR/FCR Abdominal pain/
bloating
1 2 Possibly Possibly
FCM-miniR/FCR Neutropenia 2 3 Probably Probably
FCM-miniR/FCR Lymphopenia 2 3 Probably Probably
FCM-miniR/FCR Dry skin/erythema 1 4 Unlikely Unlikely
FCM-miniR/FCR Non-specific pain 1 4 Unlikely Unlikely
FCM-miniR/FCR Lymphopenia 2 4 Probably Probably
FCM-miniR/FCR Other AE
description
Cold hands 1 5 Possibly Possibly
FCM-miniR/FCR Dyspnoea 1 5 Possibly Possibly
FCM-miniR/FCR Infections (not
neutropenic sepsis)
1 5 Unlikely Unlikely
FCM-miniR/FCR Other AE
description
R pulmonary
effusion
1 5 Unlikely Unlikely
FCM-miniR/FCR Rash/flushing 1 6 Possibly Possibly
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Related to
Mitoxantrone?
Related to
low-dose
Rituximab?
Related to
Rituximab? Date of onset Recovered? Date of recovery
Duration
of AE
(days)
Unrelated Unrelated Missing 11 September 2012 No
Unrelated Unrelated Missing Yes 23 October 2012
Missing Missing Possibly 16 October 2012 No
Missing Missing Possibly 2 October 2012 No
Missing Missing Possibly 22 October 2012 No
Missing Missing Possibly 22 October 2012 No
Missing Missing Possibly 24 October 2012 No
Missing Missing Unlikely 19 November 2012 No
Missing Missing Unlikely 19 November 2012 No
Missing Missing Possibly 27 November 2012 No
Missing Missing Unlikely 13 December 2012 Yes
Missing Missing Unlikely 17 December 2012 No
Missing Missing Possibly 17 December 2012 No
Missing Missing Possibly 19 October 2012 Yes 24 January 2013 97
Missing Missing Unlikely 26 December 2012 Yes 24 January 2013 29
Missing Missing Unlikely 26 December 2012 No
Missing Missing Possibly 6 February 2013 No
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Appendix 3 Baseline patient health economics
questionnaire booklet
For Hospital Use
To be completed at baseline 
(Prior to the patient being informed of their randomisation allocation) 
Information
We need to ask you some questions about your general health and your 
employment. Some questions will seem more relevant to you than others, 
but please try to answer all the questions. The responses are confidential 
and will not be seen by the doctors or nurses. 
When you have completed the questionnaire booklet, please place it in the 
envelope provided and return the sealed envelope to the nurse.
Thank you
Patient initials
Patient date of birth 
Hospital name 
Today’s date                    
Month YearDay 
Month YearDay 
Baseline 
ARCTIC 
Patient Health Economics Questionnaire Booklet
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For office
use only
computerised
  Date   Initials
verified/checked
  Date   Initials
ARCTIC
Patient Initials              Date of Birth         Patient ID
Month YearDay Centre No   Trial No
Baseline
Patient Health Economics 
Questionnaire Booklet
Version 3.0  13/10/2009
Employment status before diagnosis
This section is about how your diagnosis has affected your work. 
1. Please tick one box for the category that describes your employment status
in the month before your diagnosis.
Employment status:
Full time employee (more than 30 hours a week) ...............................
Part time employee (less than 30 hours a week) ..................................
Self-employed........................................................................................
Full or part time training or education ..................................................
Employee on sick leave ........................................................................
Not in paid employment due to long standing illness or disability .........
Retired and not in paid employment ....................................................
2. Please state approximately how many years had you been in this employment
status, before your diagnosis? 
Years  
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For office
use only
computerised
  Date   Initials
verified/checked
  Date   Initials
ARCTIC
Patient Initials              Date of Birth         Patient ID
Month YearDay Centre No   Trial No
Baseline
Patient Health Economics 
Questionnaire Booklet
Version 3.0  13/10/2009
General health 
3. For each of the five sets of statements below, please tick the one box that 
best describes your own health state today.
(i)     Mobility
I have no problems in walking about….………………………. 
I have some problems in walking about ………………………..
I am confined to bed ………………………………………......…
(ii)    Self-care
I have no problems with self-care.…………………………….…….
I have some problems washing and dressing myself.……...…
I am unable to wash or dress myself.…………………………….
(iii)    Usual activities (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities.………
I have some problems with performing my usual activities.……
I am unable to perform my usual activities.……………………….
(iv)    Pain/discomfort
I have no pain or discomfort.………………………………………
I have moderate pain or discomfort.……………………………..
I have extreme pain or discomfort.………………………………
(v)    Anxiety/depression
I am not anxious or depressed……………………………………
I am moderately anxious or depressed.…………………………..
I am extremely anxious or depressed.…………………………….
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For office
use only
computerised
  Date   Initials
verified/checked
  Date   Initials
ARCTIC
Patient Initials              Date of Birth         Patient ID
Month YearDay Centre No   Trial No
Baseline
Patient Health Economics 
Questionnaire Booklet
Version 3.0  13/10/2009
(vi)   Health State Scale
To help people say how good or bad their 
health is, we have drawn a scale (rather 
like a thermometer) on which the best 
health state you can imagine is marked 
100 and the worst health state you can 
imagine is marked 0. 
We would like you to indicate on this 
scale how good or bad you think your own 
health is today. Please do this by drawing 
a line from the box below to whichever 
point on the scale indicates how good or 
bad your health state is today.
Best Imaginable 
Health State
Worst Imaginable 
Health State
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
  5
  0
Your own health 
state today
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For office
use only
computerised
  Date   Initials
verified/checked
  Date   Initials
ARCTIC
Patient Initials              Date of Birth         Patient ID
Month YearDay Centre No   Trial No
Baseline
Patient Health Economics 
Questionnaire Booklet
Version 3.0  13/10/2009
General health 
4. Finally, some questions about your health in general.
(i) In general, how would you say your health is?
Excellent Very good Good Fair Poor
SF-12v2™ Health Survey © 1992–2002 by Health Assessment Lab, Medical Outcomes Trust and QualityMetric Incorporated.  
All rights reserved. SF-12® is a registered trademark of Medical Outcomes Trust.
(IQOLA SF-12v2 Standard, English (United Kingdom) 8/02)
(ii) The following questions are about activities you might do during a typical day. 
Does your health now limit you in these activities? If so, how much?
Yes,
limited
a lot
Yes,
limited
a little
No, not
limited
at all
a Moderate activities, such as moving 
a table, pushing a vacuum cleaner, 
bowling, or playing golf
b Climbing several flights of stairs
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For office
use only
computerised
  Date   Initials
verified/checked
  Date   Initials
ARCTIC
Patient Initials              Date of Birth         Patient ID
Month YearDay Centre No   Trial No
Baseline
Patient Health Economics 
Questionnaire Booklet
Version 3.0  13/10/2009
(iii) During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of your  
physical health? 
All of
the time
Most of
the time
Some of
the time
A little of
the time
None of
the time
a Accomplished less than you 
would like
b Were limited in the kind of 
work or other activities
(iv) During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of any 
emotional problems (such as feeling depressed or anxious)?
All of
the time
Most of
the time
Some of
the time
A little of
the time
None of
the time
a Accomplished less than you 
would like
b Did work or other activities 
less carefully than usual
(v) During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)?
Not at all A little bit Moderately Quite a bit Extremely
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For office
use only
computerised
  Date   Initials
verified/checked
  Date   Initials
ARCTIC
Patient Initials              Date of Birth         Patient ID
Month YearDay Centre No   Trial No
Baseline
Patient Health Economics 
Questionnaire Booklet
Version 3.0  13/10/2009
Thank you for completing this questionnaire.
(vi) These questions are about how you feel and how things have been with you during 
the past 4 weeks. For each question, please give the one answer that comes closest 
to the way you have been feeling. How much of the time during the past 4 weeks…
All of
the time
Most of
the time
Some of
the time
A little of
the time
None of
the time
a Have you felt calm and  
peaceful?
b Did you have a lot of energy?
c Have you felt downhearted 
and low?
(vii) During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with friends, 
relatives, etc.)?
All of
the time
Most of
the time
Some of
the time
A little of
the time
None of
the time
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Appendix 4 Follow-up patient health economics
questionnaire booklet
 Follow-up
For Hospital Use
To be completed 3 months after the end of therapy and 
6, 9, 12, 15, 18, 21 and 24 months post-randomisation. 
Information
We need to ask you some questions about the health care services you 
have used and anything you have had to buy because of your diagnosis 
during the last 3 months. We are doing this to find out the costs of the 
different approaches to treatment.  
Some questions will seem more relevant to you than others, but please 
try to answer all the questions so that we can compare the costs of the 
treatments fairly. The responses are confidential and will not be seen by 
the doctors or nurses. 
When you have completed the questionnaire booklet, please place it in 
the envelope provided and return the sealed envelope to the nurse.
Thank you
Patient initials
Patient date of birth 
Hospital name 
Today’s date                    
Month YearDay 
Month YearDay 
Timepoint:   3 months after the end of therapy
    6 months post-randomisation
    9 months post-randomisation
             12 months post-randomisation
             15 months post-randomisation
             18 months post-randomisation
             21 months post-randomisation
             24 months post-randomisation
ARCTIC 
Patient Health Economics Questionnaire Booklet
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Patient Health Economics 
Questionnaire Booklet
Use of health and social services 
1. Please record information on the health and social services that you have used
during the last 3 months.
Type of service Which services 
have you used 
since during the 
last 3 months? 
Total number 
of face to face 
contacts you have 
had during the 
last 3 months
Total number of 
contacts you had 
by telephone or 
e-mail during the 
last 3 months
GP surgery visit Yes            No
GP home visit Yes            No
District nurse Yes            No
Health visitor Yes            No
Community-based 
Occupational Therapist Yes            No
Community-based 
Physiotherapist Yes            No
Macmillan social worker Yes            No
Palliative care social worker Yes            No
Counsellor Yes            No
Home help or care worker Yes            No
Citizens advice or 
welfare rights advisor Yes            No
Psychiatrist or psychologist Yes            No
Food, medicine or 
laundry delivery service Yes            No
Family or patient support or 
self help groups Yes            No
Other services:
Please specify in the boxes 
and for each service also 
provide the total number of 
contacts.
1. 1. 1.
2. 2. 2.
3. 3. 3.
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Use of hospital-based care services 
2. Please tick the hospital-based care services that you have used during the 
last 3 months because of your diagnosis. If you have used any of the services 
then please also provide the hospital name and address and tell us about the 
number of visits or stays you have had at the hospital.
Type of 
service
Which services 
have you used 
during the last 
3 months?
Name and town 
of hospital
Total number 
of days’ stay 
during the 
last 3 months
Total number 
of visits 
during the 
last 3 months
Hospital 
inpatient stay
Yes            No
Hospital:
Town:
Hospital 
day centre
Yes            No
Hospital:
Town:
Hospital 
outpatient 
clinic
Yes            No
Hospital:
Town:
Hospital 
accident and 
emergency 
department
Yes            No
Hospital:
Town:
Convalescent 
home
Yes            No
Nursing home Yes            No
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Patient Health Economics 
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Travel costs & additional expenses
This section is about expenses which you may have had to meet during the last 3 
months because of your diagnosis. 
3. During the last 3 months, how much do you think you have spent on travel
because of your diagnosis? 
If you have not spent anything on travel please tick the box:   
Type of service Your spending on 
travel during the last 
3 months. (Fares for 
public transport, taxis 
and car park fees.)
If you have used your 
own car, approximate 
number of miles 
travelled during the 
last 3 months. 
GP, surgery visit £
District nurse, health visitor 
or member of community 
health team
£
Social worker £
Physiotherapy £
Occupational therapy £
Counsellor £
Citizens advice or
welfare rights advisor £
Psychiatrist or psychologist £
Hospital £
Day centre £
Lunch or social club £
Family or patient support or 
self help groups £
Other (please specify): £
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Follow-up
Patient Health Economics 
Questionnaire Booklet
5. If you have ticked ‘Yes’ to Question 4, please also describe the expenses that
you have had to meet in the table below.
6. We are interested in how much you have spent on medicines as a result of
your diagnosis. This might be prescribed medicines, over the counter 
medicines or homeopathic or herbal remedies. 
During the last 3 months, what medicines have you used as a result of your 
diagnosis and what was the cost?
Medicine 
(Copy name from the bottle /packet)
Cost to you
Brief description of item Cost to you during 
the last 3 months
£
£
£
£
4. Have had to meet any major expenses of £50 or more during the last 3 months
because of your diagnosis? (Please tick Yes or No.)
Yes   No
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Employment and usual activities 
This section is about how your diagnosis has affected your work and usual 
activities that you do on a regular basis. 
7. Please tick the box or boxes for your employment status(es) during the last 3
months. You may tick more than one box, for example you may be in full time 
employment but have had time off work (sick leave). 
Please also tell us which employment status you are currently in.
8.  Have you lost any earnings because of your diagnosis? (Please tick Yes or No.)
Yes   No
Please also provide an estimate of your gross amount lost during the last 3 months. 
(Gross amount refers to money lost before tax and national insurance has been deducted.)
Gross amount lost £
Employment status Which employment status 
have you been during the 
last 3 months? 
Current 
employment status
(Please tick 
one box only)
Full time employee 
(more than 30 hours a week) Yes                   No
Part time employee 
(less than 30 hours a week) Yes                   No
Self-employed Yes                   No
Full or part time training or 
education Yes                   No
Employee on sick leave Yes                   No
Not in paid employment due to 
long standing illness or disability Yes                   No
Retired and not in paid 
employment Yes                   No
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
350
For office
use only Version 3.0  13/10/2009
computerised
  Date   Initials
verified/checked
  Date   Initials
ARCTIC
Patient Initials              Date of Birth         Patient ID
Month YearDay Centre No   Trial No
Follow-up
Patient Health Economics 
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This section is about your general health following your diagnosis.
9. For each of the five sets of statements below, please tick the one box that best 
describes your own health state today.
(i)     Mobility
I have no problems in walking about….………………………. 
I have some problems in walking about ………………………..
I am confined to bed ………………………………………......…
(ii)    Self-care
I have no problems with self-care.…………………………….…….
I have some problems washing and dressing myself.……...…
I am unable to wash or dress myself.…………………………….
(iii)    Usual activities (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities.………
I have some problems with performing my usual activities.……
I am unable to perform my usual activities.……………………….
(iv)    Pain/discomfort
I have no pain or discomfort.………………………………………
I have moderate pain or discomfort.……………………………..
I have extreme pain or discomfort.………………………………
(v)    Anxiety/depression
I am not anxious or depressed……………………………………
I am moderately anxious or depressed.…………………………..
I am extremely anxious or depressed.…………………………….
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(vi)   Health State Scale
To help people say how good or bad their 
health is, we have drawn a scale (rather 
like a thermometer) on which the best 
health state you can imagine is marked 
100 and the worst health state you can 
imagine is marked 0. 
We would like you to indicate on this 
scale how good or bad you think your own 
health is today. Please do this by drawing 
a line from the box below to whichever 
point on the scale indicates how good or 
bad your health state is today.
Best Imaginable 
Health State
Worst Imaginable 
Health State
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
  5
  0
Your own health 
state today
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General health 
10. Finally, some questions about your health in general.
(i) In general, how would you say your health is?
Excellent Very good Good Fair Poor
(ii) The following questions are about activities you might do during a typical day. 
Does your health now limit you in these activities? If so, how much?
Yes,
limited
a lot
Yes,
limited
a little
No, not
limited
at all
a Moderate activities, such as moving 
a table, pushing a vacuum cleaner, 
bowling, or playing golf
b Climbing several flights of stairs
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(iii) During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of your  
physical health? 
All of
the time
Most of
the time
Some of
the time
A little of
the time
None of
the time
a Accomplished less than you 
would like
b Were limited in the kind of 
work or other activities
(iv) During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of any 
emotional problems (such as feeling depressed or anxious)?
All of
the time
Most of
the time
Some of
the time
A little of
the time
None of
the time
a Accomplished less than you 
would like
b Did work or other activities 
less carefully than usual
(v) During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)?
Not at all A little bit Moderately Quite a bit Extremely
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
354
For office
use only Version 3.0  13/10/2009
computerised
  Date   Initials
verified/checked
  Date   Initials
ARCTIC
Patient Initials              Date of Birth         Patient ID
Month YearDay Centre No   Trial No
Follow-up
Patient Health Economics 
Questionnaire Booklet
Thank you for completing this questionnaire.
(vi) These questions are about how you feel and how things have been with you during 
the past 4 weeks. For each question, please give the one answer that comes closest 
to the way you have been feeling. How much of the time during the past 4 weeks…
All of
the time
Most of
the time
Some of
the time
A little of
the time
None of
the time
a Have you felt calm and  
peaceful?
b Did you have a lot of energy?
c Have you felt downhearted 
and low?
(vii) During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with friends, 
relatives, etc.)?
All of
the time
Most of
the time
Some of
the time
A little of
the time
None of
the time
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Appendix 5 Participant Information Sheet
ARCTIC_PISICD01_V5.0_110705
TEM15_T19_V3.0_071006
Delete this line, then print on Hospital headed paper
ARCTIC Trial
Attenuated dose Rituximab with ChemoTherapy In CLL:
A randomised, phase IIB trial in previously untreated patients with
Chronic Lymphocytic Leukaemia (CLL) to
compare fludarabine, cyclophosphamide and rituximab (FCR) with
FC, mitoxantrone and low dose rituximab (FCM-miniR)
PATIENT INFORMATION SHEET AND INFORMED CONSENT
DOCUMENT
A large-print version of this sheet is available on request.
You have been invited to take part in a research study called “ARCTIC”. Before you decide
whether to accept, we would like to explain why the research is being done and what it will
involve. Please read this information carefully, and discuss it with others if you wish. Ask us if
anything is unclear, or if you would like more information.
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Take time to decide whether or not you wish to take part.
Thank you for reading this information sheet.
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Part 1
What is the purpose of the study?
You are invited to take part in a research study known as a clinical trial. The study is looking at
two combinations of drugs, one called fludarabine, cyclophosphamide and rituximab (FCR for
short) and one called fludarabine, cyclophosphamide, mitoxantrone and reduced dose
rituximab (FCM-miniR for short). This is a variation on established treatments and we wish to
find out if they will be effective in treating patients with chronic lymphocytic leukaemia (CLL)
who have not yet received any treatment for their disease and whether or not they cause a
better response than other treatments.
A total of 206 patients with CLL will be invited to take part in this study. Half of the patients will
be randomly selected (by computer) to receive FCR and the other half will be randomly
selected to receive FCM-miniR. You will receive up to 6 cycles of treatment, with each cycle
being given every 4 weeks and this is the same for all patients. This means that the total
duration of your treatment will be approximately 24 weeks (6 months).
This study is being carried out at approximately 20 hospitals in the UK. It is expected that the
study will take approximately 1.5 years to complete.
Why have I been chosen?
You have been invited to participate because you have been diagnosed with CLL which now
requires treatment and your doctor believes that treatment with either FCR or FCM-miniR is
appropriate at this time.
Do I have to take part?
No, ARCTIC is entirely voluntary. If you decide to take part you will be given this information
sheet to keep. You will be asked to sign a consent form, but you are still free to withdraw at
any time and without giving a reason. If you decide not to take part, your specialist will be
happy to talk through alternative options with you and your treatment and care will not be
affected in any way.
What will happen to me if I take part?
The best way of finding out whether one treatment is as effective as another treatment is in a
randomised study. ‘Randomised’ means that a computer will allocate you randomly (as if by
the roll of dice) to receive either FCR or FCM-miniR. Neither your doctor nor you will choose
which treatment you receive. In this way, a fair comparison can be made.
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Before going onto the study you will have a number of blood tests, a heart trace (ECG) and a
CT scan (a type of X-ray). You will be examined thoroughly by your study doctor. If you are a
woman, and capable of having children, a pregnancy test will be done before starting
treatment to make sure you are not pregnant. This is to make sure that it is safe for you to
receive the drugs in the trial. Only after we have completed all these tests will we be able to
confirm that you may go ahead with the study.
Your treatment will be similar to the treatments usually used in CLL. You will receive up to a
total of 6 cycles of treatment. Each cycle lasts 5 days and will be repeated every 4 weeks. You
will be required to attend the day unit/ward in your hospital on the first day of each cycle of
treatment to receive intravenous chemotherapy and the first day of your oral chemotherapy.
The remaining 4 days of your oral chemotherapy will be taken at home.
During the study we will also need to take some blood and bone marrow samples at some of
your routine visits to the hospital. Most of the blood tests and other investigations, such as
bone marrow tests or CT-scans, are routine and would be performed to assess the safety of
and response to your treatment whether or not you are taking part in the study; however, you
should be aware that the bone marrow test may cause you some discomfort. At the initial visit,
prior to commencing the first cycle of therapy, some extra tubes of blood (4 to 10
teaspoonfuls) will be taken to study your CLL in more detail, but this will not require an extra
needle puncture. This is part of the study that we hope will allow us to identify which patients
will respond the best to the treatments. Similar tests will be performed on samples of your
bone marrow taken prior to the first cycle of therapy. In addition, a blood sample will be taken
after your third cycle of treatment and blood and bone marrow samples will be taken 3 months
after your final cycle of treatment to assess the response of your disease to the treatment. A
CT scan will also be performed at this time. You should be aware that by receiving a CT scan
you will be exposed to additional radiation although the health risks associated with this are
low and are considered to be justified.
We will follow your progress for 2 years and this will involve at least 3 visits after the end of
your therapy, usually on a 6 monthly basis. Depending on the results of the previous tests, we
may need to take additional blood samples at these visits. If your doctor feels that it is
appropriate, and depending upon the response of your disease, you may also need to have
another CT scan at these time points. Once you have reached the 2 year post randomisation
time point we would then like to follow you annually for the rest of your life in order to assess
your long term progress after taking part in the trial.
The study also involves a health economics assessment which will help to find out the costs of
the different approaches to treatment. This will involve you completing a questionnaire which
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will ask you questions about your health and wellbeing and any health care services you have
used. You will be asked to complete this questionnaire during your clinic visits at regular time
points during the study.
If you are unable to travel to the hospital at any time during the study you should contact your
haematology unit. If you need to see your own GP during the course of the study then he or
she will already have been informed of your participation in the study.
What is the standard treatment?
The standard treatment for many patients with CLL who have not received any previous
treatment in the United Kingdom is fludarabine, cyclophosphamide and rituximab (FCR).
What are the new treatments?
It is believed that adding mitoxantrone to FCR (FCM-R) may result in an improvement in
response rates and that using a reduced dose of rituximab (miniR) may be just as effective as
using the full dose. This study will therefore test whether FCM-miniR is as effective as FCR at
improving response rates for previously untreated patients with CLL.
How long does treatment go on?
You will receive 6 cycles of treatment with either FCR or FCM-miniR. Each cycle is repeated
every 28 days meaning that you can expect to receive treatment for approximately 6 months.
If you experience any side effects it may be the case that your doctor wishes to delay some or
all of your treatment cycles; side effects, which are common to all chemotherapy treatments,
are further discussed later in this information sheet.
Your doctor will assess your progress after you have received 3 cycles of treatment and will
make the decision for you to receive the next three cycles. If you are unable to tolerate
treatment with FCR or FCM-miniR or are not responding to treatment your doctor may decide
to stop your treatment before you have received 6 cycles.
What if the treatment doesn’t help?
If your CLL levels start to increase then your doctor may decide to offer you a different
treatment; details of this will be discussed with you at that time.
Unwanted effects of treatment
It is important to remember that all drugs have side effects. All chemotherapy can cause
nausea, though this is usually well controlled with anti-sickness tablets. Chemotherapy for
CLL with FCR and FCM-miniR is frequently associated with effects on the bone marrow. This
can show itself in any of the following ways:
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Lower white blood cells which can increase the risk of infection.
Lower red blood cells (called anaemia) which may give you shortness of breath,
weakness and fatigue.
Lower platelets (blood cells which make your blood clot) which may cause easy bruising or
bleeding
In addition the following side effects may also occur:
Fludarabine has very commonly (that is, in over 10% of patients), been associated with
increased coughing, vomiting, diarrhoea, fever; feeling tired, weakness, bruising, bleeding and
infections (some serious) including infections of the lungs (pneumonia) with possible
symptoms such as breathing difficulties. Fludarabine has commonly (that is around 10% of
patients) been associated pins and needles, disturbed vision, mouth ulcers / sore mouth, skin
rash, swelling due to increased fluid retention, chills and loss of appetite leading to weight
loss. Cyclophosphamide has commonly (that is, around 10% of patients) been associated
with irregular or absent menstrual periods in women, blood in the urine, hair loss (generally
reversible), mouth ulcers / sore mouth, abnormal colouring of the skin usually affecting the
palms of the hands, soles of the feet or nails, changes to the way food and drink tastes and
loss of appetite leading to weight loss.
Cyclophosphamide may reduce the level of normal blood cells and make you more likely to
get infections, anaemia or to excessive bleeding. These are monitored by blood tests but if
they occur unexpectedly you should contact the hospital immediately. Rarely (less than 5% of
patients) patients may become anaemic enough to need a blood transfusion.
Mitoxantrone has commonly (that is, around 10% of patients) been associated with pins and
needles, confusion, sleepiness, anxiety, abnormal colouring of the skin usually affecting the
palms of the hands, soles of the feet or nails, loosening of nails, sore mouth, skin rash,
conjunctivitis (inflammation of the eye), constipation, black stools or blood in your urine or
stools, stomach pain, changes to the way food and drink tastes and loss of appetite leading to
weight loss
Mitoxantrone has rarely (that is less 5% of patients) been associated with blue/green
discolouration to whites of the eyes or urine, hair loss, damage to the muscles of the heart,
which may change the rhythm of the heartbeat, but it is unlikely to cause a problem in this
study as the total dose of mitoxantrone is smaller than that likely to cause heart problems.
Your heart will be monitored before you start the treatment to make sure that you are not at
risk of these side effects.
Rituximab infusion can often cause mild and temporary side effects occurring mainly during
the first infusion: fever, chills, headache, generally feeling unwell, tiredness, itching, redness
of the skin, nausea and a mild drop in blood pressure. Most of these side effects disappear
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upon temporary slowing or discontinuation of the infusion, or administration of paracetamol
and/or anti-allergic medication. Less than 10% of patients have suffered from severe side
effects with the first dose of rituximab including shortness of breath, dizziness and a fall in
blood pressure. This has proved fatal in a very small number of cases. You will be monitored
very carefully during and after the first dose to ensure that the rituximab may be stopped and
appropriate treatment given if such side effects occur. Rituximab is given as a day case by a
slow infusion to reduce the risk of reactions. If you are receiving FCR in the trial then the
rituximab infusion will take 5 to 6 hours on the first dose and then slightly less on the
subsequent courses of treatment. Since a lower dose of rituximab is given in the FCM-miniR
patients then the initial infusion should take about 90 minutes and subsequent infusions
should be completed in about an hour. Treatment with rituximab has also been associated
with an increased risk of developing a viral or bacterial infection. In most cases these
infections can be treated very easily but very rarely (that is less than 1% of patients) these
may become serious and have occasionally proven fatal.
If you do decide to take part in the study, you must report any problems you have to your
study nurse or doctor. There is also a contact number given at the end of this information
sheet for you to phone if you become worried at any time. In the unlikely event of an
emergency occurring during the conduct of the study, we may contact your nominated next of
kin.
Do I need to make any lifestyle changes?
Your body’s ability to fight infections will be lowered while you are on the treatment and for a
few months afterwards. There is a slightly increased risk of getting rare and unusual infections
while your immunity is lowered. During that period it is advisable to avoid contact with people
who have sore throats, colds, flu, diarrhoea and vomiting, or other kinds of infection, such as
chickenpox.
If you have pets or work with animals you will need to be extra careful. It is usually safe to pet
or stroke animals as long as you wash your hands thoroughly afterwards. It is best to avoid
handling any animal waste, such as litter trays or manure, as this can increase your chances
of getting an infection.
It is important to avoid places and activities which make you more vulnerable to get infection
with fungus like aspergillus. This can grow in dead leaves, grain stores, compost piles or other
decaying vegetation. Brick, mortar and cement dust may also contain this fungus. It is
preferable to avoid gardening activities like mowing the lawn. Wash your hands well after
gardening and other outdoor activities
It is better to avoid any vaccination while you are on the treatment as some of the vaccinations
can be harmful and most of them will not mount an adequate immune response while you are
on the treatment.
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It is preferable to avoid going abroad due to various reasons like accessibility to healthcare
services, the drugs used and their complications may be unfamiliar in certain areas and
vaccination if needed.
While you are on the treatment a 'clean' diet is recommended. This means avoiding certain
food items like raw or lightly cooked eggs, shellfish, liver pâté, soft cheeses, takeaway food,
uncooked salads. All food should be cooked thoroughly and stored in recommended
temperature and use by date. It is still important to eat fruits and vegetables and it is
recommended to eat those fruits and vegetables which are peelable.
Pregnancy during treatment, information for women and / or men
The effects of the drugs in both arms of the study on the unborn child are unknown. You
cannot take part in the study if you are pregnant or breast feeding.
If, as a woman, you are able to become pregnant you must use a medically approved form of
contraception; an intra-uterine device (‘coil’), the contraceptive pill or injection and condoms
are considered medically approved forms of contraception. You must continue to use a
medically approved form of contraception whilst receiving any of the study drugs and for
twelve months after you finish your last treatment cycle. Talk to your doctor if you are unsure
about any other forms of contraception you may be using.
If, as a man, you are engaging in heterosexual activity with a woman who is able to become
pregnant, you must use a medically approved form of contraception. You must continue
using a medically approved form of contraception whilst receiving any of the study drugs and
for twelve months after you finish your last treatment cycle.
If you are female and become unexpectedly pregnant you must inform your doctor
immediately and you will be withdrawn from the study treatment. Other treatment options will
be discussed with you at that time. If you are a male and your partner becomes unexpectedly
pregnant you must also inform your doctor immediately so that your partner’s pregnancy can
be monitored.
How is my condition monitored?
Your progress will be monitored carefully. Your doctor will perform an examination before you
start treatment and then after you have received 3 cycles of treatment. If your doctor is happy
that you are tolerating the treatment he/she will then decide that you can receive the next 3
cycles of treatment. If you are not tolerating treatment your doctor may decide that you need to
stop receiving further treatment. Your doctor will then assess you at the end of treatment and
also 3 months after treatment and then 12 months, 18 months and 24 months after you first
agreed to take part in the study. Further long term follow up will be discussed by your doctor at
the time.
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As already mentioned you may experience side effects which should be reported to your doctor
at each visit.
Please tell us about any problems, as we can often help.
What are the possible disadvantages and risks of taking part?
As already discussed you may experience side effects following treatment with any of the
study drugs. You will be monitored regularly whilst receiving study treatment. You will be
examined by the study doctors and blood tests will be taken to check for side effects. If you
suffer any side effects which you think may be related to the study, please inform the study
nurse or doctor as soon as possible.
The effectiveness of the treatments may be different in certain individuals and therefore may
have no direct benefit to your disease.
Taking bone marrow samples may cause you some pain or discomfort. If you decide to
participate in the study a bone marrow sample will be collected before you receive treatment
and 3 months after your treatment has ended. However, you should be aware that a bone
marrow sample would also be collected at these time points as part of your standard care if
you decide not to participate in the study.
The number of blood samples taken as part of the study is also the same as that taken as part
of your routine care.
The additional CT scans will give a radiation dose equivalent to that received from normal
background radiation over approximately 15 years. This carries a very small increase in your
risk of developing cancer in later years (with a risk of about 1 in 400 of fatal cancer), but a
Clinical Radiation Expert has certified that the exposures are justified by the potential benefits
of the new treatment to yourself and to future patients.
Being involved in a research study such as a clinical trial involves a degree of commitment
such as regular hospital visits and additional tests, as described above. It is not expected that
you will need to stay in hospital over night but occasionally this may be necessary to treat any
side effects.
What are the possible benefits of taking part?
If you agree to take part in this study, there may or may not be direct medical benefit to you.
We hope that the treatments will help you, but the effectiveness of the treatments may be
different in certain individuals and therefore this cannot be guaranteed. The addition of
rituximab to chemotherapy appears to add to the effectiveness of treatment in CLL and all
patients within this study will receive rituximab as part of their treatment. It is believed that low
dose rituximab may be just as effective as full dose rituximab and that it may have fewer side
effects than full dose rituximab, but the trial will need to show this. Research studies such as
clinical trials are essential for progress in the development of treatments for diseases.
Although we cannot guarantee that the treatments will be beneficial to you, the results
DOI: 10.3310/hta21280 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 28
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Howard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
365
ARCTIC_PISICD01_V5.0_110705
TEM15_T19_V3.0_071006
obtained from this study will also provide important information which may help people with
CLL in the future. Without research such as this, no improvement is possible.
What if something goes wrong?
If you are harmed by taking part in this research project, there are no special compensation
arrangements. If you are harmed due to someone’s negligence, then you may have grounds
for legal action but you may have to pay for it. Regardless of this, if you wish to complain, or
have concerns about any aspect of the way you have been approached or treated during the
course of this study, the normal National Health Service complaints mechanisms should be
available to you. Your doctor will give you further information, if necessary.
What happens when the research study stops?
Should you require further treatment for your disease after you have finished treatment in this
study, further treatment options will be discussed with you by your doctor. Whether further
treatment is required or not, you will continue to be reviewed on a regular basis as part of the
study. We will follow your progress for 2 years after you have finished trial treatment and this
will involve at least 3 visits after the end of your therapy, usually on a 6 monthly basis. Once
you have reached the 2 year post randomisation time point we would then like to follow you
annually for the rest of your life in order to assess your long term progress after taking part in
the study.
Additional research
There is also the opportunity to take part in an additional research project called the UK CLL
Trials BioBank. This project involves having additional blood samples and a saliva sample
taken before you start treatment. If your doctor is able to extract enough bone marrow when a
sample is taken before you start treatment and 3 months after treatment has ended, part of
the sample will also be sent to the UK CLL Trials BioBank. Another blood sample will also be
taken if your disease re-occurs. The samples will be sent to and stored by the UK CLL Trials
BioBank at the Royal Liverpool University Hospital, and they will then be will be analysed for
things that might be of value in predicting how well individual patients respond to treatment
and shed light on possible new treatments. If you wish to take part in the UK CLL Trials
BioBank your doctor will provide you with a separate consent form and patient information
sheet which are specific to this project. Participation in the additional research is entirely
optional, and your decision to participate will not affect your participation in the rest of the
study.
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Will my taking part be kept confidential?
If you consent to take part in this study, the records obtained while you are taking part as well
as related health records will remain strictly confidential at all times. Please refer to Part 2 of
this information sheet which provides further details of confidentiality.
Contact Details
If you have any further questions about your disease or clinical studies, please discuss them
with your doctor. You may also find it helpful to contact Cancerbackup, an independent cancer
information charity (freephone:         ; address:
        ; website www.cancerbackup.org.uk) or CancerHelp, an information
service about cancer and cancer care for people with cancer and their families by Cancer
Research UK (Tel:         ; website www.cancerhelp.org.uk). If you would like further
information about clinical research, the UK Clinical Research Collaboration (a partnership of
organisations working together on clinical research in the UK) has published a booklet titled
‘Understanding Clinical Trials’. Contact UKCRC: Tel: ; website www.ukcrc.org
Your contact telephone numbers:
……………………………………………………………………………………………………………..
……………………………………………………………………………………………………………..
This completes Part 1 of the Information Sheet. If the Information in Part 1 has
interested you and you are considering participation, please continue to read the
additional information in Part 2 before making any decision.
Part 2
What if relevant new information becomes available?
Sometimes during the course of a clinical trial or study, new information becomes available or
the drugs that are being studied. If this happens, we will tell you about it and discuss with you
whether you want to continue in the study. If you decide to withdraw, we will make
arrangements for your care to continue. If you decide to continue in the study, you may be
asked to sign an updated consent form.
On receiving new information, we might consider it to be in your best interests to withdraw you
from the study. If so, we will explain the reasons and arrange for your care to continue.
What will happen if I don’t want to carry on with the study?
If you withdraw consent from further study treatment, your data and samples will remain on file
and will be included in the final study analysis. In line with Good Clinical Practice guidelines, at
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the end of the study, your data will be securely archived for a minimum of 15 years.
Arrangements for confidential destruction will then be made.
Who has organised, reviewed and funded the research and who will be supervising it?
The study is being organised by the University of Leeds, who will collect and analyse your
data. The study was reviewed and approved by the National Cancer Research Institute CLL
Sub-Group Committee, the Leeds East Research Ethics Committee and the Local Research
Ethics Committee situated at your hospital.
The study is being funded by the Health Technology Assessment Programme (HTA) which is
part of the National Institute for Health Research (NIHR). Part of the funds will be used by the
University of Leeds who are organising the study and collecting and analysing your data. Part
of the funds will also be used by the Haematological Malignancy Diagnostic Service (HMDS)
at St. James’s University Hospital who will study the blood and bone marrow samples which
you have given.
What if there is a problem?
If a medical emergency related to your treatment for this study occurs while you are at home,
you should initially try to contact the haematology unit where you received your treatment
<<contact details will be added>>. If this is not possible you should go to the Accident and
Emergency (A&E) department at your local hospital. If you are unable to get to the hospital
you should contact your GP who, with your consent, will already have been informed of your
participation in the study.
Complaints:
If you wish to complain, or have concerns about any aspect of the way you have been
approached or treated during the course of this study, the normal National Health Service
complaints mechanisms should be available to you.
Harm:
If you are harmed by taking part in this research project, there are no special compensation
arrangements. If you are harmed due to someone’s negligence, then you may have grounds
for legal action but you may have to pay for it.
Will my taking part in this study be kept confidential?
If you decide to participate in ARCTIC, the information collected about you during the course
of the study will be kept strictly confidential. This information will be securely stored, on paper
and electronically, at the Clinical Trials Research Unit (CTRU) at the University of Leeds
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under the provisions of the 1998 Data Protection Act. The CTRU will hold a copy of the
consent form that you sign, which will have your name on it. This information will not be
accessed by any other personnel. In addition some of the study information collected, for
example the Health Economics Patient Questionnaire Booklets, will be securely stored on
paper and electronically at the Academic Unit of Health Economics at the University of Leeds;
this information will only be accessible by a member of the research team.
Every effort will be made to ensure that any further information about you that leaves the
hospital will have your name and address removed so that you cannot be recognised from it.
This information will usually be removed by a member of the study team at your hospital, but
may also be removed by the CTRU upon receipt. You will be allocated a study number, which
will be used as a code to identify you on all study forms. Only the CTRU and your hospital will
be able to identify you from this number.
With your permission, the CTRU may register your details (which will include your full name,
date of birth, NHS number and last known address) with the Office of National Statistics, so
that if you move away we will be able to find out how you are doing.
With your permission, your relevant medical records may be inspected by authorised
individuals from the research team or the University of Leeds (the study Sponsor). They may
also be looked at by the regulatory authorities to check that the study is being carried out
correctly. In addition, some of your data may be passed to other organisations (possibly in
other countries where the data protection standards and laws are different from the UK) to
monitor the safety of the treatment(s) that you are receiving. This data will have your name
removed so that you cannot be identified from the information.
When the study is complete the results will be published in a medical journal, but no individual
patients will be identified. If you would like to obtain a copy of the published results, please
ask your doctor.
Involvement of the General Practitioner/Family Doctor (GP):
Your GP, and the other doctors involved in your clinical care, will be notified and kept informed
of your participation in ARCTIC, but otherwise all information about you and your treatment
will remain confidential.
What will happen to any samples I give?
Researchers at the central laboratories at the Leeds Teaching Hospitals NHS Trust will have
access to your blood and bone marrow. The researchers will use the samples to look at a
variety of factors in your CLL cells. These factors might have a positive or negative impact on
the probability of your CLL responding to treatment. This information will help to identify which
factors are important and will help our treatment of future patients with CLL. Although these
samples will be analysed for this study, (i.e. research) some of the results may be useful to
your doctor for your clinical management.
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The samples will therefore be labelled according to NHS standard practice and will not be
made anonymous, so that the results can be fed back to your study doctor. The laboratories
will handle your samples with the same duty of confidentiality as they would for any clinical
sample. They will be retained at the end of the study as a record of the completed research
study in order to verify the research results, if required.
If any information from this study is used to develop new research, data protection regulations
will be observed and strict confidentiality maintained; your data will have your personal details
removed, but will be coded so it can be linked back to your details. You will not be identified in
the results of future studies. Ethical approval will be obtained for any future studies involving
your data or samples.
There is also the opportunity to take part in an additional research project called the UK CLL
Trials BioBank. As previously discussed, this project involves having additional blood samples
taken along with a saliva sample before you start treatment. If your doctor is able to extract
enough bone marrow when a sample is taken, before you start treatment and 3 months after
treatment has ended, part of the sample will also be sent to the UK CLL Trials BioBank. In
addition, if and when your CLL progresses after therapy then a further blood sample will be
taken for the UK CLL Trials BioBank to help investigate why the CLL has returned. The
samples will be sent to and stored by the UK CLL Trials BioBank at the Royal Liverpool
University Hospital, and they will be analysed for things that might be of value in predicting
how well individual patients respond to treatment and shed light on possible new treatments. If
you wish to take part in the UK CLL Trials BioBank your doctor will provide you with a
separate consent form and patient information sheet which are specific to this project.
Your samples will not be used for commercial purposes.
Will any genetic tests be done?
If you decide to take part in the additional UK CLL Trials BioBank project then genetic tests
may be performed on your samples.
Certain genetic changes in the CLL cells are important for the development of CLL and also
for the likelihood of individual patients responding to treatment. These genetic changes will be
analysed in your CLL. In addition it is likely that certain genes may increase the likelihood that
an individual will develop CLL and increasing numbers of genes and combinations of certain
genes are being identified. These current and new genetic changes will be studied in the
samples taken from this study. This work is important to understand that leukaemia develops
and progresses because something goes wrong with one or more genes. In order to
understand more about CLL and improve its treatment it is therefore necessary to examine
leukaemia cells for genetic abnormalities.
In addition, many normal genes can exist in slightly different forms called “polymorphisms”;
this is what makes each human being unique. It is important to study gene polymorphisms in
CLL as doing so could shed light on why the disease affects some people but not others, why
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it behaves differently in different patients, and why treatments work better in some patients
than others.
What will happen to the results of the research study?
The results of the study will be available after it finishes and will usually be published in a
medical journal and also on the CancerHelp website. Should you wish to see the results, or
the publication, please ask your study doctor. You will not be identified in any report or
publication.
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Delete this line, then print on Hospital headed paper
ARCTIC
Attenuated dose Rituximab with ChemoTherapy In CLL:
A randomised, phase IIB trial in previously untreated patients with Chronic
Lymphocytic Leukaemia (CLL) to compare fludarabine, cyclophosphamide and
rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR)
PATIENT CONSENT FORM
1. I confirm that I have read and understand the information sheet for the above
study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw at
any time without my medical care or legal rights being affected.
3. I understand that my medical records may be looked at by authorised
individuals from the research team, regulatory bodies or Sponsor in order to
check that the study is being carried out correctly. I give permission, provided
that strict confidentiality is maintained, for these bodies to have access to my
medical records for the above study and any further research that may be
conducted in relation to it.
4. I understand that even if I withdraw from the above study, the data and
samples collected from me will be used in analysing the results of the trial,
unless I specifically withdraw consent for this. I understand that my identity will
remain anonymous outside of the NHS.
5. I agree to allow any information or results arising from this study to be used for
healthcare and/or medical research purposes including monitoring the safety
of the treatment that I will receive. I understand that my identity will remain
anonymous outside of the NHS.
6. I agree for my details (which will include my name, date of birth, NHS number
and address) to be registered with the Office of National Statistics (ONS) or
traced via the NHS Strategic Tracing Service so that information about my
health status may be obtained by the CTRU if necessary.
7. I understand that a copy of this Consent Form will be sent to the CTRU
Patient ID: Initials:
Date of Birth: Hospital Number:
EudraCT Number: Version:
Principal Investigator:
Patient initial after
each question
..........
..........
..........
..........
..........
..........
..........
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8. I agree that my GP, or any other doctor treating me, will be notified of my participation
in this study.
9. I agree to take part in the study
The following points are OPTIONAL.
Even if you agree to take part in this study, you do not have to agree to this section
10. I give permission for surplus specimens from my leukaemia that have been stored in
the hospital pathology laboratory to be retrieved and used in the future for CLL cancer
research.
Name of patient Date Signature
Name of Person taking
consent
Date Signature
(1 copy for patient; 1 for the CTRU; Original stored in Investigator Site File)
Yes No
Please initial
after each
question
..........
..........
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